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Abstract	  
	  SOX2	   is	   expressed	   in	   the	   pituitary	   anlagen,	   Rathke’s	   Pouch	   (RP),	   from	   its	  induction	  at	  9.0dpc.	  RP	  progenitors	   initially	  expand,	   later	  giving	   rise	   to	  all	  pituitary	   cell	   types.	   As	   cells	   differentiate,	   SOX2	   expression	   is	   down-­‐regulated,	  but	  a	  population	  of	  SOX2+ve	  cells	  persists	  until	  adulthood.	  These	  represent	   adult	   stem	   cells,	   displaying	   regenerative	   potential	   upon	  physiological	   demand.	   In	   humans	   and	  mice,	   heterozygous	   loss-­‐of-­‐function	  mutations	   in	   SOX2/Sox2	   are	   associated	   with	   hypopituitarism.	   It	   was	  therefore	   decided	   to	   investigate	   the	   role	   of	   SOX2	   during	  murine	   pituitary	  development.	  	  Homozygous	   null	   mutations	   of	   Sox2	   lead	   to	   embryo	   lethality	   following	  implantation;	   consequently	   conditional	   strategies	   were	   used	   to	   delete	   the	  gene	   specifically	   in	   RP.	   Nkx3.1Cre	   and	   FoxG1Cre,	   display	   different	   spatio-­‐temporal	  patterns	  of	  activity	  in	  RP.	  The	  severity	  in	  hypoplasia	  and	  reduced	  progenitor	  cell	  proliferation	  correlated	  with	  the	  efficiency	  and	  timing	  of	  Cre-­‐mediated	  deletion	  of	  Sox2.	  The	  expression	  of	   the	   transcription	   factor	  SIX6,	  known	   for	   its	   role	   in	   promoting	   cell	   proliferation,	   was	   downregulated.	  Conversely	  expression	  of	  the	  cell	  cycle	  inhibitor	  p27kip1	  is	  up-­‐regulated,	  in	  the	  absence	  of	  Sox2.	  Furthermore,	   the	  proliferation	  defect	   in	  Sox2	  mutants	  can	   be	   rescued	   by	   homozygous	   loss	   of	   p27kip1,	   demonstrating	   a	   genetic	  interaction.	  This	  suggests	   that	  SOX2	  promotes	  progenitor	  cell	  proliferation	  in	  the	  early	  RP	  and	  may	  do	  so,	  at	  least	  in	  part,	  by	  regulating	  Six6	  and	  p27kip1	  expression.	  
Sox2	  RP	  mutants	  display	  a	  disproportionate	   reduction	   in	  melanotroph	  cell	  numbers	   in	   the	   intermediate	   lobe	   (IL).	   The	   Sox2-­‐deleted	   cells	   display	   a	  downregulation	   of	   the	  melanotroph	   lineage	   specifier,	   PAX7.	   Consequently,	  the	  few	  differentiated	  cells	  present	  in	  mutant	  IL	  switch	  from	  a	  melanotroph	  identity	  to	  a	  corticotroph	  fate,	  despite	  these	  cells	  never	  being	  present	  in	  the	  normal	   IL.	   This	   phenotype	   was	   not	   rescued	   in	   p27kip1;Sox2	   compound	  mutants.	   This	   suggests	   that	   SOX2	   plays	   two	   independent	   roles	   during	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  PBT	   	   	   Phosphate	  Buffered	  Saline	  Triton	  PCR	   	   	   Polymerase	  Chain	  Reaction	  PD	   	   	   Paired	  Domain	  PFA	   	   	   Paraformaldehyde	  PIT1	   	   	   Pituitary	  Specific	  Transcription	  Factor	  1	  PITX1	   	   	   Paired-­‐Like	  Homeodomain	  1	  PITX2	   	   	   Paired-­‐Like	  Homeodomain	  2	  PL	   	   	   Posterior	  Lobe	  POMC	   	   	   Pro-­‐opiomelanocortin	  POU1f1	   	   POU	  Class	  1	  Homeobox	  1	  PP	   	   	   Posterior	  Pituitary	  PrL	   	   	   Prolactin	  PROP1	  	   	   Paired-­‐like	  Homeobox	  1	  PTC1	   	   	   Patched	  1	  qPCR	   	   	   quantitate	  Polymerase	  Chain	  Reaction	  R26R	   	   	   Rosa26	  Reporter	  RP	   	   	   Rathke’s	  Pouch	  SC	   	   	   Stem	  Cell	  SCA1	   	   	   Stem	  Cell	  Antigen	  1	  SD	   	   	   SIX	  Domain	  SF1	   	   	   Steroidogenic	  Factor	  1	  SHH	   	   	   Sonic	  Hedgehog	  SIX3	   	   	   SIX	  Homeobox	  3	  SIX6	   	   	   SIX	  Homeobox	  6	  SK1	   	   	   Schedule	  1	  Kill	  SOD	   	   	   Septo-­‐Optic	  Dysplasia	  SOX	   	   	   SRY	  (Sex	  determining	  region	  T)-­‐box	  SOX2	   	   	   SRY	  (Sex	  determining	  region	  T)-­‐box	  2	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SOX9	  	   	   	   SRY	  (Sex	  determining	  region	  T)-­‐box	  9	  	  	   	  SP	   	   	   Side	  Population	   	  SRY	   	   	   Sex-­‐determining	  region	  Y	  TAE	   	   	   Tris-­‐acetate-­‐EDTA	  TBX19	  	   	   T-­‐Box	  19	  TF	   	   	   Transcription	  Factor	  TFBS	   	   	   Transcription	  Factor	  Binding	  Sites	  TLE1	   	   	   Transducin-­‐Like	  Enhancer	  of	  Split	  1	  TPIT	   	   	   T-­‐Box	  Factor	  Pituitary	  TRH	   	   	   Thyrotropin-­‐Releasing	  Hormone	  TSH	   	   	   Thyroid-­‐Stimulating	  Hormone	  UTF1	   	   	   Undifferentiated	  Transcription	  Factor	  1	  VD	   	   	   Ventral	  Diencephalon	  WT	   	   	   Wild	  Type	  WNT	   	   	   Wingless-­‐Type	  YSB	   	   	   Yellow	  Submarine	  	  α-­‐GSU	   	   	   Glycoprotein	  Hormones,	  α-­‐Subunit	  β	   	   	   Beta	  °c	   	   	   Degrees	  Centigrade	  μl	  	   	   	   Micro	  Liters	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1.	  General	  Introduction	  	  
	  The	  studies	  presented	   in	  this	   thesis	  aim	  to	  examine	  the	  role	  SOX2	  plays	   in	  embryonic	   pituitary	   progenitors.	   Throughout	   this	   chapter	   I	  will	   introduce	  the	  topics	  studied	  in	  the	  thesis.	  Moreover	  I	  will	  outline	  the	  aims	  of	  the	  thesis	  in	  addition	  to	  discussing	  previously	  published	  data	  that	  helped	  form	  some	  of	  the	  hypothesis	  we	  used	  as	  the	  basis	  of	  this	  study.	  	  	  	  
1.1 SOX2:	  a	  stem	  cell	  transcription	  factor	  
	  The	   founding	   member	   of	   the	   Sox	   gene	   family,	   encoding	   for	   transcription	  factors	   (TFs),	   and	  with	  which	   all	   19	   other	  mammalian	   Sox	   genes	   share	   at	  least	  50%	  homology,	  is	  Sry	  (Sex-­‐determining	  region	  Y).	  Discovered	  in	  1990,	  SRY	   is	   solely	   responsible	   for	   the	   primary	   male	   characteristics	   associated	  with	  the	  Y	  chromosome	  (Gubbay	  et	  al.,	  1990;	  Koopman	  et	  al.,	  1991;	  Sinclair	  et	  al.,	  1990).	  Containing	  only	  one	  exon,	  Sry	  codes	  for	  a	  protein	  containing	  a	  high	  mobility	  group	  (HMG)	  domain,	  which	  is	  well	  conserved,	  while	  the	  rest	  of	  the	  protein	  displays	  high	  variability	  between	  mouse	  and	  human	  (Gubbay	  et	   al.,	   1990)	   and	   is	   poorly	   conserved	   amongst	   other	   animals.	   This	   HMG	  domain	  specifically	  binds	  to	  the	  minor	  groove	  of	  DNA,	  resulting	  in	  bending	  of	   the	   DNA	   through	   90-­‐120°.	   This	   bending	   of	   the	   DNA	   is	   critical	   for	   the	  correct	   function	   of	   SRY.	   Mutation	   of	   the	   protein	   to	   prevent	   this	   bending	  results	  in	  male	  to	  female	  sex	  reversal	  (Gubbay	  et	  al.,	  1990;	  Koopman	  et	  al.,	  1991;	  Pontiggia	  et	  al.,	  1994).	  	  The	   SOX	   (Sex	   determining	   region	   Y)-­‐box	   of	   TFs	   comprises	   nine	   distinct	  groups	   (A-­‐H),	   based	   on	   sequence	   homology.	   SRY	   is	   the	   sole	   member	   of	  group	  A.	  Other	  Sox	   genes	  are	  mostly	  highly	  evolutionarily	   conserved,	  with	  two	   additional	   groups	   being	   identified	   in	   Xenopous	   (SoxI)	   and	   C.elegans	  (SoxJ)	  (Bowles	  er	  al.,	  2000).	  Moreover	  the	  evolutionary	  origin	  of	  Sox	  genes	  may	  go	  back	  even	  further	  with	  the	  more	  recent	  discovery	  of	  Sox-­‐like	  genes	  in	   single	   cell	   organisms	   (Monosiga	   brevicollis)	   (King	   et	   al.,	   2008).	  Nevertheless,	  the	  defining	  characteristic	  shared	  between	  all	  Sox	  genes	  is	  the	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high	   sequence	   similarity	   within	   the	   HMG	   domain.	   Consequently	   all	   Sox	  genes	   recognise	   the	   transcription	   factor	   binding	   motif	  [(A/T)(A/T)CAA(A/T)G]	   (Harley	  et	  al.,	  1994;	  van	  de	  Wetering	  et	  al.,	  1992;	  Wright	  et	  al.,	  1993).	  
Sox2	  (SRY-­‐like	  HMG	  box	  containing	  gene	  2),	  was	  discovered	  along	  with	  the	  other	   SoxB1	   genes	   (Sox1	   &	   Sox3)	   at	   the	   same	   time	   as	   Sry	   (Figure	   1.1)	  (Gubbay	   et	   al.,	   1990).	   Located	   on	   chromosome	   3	   in	   human	   and	   mouse	  genome,	  Sox2	  like	  Sry	  consists	  of	  only	  one	  exon	  coding	  for	  a	  TF	  including	  the	  HMG	  box	  and	  a	  C-­‐terminal	   transactivation	  domain	   (Figure	  1.1)	   (Gubbay	  et	  al.,	  1990;	  for	  review	  see	  Kamachi	  &	  Kondoh.,	  2013).	  
1.1.1	  SOX2	  and	  Embryonic	  Stem	  (ES)	  cell	  pluripotency	  
Sox2	   mRNA	   transcription	   starts	   in	   the	  mouse	   embryo	  morula	   at	   2.5	   days	  post	  coitum	  (dpc),	  but	  in	  fact	  the	  protein	  and	  its	  messenger	  are	  present	  from	  fertilization,	  as	  they	  are	  stored	  in	  the	  oocyte	  (Avilion	  et	  al.,	  2003;	  Keramari	  et	  al.,	  2010).	  SOX2	  is	  essential	  for	  development	  to	  progress,	  as	  Sox2	  deletion	  is	   lethal	   at	   peri-­‐implantation	   stages.	   This	   is	   due	   to	   failure	   to	   maintain	  development	   of	   the	   epiblast	   and	   extra-­‐embryonic	   ectoderm,	   identified	  through	  the	  reduction	  in	  OCT4	  expression	  and	  absence	  of	  Ffg4,	  a	  target	  gene	  of	   SOX2	   (Avilion	   et	   al.,	   2003;	   Yuan	   et	   a.,	   1995).	   The	   presence	   of	  maternal	  SOX2	  was	  suggested	  to	  delay	  the	  appearance	  of	  the	  embryonic	  Sox2	  deletion	  phenotype	  in	  the	  inner	  cell	  mass	  (ICM)	  (Avilion	  et	  al.,	  2003).	  More	  recently	  it	   was	   observed	   that	   knock	   down	   of	   both	   maternal	   and	   embryonic	   Sox2	  mRNAs	   by	   siRNA	   at	   the	   two-­‐cell	   stage	   results	   in	   an	   even	   earlier	   arrest	   in	  development,	  at	  the	  morula	  stage	  (Keramari	  et	  al.,	  2010).	  The	   ICM	   in	   the	   blastocyst	   contains	   the	   pluripotent	   cells	   from	   which	   the	  extraembryonic	   endoderm	   and	   all	   embryonic	   tissues	   are	   derived.	   ES	   cells	  are	   derived	   from	   isolated	   ICMs	   (Evans	   &	   Kaufman.,	   1981;	   Martin.,	   1981).	  They	  retain	  their	  pluripotent	  state	  thanks	  to	  the	  maintenance	  of	  expression	  of	  the	  ‘core’	  pluripotency	  factors,	  SOX2,	  OCT4	  and	  NANOG	  (Chambers	  et	  al.,	  2003;	   Masui	   et	   al.,	   2007;	   Niwa	   et	   al.,	   2000).	  SOX2	   is	   also	   one	   of	   the	   four	  ‘Yamanaka	   factors’	   used	   to	   reprogram	   terminally	   differentiated	   cells	   into	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Figure	   1.1:	   SOXB	   subgroup	   of	   transcription	   factors.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  The	   SOXB1	   group	   of	   TFs	   consists	   of	   SOX1,	   SOX2	   and	   SOX3.	   They	   contain	   of	   a	  N-­‐terminal	  region	   followed	   by	   the	   HMG	   DNA	   binding	   domain	   in	   addition	   to	   a	   C-­‐terminal	   activation	  domain.	  The	  SOXB2	  group	  of	  TFs	  consisting	  of	  SOX14	  an	  SOX21	  also	  contains	  a	  N-­‐terminal	  and	   HMG	   domain,	   however	   the	   c-­‐terminal	   domain	   acts	   as	   a	   repressor.	   (Kamachi	   et	   al.,	  2000)	  
	  
1.1.2	   SOX2	   is	   important	   during	   CNS	   development	   and	   for	   adult	   NSC	  
maintenance	  As	   development	   progresses	   SOX2	   expression	   becomes	   progressively	  restricted	  and	  by	  9.5dpc	  it	  is	  observed	  in	  the	  neural	  tube,	  sensory	  placode’s,	  branchial	   arches,	   gut	   endoderm	   and	   gonads	   (Avilion	   et	   al.,	   2003;	  Wood	  &	  Episkopou.,	   1999).	   The	   expression	   of	   the	   other	   SoxB1	   genes	   is	   mainly	  restricted	  to	  the	  central	  nervous	  system	  (CNS)	  and	  overlap	  with	  that	  of	  Sox2	  (Wood	   &	   Episkopou.,	   1999).	   More	   detailed	   analysis	   reveals	   that	   SOX2	   is	  expressed	  throughout	  the	  neuroepithelium	  and	  is	  maintained	  post-­‐natally	  in	  undifferentiated	   cells	   that	   line	   the	   neuroretina,	   dentate	   gyrus,	   rostral	  migratory	   stream	   and	   subventricular	   zone.	   The	   adult	   neurogenic	   regions	  within	  the	  brain	  that	  express	  SOX2	  remain	  proliferative,	   identified	  through	  the	   incorporation	   of	   BrdU.	   Moreover	   neurospheres	   derived	   from	   SOX2-­‐
SOX (SRY-related HMG b
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EGFP+ve	   subventricular	   zone	   cells	   retain	   the	   ability	   to	   differentiate	   into	   all	  adult	  CNS	  cell	  types	  (Ellis	  et	  al.,	  2004;	  Ferri	  et	  al.,	  2004).	  This	  suggests	  that	  these	   cells	   represent	   neural	   stem	   cells	   (NSCs).	   In	   addition	   SOX2	   is	   also	  observed	   in	   terminally	   differentiated	   cells	   of	   the	   cortex,	   notably	   in	  pyramidal	  neurons	  (Ferri	  et	  al.,	  2004).	  
1.1.2.1	  SOX2	  is	  required	  in	  neural	  progenitors	  Due	  to	  the	  early	  lethality	  of	  Sox2	  null	  embryos,	  investigations	  into	  the	  role	  of	  SOX2	   in	   the	   CNS	   required	   the	   generation	   of	   hypomorphic	   and	   conditional	  deletion	  alleles.	  Moreover,	   functional	  redundancy	  between	  the	   three	  Soxb1	  members	  often	  masks,	   lessens	  or	  delays	   the	   consequences	  of	  deletion	  of	   a	  single	   gene.	   Misexpression	   studies	   in	   chick	   and	   Xenopus	   suggested	   that	  SOX2	  is	  required	  to	  maintain	  neural	  progenitor	  identity	  (Kishi	  et	  al.,	  2000).	  In	   mammals	   identification	   of	   the	   role	   of	   SOX2	   in	   the	   CNS	   has	   primarily	  focused	  on	  regions	  such	  as	  the	  hippocampus	  and	  subventricular	  zone	  due	  to	  their	   neurogenic	   potential.	  Moreover	   research	   has	   also	   been	   conducted	   in	  the	  cortex	  due	  to	  the	  expression	  of	  SOX2	  in	  differentiated	  cells	  in	  this	  region.	  	  SOX2	   heterozygosity	   in	   mice	   does	   not	   give	   rise	   to	   any	   obvious	   CNS	  phenotype.	   Consequently	   compound	   mutant	   mice	   have	   been	   used	   with	  greater	  reduction	  in	  Sox2	  dosage.	  Compound	  Sox2β-­‐Gal/ΔENH	  mutant	  mice	  have	  one	  allele	  of	  Sox2	  replaced	  by	  the	  β-­‐Galactocidase	  open	  reading	  frame	  and	  a	  second	   allele	   with	   a	   mutated	   Sox2	   CNS	   enhancer	   (ΔENH).	   These	   express	  approximately	  25-­‐30%	  of	  the	  normal	  levels	  of	  SOX2.	  These	  mice	  have	  been	  used	  to	  study	  later	  roles	  of	  SOX2	  in	  the	  developing	  CNS	  (Favaro	  et	  al.,	  2009;	  Ferri	  et	  al.,	  2004).	  Morphological	  CNS	  defects	  including	  a	  smaller	  cortex	  and	  enlarged	   third	   ventricle	   are	   seen	   in	   Sox2β-­‐Gal/ΔENH	  mice	   (Ferri	   et	   al.,	   2004).	  Epileptic	  spikes	  are	  recorded	  in	  the	  hippocampus	  and	  cortex	  and	  these	  mice	  also	  display	  a	  circling	  phenotype	  of	  neurological	  origin.	  Defects	  are	  also	  seen	  at	   the	   cellular	   level	   including	   nuclear	   and	   cytoplasmic	   condensation	   and	  hyperchromatic	   cell	   bodies,	   markers	   of	   neurodegeneration	   (Ferri	   et	   al.,	  2004).	  Hippocampal	  defects	  are	  also	  observed	  in	  mice	  where	  SOX2	  has	  been	  conditionally	   deleted	   using	   the	  Nestin-­‐Cre	   transgene	   (Favaro	   et	   al.,	   2009).	  Interestingly	   both	  models	   result	   in	   the	   downregulation	   of	   NSC	   radial	   glial	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markers,	  Glial	  Fibrillary	  Acidic	  Protein	  (GFAP)	  and	  nestin	  (Ferri	  et	  al.,	  2004;	  Favaro	   et	   al.,	   2009).	   This	   is	   also	   associated	   with	   the	   reduction	   in	   the	  proliferation	  of	  these	  cell	  types,	  indicating	  that	  SOX2	  in	  NSCs	  is	  essential	  for	  their	   maintenance	   and	   proliferation.	   Furthermore,	   Sox2	   hypomorphic	  mutant	   mice	   display	   severely	   impaired	   neurogenesis	   as	   the	   number	   of	  differentiated	   cells	   is	   significantly	   reduced	   (Ferri	   et	   al.,	   2004).	   A	   similar	  phenotype	   is	   observed	   in	   neural	   retinal	   progenitors	   as	   conditional	   Sox2	  deletion	   in	   these	  cells	  using	  αP0-­‐CREiresGFP	   induces	  a	   loss	  of	  proliferation	  and	  prevents	   terminal	  differentiation,	   through,	   in	  part,	  down-­‐regulation	  of	  the	  direct	  SOX2	  target	  Notch1	  (Taranova	  et	  al.,	  2006).	  
1.1.2.2	  SOX2	  and	  Sonic	  Hedgehog	  interact	  during	  CNS	  development	  and	  
for	  NSC	  maintenance	  In	   the	   early	   ventral	   diencephalon	   (VD),	   SOX2,	   along	   with	   SOX3,	   directly	  transcriptionally	  regulates	  Sonic	  Hedgehog	  (SHH)	  expression,	  a	  mechanism	  essential	  for	  maintenance	  of	  VD	  (Zhao	  et	  al.,	  2012).	  SHH	  down-­‐regulation	  in	  VD	  midline	  by	  a	  BMP2-­‐TBX2	  pathway	   is	  required	  for	  proper	  hypothalamic	  morphogenesis	   (Manning	  et	   al.,	   2006).	   It	  was	   recently	   shown	   that	   the	  TFs	  TBX2	  and	  3	  act	  to	  sequestrate	  SOX2	  away	  from	  the	  Shh	  VD	  enhancer	  (Zhao	  et	   al.,	   2012),	   this	   is	   necessary	   to	   define	   a	   SHH	   negative	   domain	  corresponding	   to	   the	   future	   infundibulum	   (Trowe	   et	   al.,	   2013).	   SHH	   has	  itself	   been	   shown	   to	   upregulate	   SOX9	   expression	   in	   neurospheres	   that	  already	   express	   SOX2	   (Scott	   et	   al.,	   2010).	   Significantly	   this	   SHH	   induced	  upregulation	   of	   SOX9	   is	   required	   for	   the	   progression	   of	   SOX2+ve	  neuroepethelial	   cells	   into	   NSCs	   (Scott	   et	   al.,	   2010).	   Moreover,	   GLI2,	   a	  downstream	   mediator	   of	   SHH	   signaling,	   directly	   activates	   SOX2	   in	  embryonic	   neuroepethelial	   cells	   to	   maintain	   a	   proliferative	   and	  undifferentiated	  state	  (Takanaga	  et	  al.,	  2009).	  Reciprocally,	  SOX2	  exerts	   its	  role	   for	   NSC	   maintenance	   post-­‐natally	   at	   least	   in	   part	   through	   the	  upregulation	   of	   SHH	   (Favaro	   et	   al.,	   2009).	   Altogether	   these	   studies	   show	  that	  complex	  relationships	  that	  exist	  between	  SOX2	  and	  SHH	  in	  the	  CNS,	  and	  that	  they	  are	  important	  in	  different	  contexts.	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1.1.2.3	  SOXB1	  regulation	  of	  SIX	  transcription	  factors	  in	  the	  CNS	  In	   addition	   to	   Shh,	   Six6	   and	   Six3	   (see	   below)	   are	   also	   important	  transcriptional	   targets	   of	   SOX2	   in	   the	   CNS.	   Specifically	   this	   transcriptional	  control	   is	   demonstrated	   in	   the	   VD	   where	   SOX2	   and	   SIX6/3	   expression	  patterns	  overlap	  and	  expression	  of	  SIX6/3	   is	  SOXB1	  dependent	   (Lee	  et	  al.,	  2012,	   Lee	   et	   al.,	   2013).	   This	   interaction	   is	   also	   evolutionally	   conserved	   as	  SOX2	  can	  bind	  the	  Six3.2	  promoter	  in	  Medaka	  fish,	  driving	  its	  expression	  in	  the	   forebrain	   (Beccari	   et	   al.,	   2012).	   In	   addition	   to	   directly	   promoting	   SIX	  expression,	  SOX2	  can	  also	  form	  a	  complex	  with	  another	  member	  of	  the	  SIX	  TF	   family,	   SIX1.	   SOX2	   and	   SIX1-­‐EYA	   physically	   interact	   to	   regulate	  Atonal	  expression	  in	  the	  mouse	  cochlea	  (Ahmed	  et	  al.,	  2012).	   In	  the	  VD	  SOX2	  and	  SIX3	   have	   been	   shown	   to	   bind	   the	   same	   Shh	   enhancer,	   SBE2,	   suggesting	  transcriptional	   activation	   my	   require	   co-­‐operative	   binding	   between	   SOX2	  and	   SIX3	   (Zhao	   et	   al.,	   2012).	   These	   studies	   indicate	   SOX2	  may	   be	   both	   a	  direct	  transcriptional	  activator,	  in	  addition	  to	  a	  transactivational	  partner	  of	  SIX	  proteins.	  In	   conclusion,	   SOX2	   is	   required	   in	   CNS	   development,	   for	   the	  maintenance	  and	   proliferation	   of	   progenitors.	   SOX2	   is	   also	   required	   for	   direct	  reprograming	  of	  fibroblasts	  into	  induced	  Neural	  SC	  (NSC)	  (Mirakhori	  et	  al.,	  2013),	  highlighting	  its	  importance	  for	  both	  stemness,	  and	  neural	  fate.	  
1.1.3	  SOX	  proteins	  interact	  with	  partners	  to	  regulate	  transcription	  	  Transcriptional	   regulation	  mediated	   by	   SOX	   proteins	   usually	   requires	   the	  formation	  of	  complexes	  with	  other	  TFs	  (for	  review	  see	  Kondoh	  &	  Kamachi.,	  2010).	  Members	  of	  the	  different	  SOX	  groups	  interact	  with	  a	  diverse	  number	  of	   partners.	  SoxB1,	  C	  and	  F	   TFs	   primarily	   bind	   POU	   and	   PAX	  TFs,	   such	   as	  SOX2-­‐PAX6	   complexes	   in	   the	   eye	   and	   SOX11-­‐BRN2	   in	   neural	   progenitors	  (Kamachi	   et	   al.,	   2001;	   Tanaka	   et	   al.,	   2004),	  while	  SoxE	  TFs	   can	   form	  both	  heterologous	   and	   homologous	   complexes	   such	   as	   SOX10-­‐MITF	   in	  melanocytes	   and	   SOX9-­‐SOX9	   in	   chondrocytes	   (Bridgewater	   et	   al.,	   2003;	  Ludwig	  et	  al.,	  2004).	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One	   of	   the	   best-­‐characterised	   examples	   of	   how	   SOX	   proteins	   regulate	  expression	  in	  combination	  with	  a	  co-­‐factor	  is	  the	  activation	  of	  δ-­‐crystallin	  in	  the	  developing	  eye.	  δ-­‐crystallin	  is	  one	  of	  the	  first	  genes	  expressed	  in	  the	  lens	  placode	   and	   is	   essential	   for	   eye	   morphogenesis	   (Kondoh	   et	   al.,	   1987).	   δ-­‐
crystallin	  only	  becomes	  expressed	  following	  the	  close	  apposition	  of	  the	  head	  ectoderm	  (future	   lens)	  and	  optic	  vesicle	  (future	  neural	  retina)	  (Shinohara.,	  1976).	  Inductive	  signal	  from	  the	  optic	  vesicle	  also	  activates	  SOX2	  expression	  in	   the	  chick	  head	  ectoderm	  prior	  placode	   induction	  (Kamachi	  et	  al.,	  1998).	  The	   head	   ectoderm	   also	   expressed	   PAX6,	   in	   a	   broader	   domain	   initially	  (Kamachi	  et	  al.,	  1998).	  Co-­‐operative	  binding	  of	  SOX2	  and	  PAX6	  on	  the	  DC5	  δ-­‐
crystallin	   enhancer	   initiates	   its	   expression.	   Moreover	   co-­‐operativity	   is	  essential,	  as	  either	  factor	  alone	  does	  not	  induce	  expression	  (Kamachi	  et	  al.,	  2001).	  SOX2	  and	  PAX6	  transcription	  factor	  binding	  sites	  (TFBS)	   lie	  next	   to	  each	  other	  on	   the	  DC5	  enhancer,	  however	   the	  strength	  of	  PAX6	  binding	   to	  the	   consensus	   sequence	   is	   considerably	   stronger	   when	   SOX2	   is	   present	  (Kamachi	   et	   al.,	   2001).	   SOX2-­‐PAX6	   complexes	   can	   form	   in	   the	   absence	   of	  DNA	  and	  this	  interaction	  appears	  to	  only	  require	  the	  HMG	  domain	  of	  SOX2	  and	  paired	  domain	  (PD)	  of	  PAX6.	  Nevertheless	  addition	  of	  DNA	  results	  in	  a	  higher	  concentration	  of	  complex	  formation.	  Moreover	  spacing	  between	  the	  two	   consensus	   sites	   is	   critical	   for	   activity	   (Kamachi	   et	   al.,	   2001).	   This	  demonstrates	   that	   both	   protein-­‐protein	   and	   DNA-­‐protein	   interactions	   are	  required	  for	  optimal	  transactivation	  activity.	  	  	  Other	   important	  partners	  of	  SOX2	  are	  members	  of	   the	  paired	  domain	  POU	  TFs.	  The	  SOX2-­‐OCT3/4	  complex	   specifically	  binds	   to	   the	  Fgf4	   promoter	   to	  drive	  its	  expression	  in	  ES	  cells.	  In	  similarity	  to	  the	  SOX2-­‐PAX6	  complex,	  co-­‐operative	   binding	   of	   both	   proteins	   is	   required	   to	   drive	   Fgf4	   expression	  (Yuan	  et	  al.,	  1995).	  The	  importance	  in	  the	  spacer	  size	  between	  either	  TFBS	  is	  also	   extremely	   important	   with	   the	   addition	   of	   just	   2	   base	   pairs	   (bp)	  decreasing	   enhancer	   activity	   by	   a	   factor	   of	   two	   and	   3bp	   extinguishing	   it	  (Ambrosetti	  et	  al.,	  1997).	  The	  SOX2-­‐OCT3/4	  complex	  is	  also	  responsible	  for	  the	  expression	  of	  Undifferentiated	  Transcription	  Factor	  1	  (Utf1)	  in	  ES	  cells.	  In	   this	   enhancer,	   the	   3bp	   spacer	   between	   the	   SOX2	   and	   OCT3/4	   TFBS	   is	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however	  absent.	  Resolution	  of	  crystal	  structures	  of	  the	  transcription	  factors	  on	  DNA	  demonstrated	  that	  in	  fact	  different	  enhancers	  mediate	  the	  assembly	  of	  distinct	  POU-­‐HMG	  complexes	   (Reményi	  et	   al.,	   2003).	  Complexes	   formed	  by	  members	  of	  other	  SOX	  groups	  are	  also	  affected	  by	  the	  size	  of	  the	  spacer	  sequence	   between	   either	   TFBS.	   SoxE	   proteins	   such	   as	   SOX10	   form	  homodimer	  complexes	   that	  are	  disrupted	  by	  a	  decrease	  of	  2bp,	  but	  unlike	  the	   SOX2-­‐OCT3/4	   complex	   on	   the	   Fgf4	   enhancer,	   not	   affected	   by	   a	   2bp	  increase	   (Peirano	  et	  al.,	  2000).	  Complex	   formation	  between	  SOXE	  proteins	  however	  is	  heavily	  reliant	  on	  the	  N-­‐terminal	  extension	  adjacent	  to	  the	  HMG	  domain.	   (Peirano	   et	   al.,	   2000).	   The	   requirement	   of	   co-­‐factors	   for	   complex	  formation	  with	  SOX	  proteins	   is	   extremely	   important	   to	  allow	  highly	   tissue	  specific	  transactivation	  or	  repression	  of	  downstream	  targets.	  	  
1.1.4	   SOX2	   is	   required	   for	   development	   of	   different	   organs	   and	  
mutations	  in	  the	  gene	  are	  associated	  with	  human	  diseases	  
	  
1.1.4.1	  Extra-­‐hypothalamo-­‐pituitary	  axis	  defects	  in	  mice	  
	  In	   mice,	   Sox2	   mutations	   are	   associated	   with	   a	   wide	   range	   of	   extra-­‐hypothalamo-­‐pituitary	  defects,	  including	  in	  the	  CNS	  (discussed	  above).	  Sox2	  heterozygous	  mice	   are	   grossly	   normal	   (Avilion	   et	   al.,	   2003)	   but	   around	   a	  third	  of	  mutants	  are	  lost	  prior	  weaning	  (Kelberman	  et	  al.,	  2006).	  Male	  Sox2	  heterozygous	   mice	   have	   reduced	   fertility,	   smaller	   testicles	   and	   blocked	  sperm	   in	   the	   seminiferous	   tubules,	   in	   addition	   to	   reduced	   levels	   of	   LH	  (Avilion	  et	  al.,	  2003;	  Kelberman	  et	  al.,	  2006).	  Despite	  the	  known	  role	  of	  LH	  in	  promoting	  spermatogenesis,	  the	  infertility	  phenotype	  is	  likely	  a	  result	  of	  impaired	   sperm	   maturation	   at	   the	   testes	   level	   and	   not	   due	   to	   reduced	  pituitary	  LH,	  as	  there	  is	  no	  effect	  on	  female	  fertility.	  	  Mutations	  in	  the	  regulatory	  regions	  of	  Sox2	  that	  affect	  expression	  of	  the	  gene	  in	  a	  specific	  subset	  of	  tissues	  are	  also	  associated	  with	  developmental	  defects	  and	   have	   proved	   useful	   to	   study	   its	   later	   functions.	   Homozygous	   Yellow	  Submarine	   (ysb;ysb)	   mice	   have	   severe	   balance	   and	   hearing	   impairment	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resulting	   from	   a	   20	   kilobase	   (Kb)	   deletion	   in	   Sox2	   regulatory	   regions	  resulting	  from	  transgene	  insertion	  (Dong	  et	  al.,	  2002;	  Kiernan	  et	  al.,	  2005).	  Similar	  defects	  in	  mice	  homozygous	  for	  the	  mutation	  Light	  coat	  and	  circling	  	  (LCC)	  isolated	  from	  a	  random	  genome	  mutagenesis	  screen	  are	  also	  induced	  by	  mutation	   in	   Sox2	   regulatory	   regions	   (Dong	   et	   al.,	   2002;	   Kiernan	   et	   al.,	  2005).	   In	   these	   mice	   SOX2	   is	   absent	   from	   the	   prosensory	   domain	   of	   the	  developing	   cochlea,	   resulting	   in	   failure,	   or	   severe	   impairment,	   of	   hair	   cell	  differentiation,	  inducing	  balance	  defects	  in	  adult	  mice	  (Kiernan	  et	  al.,	  2005).	  	  
1.1.4.2	  Pituitary	  abnormalities	  in	  Sox2	  heterozygous	  mice	  
	  
Sox2	   is	   expressed	   in	   the	   pituitary	   and	   hypothalamus	   throughout	  development	   and	   in	   adulthood	   (Fauquier	   et	   al.,	   2008;	   Kelberman	   et	   al.,	  2006).	  Two-­‐month-­‐old	  Sox2	  heterozygous	  mice	  have	  significantly	  but	  mildly	  reduced	  pituitary	  levels	  of	  GH	  and	  LH,	  coupled	  with	  a	  global	  growth	  defect	  and	   infertility.	   Pups,	   but	   not	   adults,	   also	   display	   reduced	   levels	   of	   ACTH	  suggesting	   that	   glucocorticoid	   deficiency	   may	   explain	   the	   loss	   of	   a	  proportion	  of	  animals	  (Kelberman	  et	  al.,	  2006).	  GH	   levels	  are	  decreased	  at	  18.5dpc,	   prior	   to	   post-­‐natal	   hypothalamic	   regulation	   of	   pituitary	   secretion	  suggesting	   that	   Sox2	   heterozygosity	   directly	   affects	   pituitary	   development	  (Kelberman	   et	   al.,	   2006).	   At	   18.5dpc	   the	   pituitary	   is	   slightly	   hypoplastic	  (Kelberman	   et	   al.,	   2006).	   Earlier	   in	   development,	   Sox2	   heterozygosity	   is	  associated	  with	  RP	  bifurcation,	   later	   giving	   rise	   to	   extra	   clefts	  observed	  at	  18.5dpc	   (Kelberman	   et	   al.,	   2006).	   Sox3	  mutant	  mice	   have	   a	   similar	   extra-­‐cleft,	  reduced	  hormone	  levels	  and	  pituitary	  hypoplasia	  (Rizzoti	  et	  al.,	  2004).	  SOX3	  however	  is	  not	  expressed	  in	  RP	  and	  this	  phenotype	  is	  a	  consequence	  of	  the	   loss	  of	  Sox3	   in	  the	  VD,	  affecting	  its	  morphogenesis	  and	  indirectly	  RP	  development	   (Rizzoti	   et	   al.,	   2004).	  These	   extra-­‐clefts	   are	  unlikely	   to	   affect	  pituitary	   hormone	   levels	   and	  deficiencies	   in	  Sox3	  mutants	   probably	   result	  from	  hypothalamic	  defects	  (Rizzoti	  et	  al.,	  2004).	  In	  Sox2	  mutants	  it	  is	  likely	  that	  the	  bifurcations	  observed	  result	  from	  requirement	  of	  the	  protein	  in	  the	  overlying	  VD.	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1.1.4.3	  SOX2	  mutation	  in	  humans	  
	  In	   humans,	   SOX2	   heterozygous	   mutations	   preventing	   or	   reducing	   its	  transcriptional	   activity	   are	   associated	  with	   severe	   eye	   defects	   and	  mental	  retardation	   (Fantes	   et	   al.,	   2003),	   a	   phenotype	   more	   severe	   than	   what	   is	  observed	  in	  Sox2	  heterozygous	  mice	  because	  the	  gene	  dosage	  sensitivity	   is	  different,	   particularly	   for	   eye	   morphogenesis.	   Indeed,	   defects	   observed	   in	  humans	  such	  as	  bilateral	  anophthalmia	  or	  severe	  microphthalmia	  are	  only	  observed	   in	  mice	   if	   Sox2	   gene	   dosage	   is	   further	   reduced,	   in	   hypomorphic	  and	  conditionally	  deleted	  mutants	  (Taranova	  et	  al.,	  2006).	  However	  a	  broad	  range	  of	  human	  CNS	  defects	   including	  hearing	   loss	  (Hagstrom	  et	  al.,	  2005)	  and	  hippocampal	  defects	   (Sisodiya	  et	   al.,	   2006),	   are	   also	  observed	   in	  mice	  with	  Sox2	  mutations	  (Ferri	  et	  al.,	  2004;	  Kiernan	  et	  al.,	  2005).	  Moreover,	  both	  murine	   and	   human	   Sox2/SOX2	   mutations	   result	   in	   pituitary	   hypoplasia,	  however	   the	   hormonal	   deficiencies	   are	   different,	   with	   gonadotropin	  reduction	  being	  more	  prominent	   in	  humans	   (Kelberman	  et	  al.,	  2006).	  This	  gonadotropin	  deficiency	  is	  likely	  to	  originate	  from	  hypothalamic	  defects,	  as	  exogenous	   GnRH	   administration	   results	   in	   increased	   LH/FSH	   production	  and	  the	  number	  of	  GnRH	  neurons	  is	  reduced	  in	  Sox2	  mutant	  mice	  (Jayakody	  et	  al.,	  2012).	  In	  vitro	  analysis	  of	  the	  various	  human	  mutated	  SOX2	  proteins	  indicated	   a	   loss	   in	   DNA	   binding	   ability	   in	   mutations	   that	   resulted	   in	   a	  protein	   truncation.	   Loss	   of	   the	   HMG	   domain	   resulted	   in	   sequestration	   of	  SOX2	   in	   the	   cytoplasm	   and	   reduced	   transcriptional	   activity	   was	   observed	  when	   deletions	   occurred	   in	   the	   transactivation	   domain	   (Kelberman	   et	   al.,	  2006).	  	  In	   summary,	   SOX2	   is	   crucial	   for	   proper	   embryonic	   development	   as	   it	   is	  required	   in	   many	   different	   contexts.	   Predominantly	   expressed	   in	  progenitors,	  SOX2	  promotes	  proliferation	  and	  cell	  fate	  specification	  through	  the	   binding	   of	   co-­‐factors.	   In	   humans,	   heterozygous	  mutations	   in	   SOX2	   are	  also	  associated	  with	  pleiotropic	  defects,	  comprising	  pituitary	  defects.	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1.2	  Pituitary	  function	  and	  regulation	  
	  Homeostasis	   is	   the	   physiological	   status	   defined	   as	   the	   normal	   state	   of	  internal	  equilibrium.	  	  As	  the	  master	  endocrine	  gland,	  the	  pituitary	  is	  key	  in	  sustaining	   homeostasis,	   acting	   as	   the	   mouthpiece	   from	   which	   the	  hypothalamus	  speaks	  to	  the	  rest	  of	  the	  body.	  Situated	  at	  the	  base	  of	  the	  skull	  in	   the	   sella	   turcica	   of	   the	   sphenoid	   bone,	   the	   pituitary	   is	   central	   to	   the	  neuroendocrine	  hypothalamic-­‐pituitary	  axis.	  Its	  secretions	  are	  controlled	  by	  the	  hypothalamus	  that	  directly	  innervates	  the	  neural	  lobe	  of	  the	  gland,	  and	  also	  secretes	  neuro-­‐hormones	  that	  reach	  the	  pituitary	  via	   the	  hypophyseal	  portal	   system	   (Figure	   1.2)	   (for	   review	   see	   Pearson	   &	   Placzek.,	   2013).	  Subsequently	   the	   pituitary	   releases	   its	   own	   endocrine	   hormones	   into	   the	  blood,	   regulating	   physiological	   functions	   such	   as;	   growth,	   metabolism,	  sexual	   maturation	   and	   function,	   and	   skin/coat	   colour.	   The	   pituitary	   is	  formed	  by	  three	   lobes;	  posterior,	   intermediate	  and	  anterior.	  Each	  of	  which	  secretes	   its	   own	   set	   of	   hormones	   from	  distinct	   endocrine	   cell	   populations	  (Figure	  1.2).	  	  	  Also	   known	   as	   the	   neurohypophysis,	   the	   posterior	   lobe	   (PL),	   unlike	   the	  other	   two	   lobes	   is	   an	   extension	   of	   the	   embryonic	   neuroepithelium	   and	  therefore	  is	   linked	  to	  the	  hypothalamus	  via	  the	  pituitary	  stalk	  (Figure	  1.2).	  As	   a	   consequence,	   the	   two	   hormones	   that	   are	   secreted	   by	   the	   posterior	  pituitary	   (PP),	   oxytocin	   and	   vasopressin	   are	   synthesised	   in	   the	  hypothalamus	   and	   released	   in	   the	   general	   blood	   circulation	   by	   axonal	  termini	  reaching	  the	  PP.	  Specifically	  oxytocin	  and	  vasopressin	  are	  produced	  in	   the	   supraoptic	   and	   paraventricular	   nuclei	   of	   the	   hypothalamus	   where	  they	   travel	   via	   the	   axonal	   projections	   of	   magnocellular	   neurons	   in	   the	  pituitary	  stalk	  to	  the	  PP	  (Figure	  1.2).	  This	  hypothalamic-­‐neurohypophyseal	  axis	   regulates	   in	   particular	   parturition	   (oxytocin)	   and	   blood	   osmolarity	  (vasopressin).	  	  The	  intermediate	  lobe	  (IL),	  also	  known	  as	  the	  neurointermediate	  lobe,	  only	  comprises	   one	   type	   of	   endocrine	   cell	   type,	   melanotrophs.	   In	   mice	   the	   IL	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forms	  a	  defined	  structure,	  distinct	  from	  the	  anterior	  pituitary	  (AP),	  however	  in	  humans	   this	   structure	  only	   consists	   of	   a	   thin	   layer	   of	   cells	   (Figure	  1.2).	  Melanotrophs	   secrete	   melanocyte-­‐stimulating	   hormone	   (MSH),	   a	   type	   of	  melanocortin	   that	   is	   proteolytically	   cleaved	   from	   pro-­‐opiomelanocortin	  (POMC),	   which	   stimulates	   the	   production	   of	   melanin	   in	   skin	   cells.	   In	  humans,	  melanotroph	  cells	  are	  located	  in	  particular	  in	  the	  skin.	  	  The	  anterior	  lobe	  (AL)	  is	  the	  largest	  lobe	  of	  the	  pituitary,	  and	  has	  the	  same	  ectodermal	  embryonic	  origin	  as	   the	   IL	   (Figure	  1.2,	  1.3).	  The	  AP	  comprises	  six	   different	   endocrine	   cell	   types,	   somatotrophs,	   lactotrophs,	   thyrotrophs,	  corticotrophs	   and	   gonadotrophs	   (Figure	   1.2).	   Corticotrophs	   secrete	  adrenocorticotropic	   hormone	   (ACTH),	   which	   like	   MSH,	   is	   proteolytically	  cleaved	   from	   POMC.	   ACTH	   secretion	   is	   under	   corticotropin	   releasing	  hormone	   (CRH)	   control.	   ACTH	   acts	   on	   the	   adrenal	   cortex,	   stimulating	   the	  production	  of	  glucocorticoids,	  mainly	  cortisol	   in	  human	  and	  corticosterone	  in	   rodents,	   in	   response	   to	   stress.	   Pituitary	   tumors	   associated	   with	  corticotrophs	   (Cushing’s	   disease)	   can	   cause	   chronic	   high	   levels	   of	   ACTH,	  resulting	  in	  particular,	  in	  extremely	  high	  blood	  pressure.	  Under	  the	  control	  of	   thyrotropin-­‐releasing	   hormone	   (TRH)	   secreted	   from	   the	   hypothalamus,	  thyrotrophs	   secrete	   thyroid-­‐stimulating	   hormone	   (TSH).	   TSH	   acts	  specifically	  on	   the	   thyroid	  gland	   to	   induce	   the	  production	  and	  secretion	  of	  thyroxine	   and	   triiodothyronine,	   two	   hormones	   that	   increase	   cellular	  metabolism.	   Gonadotrophs	   secrete	   two	   distinct	   hormones,	   lutenising	  hormone	   (LH),	  and	   follicle-­‐stimulating	  hormone	   (FSH).	  Both	  hormones	  act	  in	   tandem	   in	   development,	   FSH	   maturing	   follicles	   while	   LH	   triggers	  ovulation	  in	  females,	  and	  induces	  testosterone	  production	  in	  males.	  LH/FSH	  secretion	   is	   under	   the	   control	   of	   hypothalamic	   gonadotropin-­‐releasing	  hormone	  (GnRH).	  Pituitary	  gonadotrophins	  deficiencies	  are	  associated	  with	  infertility	   and	   hypogonadism.	   Growth	   hormone	   (GH)	   is	   secreted	   by	  somatotrophs	  in	  the	  AP	  and	  is	  involved	  in	  different	  physiological	  processes,	  however	  it	  is	  primarily	  required	  for	  post-­‐natal	  growth.	  GH	  is	  secreted	  under	  the	   control	   of	   growth-­‐hormone	   releasing	   hormone	   (GHRH)	   and	  somatostatin.	  Most	  GH	  associated	  diseases	  originate	  from	  pituitary	  defects,	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1.3	  Rathke’s	  Pouch	  development	  
	  The	  pituitary	  embryonic	  development	  was	  first	  studied	  in	  1839	  by	  German	  embryologist	  Martin	  Rathke,	  therefore	  the	  pituitary	  anlagen	  is	  subsequently	  referred	   as	   Rathke’s	   Pouch	   (RP).	   RP	   gives	   rise	   to	   both	   the	   anterior	   and	  intermediate	   lobes	   while	   the	   posterior	   pituitary	   and	   the	   pituitary	   stalk,	  referred	  as	  the	  infundibulum,	  derive	  like	  the	  hypothalamus	  from	  the	  VD,	  and	  are	  therefore	  of	  neurectodermal	  origin	  (for	  review	  see	  Pearson	  &	  Placzek.,	  2013).	   Consequently,	   the	   pituitary	   has	   a	   dual	   embryonic	   origin	   and	  interactions	   between	   both	   territories	   are	   required	   for	   correct	  morphogenesis,	   but	   also	   later	   for	   proper	   function	   of	   the	   differentiated	  hypothalamo-­‐pituitary	  axis	  (Figure	  1.3)	  (for	  review	  see	  Davis	  et	  al.,	  2013).	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1.3.2	  Rathke’s	  pouch	  induction	  
	  RP	   forms	  as	   the	  hypophyseal	  placode	  extends	   toward	   the	  VD,	  by	  9dpc.	  RP	  formation	  requires	  the	  presence	  of	  the	  overlying	  VD	  and	  the	  infundibulum,	  that	   starts	   to	   form	   a	   funnel	   shaped	   structure	   as	  RP	   develops	   (Figure	   1.3).	  Physical	  ablation	  of	  the	  VD	  in	  chick	  prevents	  formation	  of	  RP	  (Kawamura	  &	  Kikuyama.,	  1998).	  Conversely	  early	  ectopic	  formation	  of	  RP	  at	  the	  10-­‐somite	  stage	   in	   chicks	   can	   be	   induced	   in	   explants	   using	   VD	   and	   head	   ectoderm	  (Gleiberman	   et	   al.,	   1999).	   This	   shows	   that	   head	   ectoderm	   is	   competent	   to	  form	  RP	  and	  requires	  contact/signals	  from	  the	  VD	  to	  do	  so.	  In	  mammals,	  the	  requirement	   of	   VD	   and	   infundibulum	   for	   proper	   RP	   development	   is	  highlighted	  in	  particular	  by	  Nkx2.1	  null	  phenotype.	  Nkx2.1	  is	  a	  TF	  expressed	  at	   the	  midline	   in	   the	   VD,	   but	   not	   in	   RP.	  Nkx2.1	   null	   embryos	   have	   no	   VD	  midline	  and,	  as	  a	  consequence,	  no	  pituitary	  (Kimura	  et	  al.,	  1996).	  The	  early	  physical	   ablation	   studies	   indicated	   that	   the	   VD	   and	   infundibulum	   might	  secrete	   factors	   required	   for	   the	   development	   of	   RP.	   	   More	   recent	   studies	  have	   identified	  a	  number	  of	   factors	  expressed	  and	  secreted	   in	   the	  VD	   that	  help	   control	   RP	   development	   (Brinkmeier	   et	   al.,	   2003;	   Brinkmeier	   et	   al.,	  2007;	  Davis	  &	  Camper.,	  2007;	  Ericson	  et	  al.,	  1998;	  Treier	  et	  al.,	  1998).	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Figure	  1.3:	  Development	  of	  RP	  and	  adult	  pituitary	  gland	  Formation	  of	  the	  pituitary	  in	  the	  embryo,	  developmental	  stages	  (in	  days	  post-­‐coitum,	  (dpc))	  as	   indicated.	  RP	  (pink)	   forms	   from	  the	  hypophyseal	  placode	   following	   invagination	  of	   the	  oral	   ectoderm	   ventrally	   at	   8.5dpc.	   By	   12.5dpc	   the	   infundibulum	  has	   evaginated	   from	   the	  overlying	  neurectoderm	  and	  lies	  adjacent	  the	  dorsal	  region	  or	  RP	  which	  will	  form	  the	  future	  IL.	   But	   18.5dpc/adult	   the	   anterior	   pituitary	   has	   expanded,	   while	   the	   IL	   forms	   a	   layer	  surrounding	   the	   PL,	   which	   has	   extended	   from	   the	   hypothalamus	   via	   the	   pituitary	   stalk.	  8.5dpc	   –	   12.5dpc	   are	   orientated	   sagittally,	   adult	   is	   orientated	   coronally	   (from	   Rizzoti	   &	  Lovell-­‐Badge.,	  2011).	  
	  
	  
1.3.3	  Ventral	  Diencephalon	  regulation	  of	  Rathke’s	  Pouch	  formation	  	  
	  
1.3.3.1	   BMP4	   is	   required	   for	   induction	   and	  maintenance	   of	   Rathke’s	  
Pouch	  
	  Bone	   morphogenetic	   proteins	   (BMP’s),	   are	   secreted	   growth	   factors	   that	  belong	   to	   the	   TGFβ	   superfamily.	   Binding	   to	   serine/threonine	   kinase	  receptors	   BMPs	   induce	   transcription	   of	   target	   genes	   through	   the	   Smad	  signalling	   pathway	   (for	   review	   see	   Chen	   et	   al.,	   2004).	   	   Of	   the	   20	   known	  BMPs	  only	  BMP4	  is	  expressed	  in	  the	  VD,	  with	  its	  expression	  first	  observed	  at	  8.5dpc,	   just	   after	   the	   onset	   of	   hypophyseal	   placode	   formation	   at	   8.0dpc	  (Ericson	   et	   al.,	   1998).	   BMP4	   secretion	   from	   the	   VD	   is	   essential	   in	   RP	  induction	  as	  deletion	  of	  Bmp4	  result	  in	  a	  failure	  to	  form	  RP	  (Takuma	  et	  al.,	  1998).	  Similarly	  to	  what	   is	  observed	  in	  Bmp4	  null	  mice,	  ectopic	  expression	  of	  noggin	   (secreted	  BMP	  antagonist)	  arrests	  RP	  development	  (Treier	  et	  al.,	  1998).	   Conversely,	  Noggin	   null	   embryos	   have	   an	   expanded	   area	   of	   BMP4	  expression	  in	  the	  VD	  and	  display	  a	  variable	  phenotype,	  from	  induction	  of	  a	  rostral	  shift	  in	  RP	  formation	  to	  formation	  of	  a	  second	  RP	  (Davis	  &	  Camper.,	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2007).	   The	   expanded	   area	   of	   BMP4	   expression	   in	   noggin	   null	   embryos	  induces	  a	  rostral	  shift	   in	  the	  expression	  domain	  of	  the	  secreted	  factor	  SHH	  and	  the	  transcription	  factor	  SIX6	  (see	  below)	  (Davis	  &	  Camper.,	  2007).	  	  	  In	   addition	   to	   participating	   in	   RP	   induction,	   BMP4	   is	   likely	   involved	   in	  progenitor	   maintenance	   and	   proliferation.	   This	   regulation	   is	   likely	   to	   be	  exerted	   at	   several	   levels.	   First,	   conditional	   deletion	   of	   the	   Bmp	   receptor	  
Bpmr1a,	   expressed	   in	   RP,	   prevents	   expression	   of	   the	   TF	   ISL1	   in	   RP	   (see	  below),	   indicating	   that	   BMPs	   modulates	   TF	   expression	   in	   RP	   (Davis	   and	  Camper.,	  2007).	  Second,	  BMP4	  can	  also	  regulate	  expression	  of	  the	  fibroblast	  growth	   factor	   member	   FGF10	   in	   VD	   (see	   below).	   FGF10	   is	   normally	  expressed	   in	   an	   overlapping	   pattern	   with	   BMP4	   in	   the	   VD,	   however,	  increased	   BMP4	   expression	   in	   noggin	   null	   embryos	   results	   in	   down-­‐regulation	  of	  FGF10	  expression	  in	  the	  VD,	  which	  in	  turns	  affect	  expression	  of	  FGF	   dependent	   targets	   in	   VD	   (see	   below,	   Davis	   and	   Camper.,	   2007).	   The	  influence	   of	   BMP4	   expression	   on	   other	   factors	   expressed	   in	   the	   VD	  highlights	  the	  balance	  that	  must	  be	  achieved	  between	  BMP	  and	  FGF	  in	  order	  to	  promote	  correct	  RP	  development.	  	  	  
1.3.3.2	  FGFs	  control	  Rathke’s	  Pouch	  progenitor	  proliferation	  
	  Fibroblast	  Growth	  Factors	  (FGF’s),	  FGF8,	  FGF10	  and	  FGF18	  are	  members	  of	  a	  large	  family	  of	  secreted	  molecules	  that	  activate	  tyrosine	  kinase	  receptors	  (for	   review	   see	   Ornitz	   &	   Itoh.,	   2001).	   All	   three	   are	   expressed	   in	   the	   VD	  slightly	   later	   than	   BMP4,	   from	   9.5dpc,	   while	   only	   one	   receptor,	   FGFr2IIIb	  that	  binds	  FGF10,	  is	  expressed	  in	  RP	  (Ericson	  et	  al.,	  1998;	  De	  Moerlooze	  et	  al.,	  2000;	  Treier	  et	  al.,	  2001;	  Treier	  et	  al.,	  1998).	  Interestingly	  Fgfr2IIIb	  null	  mice	  can	  only	  form	  a	  small,	  undeveloped	  RP.	  Fgf10	  null	  mice	  closely	  mimic	  this	   phenotype,	   indicating	   the	   importance	   of	   FGF	   signalling	   in	   RP	  development	  (De	  Moerlooze	  et	  al.,	  2000;	  Ohuchi	  et	  al.,	  2000).	  	  	  FGF8	  has	  been	   shown	   to	  bind	   to	   FGFR4	  and	  FGFRc	   splice	   forms,	   however	  none	   of	   these	   as	   yet	   have	   been	   reported	   in	   RP	   (Zhang	   et	   al.,	   2006).	   It	   is	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suggested	   that	   it	   can	   interact	   with	   Fgfr2IIIb,	   of	   which	   transcripts	   are	  observed	  in	  the	  dorsal	  region	  of	  RP,	  adjacent	  to	  the	  FGF8	  signalling	  from	  the	  VD	  (Takuma	  et	  al.,	  1998).	  RP	  is	  competent	  to	  respond	  to	  FGF8	  as	  pMAPK,	  an	  intracellular	  mediator	  of	  FGF	  signalling	  is	  found	  in	  its	  active,	  phosphorylated	  from,	   in	   RP	   between	   10.5dpc	   and	   14.5dpc	   (Davis	   &	   Camper	   et	   al.,	   2007).	  Significantly,	  pMAPK	  is	  observed	  forming	  a	  gradient	  in	  RP	  at	  10.5dpc,	  which	  is	  higher	  in	  the	  dorsal	  region,	  close	  to	  the	  source	  of	  FGF8	  (Davis	  et	  al.,	  2011).	  This	   gradient	   is	   downregulated	   following	   cell	   cycle	   exit	   at	   11.5dpc,	  suggesting	   that	   it	   promotes	   early	   progenitor	   proliferation	   (Davis	   et	   al.,	  2011).	  The	  loss	  of	  FGF8	  in	  the	  VD	  of	  Nkx2.1	  null	  mice	  is	  suggested	  to	  result	  in	   failure	   of	   RP	   development,	   as	   BMP4	   is	   initially	   maintained	   in	   these	  mutants	  as	  RP	  is	  induced,	  but	  fails	  to	  progress	  further	  (Takuma	  et	  al.,	  1998).	  The	  role	  of	  FGF8	  is	  likely	  to	  induce	  progenitor	  cell	  proliferation	  through	  the	  upregulation	  of	  the	  TFs	  LHX3	  and	  LHX4	  (see	  below)	  as	  both	  of	  these	  factors	  are	  downregulated	  in	  Nkx2.1	  null	  mice	  (Takuma	  et	  al.,	  1998).	  But	  its	  role	  is	  more	  complex	  because	  it	  can	  also	  induce	  the	  downregulation	  of	  the	  TF	  ISL1	  (see	   below)	   in	   pituitary	   explants	   (Ericson	   et	   al.,	   1998,	   see	   below).	   In	  vivo,	  restriction	   of	   ISL1	   to	   the	   ventral	   region	   of	   RP	   is	   associated	   with	   loss	   of	  proliferation	   and	   onset	   of	   thyrotroph	   and	   corticotroph	   differentiation	  (Norlin	  et	  al.,	  2000).	  Consequently	  the	  role	  of	  FGF	  signalling	  in	  the	  VD	  is	  to	  promote	   proliferation	   in	   the	   dorsal	   region	   of	   RP	   and	   preventing	   early	  differentiation.	  	  	  	  
1.3.3.3	   Wnt/β-­‐catenin	   pathway	   controls	   VD	   patterning	   and	   Rathke’s	  
Pouch	  proliferation	  
	  The	   Wingless-­‐type	   (Wnt)	   family	   of	   signalling	   molecules	   is	   involved	   in	  multiple	   developmental	   processes	   (for	   review	   see	   Amerongen	   &	   Nusse.,	  2009).	   	   Wnt	   ligands	   bind	   to	   the	   frizzled	   family	   of	   seven	   transmembrane	  domain	   receptors	   in	   addition	   to	   co-­‐receptors	   of	   the	   LRP	   family.	   The	  canonical	   Wnt	   pathway	   acts	   via	   cytoplasmic	   β-­‐catenin.	   In	   the	   absence	   of	  Wnt,	   β-­‐catenin	   is	   targeted	   for	   ubiquitination	   through	   complex	   formation	  with	  the	  destruction	  complex.	  Conversely	  in	  the	  presence	  of	  Wnt,	  β-­‐catenin	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can	   shuttle	   into	   the	   nucleus	   to	   activate	   transcription	   (for	   review	   see	  Amerongen	  &	  Nusse.,	  2009).	  	  	  Two	  Wnt	  ligands	  are	  expressed	  during	  RP	  development.	  Wnt5A	  is	  expressed	  throughout	   the	   VD	   midline	   from	   9.5dpc	   and	   is	   maintained	   in	   the	  infundibulum	  until	   14.5dpc	   (Potok	   et	   al.,	   2008).	  Wnt5A	   deletion	   results	   in	  alteration	   of	   FGF8	   and	   BMP4	   expression	   pattern	   boundaries	   and	   in	  consequence	  RP	  bifurcations	   (Cha	  et	  al.,	  2004;	  Potok	  et	  al.,	  2008).	  Wnt4	   is	  similarly	   expressed	   in	   the	   VD	   at	   9.5dpc,	   however	   it	   is	   also	   present	   in	   RP	  (Treier	   et	   al.,	   1998).	   Wnt4	   mutant	   mice	   only	   display	   mild	   defects	   in	  endocrine	  cell	  expansion,	  likely	  a	  result	  of	  loss	  of	  Wnt4	  in	  the	  RP,	  and	  not	  VD	  (Treier	  et	  al.,	  1998;	  Potok	  et	  al.,	  2008).	  TCF4,	  a	  downstream	  TF	  activated	  by	  the	   canonical	   Wnt	   pathway	   is	   expressed	   in	   the	   VD	   and	   RP.	   Like	  Wnt5A	  mutants,	  Tcf4	  null	  mice	  have	  expanded	  BMP	  and	  FGF	  expression	  domains	  in	  the	   VD,	   likely	   contributing	   to	   the	  mild	   hypoplasia	   observed	   in	   these	  mice	  (Brinkmeier	  et	  al.,	  2003,	  Brinkmeier	  et	  al.,	  2007).	  	  	  As	   described	   above	   the	   canonical	  Wnt	   pathway	   acts	   in	   particular	   through	  intracellular	  β-­‐catenin	  signalling.	  Initial	  experiments,	  including	  in	  particular	  treatment	   of	   embryos	   with	   the	   β-­‐catenin	   activator	   lithium	   chloride,	   that	  stabilises	  β-­‐catenin,	  suggested	  that	  Wnt	  signalling	  was	  in	  involved	  induction	  of	  expression	  of	  Pitx2	  (see	  below),	  a	  TF	  expressed	  in	  RP	  progenitors	  that	  in	  turn	   promoted	   progenitor	   proliferation	   through	   upregulation	   of	  Cyclin	  D1	  (Kioussi	   et	   al.,	   2002).	   Subsequently,	   β-­‐catenin	   gain	   and	   loss	   of	   function	  experiments	   revealed	   that	   the	   protein	   may	   be	   involved	   in	   later	  determination	  events	  and	  that	  it	   interacted	  with	  the	  TF	  PROP1	  (see	  below,	  Olson	  et	  al.,	  2006).	  In	  a	  more	  recent	  study,	  however,	  different	  results	  were	  obtained	  by	   inducing	  early	   expression	  of	   a	   constitutively	   active	   form	  of	  β-­‐catenin	   (Gaston-­‐Massuet	   et	   al.,	   2011).	  Gain	  of	   function	   resulted	  here	   in	   an	  increase	   in	   the	   progenitor	   pool	   and	   subsequent	   development	   of	   tumors	  displaying	   features	   of	   craniopharyngiomas,	   human	   pituitary	   paediatric	  tumours	  associated	  with	  β-­‐catenin	  mutations	  (Gaston-­‐Massuet	  et	  al.,	  2011).	  All	   together	   these	   studies	   suggest	   Wnt	   signalling	   is	   necessary	   for	   proper	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patterning	  of	  VD,	  which	  indirectly	  affects	  RP	  development,	  and	  also	  that	  it	  is	  required	  within	  RP	  for	  proliferation	  of	  progenitors.	  	  	  
1.3.4	  Oral	  ectoderm	  regulation	  of	  Rathke’s	  Pouch	  formation	  	  
	  
1.3.4.1	  BMP2	  dependent	  ventral	  Rathke’s	  Pouch	  patterning	  
	  BMP2	  is	  expressed	  in	  the	  oral	  ectoderm,	  the	  ventral	  region	  of	  RP	  at	  10.5dpc	  and	  also	  in	  the	  mesenchyme	  surrounding	  RP	  	  (Ericson	  et	  al.,	  1998;	  Treier	  et	  al.,	   1998;	   Davis	   et	   al.,	   2011).	   By	   11.5dpc	   BMP2	   expression	   expands	  throughout	  RP	  and	  the	  active,	  phosphorylated	  form	  of	  SMAD,	  transducer	  of	  BPM	   signaling,	   follows	   this	   pattern	   	   (Davis	   et	   al.,	   2011).	   By	   14.5dpc	   both	  BMP2	  and	  pSMAD	  are	  downregulated	  in	  the	  majority	  of	  cells	  in	  RP	  (Davis	  et	  al.,	  2011).	  As	  mentioned	  above,	  BMP	  signaling	  is	  involved	  in	  ISL1	  activation	  in	   RP	   and	   BMP2	  may	   induce	   its	   ventral	   expression	   at	   10.5dpc	   (Davis	   and	  Camper.,	   2007).	   Finally,	   ectopic	   overexpression	   and	  maintenance	  of	  BMP2	  expression	   result	   in	   failure	   to	   produce	   terminally	   differentiated	  somatotrophs,	   thyrotrophs,	   lactotrophs	   and	   gonadotrophs	   (Treier	   et	   al.,	  1998).	  In	  conclusion,	  BMP2	  within	  and	  around	  the	  pouch	  may	  be	  necessary	  at	   10.5dpc	   for	   emergence	   of	   the	   first	   cell	   type	   to	   differentiate,	   rostral-­‐tip	  thyrotrophs,	  trough	  ISL1	  activation,	  but	  its	  activity	  must	  be	  down-­‐regulated	  for	  terminal	  differentiation	  to	  proceed.	  	  	  
	  1.3.4.2	  SHH	  dependent	  Rathke’s	  Pouch	  proliferation	  
	  Sonic	  Hedgehog	  (SHH)	  and	  its	  mammalian	  paralogues,	  Indian	  Hedgehog	  and	  Desert	  Hedgehog	  are	   classical	  morphogens	   involved	   in	  patterning	   and	   cell	  fate	   decisions	   (for	   review	   see	   Ribes	   &	   Briscoe.,	   2009).	   SHH	   binds	   the	  Patched	  receptor	  on	  the	  cell	  membrane,	  inducing	  activation	  of	  the	  Gli	  family	  of	  TFs.	  Gli1,	  Gli2	  and	  Gli3	  are	  all	  expressed	  in	  RP	  demonstrating	  its	  capacity	  to	   respond	   to	   SHH	   signals	   (Hui	   et	   al.,	   1994).	   SHH	   is	   expressed	   in	   the	   VD	  where	  it	  is	  transcriptionally	  regulated	  by	  SOXB1	  proteins	  (see	  above),	  and	  it	  is	  also	  present	  throughout	  the	  oral	  ectoderm,	  but	  excluded	  from	  RP	  (Treier	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et	  al.,	  2001).	  Ectopic	  overexpression	  of	  SHH	  in	  RP	  using	  the	  α-­‐GSU	  promoter,	  
α-­‐glycoprotein	  sub-­‐unit,	  first	  marker	  of	  endocrine	  differentiation	  appearing	  ventrally	  at	  11.5dpc,	  results	  in	  expansion	  of	  thyrotrophs	  and	  gonadotrophs	  ventrally	  (Treier	  et	  al.,	  2001).	  Conversely,	  overexpression	  of	  SHH	  antagonist,	  Hip,	   results	   in	  pituitary	  hypoplasia	   (Treier	  et	  al.,	  2001).	  This	   suggests	   that	  SHH	  may	  induce	  progenitor	  proliferation.	  	  More	   recently,	   conditional	   deletion	   of	  Gli2	   in	  RP	  was	   shown	   to	   result	   in	   a	  reduction	  of	  progenitor	  proliferation	  in	  the	  ventral	  region	  of	  RP	  at	  10.5dpc	  (Wang	  et	  al.,	  2010).	  Conversely	  constitutive	  activation	  of	   the	  SHH	  pathway	  in	  RP	  results	  in	  enhanced	  proliferation	  in	  the	  dorsal	  region	  of	  RP	  (Wang	  et	  al.,	  2010).	  This	  suggests	  that	  the	  dorsal	  region	  of	  RP	  proliferates	  in	  response	  to	  SHH	  from	  the	  VD.	  In	  mutant	  pituitaries,	  cell	  determination	  is	  not	  affected	  (Wang	  et	  al.,	  2010).	  Therefore	  SHH	  signaling	  from	  the	  VD	  and	  oral	  ectoderm	  may	   promote	   progenitor	   proliferation	   in	   the	   early	   RP	   but	   not	   cell	   fate	  specification.	  	  Midline	   defects	   in	   humans	   including	   holoprosencephaly	   (HPE)	   and	   Septo-­‐optic	   Dysplasia	   (SOD)	   are	   associated	   in	   particular	   with	  mutations	   in	   SHH	  (Gorbenko	  et	  al.,	  2013).	  These	  midline	  defects	  comprise	  a	  failure	  to	  fuse	  the	  basisphenoid	   bone,	   upon	   which	   the	   pituitary	   is	   located	   (Figure	   1.3).	   This	  defect	   is	  also	  seen	   in	  mutations	   in	  genes	  encoding	   for	  proteins	   involved	   in	  the	   intracellular	   transduction	   of	   SHH	   signaling	   (Khonsari	   et	   al.,	   2013).	  Failure	  to	  fuse	  the	  sphenoid	  bone	  is	  associated	  with	  a	  failure	  of	  RP	  to	  detach	  form	  the	  underlying	  oral	  ectoderm	  (Khonsari	  et	  al.,	  2013).	  This	  suggests	  that	  ventral	   SHH	   signaling	   in	   the	   oral	   ectoderm	   is	   also	   essential	   for	   correct	  sphenoid	  bone	  formation,	  which	  indirectly	  affects	  pituitary	  morphogenesis.	  	  
1.3.5.	  Notch	  Signaling	  in	  Rathke’s	  Pouch	  
	  The	  Notch	  pathway	  is	  initiated	  by	  the	  binding	  of	  a	  transmembrane	  ligand	  to	  a	   Notch	   receptor	   located	   on	   an	   adjacent	   cell.	   Subsequent	   cleavage	   of	   the	  Notch	  intracellular	  domain	  allows	  it	  to	  activate	  transcription	  of	  downstream	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1.4	   Transcription	   factors	   required	   for	   Rathke’s	   Pouch	   progenitor	  
maintenance	  and	  proliferation	  
	  
1.4.1	  SIX6/3	  
	  The	   Six	   genes	   are	   evolutionarily	   derived	   from	   the	   Sine	   Oculis	   homeobox	  group	  of	  TFs.	  In	  Drosophila	  Melanogaster	  where	  they	  were	  first	  identified	  as	  inducing	  eye	   formation,	   there	  are	   three	  Six	   subgroups,	  SO,	  Opitx	  and	  Dsix4,	  however	   a	   genome	   duplication	   event	   in	   evolution	   has	   resulted	   in	   six	   Six	  genes	   in	   vertebrates:	   Six1/2	   (SO),	   Six6/3	   (Opitx)	   and	   Six4/5	   (DSix4).	   In	  addition	   to	   Drosophila	   and	   humans	   the	   SIX	   genes	   have	   been	   highly	  conserved	   throughout	   evolution,	   with	   at	   least	   one	   subgroup	   found	   in	   40	  invertebrate	   genomes	   and	  50	  vertebrate	   genomes	   (for	   review	   see	  Kumar.,	  2009).	  At	  the	  protein	  level	  the	  SIX	  TFs	  consist	  of	  DNA	  binding	  homeodomain	  (HD),	   sharing	   at	   least	  63%	  homology	   across	   the	   subgroups	   and	  a	  protein-­‐protein	   binding	   SIX	   domain	   (SD).	   Significantly	   the	   SD	   can	   bind	   both	   co-­‐activators	   such	   as	   EYA	   and	   induce	   ectopic	   eye	   formation	   or	   co-­‐repressors	  DACH	  and	  Groucho	   to	   inhibit	   eye	   formation	   (Li	   et	   al.,	   2003;	  Pignoni	   et	   al.,	  1997;	  Zhu	  et	  al.,	  2002).	  	  	  	  	  	  
	  Of	  the	  six	  SIX	  TFs	  found	  in	  vertebrates,	  only	  SIX	  Homeobox	  6	  (SIX6)	  and	  SIX	  Homeobox	  3	  (SIX3)	  are	  expressed	  in	  the	  pituitary.	  As	  paralogues,	  SIX6	  and	  SIX3	  often	  share	  overlapping	  patterns	  of	  expression	  and	  are	  both	  observed	  in	   the	   invaginating	  RP	   at	   10.5dpc	   (Jean	   et	   a.,	   1999;	  Oliver	   et	   al.,	   1995).	   In	  addition	   both	   are	   expressed	   in	   the	   overlying	   VD,	   infundibulum	   and	  presumptive	  hypothalamus	  (Jean	  et	  al.,	  1999;	  Oliver	  et	  al.,	  1995).	  Both	  Six6	  and	   Six3	   null	   mice	   display	   similar	   phenotypes,	   including	   small	   or	   absent	  eyes.	  In	  Six3	  null	  embryos,	  forebrain	  defects	  are	  so	  severe	  that	  formation	  of	  RP	   is	  prevented.	  However,	   conditional	  deletion	  of	   the	  gene	   in	   the	  brain	  or	  pituitary	  leads	  to	  post-­‐natal	  growth	  defects	  and	  early	  death	  suggesting	  that	  SIX3	   is	   required	   both	  within	   the	   VD	   and	   RP	   for	   normal	   pituitary	   function	  (Gaston-­‐Massuet	  et	  al.,	  2008).	  Six6	  null	  mice	  display	  a	  hypoplastic	  pituitary	  (Li	   et	   al.,	   2002)	  and	   this	   is	   likely	   explained	  by	  a	   reduction	   in	  proliferation	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observed	   in	   RP	   (Li	   et	   al.,	   2002).	   This	   is	   potentially	   caused	   by	   direct	  repression	   of	   cyclin	   dependent	   kinase	   inhibitor	  p27kip1,	   as	   in	  vitro	   assays	  demonstrate	   the	  ability	  of	   SIX6	   to	  directly	  bind	   the	  p27kip1	  promoter	  and	  repress	  its	  activity	  in	  αT3	  pituitary	  cells	  (Li	  et	  al.,	  2002).	  Conversely,	  in	  Tcf4	  null	   mice,	   recruitment	   of	   a	   larger	   domain	   of	   oral	   ectoderm	   results	   in	  expansion	  of	  SIX6	  expression	  and	  is	  associated	  with	  increased	  proliferation	  (Brinkmeier	   et	   al.,	   2007).	  Human	  mutations	   in	  SIX6/3	   are	   associated	  with	  mid-­‐line	   defects	   including	   bilateral	   anophthalmia	   and	   panhypopituitarism	  reminiscent	   of	   the	   phenotype	   observed	   in	   Six6	   null	   mice	   (Gallardo	   et	   al.,	  1999).	   These	   studies	   suggest	   SIX6/3	   play	   an	   important	   role	   in	   RP	  development	   and	   are	   involved	   in	   the	   regulation	   of	   RP	   progenitor	  proliferation.	  	  	  
1.4.2	  LHX3/4	  
	  
Lhx3	   and	   Lhx4	   are	   members	   of	   the	   LIM-­‐homeodomain	   group	   of	   TFs	   (for	  review	  see	  Mullen	  et	  al.,	  2007).	  LHX3	  and	  LHX4	  contain	  a	  DNA	  binding	  HD	  domain	  and	  a	  protein-­‐protein	  binding	  LIM	  domain.	  Both	  are	  first	  expressed	  in	  RP	  at	  9.5dpc	  and	  their	  function	  is	  initially	  redundant	  (Sheng	  et	  al.,	  1996).	  	  
Ex	   vivo	   experiments	   suggest	   that	   their	   expression	   is	   induced	   by	   FGFs,	  starting	  to	  be	  secreted	  from	  the	  VD	  at	  the	  same	  stage	  (Ericson	  et	  al.,	  1998).	  
In	  vivo,	  absence	  of	  FGF8	  in	  Nkx2.1	  null	  mutants	  VD	  correlates	  with	  a	  failure	  to	   activate	   both	   LHX3	   and	   LHX4	   expression	   (Takuma	   et	   al.,	   1998)	   and	   a	  failure	  to	  maintain	  RP,	  also	  observed	  in	  Lhx3;Lhx4	  double	  mutants	  (Sheng	  et	  al.,	  1997).	  Lhx3	  expression	  can	  also	  be	  directly	  regulated	  by	  ISL1	  and	  PITX1	  (see	  below)	  as	  both	  have	  the	  capacity	  to	  bind	  a	  180bp	  upstream	  enhancer,	  driving	  Lhx3	  expression	  in	  the	  pituitary	  and	  spinal	  cord	  (Mullen	  et	  al.,	  2012).	  	  	  LHX3	   is	   required	   at	   two	   different	   phases.	   It	   is	   initially	   involved	   in	  maintaining	   the	   progenitor	   cell	   pool	   early	   in	   development.	  Lhx3	   null	  mice	  can	   form	   an	   RP,	   however	   its	   expansion	   is	   arrested	   at	   12.5dpc.	   This	   is	  associated	   with	   downregulation	   in	   ISL1	   and	   HESX1	   and	   an	   increase	   in	  apoptosis	  (Sheng	  et	  al.,	  1996).	  Thereafter,	  at	  16.5dpc	  in	  wild	  type	  embryos,	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as	  LHX3	  is	  expressed	  ubiquitously,	  homozygous	  deletion	  results	  in	  failure	  to	  express	  the	  transcription	  factor	  PIT1	  and	  consequently	  a	  severe	  reduction	  in	  somatotrophs,	   lactotrophs	  and	  thyrotrophs	  (Sheng	  et	  al.,	  1996).	  Additional	  analysis	   of	   Lhx3	   null	   mice	   also	   revealed	   downregulation	   in	   TPIT	   and	  NeuroD1,	  coupled	  with	   further	   increase	   in	   apoptosis	   and	   a	   loss	   of	  Notch2	  signaling	   (Ellsworth	   et	   al.,	   2008).	   LHX3	   can	   also	   directly	   activate	  transcription	  of	  Pit1,	  TSH,	  FSH	  and	  Foxl2	  (Bach	  et	  al.,	  1995;	  Ellsworth	  et	  al.,	  2006;	  Sloop	  et	  al.,	  1999;	  West	  et	  al.,	  2004).	  Mutations	  in	  LHX3	  in	  humans	  are	  associated	  with	  Combined	  Pituitary	  Hormone	  Deficiency	  (CPHD)	  where	  only	  ACTH	  is	  unaffected	  (Netchine	  et	  al.,	  2000).	  	  In	   contrast	  with	   LHX3,	   LHX4	   is	   downregulated	   during	   late	   embryogenesis	  (Sheng	   et	   al.,	   1997).	   Lhx4	   null	   mice	   die	   shortly	   after	   birth,	   displaying	   a	  hypoplastic	   pituitary,	   however	   in	   contrast	  with	  Lhx3	  null	  mice,	   all	   five	   AP	  endocrine	  cells	  form,	  highlighting	  the	  specific	  and	  exclusive	  role	  of	  LHX3	  in	  regulating	   endocrine	   differentiation	   (Sheng	   et	   al.,	   1997).	   LHX4	   may	   be	  required	  along	  with	  PROP1	  (see	  below)	  for	  the	  transcriptional	  activation	  of	  
Lhx3	  expression,	  as	  Lhx4-­‐/-­‐;Prop1-­‐/-­‐	  mice,	  in	  contrast	  with	  single	  mutants,	  do	  not	  express	  LHX3	  (Raetzman	  et	  al.,	  2002).	  In	  humans	  mutations	  in	  LHX4	  also	  result	  in	  CPHD	  (Machinis	  et	  al.,	  2001).	  
	  
1.4.3	  ISL1	  
	  Insulin	   gene	   enhancer	   protein	   1	   (Isl1)	   is	   also	   a	   member	   of	   the	   LIM-­‐homeodomain	   group	   of	   TFs	   (Bhati	   et	   al.,	   2008).	   ISL1	   is	   expressed	  throughout	  the	  oral	  ectoderm	  at	  8.5dpc,	  becoming	  restricted	  to	  RP	  at	  9.5dpc	  (Ericson	  et	  al.,	  1998).	  It	  is	  then	  further	  restricted	  to	  the	  ventral	  region	  of	  RP	  between	  10.5-­‐11.5dpc	  (Ericson	  et	  al.,	  1998).	  The	  ventral	  restriction	  of	  ISL1	  is	   suggested	   to	  be	  due	  by	   the	  negative	  action	  of	  FGFs	  secreted	   from	  VD	  as	  exposure	  of	  RP	  explants	  to	  a	  FGF8	  coated	  bead	  results	  in	  downregulation	  of	  its	   expression	   (Ericson	   et	   al.,	   1998).	   This	   regulation	   is	   temporally	   specific	  however	  as	  once	   ISL1	  becomes	  restricted	   to	   the	  ventral	   region	  of	  RP	   it	  no	  longer	  responds	  to	  FGF8	  signaling.	  As	  mentioned	  above,	  BMPs	  are	  involved	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in	   activation	   of	   its	   expression	   (Davis	   and	   Camper.,	   2007).	   Upon	   ventral	  restriction,	   ISL1+ve	   cells	   begin	   to	   express	   αGSU	   and	   become	   fully	  differentiated	   PIT1	   independent	   rostral-­‐tip	   thyrotrophs	   24h00	   later	  (Ericson	  et	  al.,	  1998).	  Later	  in	  development,	  ISL1,	  in	  combination	  with	  GATA	  Binding	  Protein	  2	  (GATA2)	  and	  LHX3,	  can	  bind	  the	  gonadotropin	  releasing	  hormone	  receptor	  (GnRHr)	  promoter	  and	  may	  be	  involved	  in	  regulating	  its	  expression	  (Schang	  et	  al.,	  2013).	  	  
Isl1	   null	   embryos	   die	   at	   10.0dpc	   however	   they	   can	   form	   a	   RP,	   albeit	   a	  hypoplastic	   one,	   suggesting	   the	   protein	   is	   initially	   required	   for	   progenitor	  maintenance	   (Takuma	   et	   al.,	   1998).	   Lhx3	   null	   mice	   fail	   to	   maintain	   Isl1	  expression	  in	  RP	  at	  12.5dpc	  but	  then	  display	  a	  dorsal	  ectopic	  expression	  of	  the	   gene	   between	   16.5-­‐18.5dpc	   (Ellsworth	   et	   al.,	   2008).	   This	   highlights	   a	  complex	   transcriptional	   regulation,	   probably	   linked	   to	   its	   expression	   in	  different	   cell	   types,	   initially	   in	   progenitors	   and	   later	   in	   differentiated	  endocrine	  cells.	  	  
	  
1.4.4	  PITX1/2	  
	  Paired-­‐like	  homeodomain	  1	  and	  2	  (Pitx1/2)	  are	  members	  of	  the	  bicoid	  class	  of	  homeodomain	  proteins	  and	  share	  a	  degree	  of	  functional	  redundancy.	  The	  homozygous	  deletion	  of	  either	  gene	  does	  not	  affect	  the	  expression	  of	  LHX3,	  while	  the	  combined	  double	  mutation	  results	  in	  its	  complete	  downregulation	  with	  allelic	  series	  displaying	  intermediate	  phenotypes	  (Charles	  et	  al.,	  2005;	  Suh	   et	   al.,	   2002).	   The	   requirement	   for	   each	   TF	   in	   RP	   development	   and	  pituitary	  function	  is	  however	  different.	  	  	  PITX1	   is	   expressed	   throughout	   the	   oral	   ectoderm	   from	   8.0dpc,	   becoming	  restricted	   to	   RP	   at	   9.5dpc	   and	   thereafter	   maintained	   in	   all	   terminally	  differentiated	  endocrine	   cell	   types	   (Lanctôt	   et	   al.,	   1997).	  No	  abnormalities	  are	  initially	  observed	  in	  the	  pituitary	  of	  Pitx1	  null	  embryos,	  likely	  because	  of	  a	  functional	  redundancy	  with	  PITX2	  (Charles	  et	  al.,	  2005;	  Gage	  et	  al.,	  1999).	  Later	  in	  development	  PITX1	  is	  involved	  in	  the	  transcriptional	  regulation	  of	  a	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number	  of	  genes	  encoding	  for	  hormones,	  including;	  Prl,	  GH,	  FSH	  and	  POMC	  (Lamolet	   et	   al.,	   2001;	   Szeto	   et	   al.,	   1996;	   Trembley	   et	   al.,	   1998).	  Moreover	  PITX1	  has	  also	  been	  shown	  to	  drive	  the	  expression	  of	  lineage	  markers	  Pit1	  and	  Sf1	  (Szeto	  et	  al.,	  1996;	  Tremblay	  et	  al.,	  1998).	  In	  Pitx1	  null	  mice,	  there	  is	  a	   decrease	   in	   the	   number	   of	   gonadotrophs	   and	   thyrotrophs,	   and	  consequently	   lower	   levels	   of	   LH	   and	   TSH	   levels,	   probably	   reflecting	   the	  requirement	  for	  PITX1	  in	  transcriptional	  regulation	  in	  endocrine	  cells	  (Gage	  et	  al.,	  1999).	  	  	  PITX2	  expression	  is	  first	  detected	  in	  RP	  at	  8.5dpc,	  later	  becoming	  ubiquitous	  in	   the	   gland.	   Postnatally,	   expression	   is	   mainly	   restricted	   to	   gonadotrophs	  and	  thyrotrophs	  (Gage	  et	  al.,	  1997).	  Early	  on	  in	  development	  PITX2	  appears	  to	  play	  an	  important	  role	  in	  RP	  formation	  and	  maintenance,	  as	  development	  is	   arrested	   at	   12.5dpc	   in	   Pitx2	   null	   mice	   (Gage	   et	   al.,	   1999).	   PITX2	   is	   an	  important	  regulator	  of	  progenitor	  proliferation	  and	  was	  shown	  to	  promote	  cell	  cycle	  progression	  through	  the	  activation	  of	  Cyclin	  D1	  and	  D2	  (Kioussi	  et	  al.,	   2002).	   Progenitor	   proliferation	   can	   be	   further	   increased	   by	   the	  upregulation	  of	  PITX2	  via	  activation	  of	  Wnt/βcatenin	  signaling,	  suggesting	  a	  role	   for	   the	   Wnt	   pathway	   in	   promoting	   PITX2	   expression	   (Kioussi	   et	   al.,	  2002).	  Hypomorphic	  Pitx2	  mutants	  also	  display	   reduced	  expression	  of	  LH,	  FSH,	  GH	  and	  TSH	  (Suh	  et	  al.,	  2002).	  In	  conclusion,	  PITX2	  has	  an	  earlier,	  and	  more	   preponderant	   role	   than	   PITX1,	   in	   progenitor	   maintenance	   and	  proliferation	   and	   it	   may	   play	   a	   later	   role	   in	   promoting	   endocrine	   cell	  differentiation.	  
	  
1.4.5	  HESX1	  
	  Homeobox	  expressed	   in	  ES	  cells	  1	   (HESX1)	   is	  a	  member	  of	   the	  paired-­‐like	  class	   of	   homeodomain	   TFs	   functioning	   as	   a	   repressor,	   by	   co-­‐binding	   in	  particular	   Transducin-­‐Like	   Enhancer	   of	   Split	   1	   (TLE1)	   (a	   mammalian	  Groucho	   family	  member)	   (Dasen	  et	  al.,	  2001).	   	  HESX1	   is	   first	  expressed	   in	  the	  anterior	  neural	  ridge	  where	  the	  hypophyseal	  placode	  will	  develop,	  and	  also	  in	  the	  rostral	  neural	  plate	  that	  will	  form	  the	  forebrain	  (Paul	  Thomas	  &	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Beddington.,	  1996;	  Thomas	  et	  al.,	  1995).	   Its	  expression	  might	  be	  regulated	  by	  the	  Lim	  homeodomain	  transcription	  factors	  LHX1	  and	  LHX3	  (Chou	  et	  al.,	  2006).	   LHX1	   bind	   enhancer	   regions	   5’	   of	  Hesx1	   to	   drive	   expression	   in	   the	  forebrain,	   while	   LHX3	   binds	   an	   additional	   3’	   enhancer	   to	   activate	  transcription	   in	  RP,	  probably	   along	  with	  PITX2	  and	  GATA2/3	   (Chou	  et	   al.,	  2006).	   HESX1	   is	   essential	   for	   correct	   development	   of	   the	   forebrain,	   and	  
Hesx1	   null	  mice	   display	   post-­‐natal	   lethality	   likely	   caused	   by	   CNS	   defects	  comprising	   a	   reduced	   prosencephalon,	   anophthalmia,	   and	   pituitary	  dysplasia	  (Dattani	  et	  al.,	  1998).	  Loss	  of	  HESX1	  in	  the	  anterior	  neurectoderm	  results	   in	   posteriorisation,	   possibly	   due	   to	   ectopic	   activation	   of	   the	  Wnt/βcatenin	   pathway	   (Andoniadou	   et	   al.,	   2007;	   Martinez-­‐barbera	   et	   al.,	  2000).	   As	   development	   progresses	   HESX1	   is	   restricted	   to	   RP	   at	   9.5dpc	  where	   it	   is	   maintained	   until	   13.5dpc	   (Hermesz	   et	   al.,	   1996).	   The	   early	  development	   of	   RP	   in	   Hesx1	   null	   embryos	   is	   characterised	   by	   a	   variable	  phenotype	   comprising	   multiple	   clefts,	   over	   proliferation	   and	   often	  misplacement	  of	   the	  gland	   in	   the	  naso-­‐pharyngeal	   cavity,	   aspects	  of	  which	  are	  likely	  to	  be	  explained	  by	  loss	  of	  the	  gene	  in	  VD	  (Dasen	  et	  al.,	  2001).	  Later	  endocrine	  cell	  differentiation	  occurs	  normally,	  but	  with	  increased	  numbers	  (Dasen	  et	  al.,	  2001).	  After	  birth,	  hypoplasia	  of	  the	  pituitary	  is	  observed	  and	  this	  is	  likely	  the	  result	  of	  impaired	  hypothalamic	  control.	  In	  humans,	  HESX1	  mutations	   are	   associated	   with	   Septo-­‐optic	   Dysplasia	   (SOD),	   a	   syndrome	  whose	  characteristics	   closely	   resemble	   those	  displayed	  by	  Hesx1	  null	  mice	  (Dattani	  et	  al.,	  1998).	  	  	  An	  important	  role	  of	  the	  HESX1/TLE1	  complex	  is	  to	  inhibit	  expression	  of	  the	  TF	   PROP1	   (see	   below)	   (Dasen	   et	   al.,	   2001).	   PROP1	   is	   required	   for	  emergence	  of	  endocrine	  cell	  lineages	  and	  the	  switch	  of	  expression	  between	  HESX1	  and	  PROP1	  is	  crucial	  for	  correct	  development	  of	  the	  gland	  (Dasen	  et	  al.,	   2001).	   Hesx1	   downregulation	   is	   likely	   to	   be	   mediated	   through	   the	  Wnt/β-­‐catenin	   pathway	   as	   a	   β-­‐catenin/PROP1	   complex	   was	   shown	   to	  inhibit	  Hesx1	  expression	  (Olson	  et	  al.,	  2006).	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The	   complex	   relation	   between	   HESX1	   and	   other	   early	   TFs	   was	   further	  highlighted	  by	   the	  phenotype	  of	   compound	  Six3;Hesx1	  mutants.	  While	  Six3	  and	  Hesx1	  mutants	  display	  similar	  forebrain	  defects,	  Six3-­‐/-­‐	  defects	  are	  more	  severe	  and	  RP	  doesn’t	  form,	  probably	  due	  to	  VD	  abnormalities.	  Intriguingly,	  
Six3+/-­‐;Hesx1Cre/+	  (Cre	   replaces	  Hesx1	   so	  Hesx1Cre	   allele	   is	   effectively	   a	   null)	  	  double	  mutant	  embryos	  display	  increased	  early	  progenitor	  proliferation	  and	  multiple	   clefts,	   comparable	   to	  Hesx1-­‐/-­‐	  mutants.	   This	   is	   suggested	   to	   result	  from	   increased	  Wnt	  signaling,	  promoting	  progenitor	  proliferation	  (Gaston-­‐Massuet	  et	  al.,	  2008).	  These	  studies	  highlight	  the	  important	  yet	  complex	  role	  HESX1	  plays	  in	  pituitary	  development,	  as	  it	  acts	  in	  the	  forebrain	  and	  RP.	  	  
1.4.6	  PROP1	  
	  Paired-­‐like	   homeobox	   1	   (Prop1)	   is	   the	   earliest	   gene	   to	   be	   exclusively	  expressed	  in	  RP.	  It	  starts	  to	  be	  expressed	  at	  10.0dpc	  and	  is	  downregulated	  after	   12.0dpc,	   however	   it	   is	   maintained	   in	   some	   of	   the	   cells	   that	   line	   the	  lumen	  in	  the	  adult	  pituitary	  (Sornson	  et	  al.,	  1996;	  Yako	  et	  al.,	  2011).	  PROP1	  is	  initially	  present	  throughout	  RP,	  along	  with	  SOX2	  (see	  below)	  (Yoshida	  et	  al.,	   2009).	   Notch	   signaling	   induces	   its	   expression	   in	   RP	   (Zhu	   et	   al,	   2006).	  Later	   PROP1	   is	   maintained	   in	   a	   few	   SOX2+ve	   SC	   postnatally	   (Yako	   et	   al.,	  2011).	   	   Prop1	   null,	   and	   the	   naturally	   occurring	   Ames	   Dwarf	   mutants	  (mutation	   inducing	   low	   DNA	   binding	   activity),	   both	   display	   reduction	   in	  somatotrophs,	   lactotrophs,	   thyrotrophs	   and	   gonadotrophs	   (Sornson	   et	   al.,	  1996).	  During	  development,	  progenitors	   fail	   to	   leave	   the	  dorsal	  progenitor	  zone	   and	   to	   differentiate,	   resulting	   in	   retention	   of	   cells	   in	   the	   periluminal	  region	   of	   RP	   (Ward	   et	   al.,	   2006).	   Another	   Notch	   target,	   Hes1,	   may	   be	  involved	  in	  regulating	  these	  progenitor	  cells	  movement	  and	  differentiation,	  as	  suggested	  by	  the	  phenotype	  of	  Hes1;Prop1	  double	  mutants	  (Himes	  et	  al.,	  2009).	   An	   important	   target	   of	   PROP1	   is	   the	   TF	   Pit1,	   required	   for	   the	  emergence	   of	   several	   endocrine	   cell	   types	   (Andersen,	   1995,	   see	   below).	  Ames	  Dwarf	  mice	  also	  show	  a	  complete	  loss	  of	  PIT1	  expression	  while	  HESX1	  expression	   is	   retained	   beyond	   its	   normal	   temporal	   limit	   (Andersen	   et	   al.,	  1995;	  Olson	  et	   al.,	   2006).	  Only	  9.7%	  of	   cells	   in	  RP	   co-­‐express	  both	  PROP1	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and	  PIT1	  at	  its	  highest	  point	  at	  16.5dpc	  in	  Rattus	  Rattus	  RP	  (Yoshida	  et	  al.,	  2009)	  suggesting	  that	   the	   interaction	   is	  very	  transient.	   Importantly	  PROP1	  acts	   as	   both	   a	   repressor	   and	   activator	   simultaneously.	   Forming	   a	   complex	  with	   β-­‐catenin,	   PROP1	   can	   inhibit	   Hesx1	   expression	   and	   promote	   Pit1	  expression,	  promoting	  lineage	  specification	  (Olson	  et	  al.,	  2006).	  	  	  	  Mirroring	   the	   Ames	   Dwarf	   mouse	  model,	   human	  mutations	   in	   PROP1	   are	  associated	  with	  CPHD	  and	  more	  specifically	  reductions	  in	  GH,	  TSH,	  and	  PrL.	  This	   is	   in	   addition	   to	   failure	   to	   enter	   puberty,	   likely	   due	   to	   a	   reduction	   in	  gonadotropin	   secretion	   (Wu	   et	   al.,	   1998).	   In	   conclusion	   PROP1	   is	   an	  important	   factor	  underlining	  progression	   from	  proliferating	  progenitors	   to	  differentiating	  cells.	   In	  RP,	   this	   transition	   is	  associated	  with	  movements	  of	  cells	   that	   PROP1	   regulates,	   from	   a	   dorsal	   proliferative	   zone	   to	   a	   ventral	  region	  where	  the	  future	  AL	  takes	  shape.	  
	  
1.4.7	  SOX2	  
	  SOX2	   is	   expressed	   ubiquitously	   in	   RP	   from	   at	   least	   11.5dpc	   and	   in	   the	  overlying	   VD,	   comprising	   the	   infundibulum	   both	   in	   mice	   and	   humans	  (Fauquier	   et	   al.,	   2008;	   Kelberman	   et	   al.,	   2008;	  Wood	  &	  Episkopou,	   1999).	  Due	  to	  its	  wide	  expression	  pattern,	  study	  of	  its	  role	  within	  RP	  has	  relied	  on	  the	   development	   of	   a	   conditional	   deletion	   approach	   (this	   thesis).	   As	  development	   progresses,	   SOX2	   becomes	   progressively	   restricted	   to	   the	  dorsal	   region	   of	   RP	   containing	   progenitors	   for	   both	   AL	   and	   IL.	   It	   is	  maintained	  post-­‐natally	   in	  a	  population	  of	  cells	   that	   line	  the	  pituitary	  cleft,	  which	  is	  a	  remnant	  of	  RP	  lumen	  	  (Figure	  1.4	  and	  1.5)	  (Fauquier	  et	  al.,	  2008).	  SOX2+ve	   cells	   are	   also	   observed	   scattered	   in	   the	   AP	   parenchyma	   and	   are	  hormone-­‐ve	   (Figure	   1.5)	   (Fauquier	   et	   al.,	   2008).	   SOX2+ve	   cells	   are	   highly	  proliferative	  at	  12.5dpc,	  however	  this	  declines	  throughout	  development	  and	  the	  cells	  are	  mostly	  quiescent	  in	  adults.	  	  Recent	  studies	  have	  shown	  that	  the	  number	  of	  SOX2+ve	  cells	  is	  very	  high	  during	  the	  neonatal	  growth	  phase	  of	  the	  rodent	  pituitary,	  and	  decreases	  later	  in	  life	  (Gremeaux	  et	  al.,	  2012).	  It	  is	  now	  clearly	  established	  that	  SOX2+ve	  cells	  are	  adult	  pituitary	  stem	  cells	  (SCs)	  (see	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below).	   In	   humans,	   heterozygous	   mutations	   in	   SOX2	   are	   associated	   with	  bilateral	  anophthalmia,	  severe	  microphthalmia	  and	  hypopituitarism	  (Fantes	  et	  al.,	  2003;	  Kelberman	  et	  al.,	  2006,	  see	  above).	  	  	  
	  
1.5 Endocrine	  cell	  differentiation	  	  
	  Following	   expansion	   of	   RP	   progenitors,	   endocrine	   cell	   specification	   and	  differentiation	  take	  place.	  There	  are	  three	  endocrine	  lineages,	  characterised	  by	  the	  expression	  of	  a	  specific	  TFs,	  the	  earliest	  that	  committed	  cells	  express.	  The	  largest	  of	  the	  three	  lineages	  is	  the	  PIT1	  lineage	  (Figure	  1.4).	  This	  gives	  rise	   to	   somatotrophs,	   lactotrophs	   and	   thyrotrophs	   (excluding	   rostral-­‐tip,	  PIT1	   independent	   thyrotrophs,	   which	   form	   a	   transient	   population	  disappearing	  a	  birth).	  The	  SF1	  population	  exclusively	   forms	  gonadotrophs.	  Finally,	   the	   TPIT	   lineage	   is	   comprised	   of	   corticotrophs	   in	   the	   AL	   and	  melanotrophs	  in	  the	  IL.	  	  Birthdating	  studies	  have	  demonstrated	  that	  AP	  precursors	  exit	  the	  cell	  cycle	  concurrently	  between	  11.5dpc	  and	  13.5dpc	  (Davis	  et	  al.,	  2011).	  Within	  this	  time	  frame	  the	  different	  endocrine	  cell	  populations	  peak	  exit	  time	  is	  slightly	  different;	   gonadotroph	   and	   thyrotroph	   progenitors	   exit	   the	   cell	   cycle	  between	  11.5dpc	  –	  12.5pc,	  while	  corticotroph	  and	  somatotroph	  progenitors	  stop	   proliferating	   24h00	   later	   between	   12.5dpc	   –	   13.5dpc.	   Melanotroph	  precursors	  are	  the	  latest	  to	  exit	  the	  cell	  cycle	  12.5dpc	  –	  14.5dpc	  (Davis	  et	  al.,	  2011).	   Cell	   cycle	   exit	   is	   associated	   with	   expression	   of	   cyclin	   dependent	  kinase	  inhibitor	  (CDKI)	  p57kip1	  (Bilodeau	  et	  al.,	  2009).	  p57kip1+ve	  cells	  are	  situated	  below	  the	  dorsal	  progenitors	  and	  above	  ventral	  differentiated	  cells	  and	   mark	   an	   intermediary,	   non-­‐cycling,	   undifferentiated	   population.	  Terminal	   differentiation	   however	   is	   associated	   with	   the	   up-­‐regulation,	  initially	   in	   a	   ventral	   territory	   then	   expansion	   of	   another	   CDKI,	   p27kip1,	  preventing	  cells	  from	  re-­‐entering	  the	  cell	  cycle	  (Bilodeau	  et	  al.,	  2009).	  In	  the	  developing	   gland,	   differentiated	   endocrine	   cell	   type	   form	   homotypic	  networks.	   In	   the	   adults,	   these	   networks	   allow	   efficient	   and	   coordinated	  hormonal	  release	  (Figure	  1.4)	  (for	  review	  see	  Mollard	  et	  al.,	  2012).	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Figure	  1.4:	  SOX2	  and	  endocrine	  cell	  expression	  in	  RP	  and	  pituitary	  SOX2	   is	   ubiquitously	   expressed	   in	   RP	   at	   10.5dpc.	   In	   the	   adult	   pituitary	   the	   RP	   lumen	  persists	   as	   the	   pituitary	   cleft	   and	   is	   lined	   by	   the	   SOX2+ve	   population,	   as	   observed	   in	   the	  embryo.	   Corticotrophs	   (ACTH)	   and	   Melanotrophs	   (MSH)	   of	   the	   POMC	   lineage,	  somatotrophs	   (GH)	   of	   the	   Pit1	   lineage	   and	   gonadotrophs	   (LH)	   of	   the	   SF1	   lineage	   form	  networks	   in	   the	   anterior	   lobe	   (AL)	   and	   intermediate	   lobe	   (IL)	   of	   the	   18.5dpc	   and	   adult	  gland.	   Conversely	   the	   two	   other	   members	   of	   the	   Pit1	   lineage,	   thyrotrophs	   (TSH)	   and	  lactotrophs	   (PrL)	   do	   not	   form	   networks.	   No	   endocrine	   cells	   reside	   in	   the	   posterior	   lobe	  (PL).	  Schematic	  represents	  one	  half	  of	  the	  adult	  pituitary	  in	  a	  coronal	  orientation	  (adapted	  from	  Mollard	  et	  al.,	  2012).	  
	  
	  
1.5.1	  PIT1	  lineage	  First	   expressed	   in	   RP	   at	   13.5dpc	   POU	   class	   1	   Homeobox	   1	   (Pou1f1)	   also	  known	   as	   Pituitary	   Specific	   Transcription	   Factor	   1	   (Pit1),	   is	   induced	   by	  PROP1	   (Andersen	   et	   al.,	   1995)	   and	   marks	   a	   population	   of	   cells	   that	   will	  become	  somatotrophs,	  lactotrophs	  and	  thyrotrophs	  (Figure	  1.4)	  (Bodner	  et	  al.,	   1988).	   The	   phenotype	   of	   two	   naturally	   occurring	  mutations	   in	   Pit1	   in	  mice,	   Snell	   dwarf	   (point	   mutation	   in	   DNA	   binding	   domain)	   and	   Jackson	  
dwarf	   (no	   expression	   following	   chromosomal	   rearrangement)	   have	  highlighted	   the	   requirement	   for	   PIT1	   in	   these	   three	   cell	   types	   (Li	   et	   al.,	  1990).	   Interestingly	   the	   reduction	   in	   somatotrophs,	   thyrotrophs	   and	  lactotrophs	  observed	  in	  both	  strains	  and	  also	  engineered	  null	  mutants,	  does	  not	   occur	   until	   after	   birth	   (Li	   et	   al.,	   1990;	   Ward	   et	   al.,	   2006).	   Post-­‐natal	  hypoplasia	   is	   associated	   with	   reduction	   in	   proliferation	   and	   apoptosis,	  indicating	  that	  PIT1	  is	  not	  required	  for	  emergence	  of	  these	  cell	  types	  but	  for	  their	   post-­‐natal	   expansion	   (Ward	   et	   al.,	   2006).	   The	   aetiology	   of	   this	  phenotype	   is	   still	   unknown.	   Consistent	   with	   the	   phenotypes	   observed	   in	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Snell	  and	  Jackson	  dwarf	  mice	  human	  mutation	  in	  PIT1	  result	  in	  reductions	  in	  PrL,	  TSH	  and	  GH	  (Pfäffle	  et	  al.,	  1992;	  Radovick	  et	  al.,	  1992).	  	  PIT1,	   along	   with	   different	   co-­‐factors,	   regulates	   the	   expression	   of	   the	  hormones	   characterising	   the	   three	   cell	   types	   of	   the	   PIT1	   lineage.	   In	  lactotrophs,	  PIT1	  binds	  to	  a	  distal	  PrL	  enhancer	  to	  drive	  PrL	  expression	   in	  
vitro,	   however	   addition	   of	   estradiol	   (E2)	   greatly	   enhances	   the	   level	   of	  expression	  (Day	  et	  al.,	  1990).	  This	  interaction	  may	  play	  a	  role	  in	  pregnancy	  where	   Prl	   levels	   increase.	   In	   somatotrophs,	   PIT1	   can	   bind	   to	   the	   GH	  promoter	  to	  drive	  its	  expression	  and	  co-­‐binding	  with	  zinc	  finger	  protein	  Zn-­‐15	   greatly	   increases	   activity,	   while	   mutations	   in	   this	   region	   dramatically	  reduce	   GH	   expression	   highlighting	   the	   functionality	   of	   this	   interaction	  (Lipkin	  et	  al.,	  1993).	   Similarly	  PIT1	  and	   the	  TF	  GATA2	  co-­‐operate	   to	  drive	  expression	  of	  TSH	  (Gordon	  et	  al.,	  2002).	  	  	  
1.5.2	  SF1	  lineage	  	  Unlike	   the	   two	   other	   lineages	   discussed	   in	   this	   section	   the	   Steroidogenic	  Factor	  1	  (Sf1)	  lineage	  give	  rise	  to	  only	  one	  endocrine	  cell	  type,	  gonadotrophs	  (Figure	  1.4).	  Also	  called	  Nuclear	  Receptor	  5a1	  (Nr51a),	  SF1	  is	  also	  expressed	  in	  hypothalamus	  where	  it	  regulates	  GnRH	  expression,	  the	  adrenal	  gland	  and	  gonads	   where	   it	   up-­‐regulates	   the	   expression	   of	   Sox9	   during	   testis	  development	  (	   for	  a	  review	  of	  the	  latter	  see	  Sekido	  &	  Lovell-­‐badge.,	  2009).	  In	  RP,	   SF1	   is	   first	  observed	   in	   future	  gonadotrophs	  at	  13.5dpc,	  where	   it	   is	  maintained	   (Ingraham	  et	   al.,	   1994).	  Homozygous	  deletion	  of	  Sf1	   results	   in	  disrupted	   gonad	   development	   in	   addition	   to	   sex	   reversal,	   adrenal	  hypoplasia	  and	  reduced	  LH	  and	  FSH	  levels	  in	  the	  pituitary	  (Ingraham	  et	  al.,	  1994;	   Shinoda	   et	   al.,	   1995).	   To	   assess	   directly	   its	   role	   in	   the	   pituitary,	  conditional	  deletion	  was	  performed	  in	  RP.	  This	   leads	  to	  a	  severe	  reduction	  in	   expression	   of	   LH	   and	   FSH.	   Reduction	   in	   gonadotrophins	   results	  expectedly	  in	  severely	  hypoplastic	  gonads	  and	  infertility	  (Zhao	  et	  al.,	  2001).	  Transcriptionally	   SF1	   can	   directly	   bind	   the	   LH	   promoter	   to	   activate	   its	  expression	  and	  deletion	  of	   the	   SF1	  binding	   site	  prevents	   expression	   (Keri,	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Nilson	   et	   al.,	   1996).	   Co-­‐operation	   with	   other	   factors	   is	   also	   important	   as	  synergy	  between	  SF1,	  PITX1	  and	  Early	  Growth	  Response	  1	  (EGR-­‐1),	  a	  zinc-­‐finger	  TF,	  on	  the	  LH	  promoter	  is	  necessary	  to	  drive	  expression	  (Quirk	  et	  al.,	  2001).	  Additionally,	   FOXO1,	   a	  member	  of	   the	  FOXO	   family	  of	  Forkhead	  TF	  can	   directly	   binds	   SF1	   to	   sequester	   it	   away	   from	   the	   LH	   promoter	   and	  therefore	   inhibits	   LH	   expression,	   possibly	   in	   response	   to	   metabolic	   cues	  (Arriola	  et	  al.,	  2012).	  Mutations	  in	  SF1	  are	  associated	  with	  46XY	  sex	  reversal	  (Achermann	  et	  al.,	  2001)	  and	  ovarian	  insufficiency	  (Lourenço	  et	  al.,	  2009).	  	  
	  
1.5.3	  TPIT	  lineage	  
	  The	  T-­‐Box	  19	  (Tbx19,	  also	  known	  as	  T-­‐Box	  Factor	  Pituitary	  (Tpit))	   lineage	  comprises	   two	  endocrine	  cell	   types,	  corticotrophs	   in	  AL	  and	  melanotrophs	  in	   IL	   (Figure	   1.4).	   TPIT	  expression	   is	   first	   observed	   in	   RP	   at	   12.5dpc	   just	  before	  differentiation	  of	  the	  first	  corticotrophs.	  The	  melanotroph	  lineage	  is	  not	   specified	   until	   TPIT	   becomes	   expressed	   in	   the	   dorsal	   region	   of	   RP	   at	  15.5dpc	  (Japon	  et	  al.,	  1994;	  Lamolet	  et	  al.,	  2001).	   In	  addition	  to	  TPIT,	  both	  endocrine	   cell	   types	   also	   express	   PITX1	   and	   the	   precursor	   of	   MSH	   and	  ACTH,	   POMC.	   Transcriptional	   regulation	   of	   Pomc	   in	   both	   cell	   types	   is	  controlled	   by	   TPIT	   that,	   along	  wit	   PITX1	   binds	   to	   the	   CE3	   element	   of	   the	  
Pomc	   promoter	   (Lamolet	   et	   al.,	   2001).	   	   Neuronal	   differentiation	   1	  (NeuroD1),	   a	   basic	   Helix-­‐Loop-­‐Helix	   (bHLH)	   TF,	   is	   only	   and	   transiently	  expressed	   in	   corticotrophs	  where	   it	   can	   also	   act	   in	   tandem	  with	   PITX1	   to	  induce	  the	  expression	  of	  POMC	  (Poulin	  et	  al.,	  2000;	  Poulin	  et	  al.,	  1997).	  In	  its	  absence,	   corticotrophs	   differentiation	   is	   slightly	   delayed	   (Lamolet	   et	   al.,	  2004).	   This	   is	   in	   contrast	  with	   the	  phenotype	  displayed	  by	  Tpit	   null	  mice,	  where	   there	   is	   a	   almost	   complete	   loss	   of	   POMC	   expression	   both	   in	   the	  anterior	   and	   intermediate	   lobes	   and,	   as	   a	   consequence,	   severe	   adrenal	  deficiency	   is	   observed,	   also	   seen	   in	   humans	   carrying	   TPIT	   mutations	  (Pulichino	  et	  al.,	  2003;	  Pulichino	  et	  al.,	  2003).	  NeuroD1	  is	  still	  expressed	  in	  
Tpit	   mutants,	   indicating	   that	   TPIT	   is	   required	   for	   terminal	   differentiation	  rather	  than	  cell	  commitment	  (Pulichino	  et	  al.,	  2003).	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In	   addition	   to	   “promoting	   its	   own	   lineage”,	   TPIT	   actively	   inhibits	   the	  emergence	   of	   gonadotrophs	   and	   rostral-­‐tip	   thyrotrophs.	   In	  vitro	   TPIT	   and	  SF1	  mutually	  repress	  each	  other	  transcriptional	  activities,	  by	  direct	  protein-­‐protein	  interaction	  (Pulichino	  et	  al.,	  2003).	   	  In	  Tpit	  null	  IL,	  the	  relevance	  of	  this	  interaction	  is	  demonstrated	  by	  appearance	  of	  ectopic	  gonadotrophs	  and	  also	  rostral-­‐tip	  thyrotrophs	  (Pulichino	  et	  al.,	  2003).	  	  	  Recently,	   PAX7	   has	   been	   shown	   to	   be	   responsible	   for	   the	   melanotroph	  specification	  of	  dorsal	  TPIT+ve	  cells.	  Paired	  box	  7	  (PAX7)	  is	  a	  member	  of	  the	  PD	   TF	   family	   and	   is	   expressed	   in	   RP,	   in	   the	   future	   IL	   from	   14.5dpc	   and	  maintained	  there	  as	  TPIT+ve	  melanotrophs	  differentiate	  (Budry	  et	  al.,	  2012).	  Deletion	  of	   the	  gene	   results	   in	  a	   loss	  of	  melanotrophs,	   replaced	  by	  ectopic	  corticotrophs.	  This	  demonstrates	   its	  role	  as	  a	  selector	  of	  melanotroph	  fate,	  versus	   corticotroph	   cell	   identity	   (Budry	   et	   al.,	   2012).	   PAX7	   acts	   through	  chromatin	   re-­‐modeling,	   by	   allowing	   TPIT	   to	   bind	   on	   a	   subset	   of	  melanotroph	  specific	  binding	  sites	   (Budry	  et	  al.,	  2012).	   Interestingly	  PAX7	  co-­‐localises	  with	  SOX2	  in	  a	  few	  cells	  in	  the	  post-­‐natal	  pituitary,	  indicating	  a	  transitory	  SOX2+ve;PAX7+ve	  state	  during	  melanotroph	  specification	  (Budry	  et	  al.,	   2012).	   In	   conclusion,	   TPIT	   is	   a	  marker	   of	   differentiation,	   promoting	   in	  particular	   the	   expression	   of	   genes	   that	   posttranslationally	   modify	   POMC	  into	  MSH	  or	  ACTH.	  Conversely	  PAX7	  acts	  as	  a	  selector	  of	  melanotroph	  fate	  within	  the	  TPIT	  lineage.	  	  By	   the	   end	   of	   gestation	   all	   endocrine	   cell	   type	   have	   differentiated	   in	   the	  pituitary.	   Post-­‐natally,	   in	   rodents,	   the	   pituitary	   goes	   through	   a	   phase	   of	  rapid	   growth,	   allowing	   the	   gland	   to	   reach	   an	   adult	   size.	  During	   this	   phase	  progenitors	  and	  differentiated	  endocrine	  cells	  proliferate	  intensively.	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1.6	  Pituitary	  stem	  cell	  population	  
	  In	  order	  to	  meet	  the	  physiological	  demands	  of	   the	  body	  the	  pituitary	  must	  secrete	   hormones	   at	   varying	   levels.	   The	   pituitary	   has	   different	   ways	   of	  adapting	  its	  secretions;	  likely	  depending	  on	  how	  urgently,	  and	  how	  long	  for,	  the	   requirement	   needs	   to	   be	   met.	   The	   immediate	   need	   for	   hormones	   in	  physiological	   situations	   such	   as	   ovulation	   can	   be	   met	   via	   the	   release	   of	  intracellular	  stores	  of	  LH	   into	   the	  blood	  stream	  under	  GnRH	  hypothalamic	  control	  (Baird	  et	  al.,	  1976).	  Here,	  a	  tonic	  hypothalamic	  GnRH	  release	  into	  the	  hypophyseal	   portal	   system	   induces	   the	   LH	   pre-­‐ovulatory	   surge.	   	   Another	  mechanism	   to	   increase	   hormone	   levels	   is	   the	   probably	   less	   immediate	  increase	   in	   hormone	   synthesis.	   This	   type	   of	   mechanism	   is	   likely	   to	   be	  important	   in	   longer	   periods	   of	   increased	   hormonal	   need	   such	   as	   the	  requirement	   for	   increased	   PrL	   during	   lactation	   (Escalada	   et	   al.,	   1996).	  Finally	   and	   likely	   in	   a	   longer	   term,	   the	   number	   of	   endocrine	   cells	   in	   the	  pituitary	   can	   be	   modulated.	   	   Newly	   generated	   cells	   can	   come	   from	   self-­‐duplication	   of	   existing	   terminally	   differentiated	   endocrine	   cells,	   and	   this	  may	  be	  enough	  for	  normal	  cell	  turn-­‐over	  (Langlais	  et	  al.,	  2013).	  In	  addition,	  new	   endocrine	   cells	  may	   come	   from	  differentiation	   of	   progenitors.	   In	   this	  section	  I	  will	  discuss	  the	  characterisation	  of	  the	  pituitary	  SC	  population,	  how	  it	  was	  isolated	  and	  the	  role	  it	  plays	  in	  the	  pituitary.	  	  Chromophobes	   or	   hormone-­‐ve	   cells	  were	   first	   identified	   in	   the	   pituitary	   in	  1969	   (Yoshimura	   et	   al.,	   1969).	   Grafts	   of	   chromophobes	   cells	   in	  hypophysectomised	   rats	   induced	   appearance	   of	   acidophils	   (somatotrophs	  and	   lactotrophs)	   and	   basophils	   (corticotrophs,	   thyrotrophs	   and	  gonadotrophs)	   cells	   suggesting	   that	   they	   represented	   a	   ‘reserve’	   cell	   type,	  able	  to	  differentiate	  (Yoshimura	  et	  al.,	  1969).	  In	  the	  literature,	  the	  putative	  pituitary	   SC	   population	  was	   proposed	   to	   reside	   in	   the	  marginal	   cell	   (MC)	  layer	   of	   the	   pituitary.	   In	   the	   AL,	   Folliculostellate	   cells	   (FS)	   were	   also	  proposed	  to	  have	  progenitor	  properties	  (Inoue	  et	  al.,	  1999;	  Shirasawa	  et	  al.,	  1983).	  Both	  populations,	  MC	  and	  FS	  express	  the	  glial	  fibrillary	  acid	  protein	  S100β.	  However	   these	  populations	  are	  extremely	  heterogeneous	  and	  were	  
	   	   	  
	   59	  
subsequently	   shown	   to	   encompass	   the	   SC	   population	   in	   addition	   to	   other	  supporting	   cell	   types	   and	   undifferentiated	   endocrine	   cells	   (for	   review	   see	  Allaerts	  &	  Vankelecom.,	  2005).	  	  
1.6.1	  In	  vitro	  characterisation	  of	  the	  pituitary	  SC	  population	  	  
	  
1.6.1.1	  Side	  population	  
	  The	  first	  study	  to	  identify	  a	  putative	  SC	  population	  in	  the	  pituitary	  was	  from	  Chen	  et	   al	   (2005).	  This	   group	   identified	  a	   ‘side	  population’	   (SP)	  of	   cells	   in	  the	   AP	   characterized	   by	   their	   ability	   to	   exclude	   the	   dye	   Hoechst	   3324.	  Significantly	   cells	   in	   SP	   did	   not	   express	   any	   hormones,	   and	   showed	   high	  levels	  of	  Stem	  cell	  antigen	  1	  (Sca1)	  (Figure	  1.5),	  which	  is	  also	  expressed	  in	  SCs	  of	   the	  heart	   and	  mammary	  glands	   (Matsuura	  et	   al.,	   2004;	  Welm	  et	   al.,	  2002).	  Additionally,	  other	  SC	  markers	  such	  as	  S100β,	  Oct-­‐4,	  Nanog	  and	  Bim-­‐1	  are	  highly	  expressed	  in	  the	  Sca1	  population,	  in	  contrast	  with	  the	  remaining	  population.	  Further	   characterization	  of	   the	  SP	   identified	  a	  Sca1Hi	   and	  non-­‐Sca1Hi	  sub-­‐populations	   (Chen	   et	   al.,	   2005,	   Chen	   et	   al.,	   2009).	   Self-­‐renewal	  and	   differentiation	   potentials,	   two	   characteristics	   displayed	   in	   vivo	   by	  progenitors,	  can	  both	  be	  assessed	   in	  vitro,	   in	  spheres	  assays	  (Reynolds	  and	  Weiss.,	   1992).	   These	   assays	   have	   been	   used	   to	   identify	   progenitors	   in	  different	   tissues	   and	   organs	   (for	   review	   see	   Pastrana	   et	   al.,	   2011).	  Within	  the	  SP,	  the	  non-­‐Sca1Hi	  population	  is	  the	  only	  one	  to	  display	  sphere-­‐forming	  ability.	   These	   results	   suggest,	   along	   with	   marker	   analysis,	   that	   the	   non-­‐Sca1Hi	  population	  contains	  progenitors	  (Chen	  et	  al.,	  2009),	  and	  overlaps	  with	  the	  progenitor	  population	  identified	  in	  Fauquier	  et	  al	  (2008)	  and	  Rizzoti	  et	  al	  (2013)	  (see	  below)	  (Figure	  1.5).	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Figure	  1.5:	  In	  vitro	  characterisation	  of	  proposed	  pituitary	  SC	  populations.	  	  SOX2+ve	  cells	  line	  the	  cleft	  of	  the	  adult	  pituitary	  and	  express	  SOX2,	  SOX9,	  GRFα2	  and	  S100β.	  PROP1	  is	  found	  in	  some	  of	  these	  cells	  only	  in	  the	  early	  postnatal	  period.	  SOX2	  and	  SOX9+ve	  cells	   are	   also	   found	   scattered	   in	   the	  parenchyma,	  where	   they	   can	   co-­‐localise	  with	   S100β.	  Various	   selection	  methods	   have	   been	   used	   to	   isolate	   adult	   pituitary	   progenitors	   in	   vitro,	  resulting	   in	   different	   markers	   being	   used	   to	   identify	   these	   cells.	   Sphere	   and	   colony	  formation	  assays	  were	  used	  to	  show	  these	  cells	  to	  have	  progenitor	  characteristics.	  	  
	  
1.6.1.2	  SOX2;SOX9	  population	  
	  A	   further	   step	   toward	   identification	   of	   the	   SC	   population	   in	   the	   pituitary	  came	  from	  Fauquier	  et	  al	  (2008).	  Progenitors	  were	  shown	  to	  express	  SOX2	  and	   the	   SOXE	   protein	   SOX9,	   from	   embryonic	   stages	   to	   adulthood	   (Figure	  1.5)	   (Fauquier	   et	   al.,	   2008).	   Moreover,	   pituispheres	   were	   also	   shown	   to	  express	  both	  proteins.	   Importantly,	  differentiation	  potential	  of	   cells	  within	  pituispheres	   was	   assessed	   in	   this	   study.	   By	   removing	   growth	   factors	   and	  allowing	   spheres	   to	   attach	   on	  Matrigel,	   this	   group	   was	   able	   to	   show	   that	  pituispheres	   could	   give	   rise	   to	   all	   AP	   endocrine	   cell	   types.	   Differentiation	  was	  preceded	  by	  upregulation	  of	  S100β,	  suggesting	  that	  FS	  cells	  may	  contain	  a	  transit	  amplifying	  population	  more	  defined	  towards	  a	  particular	  endocrine	  cell	   type	   (Fauquier	   et	   al.,	   2008).	   More	   recent	   studies	   have	   shown	   that	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SOX2+ve	   and	   SOX9+ve	   cells	   are	   the	   only	   cells	   in	   the	   pituitary	   capable	   of	  forming	  pituisphere	  (Figure	  1.5)	  (Rizzoti	  et	  al.,	  2013).	  	  	  
1.6.1.3	  GPS	  population	  
	  Garcia-­‐Lavandeira	   et	   al	   (2009),	   identified	   a	   sub-­‐population	   of	   SOX2+ve	  ;SOX9+ve	  cells	  characterized	  by	  the	  co-­‐expression	  of	  PROP1	  and	  the	  Glial	  cell	  line-­‐derived	  neurotropic	  factor	  (GDNF)	  receptor	  alpha	  2	  (GFRα2),	  that	  they	  named	   GPS	   (GFRα2/PROP/Stem)	   cells	   (Figure	   1.5).	   These	   are	   found	  exclusively	  lining	  the	  cleft	  (MC	  layer).	  No	  fully	  differentiated	  endocrine	  cells	  express	   GPS	   markers,	   however	   50%	   of	   the	   GFPs	   cells	   expressed	   the	   FS	  marker	   S100β	   (Garcia-­‐Lavandeira	   et	   al.,	   2009).	   In	   the	   neonatal	   pituitary,	  proliferation	   is	  high,	   in	  particular	   in	   the	  GPS	   cells	  but	   it	   decreases	  quickly	  with	   age	   (Garcia-­‐Lavandeira	   et	   al.,	   2009;	   Nolan	   et	   al.,	   1998).	   In	   vitro,	   the	  GFRα2+ve	  population	   can	   form	   pituispheres,	   in	   contrast	   with	   the	   GFRα2-­‐ve	  population	  (Figure	  1.5)	  (Garcia-­‐Lavandeira	  et	  al.,	  2009).	  PROP1	  is	  expressed	  in	   these	   cells	   and	   is	   also	   found	   in	   the	   non-­‐Sca1Hi	   population	   identified	   in	  Chen	   et	   al	   (2009),	   which	   also	   retained	   pituisphere-­‐forming	   ability.	  Interestingly	  all	  PROP1+ve	  cells	  express	  SOX2	  and	  these	  are	   located	  around	  the	  lumen	  in	  neonatal	  mice,	  but	  not	  all	  SOX2+ve	  cells	  express	  PROP1	  (Figure	  1.5).	  SOX2;PROP1	  co-­‐localisation	  decreases	  with	  age	  as	  PROP1	  expression	  is	  quickly	  downregulated	  after	  birth	  (Yoshida	   et	   al.,	   2009).	   In	   conclusion	   the	  GPS	   population	   represents	   a	   small	   sub-­‐population	   of	   SOX2+ve;SOX9+ve	  progenitor	  population.	  	  
1.6.1.4	  Pituitary	  colony	  forming	  cells	  
	  An	   alternative	   method	   to	   identify	   SC	   populations	   within	   a	   tissue	   is	   the	  ability	   to	   form	   adherent	   colonies	   in	   vitro	   (Figure	   1.5).	   Dispersed	   adult	   AP	  cells	   can	  also	   form	  colonies	   and	   cells	  with	   this	   capacity	   represent	  3.7%	  of	  the	  entire	  AP	  (Lepore	  et	  al.,	  2005).	  The	  pituitary	  colony	  forming	  cells	  (PCFC)	  also	   have	   a	   FS	   appearance	   and	   express	   S100β	   (Lepore	   et	   al.,	   2005),	  suggesting	   that	   they	   are	   part	   of	   the	   heterogeneous	   population	   of	   non-­‐
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endocrine	   FS	   cells	   discussed	   above.	   To	   demonstrate	   this,	   the	   fluorescent	  dipeptide	   β-­‐Ala-­‐Lys-­‐Nε-­‐AMCA	  was	   used	   as	   it	   is	   selectively	   taken	   up	   in	   FS	  cells	   (Otto	   et	   al.,	   1996).	   Selection	   of	   AMCA+ve	   cells	   demonstrated	   that	   the	  colony	  forming	  ability	  was	  indeed	  restricted	  to	  this	  population	  (Figure	  1.5)	  (Lepore	  et	   al.,	   2005).	   Further	   enrichment	  using	   fluorescence	  activated	   cell	  sorting	   (FACS)	   for	   Sca1+ve	   cells	   indicated	   that	   55%	   of	   the	   AMCA+ve	  population	   expressed	   this	   marker	   (Figure	   1.5)	   (Lepore	   et	   al.,	   2006).	  Expression	  of	  Sca1,	  S100β	  and	  AMCA	  suggested	  that	  these	  cells	  form	  part	  of	  the	  heterogeneous	  FS	  population,	   likely	  more	  defined	   towards	  a	  particular	  endocrine	   cell	   type.	   Further	   purification	   and	   transplantation	   of	   these	   cells	  into	   immuno-­‐compromised	   mice	   resulted	   in	   the	   in	   vivo	   differentiation	   of	  somatotrophs,	   demonstrating	   the	   progenitor	   properties	   of	   this	   population	  (Lepore	  et	  al.,	  2007).	  	  	  
1.6.2	  In	  vivo	  characterisation	  of	  the	  pituitary	  SC	  population	  
	  
1.6.2.1	  SOX2	  and	  SOX9	  lineage	  tracing	  
	  
In	   vivo	   lineage	   tracing	   studies	   in	   different	   tissues	   have	   indicated	   that	  SOX2+ve	   cells	   represent	   SC	   populations	   that	   give	   rise	   to	   terminally	  differentiated	   cell	   types	   (for	   review	   see	   Sarkar	   &	   Hochedlinger.,	   2013).	  Recent	  lineage	  tracing	  analyses	  have	  mostly	  relied	  on	  Cre	  recombinase	  and	  a	  ubiquitous	  reporter	  allele	  such	  as	  Rosa26Reporter	  (Srinivas	  et	  al.,	  2001).	  Upon	  Cre	  expression,	  typically	  under	  control	  of	  a	  SC	  or	  progenitor	  marker,	  a	  floxed	  STOP	  codon	  upstream	  of	  the	  reporter	  is	  recombined.	  The	  reporter	  is	  then	   expressed	   and	  will	   be	  maintained	   in	   the	   progeny	   of	   the	  mother	   cell.	  Inducible	   Cre	   recombinases	   allow	   an	   added	   level	   of	   control,	   as	   Cre	  expression	  can	  be	  switched	  on	  punctually,	  to	  assess	  progenitor	  properties	  at	  different	   times	   and	   in	   different	   situations	   (for	   review	   see	   Kretzschmar	   &	  Watt.,	  2012).	  This	   technique	  was	  used	   to	   follow	   the	   lineage	  of	   the	  SOX2+ve	  cells	  in	  the	  embryonic	  and	  adult	  pituitary.	  Using	  an	  inducible	  system	  to	  label	  adult	   SOX2	   cells	   in	   the	   pituitary	   with	   eYFP	   Rizzoti	   et	   al	   (2013)	   and	  Andoniadou	  et	  al	  (2013)	  revealed	  these	  cells	  self-­‐renew	  and	  give	  rise	  to	  all	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endocrine	  cell	  types	  in	  the	  pituitary.	  In	  addition	  to	  this	  SOX9+ve	  cell	   lineage	  tracing	   using	   a	   similarly	   inducible	   system	   also	   resulted	   in	  eYFP+ve;Hormone+ve	   cells	   in	   all	   endocrine	   cell	   types	   of	   the	   adult	   pituitary	  (Rizzoti	   et	   al.,	   2013).	   Previous	   studies	   suggested	   the	   adult	   SC	   population	  was	   distinct	   from	   the	   early	   progenitor	   population	   observed	   in	   RP	  (Gleiberman	  et	   al.,	   2008).	   Induction	  of	   Cre	   activity	   in	   SOX2+ve	   and	  SOX9+ve	  cells	  in	  the	  embryos	  and	  harvesting	  of	  the	  glands	  post-­‐natally	  revealed	  that	  these	   cells	   not	   only	   give	   rise	   to	   all	   endocrine	   cell	   types	   but	   also	   to	   the	  SOX2+ve;SOX9+ve	  SC	  population	  observed	  in	  the	  adult	  pituitary	  (Rizzoti	  et	  al.,	  2013).	   	   In	  vivo	   lineage	   tracing	   in	   these	  studies	  demonstrate	   that	  SOX2	  and	  SOX9+ve	  cells	  can	  both	  differentiate	  and	  self-­‐renew	  and	  represent	  therefore	  a	  population	  of	  adult	  pituitary	  stem	  cells	  (Andoniadou	  et	  al.,	  2013;	  Rizzoti	  et	  al.,	  2013).	  	  	  
1.6.2.2	  Regenerative	  potential	  of	  the	  adult	  stem	  cell	  lineage	  	  
	  Under	  normal	  conditions	  the	  adult	  pituitary	  has	  a	  very	  low	  turnover	  of	  cells,	  similar	  to	  the	  brain	  or	  heart	  at	  about	  1.5%	  per	  day	  (Nolan	  et	  al.,	  1998).	  This	  is	  in	  contrast	  with	  the	  high	  mitotic	  activity	  observed	  in	  neonatal	  pituitaries	  reflecting	  a	  phase	  of	  rapid	  growth	  of	  the	  gland	  during	  the	  first	  weeks	  of	  life	  in	   rodents.	   Indeed	   the	   number	   of	   SOX2+ve	   cells	   lining	   the	   lumen	   and	   the	  number	  of	  proliferative	  SOX2+ve	  cells	  in	  this	  region	  are	  higher	  at	  birth,	  both	  progressively	   decreasing	   with	   age	   (Gremeaux	   et	   al.,	   2012).	   Moreover	  neonatal	  mice	  also	  have	  significantly	  more	  pituisphere	  forming	  cells;	  again	  this	   decreases	   with	   age	   (Gremeaux	   et	   al.,	   2012).	   Lineage	   tracing	  experiments	   also	   showed	   that	   progenitors	   mostly	   give	   rise	   to	   endocrine	  cells	  in	  the	  embryo	  and	  early	  post-­‐natally.	  In	  adults	  SCs	  are	  mostly	  quiescent	  (Rizzoti	  et	  al.,	  2013;	  Andoniadou	  et	  al.,	  2013).	  	  
	  
1.6.2.2.1	  Organ	  ablation	  
	  Target	   organs	   of	   the	   pituitary	   send	   to	   the	   hypothalamus	   and	   pituitary	  negative	   feed-­‐back	   cues	   in	   response	   to	   pituitary	   hormonal	   stimulation.	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Target	  organ	  ablations	  suppress	  this	  negative	  feedback	  generally	  leading	  to	  a	   transient	   mitotic	   wave	   in	   the	   pituitary	   followed	   by	   an	   increase	   in	  corresponding	   pituitary	   hormone	   production.	   More	   precisely,	  adrenalectomies	   (Adx)	  and	  gonadectomies	   (Gdx)	   induce	  an	   increase	   in	   the	  mitotic	   index	   of	   the	   overall	   pituitary	   and	   a	   significant	   increase	   in	   the	  number	   of	   corticotrophs	   and	  possibly	   gonadotrophs	   (Ibrahim	   et	   al.,	   1986;	  Nolan	  &	  Levy.,	  2006).	  However	  the	   increase	   in	  the	  number	  of	  proliferating	  corticotrophs	  and	  gonadotrophs	  as	  a	  proportion	  of	  total	  dividing	  cells	  in	  Adx	  and	   Gdx	   mice	   is	   very	   small.	   In	   fact,	   proliferation	   is	   seen	   primarily	   in	  hormone-­‐ve	   cells	   response	   to	   organ	   ablation	   (Nolan	   &	   Levy.,	   2006).	  Moreover	   ablation	  of	   both	   adrenals	   and	  gonads	  does	  not	  have	   an	   additive	  proliferative	  effect	  (Nolan	  &	  Levy.,	  2006).	  This	  suggests	  that	  a	  population	  of	  undifferentiated	   progenitors	   proliferate	   and	   differentiate	   in	   response	   to	  target	  organ	  ablation	  (Nolan	  &	  Levy.,	  2006).	  	  In	  agreement	  with	  these	  studies,	  SOX2+ve;SOX9+ve	  were	  shown	  to	  proliferate	  in	  response	  to	  organ	  ablation	  studies	  (Rizzoti	  et	  al.,	  2013).	  Moreover,	  more	  pituispheres	  were	  obtained	  from	  animals	  that	  had	  undergone	  either	  Adx	  or	  Gdx,	   probably	   reflecting	   a	   stimulated,	   more	   proliferative	   SC	   population	  (Rizzoti	   et	   al.,	   2013).	   Importantly	   lineage	   tracing	   in	   Sox9CreERT2;R26ReYFP	  mice	   following	   Adx	   demonstrated	   that,	   in	   addition	   to	   proliferation,	  progenitors	   also	   differentiate	   and	   give	   rise	   to	   a	   proportion	   of	   the	   newly	  generated	   corticotrophs	   (Rizzoti	   et	   al.,	   2013).	   This	   indicates	   that	   the	  SOX2+ve;SOX9+ve	   population	   have	   a	   regenerative	   potential	   that	   can	   be	  stimulated	  by	  physiological	  demand.	  	  
1.6.2.2.2	  Cellular	  ablation	  	  An	   alternative	   method	   of	   demonstrating	   the	   regenerative	   capacity	   of	   the	  pituitary	   and	   requirement	   of	   the	   SC	   population	   is	   cellular	   ablation.	  Somatotroph	  ablation	  using	  GHCre/iDTR	  mice,	  in	  which	  the	  diphtheria	  toxin	  receptor	  is	  specifically	  expressed	  in	  GH+ve	  cells,	  results	  in	  a	  large	  increase	  in	  the	  size	  of	  the	  SP	  (Fu	  et	  al.,	  2012).	  In	  addition,	  both	  the	  number	  of	  SOX2+ve	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cells	  in	  the	  MC	  layer,	  and	  their	  mitotic	  index	  are	  increased	  (Fu	  et	  al.,	  2012).	  Another	  report	  from	  the	  same	  laboratory	  used	  the	  same	  technique	  to	  ablate	  lactotrophs	   in	   the	   adult	   pituitary	   (Fu	   &	   Venkelecom.,	   2012).	   Similarly	   the	  number	  and	  proliferative	  capacity	  of	  SOX2	  cells	   in	   the	  MC	   layer	   increased.	  Limited	   regeneration	   of	   ablated	   endocrine	   cells	   was	   observed	   in	   both	  studies,	  new	  cells	  were	  suggested,	  but	  not	  demonstrated,	  to	  originate	  from	  the	  SOX2	  SC	  population.	  	  	  An	   elegant	   ablation	   study	   used	   invloxP;POMC-­‐Cre	   mice.	   In	   these	   mice	   Cre	  expression	  triggers	  a	  chromosomal	  re-­‐arrangement	  inducing	  apoptosis,	  only	  if	  the	  cells	  divide	  (Langlais	  et	  al.,	  2013).	  POMC	  is	  expressed	  in	  differentiated	  corticotrophs	   and	   invloxP;POMC-­‐Cre	   mice	   display	   a	   significant	   decrease	   in	  this	   cell	   population.	   This	   demonstrates	   that	   corticotroph	   cell	   turn-­‐over	  occurs	  via	  self-­‐duplication	  of	   terminally	  differentiated	  cells	   (Langlais	  et	  al.,	  2013).	   Significantly	   the	   mitotic	   index	   of	   SOX2+ve	   cells	   is	   not	   increased	   in	  these	  mice,	   suggesting	   that	   SC	   are	   not	   stimulated	   by	   the	   gradual	   loss	   of	   a	  proportion	  of	  corticotrophs	  over	  a	  long	  period.	  In	  contrast,	  following	  Adx	  in	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1.7	  Thesis	  Outline	  
	  During	   pituitary	   development	   SOX2	   is	   initially	   expressed	   in	   early	  progenitors.	  Initially	  highly	  proliferative,	  RP	  progenitors	  later	  exit	  cell	  cycle	  and	   give	   rise	   to	   all	   the	   endocrine	   cells	   of	   the	   pituitary.	   As	   development	  progresses	   and	   cells	   differentiate,	   SOX2	   is	   downregulated,	   however	   a	  population	   of	   SOX2+ve	   cells	   remains,	   lining	   the	   pituitary	   cleft.	   In	   the	   adult	  gland	   these	   cells	   represent	   a	   SC	   population,	   capable	   of	   self-­‐renewal	   and	  differentiation.	  In	  humans	  and	  mice	  mutations	  in	  SOX2/Sox2	  are	  associated	  with	  hypopituitarism.	  Consequently	  we	  decided	  to	  examine	  the	  role	  of	  SOX2	  in	  pituitary	  development.	  	  	  The	  work	   presented	   in	   this	   thesis	   aims	   to	   investigate	   the	   role	   of	   SOX2	   in	  pituitary	  development.	  As	  deletion	  of	  the	  gene	  is	  early	  embryonic	  lethal,	  we	  employed	  the	  Cre	  LoxP	  system	  to	  conditionally	  delete	  a	  floxed	  allele	  of	  Sox2.	  Disruption	  of	  SOX2	  expression	  in	  the	  overlying	  VD	  has	  been	  shown	  to	  affect	  RP	   development.	   As	   a	   consequence	   we	   identified	   appropriate	   Cre	   drivers	  that	  were	  not	  active	  in	  the	  VD.	  The	  first	  results	  chapter	  (Chapter	  3)	  outlines	  the	  analysis	  of	  two	  different	  Cre	  drivers	  and	  their	  respective	  advantages	  and	  disadvantages	  as	   tools	   to	  delete	  Sox2	   in	  RP.	  Subsequently	   in	  Chapter	  4	  we	  perform	  analysis	  of	  the	  phenotypes	  resulting	  from	  Sox2	  deletion	  using	  both	  Cre	  drivers.	  These	  include	  characterisation	  of	  morphological	  defects	  in	  early	  and	  late	  stages	  of	  RP	  development,	  identification	  of	  factors	  involved	  during	  early	   RP	   development	   and	   affected	   by	   loss	   of	   SOX2,	   and	   examination	   of	  endocrine	   cell	   differentiation.	   Finally	   in	   chapter	   5	   we	   focus	   on	   a	   specific	  defect	   caused	   by	   Sox2	   deletion,	   in	   the	   IL.	   In	   this	   chapter	   we	   aim	   to	  investigate	   further	   the	  mechanisms	  underlying	   this	  phenotype.	  To	   achieve	  this,	  we	  perform	  a	  genetic	   interaction	  assay	  using	  p27kip1	  null	  mutants	   to	  rescue	  the	  IL	  phenotype.	  	  	  The	  studies	  presented	  in	  this	  thesis	  investigate	  the	  role	  of	  SOX2	  in	  pituitary	  development	  by	  analysing	  the	  consequences	  of	  its	  deletion	  in	  RP.	  In	  the	  final	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2.	  Materials	  and	  Methods	  
	  	  
2.1	  Transgenic	  Mouse	  Lines	  
	  	  
2.1.1	  Animal	  stocks	  and	  husbandry	  
	  	  Mice	  were	   bred	   onsite	   at	   the	   NIMR	   in	   E	   type	   cages	   in	   the	   Laidlaw	   Green	  animal	  unit.	  All	  mice	  stocks	  and	  scheduled	  procedures	  were	  carried	  out	   in	  accordance	   with	   Home	   Office	   regulations.	   Mice	   were	   kept	   in	   a	   12h	  light/dark	  cycle	  and	  data	  collected	  from	  virgin	  male	  and	  female	  mice	  unless	  otherwise	  stated.	  	  	  	  
2.1.2	  Genetically	  modified	  mouse	  strains	  
	  
	  Genetic	  alteration	  of	  gene	  expression	  within	  specific	  cell	  types	  was	  achieved	  using	   the	   bacteriophage	   P1	   Cre	   recombinase/LoxP	   system.	   The	   animals	  used	   in	   this	   study	   are	   established	   transgenic	   mouse	   lines	   that	   have	   been	  previously	  described	  (Table	  2.1).	  	  
2.1.3	  Genotyping	  and	  PCR	  amplification	  	  Genotyping	   was	   performed	   by	   polymerase	   chain	   reaction	   (PCR)	  amplification	   of	   deoxyribonucleic	   acid	   (DNA)	   extracted	   from	   ear	   punches	  taken	  from	  mice	  at	  three	  weeks	  of	  age.	  Appropriate	  primers	  were	  used	  for	  amplification	   of	   each	   allele	   (Table	   2.2).	   Ear	   punches	   (adult)	   or	   tail	   tips	  (embryo)	   were	   digested	   in	   20	   micro	   liters	   (μl)	   of	   DNAreleasy	   mix	  (Anachem)	  incubated	  at	  75	  degrees	  centigrade	  (°c)	  for	  5	  minutes,	  followed	  by	  enzyme	  inactivation	  by	   incubating	  at	  95°c	  for	  2	  minutes.	   	  The	  DNA	  was	  then	   amplified	   using	   Thermoprime	   Taq	   DNA	   polymerase	   (Thermo	  Scientific)	   and	   added	   to	   a	   master	   mix	   with	   the	   following	   reagents:	   0.5µl	  genomic	   template	   DNA,	   0.2	   U/µl	   Taq	   polymerase,	   1x	   reaction	   buffer,	   0.2	  millimolar	   (mM)	   deoxynucleotide	   triphosphates	   (dNTPs),	   1.5mM	   MgCl2,	  0.6mM	  of	  each	  primer	  and	  PCR-­‐grade	  water	  up	  to	  a	  reaction	  volume	  of	  25µl.	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The	  thermocycle	  consisted	  of	  35	  cycles	  of	  95°c	  for	  30s,	  58°c	  for	  30s	  and	  72°c	  for	   1	   minute	   per	   kilobase	   of	   amplification.	   PCR	   products	   were	   then	  visualised	   and	   size	   verified	   on	   a	   1.5%	   w/v	   agarose/SB	   (Brody	   &	   Kern,	  2004),	  Tris-­‐acetate-­‐EDTA	  (TAE)	  (1xTAE	  solution:	  40mM	  Tris-­‐acetate,	  20mM	  acetic	   acid,	   1mM	   EDTA	   in	   deionized	   water)	   gel	   with	   5ng/ml	   ethidium	  bromide.	   See	   table	   2.2	   for	   genotyping	   primers	   and	   corresponding	   PCR	  product	  sizes.	  	  	  
Name	  of	  
Allele	  







Knock-­‐in	  of	  Cre	  recombinase	  into	  the	  FoxG1	  locus,	  replacing	  one	  copy	  of	  FoxG1	  	   129SvJ	   (Hébert	  &	  McConnell.,	  2000a)	  
Nkx3.1Cre	  
Knock-­‐in	  of	  Cre	  recombinase	  into	  the	  Nkx3.1	  locus,	  replacing	  one	  copy	  of	  Nkx3.1	  	   C57BL/6	   Gift	  from	  M.	  Shen	  (Lin	  et	  al.,	  2007)	  
p27-­‐/-­‐	  
Targeted	  disruption	  of	  Exons	  1	  and	  2	  of	  p27,	  replacing	  these	  with	  a	  pgk-­‐neo	  cassette	   C57BL/6	   (Fero	  et	  al.,	  1996)	  
Rosa26eYFP	  
LoxP	  sites	  flanking	  a	  STOP	  cassette	  preceding	  enhanced	  yellow	  fluorescent	  protein	  (YFP)	  inserted	  into	  the	  
Rosa26	  locus	   C57BL/6	  
(Srinivas	  et	  al.,	  2001)	  
Sox2COND	   LoxP	  sites	  flanking	  the	  Sox2	  open	  reading	  frame	   C57BL/6	   (Taranova	  et	  al.,	  2006)	  
GBSGFP	  
8GBS-­‐hsp68-­‐eGFP	  transgene	  inserted	  into	  the	  BamH1	  site	  of	  pJC13-­‐1	  locus	   C57Bl/6	   (Balaskas	  et	  al.,	  2012)	  
Table	  2.1:	  Mouse	  strains.	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Cre-­‐Rev	   CCAGCTAAACATGCTTCATC	  CGCTCGACCAGTTTAGTTAC	   Cre	  allele	   300	  
p27-­‐WT-­‐Frd	  
p27-­‐WT-­‐Rev	   TGTCAAACGTGAGAGTGTCTAACGG	  AACCCAGCCTGATTGTCTGACGAG	   WT	  p27	  allele	   400	  
p27-­‐KO-­‐Frd	  
p27-­‐KO-­‐Rev	   CCTTCTATCGCCTTCTTGACG	  TGGAACCCTTGTGCCATCTCTAT	   KO	  p27	   550	  
Sox2-­‐Frd	  
Sox2-­‐Rev	   GCTCTGTTATTGGAATCAGGCTGC	  CTGCTCAGGGAAGGAGGGG	   Sox2	  WT	   382	  
Sox2-­‐flox-­‐Frd	  
Sox2-­‐flox-­‐Rev	   CAGCAGCCTCTGTTCCACATACAC	  CAACGCATTTCAGTTCCCCG	   Floxed	  Sox2	  allele	   297	  5’-­‐Rosa26	  3’-­‐Rosa26-­‐1	  3’-­‐Rosa26-­‐2	   AAAGTCGCTCTGAGTTGTTAT	  GCGAAGAGTTTGTCCTCAACC	  GGAGCGGGAGAAATGGATATG	   WT	  and	  transgenic	  Rosa	  allele	   300	  525	  
Table	  2.2:	  PCR	  primers.	  	  




	  Between	   10.5	   and	   18.5dpc,	   embryos	   were	   fixed	   in	   4%	   paraformaldehyde	  (PFA)	  (Sigma)	  overnight	  at	  4°C.	  14.5dpc	  embryos	  had	  a	  hole	  opened	  at	  the	  top	   of	   the	   skull	   and	   16.5-­‐18.5dpc	   embryos	   has	   their	   skulls	   opened	   and	  brains	  removed	  to	  allow	  full	  penetration	  of	  PFA	  and	  complete	  fixation	  of	  the	  developing	   pituitary.	   Tissues	   were	   cryopreserved	   in	   sucrose	   (20%)	  overnight	  at	  4°C,	  embedded	  in	  OCT	  mounting	  medium	  (VWR	  Chemicals)	  and	  stored	  at	  -­‐80°C.	  Between	  10.5dpc	  and	  14.5dpc	  embryos	  were	  embedded	  and	  sectioned	   in	   a	   sagittal	   orientation	   (see	   figure	   1.3	   for	   a	   schematic	  representation).	   16.5dpc	   and	   18.5dpc	   pituitaries	   that	   had	   been	   removed	  from	  the	  skull	  or	  exposed	  to	  the	  fixative	  by	  removal	  of	  the	  brain	  but	  left	  in	  situ	  were	  embedded	  and	  sectioned	  in	  a	  coronal	  orientation	  (see	  figures	  1.3	  and	   1.4	   for	   schematic	   representation).	   All	   embryos/pituitaries	   were	  sectioned	  serially	  in	  12	  micrometre	  (µm)	  sections.	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12µm	   sections	   were	   blocked	   at	   room	   temperature	   in	   blocking	   buffer	   (1x	  phosphate	   buffered	   saline	   (PBS),	   0.1%	   triton	   x-­‐1000,	   10%	   fetal	   bovine	  serum	   (FBS))	   (BB)	   for	   one	   hour.	   Subsequently	   primary	   antibodies	   were	  added	  at	  an	  appropriate	  dilution	  (Table	  2.3).	  Primary	  antibodies	  were	  added	  individually,	   except	  when	   all	   hormones	  were	   to	   be	   identified	   on	   the	   same	  section.	   In	  this	  case	  a	  mix	  of	  all	   five	  hormonal	  antibodies	  (rbPOMC,	  rbTSH,	  rbGH,	   rbLH,	   rbPrL)	  were	   added	   together	   (Figure	   4.3).	   Primary	   antibodies	  were	   incubated	  overnight	   at	   4°C.	   The	  primary	   antibody	   solution	  was	   then	  washed	   off	   in	   three	   changes	   of	   PBT	   (1xPBS,	   0.1%	   triton	   x-­‐1000)	   for	   five	  minutes	  each.	  The	  appropriate	   secondary	  antibody	  was	   then	  added	   (Table	  2.4),	   along	   with	   4’,6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	   (1:1000),	   and	  incubated	  at	  room	  temperature	  for	  one	  hour.	  Finally	  the	  secondary	  antibody	  was	   removed	   and	   the	   slides	   washed	   with	   three	   changes	   of	   PBS	   for	   five	  minutes	  each	  and	  cover	  slip	  mounted	  using	  Aqua-­‐poly/Mount	  (Polysciences,	  Inc.).	  	  Tissues	  that	  required	  antigen	  retrieval	  were	  fixed	  in	  4%	  PFA	  overnight	  and	  embedded	  in	  paraffin.	  Sections	  were	  de-­‐waxed	  in	  two	  10-­‐minute	  washes	  in	  histoclear	   (National	   Diagnostics)	   and	   rehydrated	   by	   successive	   5-­‐minute	  incubations	   in	   decreasing	   ethanol	   solutions	   (100%-­‐99%-­‐95%-­‐70%-­‐50%).	  The	  slides	  were	  then	  incubated	  for	  20	  minutes	  in	  1x	  target	  retrieval	  buffer	  (Dako)	   at	   120°C	   in	   a	   decloaker.	   Following	   this,	   the	   slides	  were	   processed	  following	   the	   protocol	   described	   above.	   To	   assess	   cell	   proliferation,	  Bromodeoxyuridine	   (BrdU)	   (Sigma)	   or	   ethynyl-­‐2-­‐deoxyuridine	   (EdU)	  (Molecular	   Probes)	   was	   injected	   in	   pregnant	   females	   at	   an	   appropriate	  concentration	   (see	   below).	   Embryos	   were	   harvested	   one	   hour	   after	  injection.	   BrdU	   immunostaining	   was	   carried	   out	   on	   12µm	   sections	   after	  hydrolysis	  at	  37°C	   in	  2	  molar	  (M)	  hydrochloric	  acid	  (HCL)	  (Sigma)	   for	  one	  hour	   then	   neutralisation	   with	   borate	   buffer	   (Boric	   acid,	   100mM	   (BDH	  Chmicals),	   NaCl	   (sodium	   chloride)	   75mM	   (Fisher	   Scientific),	   Borax	   25mM	  (Sigma)).	   The	   same	   immunohistochemical	   protocol	   was	   performed	   as	  described	   above,	   using	   rat	   anti-­‐BrdU	   (Table	   2.3).	   EdU	   assays	   were	  performed	  using	  the	  ‘Click-­‐iT	  EdU	  Alexa	  Fluro	  594	  Imaging	  kit’	  (Invitrogen).	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TUNEL	   assays	   were	   performed	   using	   the	   ‘Apop	   Tag	   Fluorescein	   in	   Situ	  Apoptosis	  Detection	  Kit’	  (Millipore).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	  




Host	  Species	   Final	  Dilution	   Source	  BrdU	   Rat	   1:100	   Abcam	  GFP	   Rat	   1:500	   Tesque	  Nacalai	  GFP	   Goat	   1:1000	   Abcam	  GFP	   Rabbit	   1:1000	   Abcam	  GH	   Rabbit	   1:100	   National	  Hormone	  and	  Peptide	  Program	  GR	   Rabbit	   1:100	   Santa	  Cruz	  ISL1	   Mouse	   1:300	   Gift	  (J.	  Briscoe)	  LHβ	   Rabbit	   1:500	   NHPP	  LHX3	   	   1:500	   Abcam	  P27kip1	   Mouse	   1:30	   BD	  Transduction	  Laboratories	  PAX7	   Mouse	   1:50	   DSHB	  POMC	   Rabbit	   1:500	   NHPP	  POMC	   Mouse	   1:000	   Fitzgerald	  Industries	  POU1F1	   Goat	   1:500	   Gift	  (Simon	  Rhodes)	  PRL	   Rabbit	   1:200	   NHPP	  SF1	   	   1:300	   Cell	  Signaling	  Solutions	  SIX3	   Rabbit	   1:500	   Rockland	  	  SIX6	   Rabbit	   1:500	   Sigma	  SOX2	   Goat	   1:500	   Immune	  Systems	  Ltd.	  SOX9	   Goat	   1:200	   R&D	  TBX19	   Rabbit	   1:1000	   Gift	  (D.	  Drouin)	  TSHβ	   Rabbit	   1:500	   NHPP	  
Table	  2.3:	  Primary	  antibodies.	  	  	  
Secondary	  
Antibody	   Fluorophore	  
Final	  
Dilution	   Source	  Donkey	  anti-­‐goat	   Alexa-­‐555/488/647	   1:1000	   Molecular	  Probes	  Donkey	  anti-­‐rabbit	   Alexa-­‐555/488/647	   1:1000	   Molecular	  Probes	  Donkey	  anti-­‐mouse	   Alexa-­‐488	   1:1000	   Molecular	  Probes	  Donkey	  anti-­‐rat	   Alexa-­‐488	   1:1000	   Molecular	  Probes	  Goat	  anti-­‐mouse	   Alexa-­‐488	   1:1000	   Molecular	  Probes	  Goat	  anti-­‐guinea	  pit	   Alexa-­‐555/488	   1:1000	   Molecular	  Probes	  
Table	  2.4:	  Secondary	  antibodies	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2.3	  In	  vivo	  analysis	  	  
	  
2.3.1	  BrdU	  and	  EdU	  injection	  
	  BrdU	   (10mg/ml)	   was	   injected	   into	   the	   peritoneum	   of	   pregnant	   mice.	  Following	  a	  1h	   incubation	  period	  the	  mice	  were	  culled	  by	  SK1	  (schedule	  1	  kill)	   and	   embryos	   processed.	   EdU	   (10mg/ml)	   was	   injected	   into	   the	  peritoneum	   of	   pregnant	   mice.	   Following	   a	   1h	   incubation	   period	   the	   mice	  were	  culled	  by	  SK1	  and	  embryos	  processed. 
	  
2.3.2	  Harvesting	  and	  preparation	  of	  embryonic	  and	  adult	  tissues	  
	  All	  mice	  were	  culled	  by	  SK1.	  Embryos	  were	  harvested	  by	  cesarean	  section	  and	  culled	  by	  SK1	   from	  14.5dpc	  onward.	  9.5dpc	   to	  12.5dpc	  embryos	  were	  fixed	  whole	  in	  4%	  PFA,	  14.5	  to	  18.5dpc	  embryos	  had	  the	  head	  removed	  and	  fixed	  in	  4%PFA.	  	  	  
2.4	  Image	  processing	  and	  analysis	  
	  Images	  were	   taken	   using	   a	   Leica	   SPE	   confocal	  microscope	   using	   10X	   and	  20X	  objective	  lenses.	  Each	  fluorescent	  tag	  was	  imaged	  separately	  using	  the	  405,	  488,	  561	  and	  649	  channels	  respectively.	  Confocal	  images	  were	  taken	  as	  Z-­‐stacks	   and	   processed	   using	   Fiji	   (Schindelin	   et	   al.,	   2012)	   and	   Adobe	  Photoshop	  CS4.	  
	  
2.5	  Statistical	  analysis	  
	  The	   number	   of	   BrdU+ve	   nuclei	   in	   RP	   at	   12.5dpc	   was	   quantified	   in	   three	  embryos.	  Each	  embryo	  was	  sectioned	  sagittally	  and	  the	  number	  of	  BrdU+ve	  nuclei	   was	   counted	   on	   three	   sections,	   one	   mid-­‐line	   and	   two	   lateral	   RP	  sections.	  Quantification	  of	  the	  number	  of	  BrdU+ve	  nuclei	  in	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	   was	   restricted	   to	   the	   dorsal	   part	   of	   RP,	   in	   the	   region	   where	  
Nkx3.1Cre	   is	   active.	   Quantification	   of	   the	   number	   of	   BrdU+ve	   nuclei	   in	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Sox2fl/fl;FoxG1Cre/+;R26ReYFP/+	   embryos	   was	   not	   restricted	   due	   to	   the	  ubiquitous	   activity	   of	   FoxG1Cre	   in	   RP.	   The	   number	   of	   BrdU+ve	   nuclei	   is	  presented	   as	   a	   percentage	   of	   the	   total	   number	   of	   DAPI+ve	   nuclei	   in	   the	  restricted	   region	   of	   Sox2fl/fl;Nkx3.1Cre/+	   embryos,	   or	   whole	   RP	   in	  
Sox2fl/fl;FoxG1Cre/+;R26ReYFP/+	   embryos,	   with	   error	   bars	   representing	   the	  standard	  error	  of	  the	  mean.	  The	  average	  number	  of	  DAPI+ve	  nuclei	  counted	  per	   Sox2fl/+;Nkx3.1Cre/+	   embryo	   was	   482,	   reducing	   to	   322	   in	  
Sox2fl/fl;Nkx3.1Cre/+	   embryos.	   In	   Sox2fl/+;FoxG1Cre/+;R26ReYFP/+	   embryos	   the	  average	   number	   of	   DAPI+ve	   nuclei	   counted	   was	   1140	   	   per	   embryo.	   This	  reduced	  to	  718	  in	  Sox2fl/fl;FoxG1Cre/+;R26ReYFP/+	  embryos.	  	  EdU+ve	  nuclei	  quantification	  at	  18.5dpc	  was	  restricted	  to	  the	  IL	  as	  defined	  by	  its	  localisation	  and	  structure.	  The	  IL	  is	  easily	  identified	  between	  the	  AL	  and	  PL	   due	   to	   its	   separation	   from	   the	   anterior	   pituitary	   via	   the	   lumen,	   and	  distinguishable	   form	   the	   posterior	   pituitary	   as	   cell	   morphology	   is	   very	  different.	  This	  is	  true	  both	  in	  control	  and	  mutant	  pituitaries.	  The	  number	  of	  EdU+ve	   nuclei	   was	   counted	   on	   three	   sections	   per	   pituitary,	   in	   three	  pituitaries	   per	   genotype.	   The	   number	   of	   EdU+ve	   nuclei	   is	   represented	   as	   a	  percentage	   of	   the	   total	   number	   of	   DAPI+ve	   nuclei,	   with	   error	   bars	  representing	  the	  standard	  error	  of	  the	  mean.	  The	  average	  number	  of	  DAPI+ve	  nuclei	   counted	   per	   embryo	   within	   each	   genotype	   was;	   WT:	   578,	  
Sox2fl/fl;Nkx3.1Cre/+:	   375,	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+:	   793	   and	   p27-­‐/-­‐
;Sox2fl/fl;Nkx3.1Cre/+:	  540.	  	  	  	  Quantification	  of	  the	  total	  number	  of	  DAPI+ve	  nuclei	  in	  the	  IL	  was	  performed	  on	   2/3	   pituitaries	   per	   genotype.	   Each	   pituitary	   was	   entirely	   serially	  sectioned	   and	   the	   number	   of	   DAPI+ve	   nuclei	   counted	   on	   three	   equivalent	  sections.	  Data	  was	  presented	  as	  the	  total	  number	  of	  DAPI+ve	  nuclei	  for	  each	  genotype;	  WT,	  Sox2fl/fl;Nkx3.1Cre/+,	  p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+.	  	  Quantification	   of	   the	   percentage	   of	   POMC+ve	   cells	   in	   the	   IL	   of	   WT,	  
Sox2fl/fl;Nkx3.1Cre/+,	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	   embryos	   was	   performed	   on	  three	  pituitaries	  per	  genotype.	  Each	  pituitary	  was	  entirely	  serially	  sectioned	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and	   the	   number	   of	   each	   endocrine	   cell	   type	   counted	   on	   three	   equivalent	  sections.	  Number	  of	  POMC+ve	  cells	  was	  presented	  as	  a	  percentage	  of	  the	  total	  amount	  of	  DAPI+ve	  nuclei,	  with	  error	  bars	  representing	  the	  standard	  error	  of	  the	   mean.	   The	   average	   number	   of	   DAPI+ve	   nuclei	   counted	   per	   embryo	   in	  each	   genotype	   was;	   WT	   578,	   Sox2fl/fl;Nkx3.1Cre/+	   375	   and	   p27-­‐/-­‐
;Sox2fl/fl;Nkx3.1Cre/+	  793.	  	  Quantification	  of	   the	  percentage	  of	   each	  endocrine	   cell	   type	  within	   the	  AL	  and	  IL	  was	  performed	  on	  three	  pituitaries	  per	  genotype.	  Each	  pituitary	  was	  entirely	   serially	   sectioned	   and	   the	   number	   of	   each	   endocrine	   cell	   type	  counted	   on	   three	   equivalent	   sections.	   Each	   endocrine	   cell	   type	   was	  presented	  as	  a	  percentage	  of	   the	   total	  amount	  of	  DAPI+ve	  nuclei	  within	   the	  lobe	   in	  which	   the	   population	   is	   present,	   with	   error	   bars	   representing	   the	  standard	   error	   of	   the	   mean.	   The	   IL	   was	   defined	   by	   its	   localization	   and	  structure	   (see	   above)	   and	  melanotrophs	   counted	   as	   a	   percentage	   of	   total	  number	   of	   DAPI+ve	   nuclei	   in	   the	   IL	   only.	   The	   average	   number	   of	   DAPI+ve	  nuclei	   counted	   per	   embryo	   in	   the	   AL	   was	   2674.	   In	   the	   IL	   the	   average	  number	  of	  DAPI+ve	  nuclei	  counted	  per	  embryo	  was	  578.	  	  The	   number	   of	   SOX2+ve;eYFP+ve	   cells	   in	   the	   RP	   of	   Nkx3.1Cre/+;R26ReYFP/+	  embryos	   was	   quantified	   as	   a	   percentage	   of	   the	   total	   number	   of	   SOX2+ve	  nuclei	   at	   12.5dpc	   and	   18.5dpc.	   In	  Nkx3.1Cre/+;R26ReYFP/+	   embryos	   this	   was	  quantified	   in	  three	  embryos.	  Each	  embryo	  was	  sectioned	  sagittally	  and	  the	  number	  of	  SOX2+ve;eYFP+ve	  cells	  was	  counted	  on	  three	  sections,	  one	  mid-­‐line	  and	  two	  lateral	  RP	  sections.	  In	  FoxG1Cre/+;R26ReYFP/+	  	  embryos	  quantification	  was	  only	  performed	  on	  one	  embryo	  due	  to	  the	  ubiquitous	  activity	  profile	  of	  the	   Cre	   driver.	   This	   embryo	   was	   sectioned	   sagittally	   and	   the	   number	   of	  SOX2+ve;eYFP+ve	   cells	  was	  counted	  on	   three	  sections,	  one	  mid-­‐line	  and	   two	  lateral	  RP	  sections.	  The	  number	  of	  SOX2+ve;eYFP+ve	  cells	  is	  represented	  as	  a	  percentage	   of	   the	   total	   number	   of	   SOX2+ve	   nuclei,	   with	   error	   bars	  representing	   the	   standard	   error	   of	   the	   mean.	   The	   average	   number	   of	  SOX2+ve	  nuclei	   counted	  per	  Nkx3.1Cre;R26ReYFP/+	   embryo	  was	  75	  at	  12.5dpc	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and	   290	   at	   18.5dpc.	   	   The	   total	   number	   of	   SOX2+ve	   nuclei	   counted	   in	   the	  
FoxG1Cre;R26ReYFP/+	  embryo	  was	  102,	  at	  10.5dpc.	  	  	  The	   number	   of	   hormone+ve;eYFP+ve	   cells	   for	   each	   endocrine	   cell	   type	   in	  
Nkx3.1Cre/+;R26ReYFP/+	   embryos	  was	   quantified	   as	   a	   percentage	   of	   the	   total	  number	   of	   each	   endocrine	   cell	   type	   at	   18.5dpc.	   Quantification	   was	  performed	   on	   three	   pituitaries	   except	   for	   each	   endocrine	   cell	   type,	   except	  for	  somatotrophs,	  which	  were	  only	  counted	  on	  two	  pituitaries.	  Each	  embryo	  was	   sectioned	   sagittally	   and	   the	   number	   of	   hormone+ve;eYFP+ve	   cells	   was	  counted	   on	   three	   sections,	   one	   mid-­‐line	   and	   two	   lateral	   RP	   sections.	   The	  number	   of	   hormone+ve;eYFP+ve	   cells	   is	   represented	   as	   a	   percentage	   of	   the	  total	  number	  of	  each	  endocrine	  cell	  population,	  with	  error	  bars	  representing	  the	   standard	   error	   of	   the	   mean.	   The	   average	   number	   of	   endocrine	   cells	  counted	   per	   cell	   type	   in	   Nkx3.1Cre;R26ReYFP/+	   embryo	   was;	   gonadotrophs	  37.6,	   lactotrophs	   19.3,	   thyrotrophs	   74,	   corticotrophs	   102.3,	   somatotrophs	  283	  and	  melanotrophs	  178.	  	  All	   statistical	   analyses	   were	   done	   using	   the	   Graph	   Pad	   Prism	   software.	  Unpaired	   Student	   t-­‐tests	   were	   used	   to	   compare	   two	   groups	   of	   data	   and	  significance	  was	  represented	  according	   to	   the	  p-­‐values.	  0.05	  =	  *,	  0.01	  =	  **.	  0.001	  =	  ***.	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	  
	   78	  




	  Accurate	  deletion	  of	  Sox2	   in	  RP	   is	   essential	   for	   a	   correct	   assessment	   to	  be	  made	   as	   to	   its	   role	   in	   RP	   progenitors.	   Various	   considerations	   have	   to	   be	  taken	   into	   account	   when	   selecting	   the	   correct	   tool	   to	   achieve	   this.	   These	  include	  the	  timing	  of	  deletion,	  as	  SOX2	  is	  globally	  expressed	  in	  RP	  from	  its	  induction	   up	   until	   11.5dpc,	   thereafter	   it	   becomes	   restricted	   dorsally.	  Deletion	  in	  this	  time	  period	  will	  provide	  a	  better	  understanding	  as	  to	  its	  role	  in	  the	  true	  RP	  progenitors,	  that	  give	  rise	  to	  all	  endocrine	  cell	  types	  (Rizzoti	  et	  al.,	  2013).	  Secondly	  spatial	  considerations	  have	  to	  be	  taken	  into	  account	  due	  to	  the	  wide	  expression	  of	  SOX2	  in	  other	  tissues.	  A	  broad	  field	  of	  deletion	  may	   affect	   global	   embryonic	   development	   and	   thus	   the	   embryo	   may	   die	  before	   RP	   induction,	   or	   RP	   formation	   may	   be	   directly	   affected	   by	   Sox2	  deletion	  in	  surrounding	  tissues.	  	  	  	  	  An	   example	   of	   the	   need	   for	   correct	   temporal	   and	   spatial	   deletion	   is	   the	  lethality	   that	   occurs	   in	   Sox2	   homozygous	   null	   mutant	   embryos.	   This	   is	  observed	   at	   peri-­‐implantation	   stages,	   as	   the	   protein	   is	   cell-­‐autonomously	  required	   for	   both	   the	   epiblast,	   from	   which	   the	   embryo	   derives,	   and	   in	  extraembryonic	  tissues	  (Avilion	  et	  al.,	  2003).	  An	  earlier	  role	  in	  the	  ICM	  may	  be	  masked	  by	  the	  presence	  of	  maternal	  cytoplasmic	  SOX2	  protein,	  imported	  into	   the	   nucleus	   of	   zygotes	   at	   the	   two-­‐cell	   stage	   (Avilion	   et	   al.,	   2003).	  Embryonic	  lethality	  of	  Sox2	  null	  embryos	  prevented	  the	  study	  of	  later	  roles	  of	  SOX2;	  therefore	  alternative	  methods	  have	  been	  used	  to	  look	  at	  the	  role	  of	  SOX2	  in	  different	  contexts.	  	  	  As	  development	  proceeds	  SOX2	  becomes	  largely	  restricted	  to	  the	  early	  CNS	  and	  by	  9.5dpc	   is	   expressed	   throughout	   the	  brain,	  neural	   tube	  and	  sensory	  placodes	   along	   with	   other	   SoxB1	   genes	   (Avilion	   et	   al.,	   2003,	   Wood	   &	  Episkopou.,	   1999).	   Significantly,	   Sox2	   is	   expressed	   in	   the	   VD	   and	  subsequently	  in	  the	  infundibulum	  upon	  its	  formation	  (Zhao	  et	  al.,	  2012).	  The	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importance	  of	  the	  VD	  in	  RP	  development	  cannot	  be	  understated.	  Expression	  and	   secretion	   of	   a	   number	   of	   morphogens,	   including	   BMF4,	   FGF8/10,	  Wnt5A	  and	  SHH	  from	  the	  VD	  are	  essential	  for	  the	  correct	  development	  of	  RP	  (Mathias	  Treier	  et	  al.,	  1998	  Ericson	  et	  al.,	  1998,	  Potok	  et	  al	  2008,	  Wang	  et	  al.,	  2010).	   Homozygous	   deletion	   of	   Sox3	   on	   a	   Sox2	   heterozygous	   background	  prevents	  hypothalamus	  formation,	  in	  addition	  to	  shifting	  FGF10	  expression	  anteriorly	  and	  completely	  down	  regulating	  SHH.	  Moreover	  RP	  formation	  is	  severely	   impaired	   as	   a	   consequence	   (Zhao	   et	   al.,	   2012).	   Embryos	  heterozygous	  for	  a	  null	  mutation	  in	  Sox3	  alone	  display	  pituitary	  hypoplasia,	  extra	   clefts	   and	   altered	   FGF8	   and	   BMP4	   expression	   (Rizzoti	   et	   al.,	   2004).	  Similarly,	   Sox2	   heterozygous	   mice	   have	   a	   bifurcated	   RP	   and	   clefts	   in	   the	  adult	   pituitary	   in	   addition	   to	   being	   hypoplastic	   (Kelberman	   et	   al.,	   2006b).	  The	   similarity	   in	   phenotype	   between	   Sox2	   and	   Sox3	   heterozygous	   mice	  suggest	   the	   defects	   are	   a	   result	   of	   VD	   abnormalities	   instead	   of	   primary	  pituitary	   defects,	   as	   SOX3	   is	   not	   expressed	   in	  RP.	   Thus	  wild-­‐type	   levels	   of	  SOX2	   expression	   in	   the	   VD	   and	   infundibulum	   are	   essential	   in	   promoting	  correct	   morphogen	   secretion	   and	   as	   a	   result	   correct	   RP	   development,	  whereas	   it	   would	   appear	   that	   heterozygous	   levels	   of	   SOX2	   are	   at	   least	  mostly	   sufficient	   for	   RP	   development.	   Consequently,	   to	   determine	   the	  precise	   role	   of	   SOX2	   in	   RP	   progenitors	   requires	   having	   a	   conditional	  mutation	  restricted	  to	  these	  cells,	  as	  loss	  of	  even	  one	  allele	  in	  the	  overlying	  VD	  would	  result	  in	  a	  phenotype	  not	  solely	  derived	  from	  loss	  of	  SOX2	  in	  RP.	  	  	  To	  achieve	  the	  correct	  temporal	  and	  spatial	  deletion	  of	  Sox2,	  advantage	  was	  taken	   of	   the	   conditional	  method	   of	   gene	   deletion	   using	   LoxP	   flanked	  Sox2	  alleles	  (Taranova	  et	  al.,	  2006),	  which	  can	  be	  excised	  by	  Cre	  recombinase.	  In	  this	  system	  the	  Cre	  coding	  region	  is	  placed	  downstream	  of	  the	  promoter	  of	  a	  gene	  chosen	  because	  of	   its	  specific	  pattern	  of	  expression,	  such	  that	  the	  Cre	  recombinase	   will	   be	   expressed	   with	   the	   same	   pattern.	   This	   “Cre-­‐driver”	  construct	  can	  be	  derived	  by	  gene	   targeting,	  placing	   it	   into	   the	  endogenous	  locus,	  alternatively	  it	  can	  be	  constructed	  in	  vitro	  and	  randomly	  inserted	  into	  the	  genome	  as	  a	  transgene.	  Deletion	  of	  Sox2	  has	  been	  achieved	  this	  way	  in	  a	  number	  of	  cell	  types	  including	  the	  eye	  (Smith	  et	  al.,	  2009),	  teeth	  (Juuri	  et	  al.,	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2013),	   glia	   (Gomezmez-­‐Lopez	   et	   al.,	   2011)	   and	   germ	   cells	   (Campolo	   et	   al.,	  2013).	   Several	   Cre	   drivers	   exist	   with	   active	   recombination	   in	   RP.	   These	  include	  Pit1-­‐Cre	   (Gaston-­‐massuet	   et	   al.,	   2011),	  POMC-­‐Cre	   (Balthasar	   et	   al.,	  2004),	  PrL-­‐Cre	   (Castrique	  et	   al.,	   2010)	  and	  GH-­‐Cre	   (Nasonkin	  et	   al.,	   2010).	  The	   spatial	   restriction	   of	   these	   Cre	   drivers	   to	   RP	   provides	   an	   extremely	  accurate	  way	  of	  deleting	  conditional	  alleles	   in	   these	   lineages.	  Nevertheless	  these	  Cre	  drivers	  would	  be	  unable	  to	  delete	  Sox2	  in	  early	  RP	  progenitors	  due	  to	   their	   late	   onset	   of	   activity,	   which	   occurs	   exclusively	   in	   terminally	  differentiating	  or	  differentiated	  cells.	  	  The	  NK3	  homeobox	  1	  (NKX3.1)	  protein	  is	  a	  mammalian	  transcription	  factor	  homologous	   to	   Bagpipe	   in	   Drosophila.	   NKX3.1	   is	   expressed	   in	   multiple	  tissues	   in	   mice	   including	   somites,	   blood	   vessels,	   midgut	   and	   the	   male	  urogenital	  tract	  (Bieberich	  et	  al.,	  1996;	  Sciavolino	  et	  al.,	  1997;	  Tanaka	  et	  al.,	  1999)	   .	   First	   expressed	  at	  9.5dpc	   in	  RP	  and	  maintained	  until	  14.5dpc,	   it	   is	  present	   in	  a	  subset	  of	  dorsally	  restricted	  progenitors,	  where	   its	   function	   is	  unknown	  (Kioussi	  et	  al.,	  1999;	  Mathias	  Treier	  et	  al.,	  1998).	  The	  Nkx3.1-­‐LacZ	  targeted	   allele	   is	   active	   in	   all	   tissues	   described	   above	   in	   addition	   to	   RP	  where,	   like	   endogenous	   NKX3.1	   expression,	   activity	   is	   first	   observed	   at	  9.5dpc.	  Thereafter	  activity	  becomes	  restricted	  to	  the	  dorsal	  region	  of	  RP	  at	  16.5dpc	  (Schneider	  et	  al.,	  2000).	  Significantly	  Nkx3.1-­‐LacZ	  is	  not	  observed	  in	  the	  VD	  or	   infundibulum	  (Schneider	  et	  al.,	  2000).	  A	  similarly	  targeted	  allele	  driving	  Cre	  recombinase	  has	  also	  been	  generated,	  providing	  the	  possibility	  to	  conditionally	  delete	  genes	  in	  the	  areas	  in	  which	  LacZ	  reporter	  expression	  was	   observed	   (Lin	   et	   al.,	   2007).	   Nkx3.1Cre	   fills	   both	   requirements	   to	  successfully	  delete	  Sox2	  in	  RP.	  Firstly,	  unlike	  the	  Cre	  drivers	  listed	  above	  it	  fits	  the	  temporal	  requirement,	  as	  it	  will	  be	  active	  in	  the	  early	  RP	  progenitors	  (Treier	  et	  al.,	  1998;	  Schneider	  et	  al.,	  2000).	  	  Secondly	  and	  most	  importantly	  it	   fits	   the	  spatial	   requirement	  of	  not	  being	  active	   in	   the	  overlying	  VD;	   thus	  any	  phenotype	  associated	  with	  Sox2	  deletion	  in	  this	  area	  will	  be	  avoided.	  	  	  	  The	   spatially	   restricted	  pattern	  of	  Nkx3.1Cre	   activity	   in	   the	  dorsal	   region	  of	  RP	   prevents	   global	   deletion	   of	   Sox2	   during	   the	   early	   stages	   of	   pituitary	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devolvement.	  Forkhead	  box	  G1	  (FOXG1)	  is	  a	  TF	  that	  is	  expressed	  primarily	  in	   the	   telencephalon	   (Tao	  &	  Lai.,	   1992).	   It	   is	   first	   expressed	  at	  E8.0	   in	   the	  anterior	  neural	  ridge	  that	  gives	  rise	  in	  particular	  to	  the	  hypophyseal	  placode	  (Shimamur	   et	   al.,	   1995).	   Hébert	   &	  McConnell	   (2000)	   produced	   a	   targeted	  
FoxG1Cre	   mouse	   line,	   in	   which	   the	   ORF	   of	   FoxG1	  was	   replaced	   by	   the	   Cre	  recombinase.	  FoxG1Cre	  mice	  bred	  with	  a	  R26ReYFP/eYFP	   line	   revealed	   that	   its	  pattern	   of	   activity	   matched	   closely	   the	   endogenous	   pattern	   of	   FOXG1	  expression,	   providing	   the	  mice	  were	   bred	   on	   a	   129/SvJ	   or	   Swiss	  Webster	  background	  to	  avoid	  ectopic	  activation,	  which	  has	  been	  reported	  to	  occur	  on	  other	   backgrounds	   (Hébert	   &	   McConnell.,	   2000).	   Due	   to	   its	   activation	  pattern	  FoxG1Cre	  has	  primarily	  been	  used	  to	  delete	  genes	  in	  the	  forebrain,	  in	  particular	  Sox2,	   resulting	   in	   forebrain	  defects	   including	   loss	  of	  NKX2.1	  and	  SHH	   expression	   (Ferri	   et	   al.,	   2013).	   More	   detailed	   lineage	   tracing	   was	  carried	   out	   by	   Wang	   et	   al	   (2010),	   showing	   LacZ	   reporter	   expression	  throughout	   the	   invaginating	   RP	   at	   9.5dpc.	   This	   was	   maintained	   in	   RP	   at	  12.5dpc	  showing	  global	  FoxG1Cre	  activity	  in	  RP,	  however	  at	  this	  stage	  there	  are	  a	  few	  LacZ+ve	  cells	  scattered	  in	  the	  infundibulum	  (Wang	  et	  al.,	  2010).	  The	  benefit	   of	   using	   FoxG1Cre	   to	   delete	   Sox2	   in	   RP	   is	   the	   extremely	   early	   and	  ubiquitous	  pattern	  of	  activity.	  This	  will	  allow	  for	  global	  deletion	  of	  Sox2	   in	  all	   RP	   progenitors	   before	   the	   pouch	   forms	   at	   11.0dpc	   and	   before	   the	  beginning	  of	  endocrine	  cell	  differentiation	  at	  11.5dpc	  -­‐	  13.5dpc	  (Davis	  et	  al.,	  2011).	  Nevertheless	   the	  mild	  ectopic	  activity	   in	   the	  VD	  may	  disrupt	   ligand	  secretion	   in	   this	   region.	   Using	   both	   Nkx3.1Cre	   and	   FoxG1Cre	   will	   allow	   us	  delete	  Sox2	  with	  greater	  spatial	  and	  temporal	  specificity.	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	  
	   82	  
3.2	  Results	  
	  
3.2.1	  Nkx3.1Cre	  activity	  profile	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Figure	  3.1:	  Nkx3.1Cre	  activity	  profile.	  Immunofluorescence	   stain	   for	   eYFP	   (green),	   SOX2	   (red)	   counterstained	  with	  DAPI	   (blue)	  between	   10.5-­‐18.5dpc.	   Nkx3.1Cre/+	  males	   were	   bred	  with	  R26ReYFP/eYFP	   females	   to	   produce	  
Nkx3.1Cre/+;R26ReYFP/+	   embryos.	   eYFP	   can	   be	   seen	   from	   10.5dpc	   (Ai)	   and	   increases	   until	  12.5dpc	   (Bi).	   SOX2	   is	   ubiquitously	   expressed	   in	   RP	   from	   10.5dpc	   but	   becomes	   dorsally	  restricted	  from	  12.5dpc	  (Aii	  and	  Bii).	  By	  16.5dpc	  and	  18.5dpc	  SOX2	  is	  found	  in	  the	  future	  IL	  and	  scattered	  in	  the	  parenchyma	  (Dii	  and	  Eii).	  The	  main	  area	  of	  eYFP	  expression	  is	   in	  the	  dorsal	   side	   of	   RP	   at	   12.5dpc	   (Bi).	   eYFP	   co-­‐localises	  with	   SOX2+ve	   progenitors	   (inset,	   Biii)	  increasingly	  until	  12.5dpc	  and	  thereafter	  it	  co-­‐localises	  with	  SOX2	  in	  the	  dorsal	  region	  of	  RP	  in	  the	  future	  IL,	  however	  at	  all	  stages	  not	  all	  SOX2+ve	  cells	  are	  eYFP+ve	  (Aiii	  –	  Eiii).	  Sections	  at	  10.5dpc,	  12.5dpc	  and	  14.5dpc	  are	  sagittal.	  Sections	  at	  16.5dpc	  and	  18.5dpc	  are	  coronal	  (see	  figure	   1.3	   and	   1.4	   for	   schematic	   representation).	   VD	   =	   Ventral	   Diencephalon,	   Inf	   =	  Infundibulum,	   RP	   =	   Rathke’s	   Pouch,	   PL	   =	   Posterior	   Lobe,	   IL	   =	   Intermediate	   Lobe,	   AL	   =	  Anterior	  Lobe.	  D-­‐RP	  =	  Dorsal	  Rathke’s	  Pouch	  and	  future	  IL,	  star	  =	  definitive	  RP	  and	  V-­‐RP	  =	  Ventral	  Rathke’s	  Pouch.	  Scale	  =	  50μm.	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3.2.2	   Nkx3.1Cre	   activity	   profile	   in	   terminally	   differentiated	   endocrine	  
cell	  populations	  	  








	   	   	  




































	   	   	  
















Figure	  3.3:	  Nkx3.1Cre	  fate	  mapping	  in	  all	  endocrine	  cell	  types.	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3.2.3	  FoxG1Cre	  activity	  prolife	  	  
	  The	   second	  Cre	  driver	   explored	  as	   a	  means	   to	   conditionally	  delete	  Sox2	   is	  
FoxG1Cre,	  which	  has	  been	   reported	   to	  be	   active	   throughout	   the	  RP	   from	  at	  least	  9.5dpc	  (Wang	  et	  al.,	  2010).	  To	  identify	  the	  activity	  profile	  of	  this	  Cre-­‐driver,	   FoxG1Cre	  mice	   were	   crossed	   with	   a	   Rosa26	   Reporter	   eYFP	   strain	  (Srinivas	  et	  al.,	  2001).	  In	  embryos	  carrying	  both	  the	  Cre	  driver	  and	  reporter,	  at	  10.5dpc	  all	  cells	  of	  are	  eYFP+ve	   (n	  =	  1)	  (Figure	  3.2,	  3.4).	  At	   this	  stage	  no	  cells	   of	   the	   overlying	   VD	   are	   eYFP+ve,	   however	   by	   12.5dpc	   FoxG1Cre	   has	  become	  active	  in	  the	  VD,	  with	  some	  eYFP+ve	  cells	  starting	  to	  appear	  (Figure	  3.4).	  This	  VD	  expression	  may	  be	  due	  to	  the	  mice	  not	  being	  on	  a	  pure	  129/SvJ	  background	   (Hébert	   &	   McConnell.,	   2000).	   These	   data	   suggest	   that,	   when	  combined	   with	   the	   Sox2	   conditional	   mutation,	   Sox2	   will	   be	   deleted	  throughout	  the	  RP	  from	  as	  early	  as	  10.5dpc,	  however	  it	  will	  also	  be	  deleted	  in	   a	   salt	   and	   pepper	   fashion	   in	   the	   VD	   from	   12.5dpc.	   Therefore	   any	  phenotype	   that	   results	  could	  be	  affected	  by	  partial	   loss	  of	  SOX2	   in	   the	  VD.	  Due	   to	   the	  widespread	  activity	  of	  FoxG1Cre	  at	  10.5dpc	   in	  RP,	  by	  18.5dpc	  all	  cells	  of	  the	  AP	  are	  eYFP+ve	  (Figure	  3.4).	  This	  activity	   is	  prior	  to	  the	  start	  of	  endocrine	  cell	  differentiation	  at	  11.5dpc	  -­‐	  13.5dpc.	  Thus	  if	  SOX2	  is	  required	  for	  endocrine	  cell	  differentiation,	  the	  subsequent	  global	  deletion	  may	  result	  in	  the	  complete	  loss	  of	  terminally	  differentiated	  endocrine	  cells.	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3.3	  Discussion	  
	  The	   experiments	   carried	   out	   in	   this	   chapter	   aimed	   to	   investigate	   the	  properties	  of	  two	  different	  Cre	  drivers	  chosen	  to	  conditionally	  delete	  Sox2	  in	  RP.	   The	   different	   activity	   profiles	   of	   the	   Cre	   drivers	   would	   allow	   a	  comparison	   of	   the	   consequences	   of	   deleting	   Sox2	   in	   different	   spacio-­‐temporal	   patterns,	  which	  might	   help	   to	   elucidate	   any	   role	   of	   SOX2	   and	   to	  identify	  underlying	  mechanisms.	  	  	  Birthdating	   studies	   have	   shown	   all	   RP	   progenitors	   proliferate	   up	   until	  10.5dpc.	   Thereafter	   progenitors	   exit	   the	   cell	   cycle	   between	   11.5dpc	   and	  13.5dpc	   and	   begin	   to	   differentiate	   into	   each	   of	   the	   anterior	   pituitary	  endocrine	   cell	   lineages	   (Davis	   et	   al.,	   2011).	   At	   10.5dpc	   all	   cells	   of	   RP	   are	  SOX2+ve.	  The	  data	  obtained	  using	  Nkx3.1Cre	  reveal	  a	  few	  eYFP+ve;SOX2+ve	  cells	  at	   10.5dpc,	   however	   by	   12.5dpc	   the	   number	   had	   markedly	   increased.	  Consequently	  Sox2	  should	  be	  deleted	  in	  RP	  progenitors	  during	  the	  phase	  of	  cell	   cycle	   exit	   when	   using	   Nkx3.1Cre.	   Conversely	   FoxG1Cre	   is	   ubiquitously	  active	   in	   RP	   from	   10.5dpc	   and	   possibly	   earlier	   (Wang	   et	   al.,	   2010).	   This	  should	   result	   in	   Sox2	   deletion	   during	   the	   proliferative	   stage	   of	   RP	  development	  prior	   to	  10.5dpc	  and	  prior	   to	   cell	   cycle	  exit.	  One	  of	   the	  main	  advantages	   to	   using	   these	   two	   Cre	   drivers	   should	   be	   the	   ability	   to	   delete	  
Sox2	  in	  two	  temporally	  specific	  patterns.	  This	  will	  allow	  for	  the	  analysis	  of	  the	  role	  of	  SOX2	  both	  during	  the	  proliferative	  phase	  of	  RP	  development	  and	  just	  prior	  to	  differentiation.	  	  The	   second	   advantage	   to	   using	   two	   Cre	   drivers	   is	   their	   different	   spatial	  patterns	  of	  activity.	  Lineage	  tracing	  using	  either	  Sox2CreERT2	  or	  Sox9CreERT2	  as	  inducible	  Cre	  drivers	  has	  revealed	  that	   the	  SOX2+ve	  progenitors	  prior	   to	  or	  upon	   the	   start	   of	   differentiation	   give	   rise	   to	   all	   the	   endocrine	   cells	   of	   the	  anterior	  and	  intermediate	  lobes	  (Rizzoti	  et	  al.,	  2013).	  While	  strictly	  speaking	  not	  lineage	  tracing,	  the	  data	  shown	  here	  indicates	  that	  due	  to	  the	  early	  onset	  of	  FoxG1Cre	   activity	   all	   endocrine	   cells	   are	   eYFP+ve	   at	   18.5dpc.	   This	   should	  allow	  the	  consequences	  of	  Sox2	  deletion	  on	  endocrine	  cell	  differentiation	  to	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be	  studied	  and	  identify	  whether	  SOX2	  is	  necessary	  for	  the	  differentiation	  of	  all	   or	   a	   subset	   of	   endocrine	   cell	   types.	   Nkx3.1Cre	   however,	   is	   not	   active	  throughout	   the	   entire	   RP	   at	   any	   stage,	   resulting	   in	   varying	   levels	   of	  hormone+ve;eYFP+ve	  cells	  at	  18.5dpc.	  In	  the	  developing	  AP,	  Nkx3.1Cre	  is	  active	  in	   the	   ventral	   regions	   of	   RP	   in	   a	   salt	   and	   pepper	   fashion.	   At	   this	   stage	   of	  development	   endocrine	   cell	   cycle	   exit	   varies	   depending	   on	   cell	   type,	  11.5dpc-­‐12.5dpc	   for	   gonadotrophs	   and	   thyrotrophs	   to	   11.5-­‐13.5dpc	   for	  corticotrophs	  and	  somatotrophs	  (Davis	  et	  al.,	  2011).	  As	  a	  result,	  if	  this	  Cre-­‐driver	  acts	  similarly	  on	  Sox2fl/fl	  as	  it	  does	  on	  R26ReYFP,	  Sox2	  will	  be	  deleted	  in	   a	   proportion	   of	   each	   endocrine	   cell	   type	   during	   the	   period	   of	   cell	   cycle	  exit	   and	   in	   addition,	   Sox2	   will	   be	   deleted	   in	   each	   cell	   type	   to	   a	   different	  extent.	  This	  may	  result	  in	  a	  greater	  reduction	  in	  endocrine	  cell	  number	  than	  is	  predicted	  based	  solely	  on	  the	  expression	  of	  the	  eYFP	  reporter.	  	  Birthdating	   studies	   have	   shown	   that	  MSH	   cells	   exit	   the	   cell	   cycle	   between	  12.5-­‐14.5dpc,	   later	   than	   AP	   endocrine	   cells	   (Davis	   et	   al.,	   2011).	   eYFP	  expression	   in	   the	  dorsal	   region	  of	  RP	  reveals	   that	  Nkx3.1Cre	   is	  ubiquitously	  active	  in	  this	  region	  at	  12.5dpc	  and	  gives	  rise	  to	  over	  90%	  of	  POMC+ve	  MSH	  cells	   at	   18.5dpc.	   As	   a	   consequence	   of	   this,	   it	   should	   be	   possible	   to	   use	  
Nkx3.1Cre	   to	  delete	  Sox2	   just	  prior	   to	   the	  exit	  of	   the	  cell	   cycle	   in	   the	  dorsal	  region	  of	  RP.	  This	  may	  allow	  the	  role	  of	  SOX2	  to	  be	  determined	  in	  the	  cycling	  progenitors	  of	  cells	  that	  give	  rise	  to	  only	  one	  endocrine	  cell	  type.	  	  	  
Nkx3.1Cre	  offers	  additional	  advantages	  to	  the	  study	  of	  the	  role	  of	  SOX2	  in	  RP	  development.	   The	   mosaic	   deletion	   pattern,	   along	   with	   the	   presence	   of	   a	  reporter	  allele,	  allows	  the	  fate	  of	  a	  subset	  of	  Sox2	  deleted	  cells	  to	  be	  followed	  in	   the	   developing	  AL.	  While	   SOX2	  must	   function	   cell	   autonomously,	   it	   has	  been	   shown	   to	   drive	   neurogenesis	   in	   the	   hippocampus	   in	   a	   non-­‐cell	  autonomous	   fashion,	   via	   its	   direct	   transcriptional	   regulation	   of	   Shh	  transcription.	   Sox2	   conditional	   deletion	   in	   these	   cells	   downregulates	   SHH	  expression	  and	  therefore	  lowers	  SHH	  singling,	  thus	  impeding	  neurogenesis	  in	  the	  surrounding	  tissue	  (Favaro	  et	  al.,	  2009).	  SoxB1	  genes	  have	  also	  been	  identified	   as	   non-­‐cell	   autonomous	   regulators	   of	   pituitary	   development	   via	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the	  transcriptional	  regulation	  of	  Shh	  expression	  in	  the	  VD	  (Zhao	  et	  al.,	  2012).	  In	  this	  case,	  SHH	  aids	  the	  development	  of	  the	  infundibulum	  and	  RP	  (Zhao	  et	  al.,	   2012).	   Conversely,	   conditional	   deletion	   studies	   show	   the	   cell	  autonomous	  roles	  of	  SOX2	  and	  SOX3	  in	  the	  lungs	  and	  testis	  (Laronda	  et	  al.,	  2011;	  Que	   et	   al.,	   2009)	   .	  Sox3	   conditional	   deletion	  using	  VasaCre	  prevents	  spermatogonal	   differentiation	   in	   prepubertal	  mice,	   a	   phenotype	   similar	   to	  that	   seen	   in	   Sox3	  null	   mice,	   indicating	   the	   intrinsic,	   cell	   autonomous	   role	  SOX3	   plays	   in	   these	   cells	   (Laronda	   et	   al.,	   2011).	   Through	   the	   use	   of	   a	  reporter	  allele,	  it	  should	  be	  possible	  to	  trace	  and	  compare	  the	  development	  of	   cells	  deleted	   for	  Sox2	   and	   those	   that	   still	   retain	   it	   (non-­‐eYFP)	  cells.	  One	  caveat	   to	   this	   is	   one	  must	   assume	   the	   Cre	   recombinase	   excises	   the	   STOP	  codon	  in	  the	  reporter	  allele	  with	  the	  same	  efficiency	  as	  it	  excises	  conditional	  
Sox2fl/fl.	  Varying	  degrees	  of	  Cre	  recombinase	  efficiency	  has	  been	  observed	  in	  other	   studies	   (Liu	   et	   al.,	   2012),	   however	   the	   consistency	   in	   deletion	   and	  eYFP	  expression	  will	  identify	  if	  excision	  is	  equally	  efficient	  between	  R26ReYFP	  and	  Sox2fl/fl.	   	  Nevertheless	  this	  should	  address	  whether	  SOX2	  acts	  only	  in	  a	  cell	   autonomous	   fashion,	   e.g.	  Sox2	  deletion	  has	  no	   affect	   on	   the	   remaining	  population	   of	   cells	   of	   that	   lineage	   or	   any	   other	   lineage,	   or	   in	   a	   non-­‐cell	  autonomous	  fashion,	  i.e.	  Sox2	  deletion	  in	  a	  subset	  of	  cells	  directly	  affects	  the	  development	  of	  surrounding	  cells.	  	  	  The	   mosaic	   activity	   of	   Nkx3.1Cre	   may	   also	   be	   a	   drawback.	   If	   Sox2	   is	   not	  deleted	   throughout	   RP	   it	   might	   be	   difficult	   to	   ascertain	   its	   role	   in	   all	   RP	  progenitors.	   In	   contrast,	   FoxG1Cre	   is	   active	   in	   the	   hypophyseal	   placode	   at	  8.5dpc	  (Wang	  et	  al.,	  2011)	  and	  by	  10.5dpc,	  as	  shown	  here,	  100%	  of	  SOX2+ve	  cells	   express,	   or	  must	   have	   expressed	   Cre	   recombinase	   (in	   comparison	   to	  68.6%	  when	  using	  Nkx3.1Cre).	  These	  results	  suggest	  using	  FoxG1Cre	  will	  allow	  us	  to	  identify	  the	  earlier,	  global	  role	  of	  SOX2	  in	  RP	  development,	  prior	  to	  the	  onset	  of	  dorsal	  restriction.	  	  	  	  Previous	   studies	   have	   indicated	   that	   the	   genetic	   background	   on	   which	  
FoxG1Cre	   is	   bred	  makes	   a	   considerable	   difference	   to	   its	   pattern	   of	   activity	  (Hébert	  &	  McConnell.,	  2000).	  The	  pattern	  of	  activity	  induced	  by	  FoxG1Cre	  on	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a	   129/SvJ	   and	   Swiss	   Webster	   background	   is	   the	   most	   consistent,	   while	  BALB/c	   is	   the	   least	   consistent	   (Hébert	   &	  McConnell.,	   2000).	   In	   our	   study,	  
FoxG1Cre	  was	  not	  bred	  onto	  a	  pure	  129/SvJ	  background	  (it	  was	  imported	  on	  a	   mixed	   background	   and	   it	   would	   have	   taken	   too	   many	   generations	   of	  backcrossing	   to	   do	   so).	   It	   is	   assumed,	   therefore,	   that	   this	   is	   the	   reason	   it	  showed	   ectopic	   recombination	   in	   the	   VD/infundibulum,	   however	   this	   did	  not	  occur	  until	  12.5dpc.	  	  	  It	   is	   known	   that	   the	   infundibulum	   directly	   influences	   RP	   development	  through	  the	  secretion	  of	  BMP4	  and	  FGF8/10	  (Davis	  et	  al.,	  2011;	  Norlin	  et	  al.,	  2000;	   Ericson	   et	   al.,	   1998;	   Treier	   et	   al.,	   1998).	   The	   results	   shown	   here	  suggest	  that	  the	  use	  of	  the	  FoxG1Cre	  driver	  may	  lead	  to	  the	  deletion	  of	  Sox2	  in	  a	   few	  cells	  of	   the	   infundibulum,	  which	  could	  mildly	  affect	   its	  development.	  Disruption	   of	   the	   infundibulum	   could,	   as	   a	   consequence,	   impair	   the	  development	  of	  RP,	  as	  seen	  with	  Sox3	  mutants,	  resulting	  in	  a	  phenotype	  not	  wholly	  derived	  from	  the	  deletion	  of	  Sox2	  in	  RP	  (Rizzoti	  et	  al.,	  2004).	  Analysis	  of	   the	   expression	   of	   TF	   that	   are	   directly	   regulated	   by	   FGF8/10	   and	  BMP4	  secretion	  from	  the	  VD	  will	  help	  to	  determine	  whether	  this	  is	  occurring	  (See	  chapter	  4).	  	  
3.3.1	  Conclusions	  
	  In	   conclusion,	   Nkx3.1Cre	   and	   FoxG1Cre	   will	   provide	   alternative	   patterns	   of	  
Sox2	  deletion	   in	  RP.	  This	  provides	  an	  advantage,	  as	  we	  can	   investigate	   the	  role	  of	  SOX2	  in	  different	  temporal	  and	  spatial	  contexts.	  We	  can	  delete	  Sox2	  globally	  and	  extremely	  early	  on	   in	  RP	  development,	  prior	   to	  cell	   cycle	  exit	  using	  FoxG1Cre.	  In	  addition	  we	  can	  also	  investigate	  its	  role	  specifically	  in	  the	  most	   dorsal	   region,	   in	   cells	   that	   will	   give	   rise	   to	   the	   IL	   and	   in	   a	   mosaic	  pattern	  in	  the	  AL,	  with	  Nkx3.1Cre.	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4.	  Analysis	  of	  the	  role	  of	  SOX2	  in	  the	  developing	  pituitary	  	  The	   different	   activity	   profiles	   of	  Nkx3.1Cre	  and	  FoxG1Cre	   provide	   alternative	  temporal	   and	   spatial	   patterns	   to	   conditionally	   delete	   Sox2	   in	   vivo.	   In	   this	  chapter,	   the	   phenotypes	   that	   result	   from	   deletion	   using	   each	   of	   these	   Cre	  drivers	  will	  be	  described	  and	  analysed.	  The	   relevance	  of	   these	   results	  will	  then	  be	  discussed	  with	  respect	  to	  previously	  published	  data	  and	  hypotheses	  raised	  in	  earlier	  chapters.	  	  
	  
4.1	  Introduction	  
	  The	   proliferative	   capacity	   of	   cells	   in	   the	   pituitary	   varies	   significantly	  between	  development	  and	  adulthood.	  Early	  ubiquitous	  SOX2	  expression	   in	  RP	   coincides	   with	   a	   high	   level	   proliferation	   (Fauquier	   et	   al.,	   2008).	   As	  development	   proceeds,	   proliferative	   potential	   is	   reduced,	   but	   it	   remains	  mainly	   associated	   with	   SOX2	   expression,	   in	   the	   dorsal	   region	   of	   RP.	  (Fauquier	   et	   al.,	   2008;	   Rizzoti	   &	   Pires	   unpublished).	   Subsequently,	   by	  18.5dpc	  only	  1%	  of	  SOX2+ve	  cells	  incorporate	  BrdU	  following	  a	  1-­‐hour	  pulse,	  compared	   to	   80%	   at	   12.5dpc	   (Fauquier	   et	   al.,	   2008).	   The	   proliferative	  capacity	   of	   the	   adult	   SOX2+ve	   population	   remains	   very	   low,	   however	   it	  increases	   significantly	   following	   Gdx	   or	   Adx	   (Rizzoti	   et	   al.,	   2013).	   This	  indicates	   that	   these	   cells	   retain	   the	   capacity	   to	   proliferate	   in	   response	   to	  physiological	  demand.	  	  	  The	   association	   between	   SOX2	   and	   proliferation	   is	   similar	   in	   a	   number	   of	  other	   tissues	   throughout	   development,	   including	   the	   CNS.	   Initially	  expressed	   throughout	   the	   neurepithelia	   and	   neural	   tube	   proliferative	  SOX2+ve	  progenitors	  become	  progressively	  restricted	  to	  the	  ventral	  region	  of	  the	  neural	   tube	  as	  development	  progresses,	   similar	   to	  what	   is	  observed	   in	  RP	  (Ellis	  et	  al.,	  2004;	  Fauquier	  et	  al.,	  2008).	  Nevertheless,	  in	  adult	  mice,	  the	  neurogenic	  region	  of	  the	  lateral	  ventricle	  maintains	  a	  population	  of	  SOX2+ve	  cells	   that	   remain	   proliferative	   (Ferri	   et	   al.,	   2004).	   Some	   of	   these	   are	   NSC,	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although	   transit-­‐amplifying	   progenitors	   also	   express	   SOX2	   and	   can	  replicate.	  Downregulation	  of	   SOX2	  however,	   is	  necessary	   for	   these	   cells	   to	  become	  neuroblasts	  (López-­‐Juárez	  et	  al.,	  2012).	  	  	  Cells	  expressing	  Sox2	  in	  the	  eye	  share	  a	  similar	  proliferative	  profile	  as	  in	  the	  CNS	  and	  pituitary.	  SOX2+ve	  proliferative	  progenitors	  are	   found	  primarily	   in	  the	  central	  region	  of	  the	  optic	  cup	  in	  development	  (Matsushima	  et	  al.,	  2011).	  Proliferation	   in	   these	   cells	   is	   lost	   following	   Sox2	   deletion,	   moreover	   Sox2	  hypomorphic	   mice	   have	   a	   small	   eye	   defect	   (Matsushima	   et	   al.,	   2011;	  Taranova	   et	   al.,	   2006).	   Conversely	   in	   the	   adult	   eye,	   SOX2	   is	   expressed	   in	  Müller	  glial	  cells	  that	  retain	  a	  neurogenic	  capacity	  and	  are	  largely	  quiescent,	  as	   in	   the	  brain	   (Surzenko	   et	   al.,	   2013).	  Sox2	   deletion	   results	   in	   loss	   of	   the	  glial	   cells	   population	   as	   these	   cells	   re-­‐enter	   the	   cell	   cycle	   through	   the	  downregulation	  of	  p27kip1	  (Surzenko	  et	  al.,	  2013).	  	  	  In	  the	  embryonic	  cochlea	  an	  increase	  in	  the	  number	  of	  SOX2+ve	  cells	  through	  βcatenin	  overexpression	  is	  coupled	  with	  an	  increase	  in	  Cyclin	  D1	  expression	  and	  proliferation	  (Jacques	  et	  al.,	  2013).	  An	  increase	  in	  Cyclin	  D1	  expression,	  coupled	   with	   an	   increase	   in	   proliferation	   is	   also	   observed	   in	   the	   adult	  respiratory	  epithelium	  upon	  SOX2	  overexpression	  (Tompkins	  et	  al.,	  2011).	  These	   observations,	   derived	   from	   other	   SOX2+ve	   progenitor	   populations,	  imply	  that	  the	  role	  of	  SOX2	  in	  RP	  progenitors	  may	  also	  be,	  at	  least	  in	  part,	  to	  maintain	   proliferation.	   Deletion	   of	   Sox2	   early	   in	   RP	   using	   FoxG1Cre	   should	  provide	  a	  test	  of	  this	  hypothesis.	  	  The	   aim	   of	   this	   chapter	   was	   to	   analyse	   the	   effect	   that	   conditional	   Sox2	  deletion	  has	  on	  the	  embryonic	  development	  of	  the	  pituitary.	  Both	  Nkx3.1Cre	  and	   FoxG1Cre	   drivers	   were	   used	   in	   parallel,	   however	   the	   latter	   was	   used	  primarily	   in	   the	   analysis	   of	   early	   TF	   expression	   due	   to	   its	   early	   and	  ubiquitous	   activity	   profile	   in	   RP.	   Nkx3.1Cre	   activity	   starts	   later	   and	   is	  restricted,	  so	  was	  used	  to	  investigate	  later	  aspects	  of	  SOX2	  function.	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4.2	  Results	  
	  
4.2.1	  Morphological	  analysis	  of	  Rathke’s	  Pouch	  following	  Sox2	  deletion	  	  	  At	  10.dpc	  Sox2	   is	  expressed	  throughout	  RP	  (Figures	  4.1,	  4.2).	  To	  assess	  the	  effects	  of	  partial	  and	  ubiquitous	  Sox2	  deletion	  in	  RP,	  Sox2fl/fl	  mice	  were	  bred	  with	   Sox2fl/+;Nkx3.1Cre/+	   and	   Sox2fl/+;FoxG1Cre/+	   mice.	   SOX2	   expression	   is	  almost	   unaffected	   at	   10.5dpc	   in	   Sox2fl/fl;Nkx3.1Cre/+	   embryos	   (Figure	   4.1).	  This	   is	   coupled	  with	   no	  morphological	   defects	   and	   this	  matches	   the	   small	  number	  of	  cells	  in	  which	  Nkx3.1Cre	   is	  active	  in	  at	  this	  stage	  of	  development.	  
Nkx3.1Cre	   activity	   is	   markedly	   increased	   between	   10.5dpc	   and	   12.5dpc	  (Figure	  3.1).	  This	   increase	   in	  activity	   is	  mirrored	   in	   the	   reduction	  of	  SOX2	  expression	   at	   12.5dpc	   in	   Sox2fl/fl;Nkx3.1Cre/+	   embryos	   where	   only	   a	   small	  number	  of	  cells	  still	  express	  SOX2	  in	  the	  dorsal	  region	  (Figure	  4.1).	  Despite	  the	   loss	   of	   the	   protein,	   there	   are	   no	   clear	  morphological	   abnormalities	   at	  this	   stage	   of	   development	   (Figure	   4.1).	   Conversely	   by	   14.5dpc	  morphological	   defects	   start	   to	   appear	   in	   Sox2fl/fl;Nkx3.1Cre/+	   embryos.	   The	  dorsal	   region	   has	   become	   a	   thinner	   more	   rounded	   disrupted	   epithelium	  (Figure	  4.1).	  The	  number	  of	  SOX2+ve	  cells	   is	  clearly	  decreased	  compared	  to	  control	  embryos	  and	  appears	  lower	  than	  at	  12.5dpc	  (Figure	  4.1).	  	  In	   contrast	   to	   Sox2fl/fl;Nkx3.1Cre/+	   embryos,	   SOX2	   is	   completely	  downregulated	   in	   the	   RP	   of	   Sox2fl/fl;FoxG1Cre/+	  embryos	   at	   10.5dpc	   (Figure	  4.2).	  Nevertheless	   this	   is	   not	   coupled	   to	   any	  morphological	   defects	   at	   this	  stage	  (Figure	  4.2).	  By	  12.5dpc	  however,	  RP	  is	  severely	  hypomorphic	  and	  has	  failed	   to	   pinch	   off	   from	   the	   underlying	   oral	   ectoderm.	   This	   is	   in	   stark	  contrast	   to	   control	   Sox2fl/+;FoxG1Cre/+	   	   embryos,	   in	   which	   RP	   is	   a	   defined	  structure	  at	  12.5dpc	  (Figure	  4.2).	  At	  14.5dpc	  the	  morphological	  defects	  are	  even	  more	  pronounced	  as	  RP	  has	  now	  pinched	  off	   from	  the	  oral	  ectoderm,	  and	  is	  extremely	  aberrant	  (Figure	  4.2).	  Despite	  the	  pinching	  off	  that	  occurs	  at	   14.5dpc,	   the	   sphenoid	   bone	   fails	   to	   close	   up	   at	   14.5dpc	   and	   16.5dpc	  (Figure	  4.3,	  4.20).	  The	  tissue	  that	  extends	  into	  the	  gap	  between	  the	  un-­‐fused	  sphenoid	  bone	  is	  initially	  comprised	  of	  rostral-­‐tip	  thyrotrophs	  (Figure	  4.3).	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Figure	  4.1:	  Conditional	  deletion	  of	  Sox2	  using	  Nkx3.1Cre.	  Immunofluorescence	   for	  SOX2	  (red),	  counterstained	  with	  DAPI	  (blue)	  at	  10.5dpc,	  12.5dpc	  and	   14.5dpc.	   Nuclear	   SOX2	   (inset)	   is	   found	   throughout	   RP	   at	   10.5dpc	   in	   control	  
Sox2fl./+;Nkx3.1Cre/+	  embryos	  and	  is	  only	  lost	  in	  a	  handful	  of	  cells	  in	  mutant	  Sox2fl/fl;Nkx3.1Cre/+	  embryos.	   SOX2	   is	   also	   observed	   throughout	   the	   VD	   and	   infundibulum	   at	   10.5dpc.	   SOX2	  becomes	  restricted	  to	  the	  dorsal	  side	  of	  RP	  by	  12.5dpc	  and	  maintained	  there	  at	  14.5dpc	  in	  control	  Sox2fl./+;Nkx3.1Cre/+	  embryos.	  There	   is	   a	  dramatic	   reduction	   in	   the	  number	  of	   SOX2	  positive	   cells	   in	  RP	  of	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  at	  12.5dpc	  and	  14.5dpc	   in	   addition	   to	   a	  thinning	   of	   the	   dorsal	   region	   of	   RP	   at	   14.5dpc	   (arrow).	  Morphological	   differences	   can	   be	  observed	   by	   14.5dpc.	   All	   sections	   are	   oriented	   sagittally	   (see	   figure	   1.3	   for	   schematic	  representation).	  RP	  =	  Rathke’s	  Pouch,	  Inf	  =	  Infundibulum.	  Scale	  =	  50μm.	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Figure	  4.2:	  Conditional	  deletion	  of	  Sox2	  using	  FoxG1Cre.	  	  Immunofluorescence	   for	   SOX2	   (red),	   counterstained	   with	   DAPI	   (blue)	   at	   10.5,	   12.5	   and	  14.5dpc.	   Nuclear	   SOX2	   (inset)	   is	   found	   throughout	   RP	   at	   10.5dpc	   in	   Sox2fl/+;FoxG1Cre/+	  embryos,	   becoming	   progressively	   dorsally	   restricted	   at	   12.5dpc	   and	   14.5dpc.	   In	   mutant	  
Sox2fl/fl;FoxG1Cre/+	  embryos	  SOX2	  is	  almost	  completely	  downregulated	  at	  least	  from	  10.5dpc.	  No	  obvious	  morphological	  defects	  are	  observed	  until	  12.5dpc	  in	  Sox2fl/fl;FoxG1Cre/+	  embryo,	  when	  an	  hypoplastic	  RP	  failing	  to	  pinch	  off	  from	  the	  underlying	  oral	  ectoderm	  is	  observed	  (arrow).	  Detachment	  from	  the	  oral	  ectoderm	  is	  however	  achieved	  by	  14.5dpc.	  All	  sections	  are	  orientated	  sagittally	  (see	  figure	  1.3	  for	  schematic	  representation).	  RP	  =	  Rathke’s	  Pouch,	  Inf	  =	  Infundibulum.	  Scale	  =	  50μm.	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4.2.2	  Morphological	  analysis	  of	  the	  adult	  pituitary	  following	  Sox2	  

















	   	   	  
























Figure	  4.4:	  Adult	  pituitary	  phenotype	  following	  Sox2	  deletion	  using	  Nkx3.1Cre.	  
A)	   Sox2	   expression	   in	   cells	   lining	   the	   lumen	  of	   adult	   pituitaries.	   Immunofluorescence	   for	  SOX2	  (red),	  counterstained	  with	  DAPI	  (blue)	  reveals.	  SOX2+ve	  cells	  present	  in	  the	  epithelium	  lining	   the	   lumen	   of	   Sox2fl/+;Nkx3.1Cre/+	   pituitaries.	   This	   layer	   is	   severely	   disrupted	   in	  
Sox2fl/fl;Nkx3.1Cre/+	  pituitaries.	  AP	  =	  anterior	  pituitary.	  Scale	  =	  10μm.	  B)	  POMC	  expression	  in	  adult	  pituitaries.	   Immunofluorescence	  for	  POMC	  (green),	  counterstained	  with	  DAPI	  (blue).	  The	   IL	   in	   Sox2fl/fl;Nkx3.1Cre/+	   mice	   is	   severely	   reduced	   in	   size	   compared	   to	   control	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4.2.3	  Progenitor	  cell	  proliferation	  following	  Sox2	  deletion	  	  To	   explore	   whether	   SOX2	   regulates	   proliferation	   in	   RP	   progenitors,	   and	  whether	   this	   accounts	   for	   the	   hypoplastic	   phenotype	   seen	   after	   Cre-­‐mediated	   deletion	   of	   Sox2,	   proliferation	   rates	   were	   analysed	   by	   BrdU	  incorporation.	   A	   one-­‐hour	   pulse	   was	   performed	   on	   pregnant	   females	   at	  12.5dpc	   as	   SOX2	   loss	   was	   observed	   at	   this	   stage	   of	   embryo	   development	  when	   using	   each	   of	   the	   two	   Cre	   drivers	   (Figure	   4.1,	   4.2).	   In	   the	  
Sox2fl/fl;Nkx3.1Cre/+	   embryos,	   the	   number	   of	   proliferating	   cells	   was	   first	  analysed	  in	  the	  whole	  RP,	  revealing	  only	  a	  small	  decrease	  in	  the	  number	  of	  cells	  incorporating	  BrdU.	  However,	  Nkx3.1Cre	   is	  predominantly	  active	  in	  the	  dorsal	  region	  of	  RP	  at	  12.5dpc	  (Figure	  3.1),	  with	  deletion	  only	  occurring	  in	  this	  same	  region	  (Figure	  4.1).	  When	  BrdU	  incorporation	  was	  only	  quantified	  in	   the	   dorsal	   region	   of	   12.5dpc	   RP,	   this	   revealed	   a	   large	   decrease	   in	   the	  percentage	   of	   BrdU+ve	   cells	   to	   DAPI+ve	   nuclei	   in	   Sox2fl/fl;Nkx3.1Cre/+	  (11.3%,	  ±2.6,	   n	   =	   3),	   compared	   to	  Sox2fl/+;Nkx3.1Cre/+	  embryos	   (19.6%,	   ±1.8,	   n	   =	   3)	  (Figure	  4.5A).	  	  	  However,	   when	   FoxG1Cre	   was	   used	   to	   delete	   Sox2,	   the	   decrease	   in	   the	  number	   of	   BrdU+ve	   cells	   in	   RP	   was	   significant	   when	   comparing	  
Sox2fl/+;FoxG1Cre/+	  embryos	  with	  Sox2fl/fl;FoxG1Cre/+	  embryos;	  17.2%	  (±1.0,	  n	  =	  3)	  compared	  to	  7.7%	  (±2.0,	  n	  =	  3)	  (Figure	  4.5B).	  In	  this	  instance	  the	  number	  of	  BrdU	  cells	  in	  the	  whole	  RP	  was	  counted,	  as	  FoxG1Cre	  is	  active	  in	  all	  cells	  at	  10.5dpc	   (Figure	   3.2).	   These	   results	   show	   that	   loss	   of	   Sox2	   result	   in	   a	  significant	   reduction	   in	   RP	   progenitor	   proliferation,	   and	   subsequently	   the	  formation	  of	  a	  hypoplastic	  pituitary.	  	  To	   further	   analyse	   this	   proliferative	   defect	   Cyclin	   D1	   expression	   was	  examined.	  Cyclin	  D1	  is	  a	  cell	  cycle	  checkpoint	  protein	  considered	  to	  regulate	  the	   transition	  between	   the	  G1/S	  phase	  of	   the	  cell	   cycle	   (Sala	  &	  Calabretta.,	  1992).	   Along	   with	   Cyclin	   D2,	   Cyclin	   D1	   is	   found	   in	   dorsal	   proliferating	  progenitors	   of	   RP	   (Figure	   4.6)	   (Bilodeau	   et	   al.,	   2009).	   Control	  
Sox2fl/+;FoxG1Cre/+	  embryos	  have	  a	  defined	  region	  of	  Cyclin	  D1	  expression	  in	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Figure	  4.5:	  BrdU	  incorporation	  in	  RP	  following	  Sox2	  deletion	  	  
A:	   BrdU	   incorporation	   one	   hour	   after	   injection	   is	   reduced	   in	   Sox2fl/fl;Nkx3.1Cre/+	  embryos	  11.3%	  (±2.6,	  n	  =	  3),	  compared	  to	  control	  Sox2fl/+;Nkx3.1Cre/+	  embryos	  19.61%	  (±1.8,	  n	  =	  3).	  Only	   cells	   in	   the	   dorsal	   region	   of	   RP	   were	   counted	   at	   this	   is	   where	   Nkx3.1Cre	   is	   active,	  however	  the	  reduction	   is	  not	  significant.	  B:	  BrdU	  incorporation	   is	  significantly	  reduced	   in	  
Sox2fl/fl;FoxG1Cre/+	  embryos	   at	   7.7%	   (±2.0,	   n	   =	   3),	   compared	   to	   control	   Sox2fl/+;FoxG1Cre/+	  embryos	  at	  17.2%	  	  (±1.09,	  n	  =	  3).	  BrdU	  incorporation	  was	  counted	  over	  the	  whole	  RP	  in	  ‘B’	  as	  FoxG1Cre	  is	  active	  throughout	  the	  RP	  from	  10.5dpc.	  	  	  	  	  	  	  	  
A	  
B	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To	   address	   the	   role	   of	   cell	   cycle	   checkpoint	  markers	   in	  more	   detail,	   CDKI	  p27kip1	  expression	  was	  analysed.	  In	  control	  embryos	  p27kip1	  is	  expressed	  in	   the	   ventral	   region	   of	   RP	   at	   14.5dpc	   in	   cells	   that	   have	   begun	   to	  differentiate	  (Bilodeau	  et	  al.,	  2009).	  No	  expression	  is	  observed	  in	  the	  dorsal	  region	   of	   RP	   where	   SOX2	   is	   expressed	   suggesting	   they	   have	   a	   mutually	  exclusive	   pattern	   of	   expression	   in	   RP	   at	   14.5dpc	   (Figure	   4.7).	   Upon	   Sox2	  deletion	   the	   region	   of	   p27kip1	   expression	   in	   the	   ventral	   region	   of	   RP	   is	  enlarged.	  Significantly,	  p27kip1	  is	  ectopically	  expressed	  in	  the	  dorsal	  region	  of	   RP,	   though	   it	   is	   never	   ectopically	   co-­‐expressed	   in	   any	   cells	   that	   fail	   to	  delete	   Sox2	   (Figure	   4.7).	   	   Therefore	   Sox2	   deletion	   is	   also	   associated	   with	  ectopic	   up-­‐regulation	   of	   p27kip1,	   which	   would	   result	   in	   cell	   cycle	   arrest,	  thus	  lowering	  proliferation.	  	  	  Lowered	  BrdU	  incorporation,	  as	  a	  consequence	  at	  least	  in	  part	  of	  Cyclin	  D1	  downregulation	   and	   p27kip1	   up-­‐regulation	   results	   in	   a	   decrease	   in	  proliferation,	  but	  a	  hypoplastic	  phenotype	  could	  also	  result	  from	  increased	  apoptosis.	  TUNEL	  staining	  in	  RP	  of	  control	  12.5dpc	  embryos	  reveals	  there	  is	  very	   little	   programmed	   cell	   death	   occurring	   at	   this	   time	   (Figure	   4.8),	   and	  this	   is	   not	   increased	   in	   Sox2fl/fl;Nkx3.1Cre/+	   embryos.	   This	   suggests	   that	  apoptosis	  does	  not	  contribute	  to	   the	  hypoplasia	  (Figure	  4.8).	  Conversely,	  a	  large	   number	   of	   TUNEL+ve	   apoptotic	   cells	   is	   observed	   ventrally	   in	  
Sox2fl/fl;FoxG1Cre/+	  RP	  (Figure	  4.8).	   It	  has	  been	  shown	  that	  as	  RP	  pinches	  off	  from	   the	   underlying	   oral	   ectoderm	   at	   11.5dpc,	   there	   is	   a	   localised	   foci	   of	  apoptotic	   cells	   (Charles	   et	   al.,	   2005).	   The	   hypomorphic	   RP	   in	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Figure	  4.7:	  SOX2	  and	  p27Kip1	  expression	  in	  14.5dpc	  RP	  following	  Sox2	  deletion	  using	  
Nkx3.1Cre.	  Immunofluorescence	  for	  SOX2	  (red)	  and	  p27kip1	  (green),	  counterstained	  with	  DAPI	  (blue)	  at	  14.5dpc.	  SOX2	  is	  restricted	  to	  the	  dorsal	  side	  (D-­‐RP	  and	  inset)	  of	  RP	  at	  14.5dpc	  in	  control	  
Sox2fl/+;Nkx3.1Cre/+	   embryos.	   Conversely	   p27kip1	   is	   expressed	   ventrally.	   In	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Figure	  4.8:	  TUNEL	  staining	  in	  12.5dpc	  RP	  following	  Sox2	  deletion.	  	  	  TUNEL	  assay	  (green),	   counterstained	  with	  DAPI	   (blue)	  at	  12.5dpc.	  Very	   little	  apoptosis	   is	  observed	   in	   RP	   at	   12.5dpc	   as	   only	   two	   to	   three	   TUNEL+ve	   cells	   are	   observed	   in	   control	  
Sox2fl/+;Nkx3.1Cre/+	  and	   Sox2fl/+;FoxG1Cre/+	  embryos.	   No	   increase	   in	   apoptosis	   is	   observed	   in	  
Sox2fl/fl;Nkx3.1Cre/+	  embryos.	   Increased	   apoptosis	   is	   observed	   in	   Sox2fl/fl;FoxG1Cre/+	  embryos	  where	  RP	  is	  pinching	  off	  from	  the	  underlying	  oral	  ectoderm,	  indicated	  by	  an	  a	  large	  number	  of	  TUNEL+ve	  cells.	  No	  TUNEL+ve	  cells	  are	  seen	  in	  the	  dorsal	  region	  of	  RP	  in	  Sox2fl/fl;FoxG1Cre/+	  embryos.	   All	   sections	   are	   orientated	   sagittally.	   Inf	   =	   Infundibulum,	   RP	   =	   Rathke’s	   Pouch.	  Scale	  =	  50μm.	  
	  
	   	   	  
	   110	  
4.2.4	  Early	  Rathke’s	  Pouch	  transcription	  factor	  expression	  following	  
Sox2	  deletion	  
	  Many	   TFs	   expressed	   in	   the	   early	   RP	   are	   known	   to	   regulate	   progenitor	  proliferation	   (for	   review	   see	   Kelberman	   et	   al.,	   2006).	   Null	   deletion	   of	   TFs	  such	  as	  Isl1,	  Lhx3	  and	  Six6/3	  result	   in	  hypoplastic	  pituitaries	  similar	  to	  the	  ones	  observed	  when	  Sox2	  is	  deleted	  using	  either	  Cre	  driver	  (Takuma	  et	  al.,	  1998;	  Sheng	  et	  al.,	  1997	  Li	  et	  al.,	  2002).	  Analysis	  of	  early	  RP	  TF	  expression	  was	  carried	  out	  to	  identify	  any	  alteration.	  	  	  ISL1	   initially	   becomes	   restricted	   to	   RP	   from	   9.5dpc	   and	   is	   ubiquitously	  expressed	   throughout	   RP	   at	   10.5dpc	   in	   control	   embryos	   (Ericson	   et	   al.,	  1998)	   (Figure	  4.9).	  Sox2	   deletion	   in	  mutant	  Sox2fl/fl;FoxG1Cre/+	  embryos	  has	  no	   effect	   on	   ISL1	   expression	   (Figure	   4.9).	   LHX3	   expression	   also	   starts	   at	  around	  9.5dpc,	  and	   is	   found	  throughout	   the	  pituitary	  by	  16.5dpc,	  although	  with	   a	   gradient	   of	   expression	   higher	   in	   dorsal	   regions.	   ISL1	   along	   with	  PITX1	  has	  been	  shown	  to	  drive	  Lhx3	  expression	  in	  RP	  (Mullen	  et	  al.,	  2012).	  We	   therefore	   hypothesise	   that	   the	   undisrupted	   ISL1	   expression	   should	  result	   in	  undisrupted	  LHX3	  expression.	  At	  10.5dpc	  SOX2	  and	  LHX3	  are	  co-­‐expressed	  throughout	  RP	  in	  control	  embryos	  (Figure	  4.10).	  At	  12.5dpc	  SOX2	  is	   becoming	   restricted	   to	   the	   dorsal	   region	   but	   LHX3	   is	   still	   expressed	   in	  every	   cell	   of	   RP	   resulting	   in	   loss	   of	   co-­‐expression	   ventrally	   (Figure	   4.10).	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Figure	  4.10:	  LHX3	  expression	   in	  RP	  at	  10.5dpc	  and	  12.5dpc	   following	  Sox2	  deletion	  
using	  FoxG1Cre.	  Immunofluorescence	  for	  SOX2	  (red)	  and	  LHX3	  (green),	  counterstained	  with	  DAPI	  (blue)	  at	  10.5dpc	  and	  12.5dpc.	  SOX2	  and	  LHX3	  co-­‐localise	  (yellow)	  in	  every	  cell	  of	  RP	  at	  10.5dpc	  in	  control	  Sox2fl/+;FoxG1Cre/+	  embryos.	  SOX2	  is	  completely	  downregulated	   in	  Sox2fl/fl;FoxG1Cre/+	  embryos	  at	  10.5dpc,	  but	  Lhx3	  expression	  is	  retained.	  At	  12.5dpc	  SOX2	  is	  downregulated	  in	  the	  ventral	  most	  region	  of	  RP	  in	  control	  Sox2fl/+;FoxG1Cre/+	  embryos.	  LHX3	  is	  still	  found	  in	  all	  cells	   of	   RP	   in	   control	   Sox2fl/+;FoxG1Cre/+	  embryos	   and	   co-­‐localises	   with	   SOX2.	   In	   mutant	  





	   	   	  
	   113	  
Six6	  null	  mice	  have	  a	  phenotype	  very	  similar	  to	  the	  one	  we	  have	  described	  when	  deleting	  Sox2	  with	  FoxG1Cre	   (Li	   et	  al.,	  2002).	  Six6	  null	  mice	  display	  a	  hypoplastic	  pituitary	  and	  reduced	  progenitor	  proliferation	  (Li	  et	  al.,	  2002).	  In	  addition	   to	   this	  SOXB1	  genes	  have	  been	  shown	   to	  directly	   regulate	  Six6	  transcription	   in	   the	  hypothalamus	  (Lee	  et	  al.,	  2012).	  We	  therefore	  decided	  to	  look	  at	  the	  expression	  of	  SIX6	  and	  its	  paralogue	  SIX3	  upon	  Sox2	  deletion.	  SIX6	  is	  expressed	  ubiquitously	  in	  RP	  at	  10.5dpc	  along	  with	  SOX2	  in	  control	  embryos	   (Figure	   4.11).	   Upon	   Sox2	   deletion	   using	   FoxG1Cre	   SIX6	   is	   almost	  completely	   downregulated,	  with	   one	   or	   two	   cells	   remaining	   in	   the	   ventral	  region	   (Figure	   4.11).	   At	   12.5dpc	   SIX6	   and	   SOX2	   still	   co-­‐localize	   in	   control	  embryos	  (Figure	  4.11).	  In	  Sox2	  deleted	  embryos	  however,	  SIX6	  expression	  is	  completely	  lost	  (Figure	  4.11).	  The	  SIX6	  paralogue	  SIX3	  is	  also	  expressed	  in	  all	   cells	  of	  RP	  at	  12.5dpc	   in	  control	  embryos	  and	   in	  parallel	  with	  SIX6	   it	   is	  also	  downregulated	  upon	  Sox2	  deletion	  (Figure	  4.13).	   In	  Sox2fl/fl;Nkx3.1Cre/+	  embryos,	  Sox2	   is	  not	  deleted	   in	  a	   significant	  number	  of	   cells	  until	  12.5dpc	  and	  a	  phenotype	  is	  not	  observed	  until	  after	  this	  stage	  (Figure	  4.12).	  In	  line	  with	  this	  timing	  of	  deletion,	  SIX6	  is	  starting	  to	  be	  downregulated	  in	  cells	  of	  the	   dorsal	   RP	   14.5dpc	   (Figure	   4.12).	   At	   18.5dpc	   in	   Sox2fl/fl;FoxG1Cre/+	  embryos	   SIX6	   is	   still	   absent	   in	   the	  AP,	   indicating	   it	   is	   not	   re-­‐expressed	  by	  another	   factor	   later	   in	   development,	   or	   that	   the	   cell	   lineage	   that	   express	  SIX6	  no	  longer	  exists	  (Figure	  4.15).	  Altogether	  these	  results	  suggest	  that	  in	  RP,	  as	  observed	  in	  other	  tissues,	  SOX2	  may	  regulate	  Six6	  transcription.	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Figure	   4.11:	   SIX6	   expression	   in	  RP	   at	   10.5dpc	   and	   12.5dpc	   following	  Sox2	   deletion	  
using	  FoxG1Cre.	  Immunofluorescence	  for	  SOX2	  (red)	  and	  SIX6	  (green),	  counterstained	  with	  DAPI	  (blue)	  at	  10.5dpc	   and	   12.5dpc.	   SOX2	   and	   SIX6	   co-­‐localise	   (yellow)	   in	   all	   cells	   of	   RP	   at	   10.5dpc	   in	  control	  Sox2fl/+;FoxG1Cre/+	  embryos.	  In	  mutant	  Sox2fl/fl;FoxG1Cre/+	  embryos	  SOX2	  and	  SIX6	  are	  downregulated	   in	   all	   cells	   of	  RP,	   but	   remain	   co-­‐localised	   in	   the	  VD.	  At	  12.5dpc	   in	   control	  
Sox2fl/+;FoxG1Cre/+	  embryos	  SOX2	  is	  lost	  in	  the	  most	  ventral	  cells	  of	  RP.	  SIX6	  is	  also	  lost	  in	  the	  ventral	  region	  of	  RP	  but	  co-­‐localises	  with	  SOX2	  in	  the	  rest	  of	  RP.	  Mutant	  Sox2fl/fl;FoxG1Cre/+	  embryos	   have	   lost	   all	   Sox2	   expression	   RP	   and	   have	   completely	   downregulated	   SIX6.	   All	  sections	  are	  orientated	  sagittally	  (see	  figure	  1.3	  for	  schematic	  representation).	  VD	  =	  Ventral	  Diencephalon,	  RP	  =	  Rathke’s	  Pouch,	  Inf	  =	  Infundibulum.	  Scale	  =	  50μm.	  	  	  	  	  	  
	   	   	  

































Figure	   4.12:	   SIX6	   expression	   in	  RP	   at	   12.5dpc	   and	   14.5dpc	   following	  Sox2	   deletion	  
using	  Nkx3.1Cre.	  Immunofluorescence	   stain	   for	   SIX6	   (green),	   counterstained	  with	   DAPI	   (blue)	   at	   12.5dpc.	  SIX6	  is	  excluded	  from	  the	  most	  ventral	  region	  of	  RP	  in	  control	  Sox2fl/+;Nkx3.1Cre/+	  embryos,	  becoming	   progressively	   dorsally	   restricted	   at	   14.5dpc.	   In	   mutant	   Sox2fl/fl;Nkx3.1Cre/+	  embryos	  SIX6	  is	  downregulated	  in	  the	  dorsal	  region	  at	  14.5dpc.	  All	  sections	  are	  orientated	  sagittally.	  Inf	  =	  Infundibulum,	  RP	  =	  Rathke’s	  Pouch.	  Scale	  =	  50μm.	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Figure	  4.13:	  SIX3	  expression	  in	  RP	  at	  12.5dpc	  following	  Sox2	  deletion	  using	  FoxG1Cre.	  Immunofluorescence	   for	   SIX3	   (red),	   counterstained	   with	   DAPI	   (blue)	   at	   12.5dpc.	   SIX3	   is	  expressed	  throughout	  both	  RP,	  VD	  and	  Infundibulum	  at	  12.5dpc	  in	  control	  Sox2fl/+;FoxG1+/+	  embryos.	   At	   12.5dpc	   in	   mutant	   Sox2fl/fl;FoxG1Cre/+	   embryos	   SIX3	   expression	   is	   strongly	  downregulated	  in	  RP,	  while	  	  expression	  is	  maintained	  in	  VD	  and	  infundibulum.	  Sections	  are	  orientated	  sagittally.	  VD	  =	  Ventral	  Diencephalon,	  Inf	  =	  Infundibulum,	  RP	  =	  Rathke’s	  Pouch.	  Scale	  =	  50μm.	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Figure	  4.14:	  SIX6	  and	  SOX2	  expression	  in	  the	  anterior	  and	  intermediate	  lobe	  of	  WT	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Figure	  4.15:	  SOX2	  and	  SIX6	  expression	  in	  RP	  at	  18.5dpc	  following	  Sox2	  deletion	  using	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4.2.5	  Endocrine	  cell	  differentiation	  analysis	  following	  Sox2	  deletion	  
	  Based	  on	  the	  Nkx3.1Cre	  fate	  mapping,	  we	  hypothesised	  that	  all	  endocrine	  cell	  type	   would	   be	   affected	   by	   Sox2	   deletion	   (Figure	   3.3).	   At	   18.5dpc,	  
Sox2fl/fl;Nkx3.1cre/+	  	  embryos	  did	  indeed	  reveal	  that	  all	  endocrine	  cell	  types	  of	  the	   AP	   and	   IL	   were	   reduced,	   although	   to	   a	   different	   extent	   (Figure	   4.17,	  4.18A).	   The	   percentage	   of	   remaining	   endocrine	   cells	   in	   each	   population	  compared	  to	  control	  matched	  pituitaries	  were	  as	  follows:	  GH	  19.4%	  (±5.8,	  n	  =	  3),	  TSH	  35.2%	  (±17.2,	  n	  =	  3)	  LH	  25.8%	  (±8.9,	  n	  =	  3),	  PrL	  14.7%	  (±4.9,	  n	  =	  3),	  POMC	  (ACTH)	  45.5%	  (±24.7,	  n	  =	  2)	  and	  POMC	  (MSH)	  19.7%	  (±4.1,	  n	  =	  3)	  (Figure	   4.17,	   4.18A).	   Interestingly	   the	   reduction	   in	   the	   number	   of	  somatotrophs,	  thyrotrophs,	  gonadotrophs	  and	  lactotrophs	  was	  greater	  than	  expected	  based	  on	  the	   fate	  mapping	  (Figure	  3.3).	  This	  may	   indicate	  a	  non-­‐cell	   autonomous	   role	   for	   SOX2	   in	   regulating	   endocrine	   cell	   differentiation.	  Conversely	  the	  reduction	  in	  the	  number	  of	  melanotrophs	  was	  not	  as	  large	  as	  might	  be	  expected.	  Lineage	  tracing	  analysis	  showed	  92.0%	  of	  POMC+ve	  cells	  were	  Nkx3.1cre/+;R26RYFP/+	   at	   18.5dpc,	   indicating	   around	   8%	   of	   these	   cells	  should	   retain	   SOX2	   expression	   following	   deletion	   (Figure	   3.3B).	   The	  discrepancy	  in	  the	  reduction	  in	  POMC+ve	  cells	  in	  Sox2fl/fl;Nkx3.1cre/+	  	  embryos	  may	  be	   caused	  by	  differences	   in	   recombination	   efficiency	  between	  Sox2fl/fl	  and	  R26RYFP/YFP	  alleles	  (Liu	  et	  al.,	  2012),	  allowing	  some	  cells	  to	  appear	  YFP+ve	  without	   actually	   having	   Sox2	   deleted.	   Conversely	   there	   may	   be	  compensative	  proliferation	  in	  mutants.	  	  Melanotrophs	  make	  up	  72.0%	  (±3.3,	  n	  =	  3)	  of	   cells	   in	   the	   IL	  at	  18.5dpc	   in	  control	  (Sox2fl/+;Nkx3.1cre/+)	  embryos	  (Figure	  4.18B).	   If	   the	  reduction	  in	  the	  size	   of	   the	   IL	   was	   solely	   down	   to	   a	   reduction	   in	   early	   progenitor	  proliferation	   one	  would	   expect	   the	  proportion	   of	  melanotrophs	   that	  make	  up	   the	   mutant	   IL	   to	   be	   the	   same.	   However,	   the	   proportion	   decreases	  significantly	   in	   Sox2fl/fl;Nkx3.1cre/+	   embryos	   to	   23.2%	   (±3.5,	   n	   =	   3)	   (Figure	  4.18B).	  Moreover,	  many	   if	  not	  all	  of	   these	  melanotrophs	  are	   likely	   to	  have	  been	  generated	   from	  progenitors	   in	  which	  Nkx3.1Cre	  was	  not	   active.	  These	  results	  therefore	  suggest	  a	  differentiation	  defect,	  where	  the	  lack	  of	  SOX2	  in	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the	   progenitors	   compromises	   their	   ability	   to	   form	   melanotrophs	   (Figure	  4.18B).	  	  In	  Sox2fl/fl;FoxG1Cre/+	  	  embryos	  all	  endocrine	  cell	  types	   	  are	  severely	  affected	  at	  16.5dpc	  (Figure	  4.19A).	  The	  endocrine	  cell	  populations	  that	  differentiate	  later:	   somatotrophs,	   lactotrophs	   and	   gonadotrophs,	   are	   more	   severely	  affected	   than	   thyrotrophs,	   comprising	   a	   sub-­‐population	   of	   transient	   cells,	  the	  rostral	  tip	  thyrotrophs	  which	  are	  the	  earliest	  to	  differentiate,	  along	  with	  corticotrophs,	  at	  12.5dpc.	  The	  effect	  on	  corticotrophs	  appears	  intermediary	  between	   early	   differentiating	   thyrotrophs	   and	   later	   somatotrophs.	   The	  latter	   however	   are	   still	   severely	   reduced	   in	   number	   compared	   to	   control	  
Sox2fl/fl;FoxG1+/+	  embryos	  (Figure	  4.19A).	  Indicating	  the	  loss	  of	  SOX2	  so	  early	  on	  impairs	  the	  differentiation	  of	  most	  endocrine	  cells.	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Figure	  4.17:	  Endocrine	  cell	  reduction	  following	  Sox2	  deletion	  using	  Nkx3.1Cre.	  Immunofluorescence	  for	  each	  anterior	   lobe	  endocrine	  cell	   type	  (red),	  counterstained	  with	  DAPI	  (blue)	  at	  18.5dpc.	  All	  endocrine	  cell	  populations	  are	  reduced,	   to	  different	  extents,	   in	  
Sox2fl/fl;Nkx3.1Cre/+	  embryos.	  The	  AL	  and	  IL	  have	  become	  hypoplastic	  with	  the	  IL	  being	  more	  severely	  disrupted.	  All	  sections	  are	  orientated	  coronally	  and	  each	  represents	  one	  half	  of	  a	  pituitary	   (see	   figure	   1.4	   for	   schematic	   representation).	   PL	   =	   Posterior	   Lobe,	   IL	   =	  Intermediate	  lobe,	  AL	  =	  Anterior	  Lobe.	  Scale	  =	  100μm.	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Figure	  4.18:	  Reduction	  in	  endocrine	  cells	  following	  Sox2	  deletion	  using	  Nkx3.1Cre.	  
A:	   Percentage	   of	   each	   endocrine	   cell	   type	   remaining	   in	  mutant	   (Sox2fl/fl;Nkx3.1Cre/+)	   RP	   at	  18.5dpc	  compared	  to	  the	  control	  (Sox2fl/fl;Nkx3.1Cre/+)	  matched	  cell	  type.	  Percentages;	  POMC	  (MSH)	  19.7	  (±4.1,	  n	  =	  3),	  POMC	  (ACTH)	  45.5	  (±24.7,	  n	  =	  2),	  GH	  19.4	  (±5.8,	  n	  =	  3),	  LH	  25.8	  (±8.9,	   n	   =	   3),	   PrL	   14.7	   (±4.9,	   n	   =	   3)	   and	   TSH	   35.2	   (±17.9,	   n	   =	   3).	   B:	   Percentage	   of	  melanotrophs	  remaining	  in	  the	  IL	  of	  mutant	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  at	  18.5dpc	  (23.2%,	  ±3.5,	  n	  =	  3),	  is	  significantly	  lower	  than	  the	  percentage	  of	  melanotrophs	  in	  the	  IL	  of	  control	  
Sox2fl/+;Nkx3.1Cre/+	  embryos	  (72.0%,	  ±3.3,	  n	  =	  3).	  	  	  
A	  
B	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Figure	  4.19:	  Endocrine	  cell	  and	  PIT1	  reduction	  following	  Sox2	  deletion	  using	  FoxG1Cre.	  
A:	  Immunofluorescence	  for	  each	  AP	  endocrine	  cell	  type	  (green),	  counterstained	  with	  DAPI	  (blue)	  at	  16.5dpc.	  The	  gland	  is	  hypoplastic	  and	  the	  morphology	  extremely	  aberrant	  with	  no	  defined	   AP	   and	   IL	   in	   Sox2fl/fl;FoxG1Cre/+	   embryos.	   All	   endocrine	   cell	   populations	   are	  dramatically	   reduced	   in	   Sox2fl/fl;FoxG1Cre/+	  embryos.	   Somatotrophs	   are	   completely	   absent,	  very	  few	  LH	  positive	  gonadotrophs	  and	  POMC	  positive	  corticotrophs	  and	  melanotrophs	  are	  observed	   while	   more	   TSH	   positive	   thyrotrophs	   persist.	   	   All	   sections	   are	   orientated	  coronally,	  control	  represents	  one	  half	  of	  an	  18.5dpc	  pituitary,	  mutant	  represents	  the	  whole	  pituitary	  at	  18.5dpc.	  PL	  =	  Posterior	  Lobe,	  IL	  =	  Intermediate	  Lobe,	  AL	  =	  Anterior	  Lobe.	  Scale	  =	   100μm.	   B:	   Immunofluorescence	   for	   PIT1	   (red),	   counterstained	   with	   DAPI	   (blue)	   at	  16.5dpc.	   PIT1	   is	   expressed	   throughout	   the	   AP	   of	   the	   gland	   at	   16.5dpc	   in	   control	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4.2.6	   Gli	   binding	   site	   activity	   in	   Sox2	   conditionally	   deleted	   embryos	  
using	  FoxG1Cre	  
	  Failure	   of	   the	   sphenoid	   bone	   to	   fuse	   is	   observed	   in	   a	   number	   of	   murine	  mutations	  associated	  with	  SHH	  signaling	  pathway	  (Balaskas	  et	  al.,	  2012).	  In	  light	   of	   this	   and	   due	   to	   the	   failure	   to	   form	   a	   fused	   sphenoid	   bone	   in	  
Sox2fl/fl;FoxG1Cre/+	   embryos	   we	   decided	   to	   breed	   these	   mice	   with	   a	   Gli-­‐binding-­‐site	  reporter	  strain	  (GBSGFP/GFP)	  (Balaskas	  et	  al.,	  2012),	  resulting	  in	  
Sox2f/+;FoxG1Cre/+;GBSGFP/+	   embryos.	   As	   a	   downstream	   mediator	   of	   SHH	  signaling	  Gli	  expression	  and	  accordingly	  GBS-­‐GFP	  provides	  a	  direct	  read	  out	  of	  cells	  that	  respond	  to	  SHH.	  Consequently	  any	  loss	  of	  GFP	  expression,	  as	  a	  result	  of	  Sox2	  deletion	  will	  us	  to	  identify	  if	  SHH	  signaling	  has	  been	  disrupted.	  	  GFP	   expression	   is	   scattered	   in	   the	   ventral	   region	   of	   RP	   in	   control	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Figure	  4.21:	  TSH	  expression	  in	  RP	  following	  Sox2	  deletion	  using	  FoxG1Cre	  on	  a	  GBSGFP	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4.3	  Discussion	  
	  The	  experiments	  carried	  out	  in	  this	  chapter	  aimed	  to	  investigate	  the	  role	  of	  SOX2	   during	   pituitary	   development	   by	   analysing	   the	   consequences	   of	   its	  conditional	  deletion	  on	  RP	  progenitors.	  Two	  Cre	  drivers	  were	  used	  to	  delete	  
Sox2.	  Firstly,	  Nkx3.1Cre,	  which	  deleted	  Sox2	  non-­‐globally	  and	  primarily	  in	  the	  dorsal	   region	   of	   RP	   and	   secondly	   FoxG1Cre,	   which	   globally	   deleted	   Sox2	  earlier	  on	  in	  RP.	  It	  was	  hypothesised	  that	  the	  more	  efficient	  deletion	  of	  Sox2	  using	   FoxG1Cre	   could	   result	   in	   a	   more	   severe	   phenotype,	   but	   that	   Sox2	  deletion	  using	  both	  Cre	  drivers	  would	  result	  in	  a	  hypoplastic	  pituitary.	  Our	  data	   showed	   that	   this	   was	   indeed	   the	   case,	   and	   that	   the	   resulting	   loss	   of	  proliferation	  may	  be	  caused	  by	  the	  downstream	  loss	  of	  SIX6/3	  expression.	  	  	  
4.3.1	  	   Pituitary	   hypoplasia	   in	   Sox2	   mutants	   results	   from	   loss	   of	  
progenitor	  proliferation	  and	  is	  associated	  with	  abnormal	  expression	  of	  
cell	  cycle	  control	  proteins	  
	  We	  find	  that	  the	  loss	  of	  SOX2	  results	  in	  a	  significant	  reduction	  of	  the	  number	  of	   actively	   proliferating	   cells	   in	   RP	   when	   Sox2	   is	   deleted	   using	   either	  
Nkx3.1Cre	  or	  FoxG1Cre,	  with	  the	  reduction	  being	  much	  greater	  when	  using	  the	  latter.	  This	  indicates	  that	  the	  more	  efficient	  the	  deletion	  of	  Sox2	  deletion	  the	  more	   pronounced	   is	   the	   reduction	   in	   proliferation.	   A	   study	   that	   was	  published	  while	  these	  experiments	  were	  underway,	  which	  used	  Hesx1Cre	   to	  delete	   Sox2	   in	   RP,	   had	   similar	   findings	   (Jayakody	   et	   al.,	   2012,	   see	   general	  discussion).	  Lineage	  tracing	   indicated	  that	  FoxG1Cre	  would	  be	  ubiquitous	   in	  RP	  by	  10.5dpc	  (Figure	  3.4).	  At	  this	  stage	  of	  development	  all	  cells	   in	  RP	  are	  proliferating	   and	   have	   not	   begun	   to	   exit	   the	   cell	   cycle	   or	   to	   begin	  differentiation	  (Davis	  et	  al.,	  2011).	  Sox2	  deletion	   throughout	   the	  RP	  at	   this	  early	   stage	   resulted	   in	   its	  extremely	  aberrant	  development.	  RP	  pinches	  off	  from	   the	   underlying	   oral	   ectoderm	   at	   11.5dpc	   (Charles	   et	   al.,	   2005),	  however	   in	   Sox2fl/fl;FoxG1Cre/+	   embryos	   this	   occurs	   between	   12.5dpc-­‐14.5dpc.	  This	  24h+	  developmental	  delay	  is	  likely	  to	  be	  a	  result	  of	  the	  under	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proliferation	   seen	   in	   the	   earlier	   RP	   in	   the	   early	   proliferative	   phase	   of	  development	  prior	  to	  cell	  cycle	  exit.	  	  The	   morphological	   defects	   in	   the	   AP	   resulting	   from	   Sox2	   deletion	   using	  
Nkx3.1Cre	  are	  much	  less	  severe.	  This	  is	  due	  in	  part	  to	  the	  restricted	  activity	  of	  
Nkx3.1Cre,	   but	   also	   to	   the	   timing	   of	   its	   activity.	   Progenitors	   for	   all	   the	  different	  endocrine	  lineages	  exit	  the	  cell	  cycle	  between	  11.5dpc	  and	  13.5dpc	  (Davis	   et	   al.,	   2011).	   Nkx3.1Cre	   is	   most	   active	   in	   the	   AP	   domain	   of	   RP	   at	  12.5dpc	  indicating	  Sox2	  deletion	  may	  occur	  after	  cell	  cycle	  exit,	  when	  SOX2	  is	  no	  longer	  expressed	  in	  a	  subset	  of	  the	  progenitors,	  thus	  resulting	  in	  a	  less	  hypoplastic	  AP.	  In	  the	  future	  IL,	  progenitors	  exit	  the	  cell	  cycle	  slightly	  later,	  between	   12.5dpc-­‐14.5dpc	   (Davis	   et	   al.,	   2011)	   hence	   Nkx3.1Cre	   is	   active	  before	   most	   progenitors	   exit	   the	   cell	   cycle	   as	   they	   still	   express	   SOX2.	  Deletion	  of	  Sox2	  in	  this	  region,	  results	  in	  an	  IL	  phenotype	  as	  severe	  as	  what	  is	   seen	   in	   the	  whole	  of	  RP	  when	  Sox2	   is	  deleted	  using	  FoxG1Cre.	  These	   two	  results	   back	   up	   the	   hypothesis	   that	   Sox2	   deletion	   prior	   to	   cell	   cycle	   exit	  results	  in	  loss	  of	  proliferation	  and	  pituitary	  hypoplasia.	  	  Cyclin	  D1	  regulates	  the	  transition	  between	  G1/S	  in	  the	  cell	  cycle	  (Sala	  et	  al.,	  1992)	   and	   is	   expressed	   in	   the	   dorsal	   region	   in	   RP	   at	   12.5dpc	   in	   an	   area	  where	   SOX2	   is	   still	   expressed	   (Figure	   4.6).	   SOX2	   expression	   in	   the	  developing	  mammalian	  cochlea	  prosensory	  region	  (Jacques	  et	  al.,	  2013)	  and	  ectopic	   expression	   of	   SOX2	   in	   adult	   airway	   epithelial	   cells	   in	   the	   lung	  (Tompkins	   et	   al.,	   2011)	   have	   both	   been	   shown	   to	   increase	   proliferation.	  Expansion	   of	   these	   cell	   populations	   was	   associated	   with	   an	   increase	   in	  Cyclin	   D1	   expression	   (Jacques	   et	   al.,	   2013;	   Tompkins	   et	   al.,	   2011).	   In	   our	  model	   it	   is	  unclear	  whether	  Cyclin	  D1	  downregulation	   is	   a	  direct	   result	   of	  
Sox2	   deletion	   as	   seen	   in	   previous	   studies,	   or	   if	   it	   is	   a	   downstream	  consequence,	  such	  as	  a	  change	  in	  cell	  fate,	  and	  associated	  with	  general	  loss	  of	   proliferation.	   Nevertheless	   reduced	   Cyclin	   D1	   expression	   indicates	   the	  loss	   of	   proliferation	   phenotype	   might	   be	   a	   result	   of	   cell	   cycle	   arrest	   and	  failure	  to	  transit	  through	  the	  G1/S	  checkpoint.	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The	  cell	  cycle	  kinase	  inhibitor	  p27kip1	  is	  located	  in	  the	  ventral	  region	  of	  RP	  from	   E13.5	   marking	   cells	   that	   have	   exited	   the	   cell	   cycle	   and	   have	  differentiated	   (Bilodeau	   et	   al.,	   2009).	   Upon	   Sox2	  deletion	   using	  Nkx3.1Cre,	  p27kip1	  becomes	  ectopically	  expressed	  in	  the	  dorsal	  region	  of	  RP;	  however	  in	  a	  mutually	  exclusive	  pattern	   from	   the	   remaining	  SOX2+ve	   cells.	  Previous	  studies	   have	   indicated	   that	   p27kip1	   directly	   participates	   in	   SOX2	  transcriptional	  repression	  in	  differentiating	  ES	  cells	  (Li	  et	  al.,	  2012).	   In	  the	  adult	  pituitary	  of	  p27kip1	  null	  mice	  the	  number	  of	  SOX2+ve	  cells	  that	  line	  the	  cleft	   is	   increased,	  and	   IL	   tumors	  develop.	  Upon	  deletion	  of	  one	  Sox2	   allele,	  these	   two	   phenotypes	   are	   suppressed,	   highlighting	   the	   physiological	  relevance	  of	  this	  repressive	  interaction	   	  (Li	  et	  al.,	  2012).	   In	  contrast,	   in	  the	  early	   embryonic	   pituitary,	   p27kip1	   and	   SOX2	   are	   never	   co-­‐expressed,	  demonstrating	  a	  different	  relationship	  between	  the	  two	  factors	  at	  this	  stage	  of	  development	  (Bilodeau	  et	  al.,	  2009).	  Our	  model	  indicated	  that	  the	  loss	  of	  SOX2	   causes	   the	   ectopic	  upregulation	  of	  p27kip1.	  This	   suggests	   that	   SOX2	  may	   be	   repressing	   p27kip1	   expression	   in	   proliferating	   cells,	   and	   upon	  deletion	   of	  Sox2	   this	   repression	   is	   lost.	   In	   quiescent	   cells,	   the	   relationship	  between	  SOX2	  and	  p27kip1	   is	   again	  different,	   as	   it	  has	  been	   shown	   in	   the	  embryonic	  auditory	  system	  that	  conditional	  deletion	  of	  Sox2	  in	  post-­‐mitotic	  supporting	  cells	  results	  in	  a	  downregulation	  of	  p27kip1	  and	  re-­‐entry	  in	  the	  cell	   cycle	   (Liu	   et	   al.,	   2012).	   In	   these	   cells,	   SOX2	   directly	   activates	  p27kip1	  expression	   (Liu	   et	   al.,	   2012).	   Alternatively,	   knock	   down	   of	   Cyclin	   D1	  increases	  p27kip1	  expression	   through	   the	   inhibition	  of	   the	  SKP2	  ubiquitin	  E3	   ligase	   complex	   (Jonason	   et	   al.,	   2007).	   This	   suggests	   that	   increased	  p27kip1	   expression	   may	   be	   linked	   to	   general	   loss	   of	   proliferation	   and	  mediated	   through	   Cyclin	   D1	   downregulation.	   Clearly	   the	   relationship	  between	   SOX2	   and	   p27kip	   is	   complex	   with	   each	   being	   able	   to	   directly	  regulate	  each	  other’s	  transcription,	  but	  perhaps	  with	  different	  consequences	  according	  to	  context	  (Li	  et	  al.,	  2012;	  Liu	  et	  al.,	  2012).	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4.3.2	   LHX3	  and	  ISL1	  are	  also	  required	  for	  progenitor	  maintenance	  but	  
are	  unaffected	  by	  the	  loss	  of	  SOX2	  
	  Analysis	  of	  the	  consequences	  of	  genetic	  deletion	  of	  several	  TFs	  expressed	  in	  early	   RP	   indicate	   they	   play	   a	   role	   in	   regulating	   the	   proliferation	   and/or	  maintenance	  of	  progenitors	  (for	  review	  see	  Kelberman	  et	  al.,	  2006).	  ISL1	  is	  expressed	   throughout	   RP	   at	   9.5dpc	   before	   becoming	   restricted	   ventrally.	  Deletion	   of	   Isl1	   indicated	   that	   the	   early	   RP	   forms	   but	   is	   extremely	  underdevelopment	   and	   fails	   to	   develop	   further	   than	   10.5dpc,	   possibly	  indicating	  it	  is	  involved	  in	  progenitor	  proliferation	  or	  maintenance	  (Takuma	  et	   al.,	   1998).	   In	   our	   study,	   global	   Sox2	   deletion	   has	   no	   effect	   on	   the	  expression	   of	   ISL1	   at	   10.5dpc,	   indicating	   SOX2	   does	   not	   regulate	   its	  expression	  at	  this	  stage.	  	  	  
Sox3	   heterozygous	   mice	   display	   a	   number	   of	   pituitary	   abnormalities	  including	  bifurcation	  during	  development	  and	  hypoplasia	   in	   the	  adult.	  Due	  to	   the	   lack	   of	   SOX3	   expression	   in	   RP,	   this	   is	   likely	   a	   result	   of	   perturbed	  FGF8/10	   and	   BMP4	   expression	   and	   consequently	   secretion	   form	   the	   VD	  (Rizzoti	   et	   al.,	   2004).	   Sox2	   heterozygous	   mice	   also	   display	   bifurcation	   in	  development	   and	   extra	   clefts	   in	   the	   adult	   (Kelberman	   et	   al.,	   2006).	  Furthermore	   Sox3	   null	   mice	   on	   a	   Sox2	   heterozygous	   background	   have	   an	  extremely	   truncated	   VD	   and	   no	   infundibulum	   (Zhao	   et	   al.,	   2011).	   These	  studies	   demonstrate	   the	   importance	   of	   SOX3	   and	   specifically	   SOX2	   in	   RP	  morphogenesis	  through	  the	  correct	  formation	  of	  VD	  and	  hence	  secretion	  of	  BMF/FGF.	   Ectopic	   FoxG1Cre	   activity	   in	   the	   VD	   will	   have	   resulted	   in	   Sox2	  deletion	  in	  a	  small	  number	  of	  cells	  in	  this	  region,	  raising	  the	  possibility	  of	  a	  disruption	   to	   BMP4	   and	   FGF8	   expression.	   Ectopic	   ventral	   expression	   of	  BMP4	  in	  RP	  can	  dorsally	  expand	  the	  region	  of	  ISL1	  expression,	  while	  FGF8	  has	   been	   shown	   to	   inhibit	   expression	   in	   pituitary	   explants	   (Treier	   et	   al.,	  1998;	  Ericson	  et	   al.,	   1998).	  Following	   the	  ventral	   restriction	  by	  BMP4	  and	  FGF8,	   ISL1	   induces	   the	   expression	   of	   Glycoprotein	   Hormones	   α-­‐Subunit	  (αGSU)	   and	   the	   differentiation	   of	   rostral-­‐tip	   thyrotrophs.	   These	   are	  expanded	  dorsally	  upon	  addition	  of	  an	  FGF	  antagonist	  (Ericson	  et	  al.,	  1998;	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Norlin	   et	   al.,	   2000).	   The	   ventral	   localisation	   of	   PIT1-­‐ve,	   rostral-­‐tip	  thyrotrophs	  at	  14.5dpc	  in	  our	  study	  further	  suggests	  ISL1	  expression	  is	  not	  disrupted	  through	  the	  ectopic	  FoxG1Cre	  induced	  Sox2	  deletion	  in	  the	  VD.	  This	  indicates	  that	  BMP4	  and	  FGF8	  expression	  and	  secretion	  was	  not	  disrupted	  in	  the	  VD,	  providing	  confidence	  that	  the	  resulting	  RP	  hypoplastic	  phenotype	  is	  entirely	  the	  result	  of	  Sox2	  deletion	  in	  RP.	  	  	  LHX3	  is	  expressed	  in	  RP	  from	  9.5dpc	  and	  maintained	  until	  adulthood	  (Sheng	  et	  al.,	  1996).	  Its	  homozygous	  deletion	  has	  also	  been	  shown	  to	  result	  in	  arrest	  of	  RP	  development	  primarily	  due	  to	  increased	  apoptosis	  (Sheng	  et	  al.,	  1996;	  Zhao	  et	  al.,	  2006;	  Ellsworth	  et	  al.,	  2008).	  SOX2	  and	  LHX3	  co-­‐localise	   in	   the	  RP.	  This	  is	  also	  observed	  in	  the	  sensory	  epithelium	  of	  the	  developing	  inner	  ear	  (Hume	  et	  al.,	  2007;	  Rajab	  et	  al.,	  2008).	  In	  this	  system,	  SOX2	  is	  expressed	  prior	   to	  LHX3	   and	   has	   been	   shown	   to	   directly	   activate	   expression	   of	   the	  
Lhx3	  proximal	  promoter	   in	  vitro	   (Rajab	  et	  al.,	  2008).	  Notwithstanding	   this,	  we	   observe	   no	   loss	   of	   LHX3	   expression	   in	   RP	   upon	   Sox2	   deletion.	   This	  indicates	   that	   SOX2	   does	   not	   control	   Lhx3	   expression	   in	   RP,	   despite	   its	  ability	  to	  bind	  Lhx3	  regulatory	  regions	  in	  vitro.	  Lhx3	  null	  embryos	  also	  fail	  to	  express	   PIT1	   and	   hence	   fail	   to	   produce	   any	   somatotrophs,	   lactotrophs	   or	  thyrotrophs	  (Sheng	  et	  al.,	  1998).	  In	  addition	  Lhx3	  null	  mice	  do	  not	  form	  any	  corticotrophs	  and	  gonadotrophs,	  but	  do	  maintain	  SF1+ve	  pre-­‐gonadotrophs	  in	  an	  ectopic,	  more	  dorsal	  localisation	  due	  to	  the	  downregulation	  of	  Notch2	  (Ellsworth	   et	   al.,	   2008).	   We	   also	   observe	   a	   loss	   of	   PIT1	   expression	   in	  addition	  to	  a	  severe	  reduction	  in	  the	  numbers	  of	  gonadotrophs,	  however	  in	  contrast	   to	   Sheng	   et	   al	   (1998)	   this	   is	   despite	   the	   continued	   expression	   of	  LHX3	   at	   12.5dpc.	   These	   results	   indicate	   LHX3	   is	   not	   responsible	   for	  PIT1	  down-­‐regulation	  in	  our	  model.	  	  	  Interestingly	  ISL1	  and	  LHX3	  may	  regulate	  progenitor	  maintenance	  through	  the	  same	  pathway,	  at	  least	  before	  11.5dpc	  when	  they	  co-­‐localise,	  as	  ISL1	  can	  bind	   an	   180bp	   enhancer	   of	   Lhx3	   and	   drive	   its	   expression	   in	   the	   pituitary	  (Mullen	   et	   al.,	   2012).	   Furthermore,	   PITX1	   may	   also	   play	   a	   role	   in	   this	  pathway	   and	   lie	   upstream	   of	  Lhx3,	   as	   it	   has	   been	   shown	   to	   regulate	  Lhx3	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expression	  in	  RP	  (Tremblay	  et	  al.,	  1998;	  Mullen	  et	  al.,	  2012).	  Moreover	  like	  LHX3	   and	   ISL1,	   PITX1	   is	   not	   affected	   by	   Sox2	   deletion	   (Jayakody	   et	   al.,	  2012).	   This	   TF	   network	   may	   promote	   maintenance	   and	   proliferation	   in	  parallel	   to	   SOX2,	   thus	   compensating	   to	   some	   extent	   for	   the	   Sox2	   deletion,	  allowing	   just	   sufficient	   proliferation	   to	   form	   a	   rudimentary	   and	   aberrant	  pituitary.	  	  	  
4.3.3	  Sox2	  deletion	  causes	  the	  downregulation	  of	  SIX6/3	  
	  A	   previously	   published	   study	   has	   shown	   a	   role	   for	   SIX6	   in	   regulating	   the	  proliferation	  of	  progenitors	  in	  RP.	  Six6	  null	  mice	  have	  hypoplastic	  pituitaries	  and	  reduced	  progenitor	  proliferation	  (Li	  et	  al.,	  2002).	  	  We	  demonstrate	  that	  the	  conditional	  deletion	  of	  Sox2	  results	  in	  an	  almost	  exact	  phenocopy	  to	  that	  seen	  by	  Li	  et	  al	  (2002),	  with	  reduced	  progenitor	  proliferation	  and	  pituitary	  hypoplasia.	  	  	  SIX6	  expression	  is	  first	  observed	  at	  8.0dpc	  in	  the	  diencephalon,	  from	  which	  the	  hypothalamus	  in	  particular	  will	  develop	  (Jean	  et	  al.,	  1999).	  Throughout	  development	   SIX6	   is	   almost	   always	   co-­‐expressed	  with	   its	   paralogue	   SIX3,	  with	  both	  being	  expressed	   in	   the	  eye,	  hypothalamus	  and	  pituitary	   (Jean	  et	  al.,	   1999;	   López-­‐Ríos	   et	   al.,	   1999;	   Toy	   &	   Sundin,	   1999).	   Transcriptional	  regulation	   of	   Six6/3	   in	   the	   eye	   has	   been	   extensively	   described.	   NeuroD1,	  LHX2	   and	   PAX6	   have	   all	   been	   shown	   to	   induce	   Six6/3	   expression	   in	   the	  retina,	   where	   Six6	   overexpression	   promotes	   proliferation	   (Conte	   et	   al.,	  2010;	  Tétreault	  et	  al.,	  2009).	  Interestingly	  despite	  LHX2	  and	  SIX6	  both	  being	  expressed	   in	  the	  same	  region	  of	   the	  VD,	  Lhx2	  null	  mice	  show	  no	  change	   in	  SIX6	   expression.	   This	   indicates	   that	   control	   of	   SIX6	   expression	   is	   highly	  tissue	  specific	  (Tétreault	  et	  al.,	  2009).	  	  	  In	  RP	  we	  observe	  a	  consistent	  co-­‐localisation	  of	  SOX2	  and	  SIX6	  throughout	  development,	   up	   until	   at	   least	   18.5dp	   where	   they	   co-­‐localise	   in	   all	   three	  lobes.	   Moreover	   the	   complete	   loss	   of	   SOX2	   in	   mutant	   mice	   results	   in	   the	  global	  downregulation	  of	  SIX6	  at	  18.5dpc.	  The	  only	  other	  TF	  known	  to	  co-­‐
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localise	  as	  closely	  as	  SIX6	  does	  with	  SOX2	  in	  RP	  and	  pituitary	  is	  SOX9	  but	  it	  does	   so	   later,	   being	   expressed	   only	   from	   about	   14.5dpc	   (Fauquier	   et	   al.,	  2008;	  Rizzoti	  et	  al.,	  2013).	  SOX2	  co-­‐localises	  with	  SOX9	  in	  99%	  of	  cells	  in	  RP,	  however	  this	  is	  only	  in	  the	  AP,	  as	  SOX9	  is	  not	  found	  in	  the	  IL	  (Fauquier	  et	  al	  2008).	   SOX2+ve;SOX9+ve	   cells	   in	   the	   AP	   have	   been	   shown	   to	   be	   the	   SC	  population	  in	  RP,	  capable	  of	   forming	  all	  endocrine	  cell	   types	  (Rizzoti	  et	  al.,	  2013).	   In	  addition	  both	  SOX2+ve	  and	  SOX9+ve	  cells	  can	   form	  pituispheres	   in	  
vitro	  (Rizzoti	  et	  al.,	  2013).	  It	  is	  likely	  that	  the	  SOX2+ve;SIX6+ve	  cells	  of	  the	  AP	  are	   also	   SOX9+ve	   (after	   E14.5),	   indicating	   SIX6+ve	   cells	   may	   be	   capable	   of	  forming	  pituispheres	   in	  vitro	  and	   thus	  also	  be	  a	  marker	   for	  pituitary	  stem	  cells.	  In	  contrast	  the	  SOX2+ve;SIX6+ve	  cells	  in	  the	  IL	  will	  not	  co-­‐express	  SOX9.	  This	   indicates	   a	   different	   identity	   of	   these	   cells	   in	   RP.	   In	   addition	   to	   the	  absence	   of	   SOX9	   expression	   in	   the	   IL,	   weaker	   SOX2	   staining	   and	   POMC	  expression	   indicates	   these	   cells	   will	   become	   terminally	   differentiated	  melanotrophs	   and	   not	   SC.	   SOX2	   has	   been	   found	   to	   co-­‐localise	   with	  endocrine	  cells	  in	  the	  AP,	  however	  this	  is	  extremely	  rare	  and	  almost	  always	  cytoplasmic.	  The	  co-­‐localisation	  of	  POMC	  and	  nuclear	  SOX2	  in	  the	  majority	  of	   cells	   in	   the	   IL	   suggests	   SOX2	   may	   have	   a	   different	   role	   in	   these	   cells	  compared	  to	  the	  SC	  of	  the	  MC	  layer	  of	  the	  AP.	  Furthermore	  SIX6	  expression	  in	   all	   SOX2+ve	   cells	   of	   the	   IL	   suggests	   a	   large	   proportion	   of	   the	  SOX2+ve;POMC+ve	  cells	  will	  also	  express	  SIX6.	  This	  indicated	  that	  the	  role	  of	  SIX6	  in	  these	  cells	  may	  be	  different	  from	  the	  proliferative	  role	  that	  has	  been	  described	  for	  it	  previously.	  	  	  Upon	   deletion	   of	   Sox2	   throughout	   RP	   with	   FoxG1Cre,	   SIX6	   is	   completely	  downregulated	   and	   SIX3	   expression	   is	   also	   reduced.	   SIX6	   is	   also	  downregulated	  when	  Nkx3.1Cre	   is	   used	   to	   delete	  Sox2,	   although	   to	   a	   lesser	  extent	   and	   only	   after	   the	   loss	   of	   SOX2	   protein	   at	   12.5dpc.	   Direct	  transcriptional	  regulation	  of	  Six6	  and	  Six3	  by	  SOXB1	  proteins	  occurs	   in	  the	  ventral	   forebrain,	   however	   this	   study	   failed	   to	   identify	   a	   pituitary	   specific	  enhancer	  of	  Six6	   (Lee	  et	  al.,	   2012).	  Sox3-­‐/Y	   ;Sox2+/-­‐	  double	  mutant	  embryos	  display	   a	   	   reduced	   area	   of	   SIX6	   expression	   in	   the	   VD	   (Zhao	   et	   al.,	   2012),	  although	   this	  phenotype	  may	  also,	  at	   least	  partially,	  be	  a	  result	  of	   reduced	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SHH	   expression,	   as	   SOX2	   can	   directly	   activate	   Shh	   expression	   in	   the	   VD	  (Zhao	  et	  al.,	  2012).	  Our	  data	  in	  addition	  to	  the	  previously	  published	  studies	  indicates	  SOX2	  as	  a	  likely	  direct	  upstream	  regulator	  of	  Six6/3	  expression.	  	  	  Developmentally	   the	   role	   of	   SIX6	   and	   SIX3	   appear	   to	   be	   promotion	   of	  progenitor	  proliferation.	  SIX6	   is	  expanded	  ventrally	   in	   the	  RP	  of	  TCF4	  null	  embryos,	   and	   this	   is	   correlated	   with	   an	   increase	   in	   proliferation	  (Brinkemeier	   et	   al.,	   2007).	   Our	   data	   shows	   a	   downregulation	   in	   SIX6	   and	  SIX3	  expression	  following	  Sox2	  deletion.	  This	  is	  coupled	  with	  a	  reduction	  in	  BrdU	   incorporation,	   Cyclin	   D1	   expression	   and	   ectopic	   expression	   of	  p27kip1.	  All	  this	  suggests	  that	  Six6/3	  are	  the	  potential	  targets	  of	  SOX2	  that	  are	   required	   to	  maintain	   PR	   progenitor	   proliferation.	   Rescue	   experiments	  where	  SIX3/6	  expression	  would	  be	  restored	   in	  Sox2	  mutants	  would	  reveal	  their	  relevance	  in	  the	  phenotype.	  Interestingly	  Li	  et	  al	  (2002)	  indicated	  that	  SIX6	  along	  with	  co-­‐repressor	  Dach2	  could	  bind	  the	  ‘repressor	  region’	  of	  the	  
p27kip1	   promoter	   in	   vitro.	   This	   provides	   a	   possible	   explanation	   for	   the	  ectopic	  upregulation	  of	  p27kip1	  observed	  in	  Sox2fl/fl;Nkx3.1cre/+	  embryos,	  as	  the	  upregulation	  is	  only	  observed	  where	  SIX6	  is	  downregulated.	  	  	  In	   summary	   our	   data	   indicates	   a	   likely	   relationship	   between	   SOX2	   and	  SIX6/3	   in	   regulating	   RP	   progenitor	   proliferation.	   Six6/3	   appears	   as	   ideal	  candidates	   for	   a	   downstream	   transcription	   factor	   target	   of	   SOX2	   in	   RP,	   a	  relationship	   that	   has	   been	   reported	   to	   occur	   also	   in	   other	   tissues.	   Future	  experiments	   to	   identify	   if	   SOX2	   can	   bind	   Six6/3	   enhancers	   and	   drive	   its	  expression	  in	  RP	  may	  reveal	  if	  this	  hypothesis	  is	  correct	  	  
4.3.4	   Early	  SOX2	  expression	  is	  required	  for	  differentiation	  of	  all	  
endocrine	  cell	  types	  
	  It	  has	  previously	  been	  shown	  that	  all	  endocrine	  cells	  are	  derived	   from	  the	  SOX2+ve	  population	  in	  the	  AP	  (Rizzoti	  et	  al.,	  2013;	  Andoniadou	  et	  al.,	  2013).	  We	   therefore	   hypothesised	   that	   SOX2	   expression	   in	   RP	   is	   similarly	  necessary	   for	   the	   emergence	  of	   endocrine	   cells.	  Sox2	   deletion	  using	   either	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Cre	  driver	   resulted	   in	   the	   reduction	   in	  each	  endocrine	   cell	   type.	  Moreover	  the	  earlier,	  global	  deletion	  of	  Sox2	  in	  RP	  using	  FoxG1Cre	  resulted	  in	  the	  loss	  of	  nearly	  all	  endocrine	  cell	  types.	  One	  explanation	  for	  the	  loss	  of	  differentiation	  is	   the	   severe	   reduction	   in	   proliferation.	   This	   may	   result	   in	   the	   pool	   of	  progenitors	  failing	  to	  reach	  the	  required	  size,	  thus	  impairing	  differentiation.	  This	   is	   observed	  when	  FoxG1Cre	   is	   used	   to	  delete	  Sox2,	  where	  many	  of	   the	  cells	  remain	  in	  a	  non-­‐endocrine,	  possibly	  immature	  state.	  Substantiating	  this	  hypothesis,	   the	   cells	   that	   do	  differentiate	   are	  PIT1	   independent	   rostral-­‐tip	  thyrotrophs,	  which	  are	  one	  of	   the	  earliest	   to	  differentiate	  and	   exit	   the	   cell	  cycle	  at	  11.5dpc	  (Lin	  et	  al.,	  1994,	  Davis	  et	  al.,	  2011).	  The	  proliferation	  that	  occurs	  up	  until	  10.5dpc	  may	  be	  enough	  to	  allow	  for	  their	  differentiation	  at	  11.5dpc.	  	  	  In	  addition	  to	  the	  reduction	  in	  proliferation,	  the	  maintenance,	  or	  loss	  of	  TF	  expression	   following	   Sox2	   deletion	   may	   also	   affect	   endocrine	   cell	  differentiation.	   For	   example	   the	   rostral-­‐tip	   thyrotroph	   population	   can	   be	  expanded	  by	  an	  increase	  in	  ISL1	  and	  LHX3	  expression	  (Norlin	  et	  al.,	  2000).	  Global	  Sox2	  deletion	  has	  no	  effect	  on	   the	  expression	  on	  either	  of	   these	  TF,	  and	  may	   allow	   rostral-­‐tip	   thyrotroph	   differentiation	   to	   occur	   normally.	   In	  contrast	   to	   this,	   PIT1,	   which	   is	   required	   for	   the	   differentiation	   of	  somatotrophs,	  lactotrophs	  and	  thyrotrophs	  (Simmons	  et	  al.,	  1990),	  is	  almost	  completely	   downregulated	   following	   Sox2	  deletion.	   Upstream	   of	   PIT1,	   the	  paired	   homeodomain	   TF	   PROP1	   is	   expressed	   in	   RP,	   along	   with	   Sox2	  (Yoshida	   et	   al.,	   2009).	   Prop1	   null	   mice	   fail	   to	   express	   PIT1,	   resulting	   in	  impaired	  somatotroph,	  lactotroph	  and	  thyrotroph	  differentiation	  (Anderson	  et	  al.,	  1995;	  Yako	  et	  al.,	  2011).	  This	  may	  indicate	  an	  indirect	  affect	  of	  SOX2	  on	  endocrine	  cell	  differentiation	  via	  the	  regulation	  of	  PROP1	  expression.	  	  	  Surprisingly,	  Sox2	  deletion	  using	  Nkx3.1Cre	  resulted	  in	  a	  greater	  reduction	  in	  the	  differentiation	  of	  endocrine	  cells	  than	  was	  predicted.	  Fate	  mapping	  data	  predicted	   that	   approximately	   50%	   of	   the	   future	   somatotrophs	   originated	  from	   Nkx3.1Cre	   positive	   progenitors	   and	   would	   therefore	   be	   potentially	  affected	  by	  SOX2	  loss	  however	  the	  observed	  reduction	  was	  80%.	  The	  reason	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for	   this	   discrepancy	   is	   unclear,	   however	   it	   may	   be	   due	   to	   non-­‐cell	  autonomous	   effects	   following	   Sox2	   deletion.	   This	   is	   in	   addition	   to	   the	  disruption	  that	  has	  occurred	  to	  the	  local	  RP	  environment	  resulting	  from	  the	  loss	   of	   proliferation	   and	   therefore	   subsequent	   lack	   of	   cells.	  Wnt	   signaling	  and	  βcatenin	  accumulation	  in	  RP	  progenitors	  actively	  promotes	  progenitor	  proliferation	   (Gaston-­‐Massuet	   et	   al.,	   2011;	   Kioussi	   et	   al.,	   2002).	   Thus	   any	  disruption	   of	   this	   pathway	   or	   disruption	   of	   Wnt	   signaling	   in	   the	   RP	  environment	   may	   perturb	   RP	   proliferation	   and	   hence	   endocrine	   cell	  differentiation.	  	  	  The	  reduction	  in	  the	  number	  of	  melanotrophs	  in	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  was	   much	   closer	   to	   what	   was	   predictions	   based	   on	   fate	   mapping.	  Interestingly,	  however,	  the	  proportion	  of	  melanotrophs	  remaining	  in	  the	  IL	  was	  considerably	  smaller	   than	   in	  control	  embryos.	  One	  would	  predict	   that	  the	  proportion	  of	  melanotrophs	   in	   the	   IL	  would	  be	   the	   same	  as	   in	   control	  embryos	   if	   the	   phenotype	   were	   solely	   a	   result	   of	   an	   earlier	   loss	   of	  proliferation.	   Nkx3.1Cre	   is	   not	   active	   in	   the	   overlying	   VD/infundibulum,	  which	   rules	   out	   a	   non-­‐cell	   autonomous	   effect	   resulting	   in	   perturbed	  endocrine	   cell	   differentiation.	   Consequently	   a	   cell-­‐autonomous	   affect	  resulting	  from	  Sox2	  deletion	  may	  be	  contributing	  to	  the	  loss	  of	  melanotroph	  differentiation	   in	   addition	   to	   progenitor	   proliferation.	   Further	   analysis	   of	  the	  transcriptional	  consequence	  of	  Sox2	  deletion	  is	  presented	  in	  chapter	  5.	  	  	  
4.3.5	   Sox2	  deletion	  from	  the	  oral	  ectoderm	  is	  likely	  to	  prevent	  fusion	  
of	  the	  Sphenoid	  bone	  
	  Coupled	  with	  pituitary	  hypoplasia,	  Sox2	  deletion	  using	  FoxG1Cre	  also	  results	  in	  defects	  in	  sphenoid	  bone	  fusion.	  Failure	  of	  the	  sphenoid	  bone	  to	  close	  is	  associated	  with	  HPE	   and	   SOD	   in	   humans	   of	  which	  mutations	   in	  SOX2	   and	  
GLI1/2	   have	   been	   described	   (Kelberman	   &	   Dettani,	   2007;	   Roessler	   et	   al.,	  1996).	   Similarly	   we	   also	   observe	   a	   reduction	   in	   GBSGFP	   expression	   in	   the	  remaining,	  unfused	  sphenoid	  bone.	  The	  SHH	  morphogen	  binds	  the	  Patched	  (Ptc1)	  receptor,	  which	  is	  often	  on	  the	  membrane	  of	  primary	  cilia	  (for	  review	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see	   Quinlan	   et	   al.,	   2008).	   Interestingly	   mouse	   mutations	   associated	   with	  perturbed	   cilia	   such	   as	   Polarisfl/fl;WntCre,	  Ofld1-­‐/-­‐	   and	  Kif3a-­‐/-­‐	  all	   display	   an	  unfused	  sphenoid	  bone	  with	  RP	  extending	  into	  the	  resulting	  cavity.	  This	  is	  in	  addition	   to	   other	   midline	   defects	   (Khonsari	   et	   al.,	   2013).	  Holoprosencephaly-­‐like	  defects	  in	  mice,	  in	  addition	  to	  an	  unfused	  sphenoid,	  bone	   are	   also	   associated	   with	   homozygous	   deletion	   of	   the	   SHH	   agonist	  Growth	   Arrest-­‐Specific	   1	   (Gas1)	   (Martinelli	   &	   Fan.,	   2007).	   Furthermore,	  
Gas1	  null	  mice	  have	  a	  severe	  reduction	  in	  Gli1	  expression	  in	  RP	  at	  10.5dpc	  (Khinsari	   et	   al.,	   2013).	   Because	   the	   same	   phenotype	   arises	   from	  multiple	  mutations	   associated	   with	   Shh,	   including	   that	   described	   here,	   it	   appears	  likely	   that	  correct	  SHH	  signaling	   is	  required	  to	  allow	  the	  sphenoid	  bone	  to	  fuse.	   Previous	   studies	   have	   shown	   SHH	   signaling	   from	   the	   VD	   and	   oral	  ectoderm	  is	  required	  for	  correct	  RP	  formation	  (Treier	  et	  al.,	  1998;	  Wang	  et	  al.,	  2010).	  However	  early	  FoxG1Cre	   activity	   in	   the	  oral	  ectoderm	  (our	  study	  and	  Wang	  et	  al.,	  2010)	  suggests	  deletion	  of	  Sox2	  in	  this	  region	  that	  leads	  to	  downregulation	   of	   GBS-­‐GFP	   expression	   and	   an	   unfused	   sphenoid	   bone,	  likely	   due	   to	   loss	   of	   SHH	   ventrally.	   SOX2	   directly	   binds	   the	   Shh	   SBE2	  enhancer	   to	  drive	   its	  expression	   in	   the	  VD	  (Zhao	  et	  al.,	  2012,	  Trowe	  et	  al.,	  2013).	  Future	  experiments	  will	  be	  required	  to	   identify	   if	  SOX2	  can	  directly	  activate	  Shh	  expression	  in	  the	  oral	  ectoderm.	  	  	  
4.3.6	   Conclusions	  
	  In	  conclusion,	  the	  studies	  presented	  in	  this	  chapter	  investigate	  the	  effect	  of	  
Sox2	  deletion	   on	   the	   development	   of	   RP	   and	   differentiation	   of	   endocrine	  cells.	   We	   show	   that	   SOX2	   is	   necessary	   for	   the	   proliferation	   of	   RP	  progenitors.	  Our	  data	  also	  shows	  that	  SIX6/3	  are	  specifically	  downregulated	  following	  Sox2	  deletion,	  unlike	  other	  early	  expressed	  TFs.	  We	  also	   indicate	  
Sox2	   deletion	   disrupts	   the	   differentiation	   of	   endocrine	   cells,	   probably	  indirectly	   through	   the	   lowering	   of	   progenitor	   proliferation,	   and	   the	  downregulation	  of	  the	  expression	  of	  TFs	  required	  for	  differentiation.	  Finally	  we	  indicate	  the	  potential	  loss	  of	  SHH	  signaling	  in	  the	  oral	  ectoderm	  prevents	  sphenoid	  bone	  closure.	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5.	   Analysis	   of	   Intermediate	   Lobe	   proliferation	   and	  
differentiation	  defects	  in	  Sox2fl/fl;Nkx3.1Cre/+	  mutants	  
	  
5.1	  Introduction	  
	  In	  the	  embryo,	  the	  IL	  develops	  from	  the	  dorsal	  region	  of	  RP,	  in	  contact	  with	  the	  infundibulum	  and	  separated	  from	  the	  future	  anterior	  lobe	  by	  the	  lumen	  of	  the	  pouch.	  Melanotrophs	  are	  the	  only	  endocrine	  cell	  type	  generated	  in	  the	  IL	  and	  two	  transcription	  factors	  are	  essential	  for	  their	  differentiation,	  PAX7	  and	  TPIT	  (Budry	  et	  al.,	  2012;	  Pulichino	  et	  al.,	  2003).	  	  	  The	   earliest	   known	   TF	   that	  marks	   the	   dorsal	   region	   of	   RP	   as	   future	   IL	   is	  PAX7	   (Budry	   et	   al.,	   2012).	   Expressed	   just	   prior	   to	   TPIT	   at	   15.5dpc,	   PAX7	  exerts	  its	  role	  as	  a	  selector	  gene,	  selecting	  for	  melanotroph	  identity	  through	  chromatin	   remodeling	   and	  opening	  up	  new	  TPIT	  binding	   sites	   in	  PC2	   and	  DrD2	   regions	   (Budry	   et	   al.,	   2012).	   TPIT	  however	   is	   a	   definitive	  marker	   of	  differentiation	   and	   essential	   for	   POMC	   expression	   in	   melanotrophs	   and	  corticotrophs	   (Lamolet	   et	   al.,	   2001,	   Pulinchino	   et	   al.,	   2003).	   An	   additional	  important	  role	  of	  TPIT	  in	  the	  IL	  and	  possibly	  the	  AP	  is	  as	  an	  inhibitor	  of	  the	  gonadotroph	   lineage,	   as	   Tpit	   null	   mice	   ectopically	   express	   SF1	   in	   the	   IL	  (Pulichino	  et	  al.,	  2003).	  The	  IL	  was	  the	  most	  severely	  affected	  region	  of	  RP	  in	  
Sox2fl/fl;Nkx3.1Cre/+	  embryos.	   As	   a	   result	   it	   was	   decided	   to	   concentrate	   the	  subsequent	  analysis	  on	  the	  phenotype	  in	  this	  area,	  focusing	  on	  the	  above	  	  mentioned	  TFs.	  	  Melanotrophs	   are	   also	   characterised	   by	   their	   extremely	   low	   proliferative	  index	  compared	  to	  other	  endocrine	  cell	  populations.	  Moreover	  in	  the	  adult	  they	  do	  not	  divide	  at	  all	  (Langlais	  et	  al.,	  2013).	  This	  quiescence	  relies	  on	  the	  presence	   of	   cell	   cycle	   inhibitors,	   such	   as	   p27kip1	   as	   homozygous	  p27kip1	  deletion	  results	  in	  IL	  tumors	  in	  addition	  to	  a	  more	  general	  organ	  hyperplasia	  (for	  review	  see	  Quereda	  &	  Malumbres.,	  2009).	  More	  specifically,	  conditional	  deletion	  of	  p27kip1	  in	  the	  IL	  results	  in	  hyperplasia,	  caused	  by	  an	  increase	  in	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5.2	  Results	  
	  
5.2.1	  Intermediate	  lobe	  cell	  fate	  in	  Sox2fl/fl;Nkx3.1cre/+	  mutants	  	  The	  activity	  of	  Nkx3.1Cre	   is	  strongest	   in	  the	  dorsal	  region	  of	  RP	  (Figure	  2.1,	  5.1).	  The	  consequence	  of	   this	   is	  a	  smaller,	  aberrant	   IL	  with	   fewer	  POMC+ve	  (MSH)	   cells	   in	   Sox2fl/fl;Nkx3.1Cre/+	   mutants	   (Figure	   3.4	   and	   3.16).	   POMC+ve	  cells	  are	  now	  scattered	  throughout	  the	  IL	  instead	  of	  having	  a	  typical	  pseudo	  epithelial-­‐like	   organization	   (Figure	   3.16,	   5.1).	   The	   resulting	   thinner	   IL	  contains	   mainly	   POMC-­‐ve	   cells	   (Figure	   5.1).	   To	   determine	   their	   fate,	   the	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Figure	   5.1:	   POMC	   expression	   in	   Sox2	   deleted	   cells	   of	   the	   IL	   and	   AP	   of	  
Sox2fl/fl;Nkx3.1Cre/+;R26ReYFP/+	  embryos.	  	  Immunofluorescence	  for	  POMC	  (red),	  and	  eYFP	  (Green),	  counterstained	  with	  DAPI	  (blue)	  at	  18.5dpc.	   POMC	   (MSH)	   is	   expressed	   throughout	   the	   thick	   pseudo-­‐epithelial	   IL	   on	   control	  











	   	   	  
	   145	  
Sox2	   deletion	   led	   to	   reduced	   progenitor	   proliferation	   and	   likely	   cell	   cycle	  arrest	   (Figure	  3.5).	  We	  then	   looked	  at	  TFs	   that	  are	  expressed	   in	  dorsal	  RP	  progenitors,	   prior	   to	   their	   differentiation	   into	  melanotrophs,	   to	   identify	   if	  
Sox2	  deleted	  POMC-­‐ve/eYFP+ve	   cells	   had	   stalled	   in	   an	   earlier	   pre-­‐endocrine	  cell	  state.	  TPIT	  is	  required	  for	  terminal	  differentiation	  of	  POMC+ve	  AP	  ACTH	  cells	   and	   IL	   MSH	   cells	   (Pulichino	   et	   al.,	   2003).	   At	   14.5dpc	   in	   control	  
Sox2fl/+;Nkx3.1Cre/+	  embryos,	  TPIT	   	   is	   expressed	   in	  AP	   corticotrophs	   (Figure	  5.2).	   It	   also	   starts	   to	   be	   expressed	   in	   the	   dorsal	   region	   of	   RP,	   however	   in	  contrast	   with	   AP,	   it	   co-­‐localizes	   with	   SOX2	   (Figure	   5.2).	   In	   14.5dpc	  
Sox2fl/fl;Nkx3.1Cre/+	   embryos,	   there	   is	   a	   small	   reduction	   in	   the	   number	   of	  TPIT+ve	   cells	   in	   the	   ventral	   RP	   (Figure	   5.2).	   Remarkably,	   TPIT	   is	   not	  observed	  in	  the	  dorsal	  region	  of	  RP	  at	  this	  stage	  in	  mutants	  (Figure	  5.2).	  By	  16.5dpc	  TPIT	  is	  expressed	  in	  nearly	  all	  cells	  of	   the	  future	  IL,	   in	  addition	  to	  AP	   corticotrophs	   in	   Sox2fl/+;Nkx3.1Cre/+	   embryos	   (Figure	   5.2).	   It	   has	   also	  started	   to	   be	   expressed	   in	   the	   future	   IL	   of	   Sox2fl/fl;Nkx3.1Cre/+	   embryos,	  however	  the	  number	  of	  TPIT+ve	  cells	  is	  severely	  reduced,	  with	  many	  TPIT-­‐ve	  IL	   cells	   (Figure	   5.2).	   Double	   immunofluorescence	   for	   TPIT	   and	   POMC	   in	  
Sox2fl/fl;Nkx3.1Cre/+;R26ReYFP/+	  embryos	  showed	  that	  TPIT	  always	  co-­‐localised	  with	  POMC,	  in	  a	  small	  population	  of	  eYFP+ve	  cells	  (Figure	  5.3).	  In	  conclusion,	  in	  Sox2fl/fl;Nkx3.1Cre/+	  embryos,	  the	  majority	  of	  Sox2	  deleted	  cells	  are	  blocked	  prior	  terminal	  differentiation	  as	  they	  express	  neither	  POMC,	  nor	  TPIT.	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Figure	  5.2:	  TPIT	  and	  SOX2	  expression	  in	  RP	  following	  Sox2	  deletion	  using	  Nkx3.1Cre.	  Immunofluorescence	  for	  SOX2	  (red)	  and	  TPIT	  (green),	  counterstained	  with	  DAPI	  (blue)	  at	  14.5dpc	   and	  16.5dpc.	   TPIT	   is	   expressed	   in	   the	   ventral	   region	   of	  RP	   and	   co-­‐localises	  with	  SOX2	  in	  a	  few	  cells	  in	  the	  dorsal	  region	  of	  control	  Sox2fl/+;Nkx3.1Cre/+	  embryos	  at	  14.5dpc.	  In	  mutant	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  at	  14.5dpc	  TPIT	  is	  downregulated	  in	  the	  ventral	  region	  and	  lost	  form	  the	  dorsal	  region	  of	  RP.	  By	  16.5dpc	  Sox2	  is	  expressed	  throughout	  the	  IL	  and	  co-­‐localises	  with	  TPIT	  in	  this	  region	  in	  control	  Sox2fl/+;Nkx3.1Cre/+	  embryos	  while	  TPIT	  and	  SOX2	  do	  not	  co-­‐localise	  in	  the	  AP.	  At	  16.5dpc	  in	  mutant	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  TPIT	  is	  slightly	  downregulated	  in	  the	  AP,	  however	  expression	  in	  the	  IL	  is	  severely	  reduced.	  Sections	  are	   orientated	   sagittally	   at	   14.5dpc	   and	   coronally	   at	   16.5dpc	   (see	   figure	   1.3	   and	   1.4	   for	  schematic	  representation).	  Inf	  =	  Infundibulum,	  RP	  =	  Rathke’s	  Pouch,	  PL	  =	  Posterior	  Lobe,	  IL	  =	  Intermediate	  Lobe	  and	  AL	  =	  Anterior	  Lobe.	  Scale	  =	  50μm.	  	  	  	  	  
	   	   	  
	   147	  
Figure	   5.3:	   TPIT	   and	   POMC	   expression	   in	   the	   IL	   following	   Sox2	   deletion	   using	  
Nkx3.1Cre.	  Immunofluorescence	   for	  POMC	  (red),	  TPIT	  (grey)	  and	  eYFP	  (green),	  at	  16.5dpc.	  TPIT	  and	  POMC	  co-­‐localise	  in	  the	  IL	  in	  control	  Sox2fl/+;Nkx3.1Cre/+;R26ReYFP/+	  and	  in	  the	  few	  remaining	  endocrine	   cells	   in	   the	   Sox2fl/fl;Nkx3.1Cre/+;R26ReYFP/+	   	   hypoplastic	   IL.	   All	   sections	   are	  orientated	  coronally.	  Scale	  =	  10μm.	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Figure	  5.4:	  SF1	  expression	  in	  RP	  following	  Sox2	  deletion	  using	  Nkx3.1Cre.	  	  Immunofluorescence	  for	  SF1	  (red)	  counterstained	  with	  DAPI	  (blue)	  at	  P0.	  SF1	  is	  expressed	  in	   the	   AP	   in	   control	   Sox2fl/+;Nkx3.1+/+	   	   embryos	   (arrow).	   High	   background	   staining	   is	  observed	   in	   these	   sections,	   primarily	   in	   the	   posterior	   lobe.	   	   Specific	   gonadotroph	   SF1	  staining	   is	  more	   intense	   and	   present,	   as	   described	   (Ingraham	   et	   al.,	   1994)	   in	   the	   ventral	  region	   of	   AL	   .	   In	   the	   hypoplastic	   Sox2fl/fl;Nkx3.1Cre/+	  	   AP,	   specific	   SF1	   staining	   is	   localised	  more	   laterally	   (arrow),	   however	   no	   expression	   is	   observed	   in	   the	   IL.	   All	   sections	   are	  orientated	  coronally.	  Scale	  =	  50μm.	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The	  TF	  PAX7	  is	  expressed	  in	  the	  future	  IL,	  earlier	  than	  TPIT,	  and	  is	  required	  for	  the	  specification	  of	  melanotrophs	  (Budry	  et	  al.,	  2012).	  PAX7	  appears	  in	  the	  developing	  IL	  of	  control	  Sox2fl/fl;Nkx3.1+/+	  embryos	  at	  14.5dpc,	  restricted	  to	  the	  dorsal	  region	  only	  (D-­‐RP)	  (Figure	  5.5A).	  By	  18.5dpc	  it	  is	  expressed	  in	  the	   future	   IL,	   but	   is	   excluded	   from	   some	   cells	   that	   line	   the	   lumen	   (Figure	  5.5C).	   All	   POMC+ve	   cells	   express	   PAX7	   at	   18.5dpc	   (Figure	   5.11).	   In	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Figure	  5.5:	  PAX7	  expression	  in	  RP	  at	  multiple	  stages	  of	  development.	  Immunofluorescence	   for	   PAX7	   (red)	   counterstained	   with	   DAPI	   (blue)	   at	   14.5dpc	   and	  18.5dpc.	  A:	  PAX7	  is	  expressed	  in	  the	  future	  IL	  (D-­‐RP)	  at	  14.5dpc	  in	  control	  Sox2fl/+;Nkx3.1+/+	  	  embryos.	  In	  Sox2fl/fl;Nkx3.1Cre/+	  	  embryos	  PAX7	  is	  completely	  downregulated	  (remaining	  red	  staining	  is	  non-­‐specific).	  D-­‐RP	  =	  Dorsal	  Rathke’s	  Pouch,	   Inf	  =	  Infundibulum,	  RP	  =	  Rathke’s	  Pouch.	   	  Sections	  orientated	  sagittally	  (see	  figure	  1.3	  for	  schematic	  representation).	  Scale	  =	  50μm.	   B:	   PAX7	   is	   exclusively	   expressed	   in	   the	   multi	   cell	   layered	   IL	   in	   control	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5.2.2	   Prospective	   Melanotroph	   -­‐	   Corticotroph	   fate	   switch	   in	  
Sox2fl/fl;Nkx3.1Cre/+	  mutants	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Figure	  5.6:	  POMC	  and	  Glucocorticoid	  receptor	  (GR)	  expression	   in	  RP	   following	  Sox2	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5.2.3	  In	  Silico	  analysis	  of	  SOX2	  transcription	  factor	  binding	  sites	  in	  the	  
Pax7	  genomic	  locus	  
	  The	  loss	  of	  PAX7	  in	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  prompted	  an	  examination	  of	  the	  Pax7	  locus	  for	  the	  presence	  of	  putative	  SOX2	  binding	  sites.	  Pax7	   lies	  on	  chromosome	   4	   in	   the	   mouse.	   Comparative	   genome	   analysis	   with	   human	  identified	   57	   evolutionary	   conserved	   regions	   (ECRs)	   with	   a	   sequence	  identity	   ≥	   70%	   over	   100bp	   in	   the	   66.7kb	   non-­‐coding	   region	   upstream	   of	  
Pax7	   (www.ecrbrowser.decode.org).	   Similar	   analysis	   of	   the	   76.9kb	   region	  downstream	   of	   Pax7	   prior	   to	   the	   next	   gene	   on	   chromosome	   4,	   Tas1r2,	  identified	  65	  ECRs.	  To	  lower	  the	  number	  of	  ECRs	  identified,	  the	  parameters	  were	   altered	   to	   ≥	   77%	   sequence	   identity	   over	   350bp.	   This	   restricted	   the	  number	   of	   total	   ECRs	   within	   the	   143.6kb	   region	   to	   12	   (Table	   5.1).	   Thus	  these	   highly	   evolutionarily	   conserved	   enhancer	   regions	   can	   be	   used	   to	  identify	  potential	  SOX2	  transcription	  TFBS.	  	  
Core	  ECR	   Genomic	  Position	   Length	   Percentage	  Identity	  1	   4:139694780-­‐139695153	   374	   75.9	  2	   4:139698566-­‐139699074	   509	   73.5	  3	   4:139710556-­‐139711331	   776	   79.5	  4	   4:139724767-­‐139725781	   1015	   81.1	  5	   4:139736936-­‐139737508	   673	   75.9	  6	   4:139832810-­‐139833756	   947	   76.8	  7	   4:139839660-­‐139840280	   621	   79.1	  8	   4:139841267-­‐139841624	   358	   76.8	  9	   4:139852917-­‐139853503	   587	   76.8	  10	   4:139878925-­‐139879322	   398	   78.9	  11	   4:139879987-­‐139880462	   467	   78.4	  12	   4:139905239-­‐139905602	   364	   76.4	  
Table	  5.1:	  ECRs	  upstream	  and	  downstream	  of	  Pax7.	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Following	  identification	  of	  the	  12	  ECRs	  upstream	  and	  downstream	  of	  Pax7;	  SOX2	   TFBS	   were	   searched	   for,	   using	   the	   www.genomix.de	   MatInspector	  software.	  No	  hits	  were	  detected	  in	  the	  12	  ECRs.	  In	  addition	  to	  this	  no	  SOX2	  peaks	   are	   observed	   in	   these	   regions	   in	   AtT-­‐20	   Sox2	   overexpressing	   cells	  following	   Sox2	   ChiP-­‐Sequencing	   (J.	   Drouin,	   personal	   communication).	  Therefore,	   it	   is	   unlikely	   that	   SOX2	   directly	   regulates	   Pax7	   expression,	   at	  least	  in	  the	  143.6kb	  we	  analysed.	  	  	  
5.2.4	  Genetic	  interaction	  between	  Sox2	  and	  p27	  during	  IL	  development	  
	  
5.2.4.1	   Intermediate	   lobe	   proliferation	   in	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	  
embryos	  
	  Upon	  Sox2	  deletion	  using	  Nkx3.1Cre,	  the	  morphology	  and	  the	  number	  of	  cells	  of	  the	  IL	  are	  severely	  reduced	  (Figure	  5.1).	  The	  reduction	  in	  proliferation	  of	  the	  progenitors	  in	  the	  IL	  may	  be	  caused	  by	  an	  earlier	  ectopic	  upregulation	  in	  p27kip1	  in	  the	  dorsal	  region	  of	  RP	  (Figure	  3.7).	  	  	  To	  investigate	  a	  possible	  genetic	  interaction	  between	  Sox2	  and	  p27kip1	  and	  potentially	   rescue	   the	   hypoplastic	   IL,	   we	   eliminated	   both	   p27kip1	   alleles	  (Fero	  et	  al.,	  1996)	  on	  the	  Sox2	  mutant	  background	  (Sox2fl/fl;Nkx3.1Cre/+).	  p27-­‐
/-­‐	  embryos	  have	  not	  been	  included	  in	  these	  results	  and	  will	  be	  analysed	  later.	  	  We	   observed	   an	   increase	   in	   the	   thickness	   of	   the	   IL	   in	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1cre/-­‐	   embryos	   compared	   to	   both	   Sox2fl/fl;Nkx3.1Cre/+	   and	  
Sox2fl/+;Nkx3.1Cre/-­‐	   embryos	   at	   18.5dpc	   (Figure	   5.7).	   The	   increase	   in	   the	  thickness	   of	   the	   IL	   in	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	   embryos	   however,	   was	   not	  uniform	   as	   some	   areas	   of	   the	   IL	   remained	   thin	   similar	   to	   the	   phenotype	  observed	  in	  Sox2fl/fl;Nkx3.1Cre/+	  embryos	  (Figure	  5.7).	  In	  addition	  to	  this	  the	  pseudo	   stratified	   epithelial-­‐like	  morphology	   of	   the	   IL	  was	   not	   restored	   in	  
p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	  embryos	  at	  18.5dpc	  (Figure	  5.7).	  The	  change	   in	   IL	  morphology	   and	   subsequent	   counting	   performed	  within	   its	   boundary	  was	  identified	  through	  its	  structure	  alone	  (see	  materials	  and	  methods).	  This	  was	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Figure	  5.7:	   Effect	   of	  p27kip1	   null	  mutation	  on	   IL	   size	   and	  POMC	  expression	   in	  Sox2	  
conditionally	  deleted	  embryos.	  Immunofluorescence	  for	  POMC	  (red),	  counterstained	  with	  DAPI	  (blue)	  at	  18.5dpc.	  POMC	  is	  uniformly	  expressed	  throughput	  the	  IL	  in	  control	  p27+/+;Sox2fl/+;Nkx3.1Cre/+	  	  embryos	  while	  it	  is	   significantly	   downregulated	   in	  Sox2fl/fl;Nkx3.1Cre/+	  	  embryos.	  Removal	   of	   both	  p27	   copies	  on	  this	  mutant	  background	  (p27-­‐/-­‐;Sox2fl/+;Nkx3.1Cre/+)	  	  results	  in	  a	  significant	  increase	  in	  the	  size	  of	  the	  IL,	  however	  its	  morphology	  is	  still	  aberrant.	  POMC	  expression	  is	  also	  increased	  compared	   to	   Sox2fl/fl;Nkx3.1Cre/+	   	  embryos,	   but	   not	   as	   uniform	   as	   in	   control	   embryos.	   All	  sections	  represent	  half	  the	  pituitary	  and	  are	  orientated	  coronally.	  PL	  =	  Posterior	  Lobe,	  IL	  =	  Anterior	  Lobe,	  AL	  =	  Anterior	  Lobe.	  Scale	  =	  100μm.	  	  	  	  	  	  	  
	   	   	  
	   159	  
The	  number	  of	  DAPI+ve	  nuclei	  in	  the	  IL	  of	  Sox2fl/fl;Nkx3.1Cre/+;p27-­‐/-­‐	  embryos	  is	   significantly	   increased	   compared	   to	   both	   control	   and	   conditionally	  deleted	  embryos	  (Figure	  5.7,	  5.8),	  suggestive	  of	  an	  increase	  in	  proliferation.	  A	   one-­‐hour	   EdU	   pulse	   was	   therefore	   given	   (via	   pregnant	   mothers)	   at	  18.5dpc.	  The	  percentage	  of	  EdU+ve;DAPI	  cells	  in	  the	  IL	  in	  Sox2	  conditionally	  deleted	   (Sox2fl/fl;Nkx3.1Cre/+)	   embryos	  was	   lower	   (6.9%,	   ±	   1.4,	   n	   =	   3),	   than	  control	   Sox2fl/fl;Nkx3.1+/+	  (WT)	   embryos	   (10.9%,	   ±	   0.4,	   n	   =	   3)	   (Figure	   5.9).	  Upon	   removal	   of	   one	   p27kip1	   allele	   of	   in	   Sox2	   mutants	   (p27+/-­‐
;Sox2fl/fl;Nkx3.1Cre/+;-­‐)	  the	  percentage	  of	  EdU+ve	  cells	  increased	  (9.7%,	  ±	  1.2,	  	  n	  =	   3)	   compared	   to	   Sox2	   single	   mutants,	   but	   remained	   below	   the	   level	  observed	  in	  control	  embryos	  (Figure	  5.9).	  In	  contrast,	  the	  percentage	  of	  EdU	  cells	   rose	   above	   that	   of	   control	   embryos	   when	   both	   p27kip1	   alleles	   were	  absent	   in	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	   embryos	   (12.8%,	   ±	   2.7,	   n	   =	   2)	   (Figure	  5.9).	   Therefore,	   dosage	   of	   p27kip1	   affects	   the	   hypoplastic	   phenotype	   of	  
Sox2fl/fl;Nkx3.1Cre/+	  embryos	  and	  somehow	  rescues	  the	  number	  of	  cells	  in	  the	  IL,	  supporting	  the	  existence	  of	  a	  antagonistic	  interaction	  between	  Sox2	  and	  















	   	   	  










Figure	  5.8:	  Number	  of	  DAPI+ve	  nuclei	   in	   the	   IL	  of	  control,	  Sox2	  conditionally	  deleted	  
and	  Sox2;p27	  compound	  mutants	  at	  18.5dpc.	  The	   total	   number	   of	   DAPI+ve	   nuclei	   in	   Sox2fl/fl;Nkx3.1Cre/+	   embryos	   (390.3	   ±35.7,	   n	   =	   3)	  compared	   to	  WT	   (B6;129SvJ)	   control	   	   embryos	   (668.3	   ±48.2,	   n	   =	   3)	   is	   reduced.	   Loss	   of	  











Figure	   5.9:	   Percentage	   of	   EdU+ve	   cells/DAPI	   in	   the	   IL	   of	   control,	   Sox2	  conditionally	  
deleted	  and	  Sox2;p27	  compound	  mutants	  after	  1h00	  pulse	  at	  18.5dpc.	  There	   is	   a	   decrease	   in	   the	   percentage	   of	   cells	   that	   incorporate	   EdU	   between	   WT	  (B6;129SvJ)	   (10.9%	   ±0.4,	   n	   =	   3)	   and	   Sox2fl/fl;Nkx3.1Cre/+	   embryos	   (6.9%	   ±1.4,	   n	   =	   3).	  Reduction	   of	   p27	   dosage	   correlates	   with	   further	   increases	   in	   EdU	   incorporation	   in	   p27-­‐
/+;Sox2fl/fl;Nkx3.1Cre/+	  (9.7%	  ±1.3,	  n	  =	  3)	  and	   in	  p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	  (12.9%	  ±2.7,	  n	  =	  2)	  embryos.	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5.2.4.2	   Intermediate	   lobe	   differentiation	   in	   p27-­‐/-­‐;Sox2fl/fl;Nkx3.1Cre/+	  
embryos	  	  Conditional	  deletion	  of	  Sox2	  results	  in	  a	  significant	  reduction	  in	  the	  number	  of	  POMC+ve	  cells	  remaining	  in	  the	  IL	  at	  18.5dpc	  (Figure	  5.10).	  The	  POMC+ve	  population	   remaining	   in	   the	   IL	   represents	   only	   13.3%	   of	   the	   population	  observed	  in	  control	  embryos.	  Removal	  of	  both	  p27kip1	  allele	  in	  the	  mutant	  background	   induces	   a	   large	   increase	   in	   the	   number	   of	   POMC+ve	   cells,	   now	  representing	   37.7%	   of	   the	   IL	   population	   observed	   in	   control	   matched	  pituitaries.	  Despite	  this	  increase	  in	  the	  number	  of	  POMC+ve	  cells	  in	  the	  IL	  of	  









	   	   	  















Figure	  5.10:	  Percentage	  of	  POMC+ve	   cells	   in	   IL	  of	   control,	  Sox2	  conditionally	  deleted	  
and	  Sox2;p27	  compound	  mutants	  at	  18.5dpc.	  72.0%	   (±3.3,	   n	   =	   3)	   of	   cells	   in	   the	   IL	   are	   POMC+ve	   in	   control	   WT	   embryos.	   This	   is	  significantly	  higher	  than	  the	  percentage	  of	  POMC	  cell	  in	  the	  IL	  of	  Sox2fl/fl;Nkx3.1Cre/+	  and	  p27-­‐
/-­‐;Sox2fl/fl;Nkx3.1Cre/+	  	  embryos	  displaying	  respectively	  14.4%	  (±1.6,	  n	  =	  3)	  and	  19.8%	  (±0.2,	  n	  =	  3).	  There	  is	  a	  slight	  but	  significant	  increase	  in	  the	  percentage	  of	  POMC+ve	  cells	  in	  the	  IL	  of	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5.3	  Discussion	  
	  The	  experiments	  carried	  out	  in	  this	  chapter	  aimed	  to	  further	  investigate	  the	  phenotype	  observed	  in	  the	  IL	  following	  Sox2	  deletion	  using	  Nkx3.1Cre,	  which	  is	  most	  active	  in	  the	  dorsal	  region	  of	  RP	  at	  12.5dpc,	  where	  the	  future	  IL	  will	  form.	   Previous	   results	   showed	   a	   severe	   reduction	   in	   the	   size	   of	   the	   IL,	   in	  addition	   to	  endocrine	   cell	  numbers.	  Moreover,	   a	   complete	  downregulation	  of	   the	   IL	   selector	   PAX7,	   inducing	   a	   fate	   change	   from	   melanotrophs	   to	  corticotrophs	  in	  the	  rare	  endocrine	  cells,	  was	  found	  in	  the	  mutant	  IL.	  Finally,	  as	   loss	   of	   proliferation	   was	   associated	   with	   ectopic	   expression	   of	   the	  negative	   cell-­‐cycle	   regulator	   p27kip1,	   we	   attempted	   to	   demonstrate	   an	  antagonistic	   genetic	   interaction	   and	   perform	   a	   rescue	   of	   the	   mutant	  phenotype	   by	   removing	   p27kip1.	   Proliferation	   was	   restored	   in	   these	  compound	  mutants	   but	   differentiation	   and	   cell	   fate	   specification	   was	   still	  impaired.	  These	  data	  suggest	  that	  SOX2	  performs	  two	  different	  roles;	  early	  on	   it	   is	   necessary	   for	   progenitor	   proliferation,	   while	   subsequently	   it	   is	  required	  for	  proper	  specification,	  at	  least	  in	  the	  IL.	  	  
5.3.1	  Sox2	  deletion	  in	  dorsal	  RP	  impairs	  differentiation	  and	  may	  induce	  
a	  cell	  fate	  switch	  
	  Fate	  mapping	  of	  Sox2	  conditionally	  deleted	  cells	  revealed	  the	  emergence	  of	  two	  populations	  in	  IL.	  	  The	  main	  population	  is	  eYFP+ve;POMC-­‐ve,	  and	  is	  made	  of	   cells	   that	   have	   had	   Sox2	   deleted	   and	   have	   failed	   to	   differentiate,	   and	  therefore	   do	   not	   express	   POMC.	   The	   second	   population,	   eYFP+ve;POMC+ve,	  represents	  a	  minor	  population	  that	  achieved	  terminal	  differentiation	  despite	  the	  loss	  of	  Sox2.	  	  	  	  The	   number	   of	   TFs	   known	   to	   be	   required	   for	   the	   specification	   and	  differentiation	  of	  dorsal	  RP	  progenitors	  to	  melanotrophs	  is	  relatively	  small.	  TPIT	   is	  required	   for	   the	   terminal	  differentiation	  of	  both	  melanotrophs	  and	  corticotrophs,	   with	  Tpit	   null	   mice	   displaying	   loss	   POMC	   expression	   and	   a	  hypoplastic	   adult	   IL	   (Lamolet	   et	   al.,	   2001;	   Pulichino	   et	   al.,	   2003).	   TPIT	   is	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normally	   expressed	   slightly	  before	  POMC	   in	   corticotrophs	   	   (Lamolet	   et	   al.,	  2001),	  however	  it	  was	  never	  observed	  in	  eYFP+ve;POMC-­‐ve	  cells.	  Conversely	  TPIT	  was	  always	  observed	  co-­‐expressed	  with	  POMC	  in	  the	  eYFP+ve;POMC+ve	  population.	   This	   data	   shows	   that	   the	   eYFP+ve;POMC-­‐ve	   cells	   have	   not	  remained	  in	  a	  TPIT+ve	  fate,	  prior	  to	  terminal	  differentiation.	  	  	  In	  addition	  to	  promoting	  the	  differentiation	  of	  POMC+ve	  melanotrophs,	  TPIT	  also	  acts	  as	  an	  inhibitor	  of	  the	  gonadotroph	  lineage	  (Pulichino	  et	  al.,	  2003).	  In	  the	  IL	  of	  Tpit	  null	  mice,	  ectopic	  gonadotrophs	  and	  also	  PIT1	  independent	  thyrotrophs	  are	  present	  (Pulichino	  et	  al.,	  2003).	  	  TPIT	  is	  thought	  to	  exert	  its	  inhibitory	  function	  on	  SF1,	  a	  TF	  required	  for	  gonadotroph	  differentiation,	  by	  direct	   protein-­‐protein	   interaction,	   thus	   sequestering	   it	   away	   from	   the	  gonadotroph	  enhancer	  (Pulichino	  et	  al.,	  2003).	  While	  we	  observe	  a	  dramatic	  decrease	  in	  the	  number	  of	  TPIT+ve	  cells	  in	  the	  IL,	  similar	  to	  what	  is	  observed	  in	   Tpit	   null	   mice,	   there	   is	   no	   ectopic	   expression	   of	   SF1	   in	   the	  
Sox2fl/fl;Nkx3.1Cre/+	   IL.	   These	   results	   suggest	   the	   TPIT-­‐ve	   (eYFP+ve/POMC-­‐ve)	  cells	   are	   retained	   in	   an	   early	   progenitor	   state	   where	   they	   are	   unable	   to	  differentiate	  into	  melanotrophs	  or	  alternatively,	  ectopic	  gonadotrophs.	  	  	  PAX7	   is	  expressed	  exclusively	   in	   the	  dorsal	   region	  and	   future	   IL	   (Budry	  et	  al.,	  2012;	  Hosoyama	  et	  al.,	  2010).	  Unlike	  in	  muscle	  where	  it	  has	  been	  shown	  to	   be	   required	   for	   the	   maintenance	   of	   satellite	   stem	   cells	   (Lepper	   et	   al.,	  2010;	  Oustanina	  et	  al.,	  2004),	  PAX7	  is	  thought	  to	  act	  as	  a	  selector	  factor	  in	  the	   developing	   pituitary,	   promoting	   melanotroph	   identity	   and	  differentiation	   over	   corticotroph	   fate	   (Budry	   et	   al.,	   2012).	  More	   precisely,	  PAX7	  opens	  up	  condensed	  chromatin	  and	  enhances	  the	  activity	  of	  TPIT	  on	  the	   regulatory	   regions	   of	   genes	   specifically	   expressed	   in	   melanotrophs	  (Budry	   et	   al.,	   2012).	   In	   Pax7	   null	   mice,	   there	   is	   a	   switch	   in	   fate	   from	  melanotroph	  to	  corticotroph	  (Budry	  et	  al.,	  2012).	  This	  is	  associated	  with	  the	  ectopic	  expression	  of	  GR	  in	  the	  IL	  in	  addition	  to	  other	  corticotroph	  markers	  NeuroD1,	   CRH-­‐R1	   and	   AVP-­‐R1b.	   In	   Sox2	   mutants,	   a	   complete	  downregulation	   of	   PAX7	   is	   also	   observed.	   Furthermore,	   mirroring	   the	  results	   from	   Budry	   et	   al	   (2012),	   we	   observe	   a	   switch	   in	   fate	   from	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melanotroph	   to	  corticotroph	   in	   the	  eYFP+ve;POMC+ve	   IL	  population.	   In	  both	  
Pax7	   null	   mice	   and	   Sox2fl/fl;Nkx3.1Cre/+	   embryos,	   this	   is	   indicated	   by	   the	  ectopic	   expression	   of	   GR,	   normally	   exclusively	   expressed	   in	   POMC+ve	  corticotrophs	   (Budry	   et	   al.,	   2012).	   Previous	   experiments	   have	   described	  changes	   in	  melanotroph	   fate	   due	   to	   loss	   of	   IL	   TFs	   (Pulichino	   et	   al.,	   2003,	  Budry	  et	  al.,	  2013),	  however	  due	  to	  the	  aberrant	  nature	  of	  the	  mutant	  IL	  and	  AP/IL	   boundary	   in	   our	   model,	   migration	   of	   POMC+ve;GR+ve	   corticotrophs	  from	  the	  AP	  to	  the	  IL	  cannot	  be	  ruled	  out.	  Future	  experiments	  will	  need	  to	  be	   performed	   to	   identify	   if	   this	   may	   account	   for	   any	   of	   the	   GR+ve	   cells	  observed	   in	   the	   mutant	   IL.	   Nevertheless	   these	   data	   suggest	   SOX2	   is	  specifically	  required	  for	  PAX7	  expression	  and	  consequently	  IL	  identity.	  	  	  
5.3.2	  SOX2	  and	  PAX7	  may	  interact	  to	  induce	  IL	  identity	  	  In	  contrast	  with	  published	  studies,	  we	  consistently	  observe	  a	  low	  expression	  level	   of	   SOX2	   throughout	   the	   IL,	   in	   addition	   to	   the	   well	   described	   high	  expression	  in	  progenitor	  cells	  lining	  the	  cleft	  (Fauquier	  et	  al.,	  2008;	  Himes	  et	  al.,	  2011;	  Goldberg	  et	  al.,	  2011;	  Budry	  et	  al.,	  2012).	  PAX7	   is	  excluded	   from	  the	  cells	  lining	  the	  cleft	  but	  in	  the	  IL	  their	  overlapping	  patterns	  of	  expression	  strongly	  suggest	  that	  SOX2	  and	  PAX7	  co-­‐localise	  in	  terminally	  differentiated	  melanotrophs.	  The	  requirement	  of	  SOX2	  for	  PAX7	  expression	  is	  unlikely	  to	  be	   direct	   as	   no	   SOX2	   TFBS	  were	   identified	   on	   the	  Pax7	   promoter.	   This	   is	  despite	  the	  co-­‐localisation	  of	  both	  proteins	  that	  occurs	  briefly	  in	  progenitors	  when	  SOX2	  is	  highly	  expressed	  (Budry	  et	  al.,	  2012)	  and	  later	  on	  when	  SOX2	  expression	  is	  maintained	  at	  a	  lower	  level	  (Figure	  4.14,	  4.16).	  	  	  Alternatively,	   SOX2	   and	   PAX7	   might	   interact.	   Indeed,	   in	   different	  developmental	  contexts,	   the	  association	  of	  SOX	  and	  PAX	  proteins	  has	  been	  extensively	  described	  (for	  review	  see	  Kondoh	  &	  Kamachi.,	  et	  al	  2010).	  Most	  notably,	  SOX2	  and	  PAX6	  interact	  to	  activate	  lens	  δ-­‐crystallin	  expression.	  This	  association	   does	   not	   only	   promote	   differentiation,	   but	   also	   initiate	   lens	  placode	   development	   (Kamachi	   et	   al.,	   2001;	   Kondoh	   et	   al.,	   2004).	   It	   is	  therefore	  possible	  that	  SOX2	  and	  PAX7	  interact	  to	  specify	  some	  aspects	  of	  IL	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identity	   and	   this	   interaction	   may	   be	   necessary,	   directly	   or	   indirectly,	   for	  PAX7	  expression.	  This	  is	  currently	  under	  investigation.	  
	  
5.3.3	  Sox2	  and	  p27kip1	  genetically	  interact	  
	  Previous	  results	  indicated	  an	  ectopic	  upregulation	  of	  p27kip1	  expression	  in	  the	  dorsal	  region	  of	  RP	  at	  14.5dpc.	  We	  hypothesised	  that	  SOX2,	  directly	  or	  indirectly,	   represses	   p27kip1	   expression,	   therefore	   resulting	   in	   ectopic	  upregulation	   in	   Sox2	   mutants	   and	   reduced	   proliferation.	   Multiorgan	  hyperplasia,	   female	   sterility,	   tumorigenesis	   and	   predominantly	   IL	   tumors	  are	  associated	  with	  the	  homozygous	  deletion	  of	  p27kip1	  in	  mice	  (Fero	  et	  al.,	  1996;	  Kiyokawa	  et	  al.,	  1996;	  Nakayama	  et	  al.,	  1996).	  In	  addition,	  deletion	  of	  
p27kip1	  in	  the	  adult	  cochlea	  and	  IL	  has	  been	  shown	  to	  increase	  proliferation	  (Roussel-­‐Gervais	   et	   al.,	   2010).	  We	   therefore	   removed	   both	  p27kip1	   alleles	  on	  conditionally	  deleted	  Sox2	  mice	  (Sox2fl/fl;Nkx3.1Cre/+)	  to	  test	  for	  a	  genetic	  interaction.	  	  	  While	   corticotrophs	   and	   melanotrophs	   share	   a	   similar	   transcriptional	  profile,	   they	  differ	   in	   their	  proliferative	  capacity.	  Corticotrophs	  can	  and	  do	  divide,	  while	  melanotrophs	  show	  a	  low	  level	  of	  proliferation	  in	  the	  embryo	  and	   none	   in	   the	   adult	   (Langlais	   et	   al.,	   2013).	  We	   also	   observe	   a	   low	   level	  proliferation	   in	   the	   IL	  of	   control	   embryos	  at	  18.5dpc,	  which	   then	  becomes	  even	   lower	   upon	   Sox2	   deletion.	   Strikingly,	   upon	   loss	   of	   p27kip1	   in	   the	  compound	  mutants,	   the	   number	   of	   dividing	   cells	   in	   the	   IL	   is	   dramatically	  increased.	   In	   addition,	   the	   size	   of	   the	   IL	   and	   number	   of	   POMC	   cells	   are	  substantially	   augmented,	   with	   the	   total	   number	   of	   cells	   in	   the	   IL	   being	  significantly	  higher.	  	  	  The	   successful	   restoration	   of	   IL	   proliferation	   demonstrates	   that	   there	   is	   a	  genetic	   interaction	   between	   Sox2	   and	   p27kip1	   in	   this	   region.	   p27kip1	   is	  initially	   expressed	   in	   the	   ventral	   differentiated	   cells	   of	   RP	   at	   13.5dpc	  (Bilodeau	  et	  al.,	  2009).	  At	  this	  stage	  SOX2	  and	  p27kip1	  expression	  patterns	  are	   mutually	   exclusive	   as	   SOX2	   is	   only	   found	   in	   the	   dorsal	   region	   of	   RP.	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Nevertheless	   as	   development	   progresses	   p27kip1	   expression	   expands	  dorsally	  and	  becomes	  ubiquitously	  present	  in	  adults	  (Bilodeau	  et	  al.,	  2009).	  It	   is	   known	   that	   p27kip1	   directly	   represses	   Sox2	   expression	   upon	   ES	   cell	  differentiation	   (Li	   et	   al.,	   2012;	   see	   chapter	   1).	   Our	   results	   suggest	   that	   in	  turn	  SOX2	  may	  also	  be	  able	  to	  repress,	  directly	  or	  indirectly,	  the	  expression	  of	  p27kip1,	  so	  that	  a	  negative	  feedback	  loop	  may	  exist	  between	  them	  as	  both	  proteins	  become	  co-­‐expressed.	  SIX6	  may	  be	  involved,	  at	  least	  in	  RP,	  as	  it	  was	  shown	   to	  directly	   repress	  p27kip1	   (Li	   et	   al.,	   2002)	  and	  we	  show	  here	   that	  
Sox2	  deletion	  induces	  a	  complete	  downregulation	  of	  SIX6	  (Figure	  4.11).	  	  
	  
5.3.4	  p27kip1	  deletion	  does	  not	  restore	  differentiation	  in	  Sox2	  mutants	  	  Despite	  the	  large	  increase	  in	  IL	  cell	  number,	  neither	  terminal	  differentiation	  nor	  PAX7	  expression	  is	  restored	  in	  compound	  mutant	  embryos.	  This	  result	  highlights	   the	   un-­‐coupling	   between	   proliferation	   and	   differentiation,	   as	  suggested	   by	   Bilodeau	   et	   al	   (2009)	   where	   it	   was	   shown	   that	   sustained	  proliferation	   in	   negative	   regulators	   of	   cell	   cycle	   mutants	   does	   not	   affect	  terminal	  differentiation	  in	  the	  pituitary.	  	  	  
5.3.5	  Conclusions	  
	  In	   conclusion	   the	   studies	   presented	   in	   this	   chapter	   aimed	   to	   further	  investigate	   the	   phenotype	   observed	   in	   the	   IL	   following	   Sox2	   conditional	  deletion	  using	  Nkx3.1Cre.	  Our	  data	  shows	  that	  PAX7	  expression	  is	  completely	  downregulated	   following	  Sox2	   deletion	   and	   this	  may	   result	   in	   a	   change	   of	  fate	   from	  melanotrophs	   to	   corticotrophs.	   There	   is	   likely	   to	   be	   a	   direct	   or	  indirect	  interaction	  between	  SOX2	  and	  PAX7,	  necessary	  for	  IL	  specification.	  Moreover,	   loss	  of	  p27kip1	  in	  Sox2	  conditionally	  deleted	  mutant’s	  results	   in	  restoration	   of	   proliferation	   but	   still	   defective	   differentiation.	   This	   is	   in	  agreement	   with	   the	   hypothesis	   of	   a	   dual	   role	   for	   SOX2	   in	   RP,	   initially	  promoting	   progenitor	   proliferation,	   then	   being	   involved	   in	   cell	   type	  specification,	   at	   least	   in	   IL.	   Both	   roles	   and	   also	   processes	   appear	  independent,	  as	  previously	  suggested	  (Bilodeau	  et	  al.,	  2009).	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6.	  General	  Discussion	  
	  The	   aim	   of	   this	   thesis	  was	   to	   use	   genetics	   to	   investigate	   the	   role	   of	   SOX2	  during	   pituitary	   development.	   This	   required	   conditional,	   Cre-­‐mediated	  deletion	  of	  the	  gene	  specifically	  in	  RP	  in	  vivo.	  The	  use	  of	  two	  Cre	  drivers	  with	  distinct	   but	   overlapping	   expression	   gave	   both	   a	   broader	   and	   deeper	  understanding	   than	   would	   have	   been	   possible	   with	   either	   alone.	   In	   this	  chapter	   I	  will	  present	  a	  synthesis	  of	   these	  results,	  propose	  a	  model	   for	  the	  role	   of	   SOX2	   in	   RP	   progenitors,	   discuss	   still	   open	   questions,	   and	   suggest	  directions	  for	  further	  investigation.	  	  
6.1	   SOX2	   is	   necessary	   for	   early	   progenitor	   proliferation	   and,	   as	   a	  
consequence,	  for	  normal	  endocrine	  cell	  numbers	  
	  SOX2	   is	   required	   for	   the	   formation	   of	   different	   organs	   including	   the	   brain	  (Favaro	  et	  al.,	  2009),	  eye	  (Taranova	  et	  al.,	  2006),	  lung	  (Que	  et	  al.,	  2009)	  and	  ear	   (Dabdoub	   et	   al.,	   2008;	   Kiernan	   et	   al.,	   2005),	   where	   it	   is	   associated	   in	  particular	   with	   proliferation	   of	   progenitors.	   Previous	   studies	   identified	  SOX2	  as	  a	  marker	  for	  both	  RP	  progenitors	  and	  adult	  pituitary	  SCs	  (Fauquier	  et	  al.,	  2008;	  Rizzoti	  et	  al.,	  2013;	  Andoniadou	  et	  al.,	  2013)	  (see	  chapter	  1).	  In	  light	  of	  this	  we	  hypothesised	  that	  SOX2	  may	  be	  important	  in	  RP	  progenitors	  for	  proper	  pituitary	  development.	  	  Our	   results	   provide	   evidence	   that	   SOX2	   is	   necessary	   for	   RP	   progenitor	  proliferation.	  Performing	  either	  global	  gene	  deletion	  thanks	  to	  FoxG1Cre,	  or	  a	  more	   restricted	   one	   using	   Nkx3.1Cre,	   we	   were	   able	   to	   show	   that	   SOX2	   is	  required	  to	  maintain	  proliferation	  in	  progenitors	  early	  in	  development.	  This	  is	   in	   agreement	   with	   a	   study	   published	   during	   the	   course	   of	   this	   work,	  where	   the	   function	  of	  SOX2	   in	  RP	  progenitors	  was	   investigated	  using	  gene	  deletion	   with	   a	   different	   Cre	   driver,	  Hesx1Cre,	   and	   also	   resulted	   in	   severe	  pituitary	   hypoplasia	   (Jayakody	   et	   al.,	   2012).	   Our	   two	   RP	   Cre	   drivers	   also	  display	   different	   temporal	   patterns	   of	   deletion.	   Deletion	   of	   Sox2	   in	   RP	  progenitors	  prior	   to	   the	  main	  wave	  of	   cell	   cycle	  exit	  between	  11.5dpc	  and	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6.2	   SOX2,	   SIX6	   and	   p27kip1	   regulate	   early	   pituitary	   progenitor	  
proliferation	  
	  
6.2.1	  SOX2	  may	  directly	  regulate	  Six6	  expression	  
	  SOX2	   and	   SIX6/3	   are	   co-­‐expressed	   in	  RP	  progenitors.	  Upon	  Sox2	   deletion,	  SIX6/3	   are	   specifically	   downregulated	   while	   other	   markers	   of	   RP	  progenitors,	  like	  LHX3	  and	  PITX-­‐1,	  are	  maintained	  (Fig	  6.1)	  (Jayakody	  et	  al.,	  2012).	  SOX2	  may	  directly	   regulate	  SIX6/3	  expression	   in	  RP,	  as	   it	  has	  been	  shown	   to	   do	   so	   in	   different	   developmental	   contexts,	   notably	   in	   the	   CNS	  (Baccari	   et	   al.,	   2012,	   Lee	   et	   al.,	   2012,	   Lee	   et	   al.,	   2013).	  More	   precisely,	   12	  highly	  evolutionarily	  conserved	  regions	   (ECRs)	  have	  been	  characterized	   in	  the	   Six6	   locus.	   Two	   of	   these	   recapitulate	   SIX6	   expression	   in	   the	   mouse	  forebrain	   (Lee	   et	   al.,	   2012).	   SOXB1	   genes	   can	   bind	   directly	   to	   these	   two	  enhancers	  and	  drive	  their	  expression	  in	  vitro.	  Conversely	  in	  vivo,	  upon	  Soxb1	  gene	   dosage	   reduction,	   endogenous	   SIX6	   expression	   is	   lost	   suggesting	   a	  direct	  regulatory	  action	  of	  SOXB1	  proteins	  (Lee	  et	  al.,	  2012).	  Unfortunately	  neither	   of	   these	   two	   ECRs	   displays	   activity	   in	   RP	   (Lee	   et	   al.,	   2012).	  More	  extensive	   analysis	   of	   the	   expression	  pattern	   induced	  by	   the	   ten	   remaining	  ECRs	   is	   required.	   In	   addition,	   RP/pituitary	   SOX2	   ChiP-­‐Sequencing	   would	  reveal	  relevant	  SOX2	  TFBS	  in	  the	  Six6	  locus.	  	  	  	  
6.2.2	  Sox2	  and	  p27kip1	  genetically	  interact	  
	  Upon	  deletion	  of	  Sox2	  using	  Nkx3.1Cre,	  we	  observed	  an	  ectopic	  upregulation	  of	  CDKI	  p27kip1	  in	  the	  dorsal	  region	  of	  RP,	  where	  proliferation	  is	  reduced.	  A	  similar	   result	  was	   also	   observed	   by	   Jayakody	   et	   al	   (2012).	  We	   decided	   to	  investigate	   this	   further	   by	   deleting	   p27kip1	   in	   Sox2	   mutant	   embryos.	   We	  observed	   a	   restoration	   of	   dorsal	   proliferation	   in	   compound	   p27kip1;Sox2	  mutant	  embryos.	  This	  demonstrates	  a	  genetic	  interaction	  between	  SOX2	  and	  p27kip1	  and	  suggests	  that	  SOX2	  may	  repress	  p27kip1	  expression,	  at	  least	  in	  the	  dorsal	  region	  of	  RP.	  The	  interaction	  clearly	  appears	  context-­‐dependent.	  
Sox2	   deletion	   in	   post-­‐natal	   cochlear	   inner	   pillar	   cells	   induces	   a	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downregulation	   of	   p27kip1	   expression,	   resulting	   in	   proliferation	   of	   these	  normally	  quiescent	  differentiated	  supporting	  cells	  (Liu	  et	  al.,	  2012).	  	  In	  this	  context,	   the	   interaction	   is	   likely	   to	  be	  direct	  as	  SOX2	  can	  bind	   the	  p27kip1	  promoter	   to	  drive	   its	   expression	   in	  vitro	   (Liu	  et	   al.,	   2012).	   In	  ES	   cells,	   and	  presumably	   in	   adult	   pituitary	   cells,	   it	   is	   known	   that	   p27kip1	   recruits	   a	  repressor	   complex	   to	   down-­‐regulate	   Sox2	   expression	   (Li	   et	   al.,	   2012).	  However,	   we	   have	   not	   studied	   the	   molecular	   mechanism,	   which	   may	   be	  reciprocal,	   underlying	   the	   Sox2/p27	   interaction	   that	   we	   have	   observed	   in	  the	  developing	  pituitary.	  	  	  Ectopic	   p27kip1	   expression	   in	   the	   dorsal	   RP	   of	   Sox2	   mutants	   is	   also	  correlated	  with	   down-­‐regulation	   of	   SIX6.	   The	   role	   of	   SIX6	   to	   promote	   cell	  proliferation	  has	  been	  described,	  primarily	  in	  the	  developing	  eye,	  in	  various	  species	   (Anderson	   et	   al.,	   2012).	   Overexpression	   of	   XOptx2,	   the	   Six6	  Xenopous	   homologue,	   results	   in	   increased	   expression	   of	   Cyclin	   D1	   and	   a	  dramatically	   enlarged	   eye	   field	   (Zuber	   et	   al.,	   1999).	   Similarly,	   in	   Medaka	  retina,	   overexpression	   of	   SIX6	   is	   associated	   with	   increased	   Cyclin	   D1	  expression	   and	   progenitor	   proliferation	   (Conte	   et	   al.,	   2010).	   Interestingly,	  reduced	   p27Xic1	   expression	   is	   also	   observed	   in	   the	   SIX6	   overexpression	  retina	  (Conte	  et	  al.,	  2010;	  Gestri	  et	  al.,	  2005).	  Pituitary	  hypoplasia	  is	  present	  in	  Six6	  null	  mice,	  alongside	  a	  reduction	  in	  the	  size	  of	  the	  eye	  (Li	  et	  al.,	  2002).	  Significantly,	   the	   latter	   was	   associated	   with	   an	   increase	   in	   p27kip1	  expression,	  while	   in	  vitro	   assays	  demonstrated	   that	   SIX6	   can	  directly	   bind	  the	  p27kip1	  promoter	  and	  repress	  its	  activity	  in	  the	  α-­‐T3	  pituitary	  cell	  line	  (Li	  et	  al.,	  2002).	  We	  observe	  a	  downregulation	  of	  SIX6,	  Cyclin	  D1	  and	  an	  up-­‐regulation	   in	   p27kip1	   in	   Sox2	  mutants.	   These	   data	   all	   suggest	   that	   SOX2	  promotes	  progenitor	  proliferation	  at	  least	  in	  part	  through	  the	  upregulation	  of	   SIX6.	   In	   turn	   SIX6	   may	   induce	   proliferation	   and	   cell	   cycle	   progression	  through	   the	   inhibition	   of	   p27kip1.	   Therefore	   the	   genetic	   interaction	   we	  observe	  between	  SOX2	  and	  p27kip1	  could	  be	  indirect,	  and	  mediated	  by	  SIX6	  (Figure	  6.1).	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6.2.3	   Proliferation	   of	   RP	   progenitors	   is	   regulated	   independently	   by	  
different	  TF	  cascades	  	  A	   rudimentary	   pituitary	   develops	   despite	   the	   significant	   reduction	   of	  proliferation	   observed	   following	   deletion	   of	   Sox2	   throughout	   RP.	   It	   is	  possible	   that	   SOX2	   was	   not	   deleted	   early	   enough	   to	   completely	   inhibit	  pituitary	   formation.	   This	   is	   however	   unlikely	   as	   FoxG1Cre	   is	   active	   in	   the	  anterior	  neural	  ridge	  at	  8.5dpc	  (Wang	  et	  al.,	  2010),	  in	  the	  region	  where	  the	  hypophyseal	   placode	   forms.	   A	   second	   and	   more	   likely	   explanation	   is	   the	  continued	  expression	  of	  at	  least	  LHX3,	  ISL1	  and	  PITX1	  in	  Sox2	  mutants	  (this	  thesis	   and	   Jayakody	   et	   al.,	   (2012),	   three	   TFs	   required	   respectively	   for	  progenitor	   maintenance	   (LHX3)	   and	   proliferation	   (Zhao	   et	   al.,	   2006,	  Ellsworth	  et	  al.,	  2008,	  Takuma	  et	  al.,	  1998).	  	  Thus	  these	  TFs	  may	  account	  for	  the	   reduced	   level	   of	   proliferation	   and	   consequently	   rudimentary	   RP	  formation.	   It	   is	   not	   known	   if	   SOX2	   and	   SIX6	   expression	   patterns	   are	  maintained	   in	   embryos	   with	   null	   mutations	   for	   LHX3,	   ISL1	   or	   PIXT1.	  However,	   our	  data	   suggest	   that	   several	  TF	   cascades,	   acting	   independently,	  may	  regulate	  proliferation	  of	  RP	  progenitors	  (Figure	  6.1).	  	  	  
6.3	  SOX2	  and	  endocrine	  cell	  differentiation	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6.3.1	  Anterior	  lobe	  
	  The	   early	   hypoplasia	   following	   Sox2	   deletion	   using	   FoxG1Cre	  results	   in	   the	  loss	  of	  nearly	  all	  endocrine	  cell	  types.	  Interestingly,	  the	  first	  cell	  type	  to	  exit	  the	  cell	  cycle,	  the	  future	  rostral-­‐tip	  thyrotrophs	  (Jean	  et	  al.,	  1994),	  is	  also	  the	  least	   affected.	  All	   other	   cell	   types,	   that	   exit	   concomitantly	  mainly	  between	  11.5dpc	   –	   13.5dpc	   (Davies	   et	   al.,	   2011),	   fail	   to	   differentiate.	   Therefore	   the	  cells	   that	   exit	   the	   cell	   cycle	   earlier	   are	   less	   affected.	   This	   was	   also	   the	  conclusion	  reached	  by	  Jayakody	  et	  al	  (2012)	  from	  their	  data.	  	  	  One	   exception	   to	   this	   rule	   in	   Jayakody	   et	   al	   (2012)	   was	   the	   unexpected	  maintenance	  of	  PrL	  expression,	  despite	  the	  complete	  loss	  of	  PIT1.	  Similarly,	  PIT1	   is	   completely	   downregulated	  when	   Sox2	   was	   deleted	   using	   FoxG1Cre,	  but	   in	  contrast	   there	  was	  no	  PrL	  expression.	  PROP1	  is	  also	  downregulated	  following	   Sox2	   deletion,	   however	   its	   expression	   is	   not	   completely	   lost	  (Jayakody	   et	   al.,	   2012).	   PROP1	   promotes	   the	   emergence	   of	   gonadotrophs	  and	  the	  PIT1	  lineage,	  but	  its	  function	  in	  the	  early	  RP	  is	  unclear	  as	  it	  is	  mainly	  co-­‐expressed	  with	  SOX2	  from	  10.5dpc,	  becoming	  progressively	  restricted	  to	  the	   dorsal	   region	   of	   RP	   (Dasen	   et	   al.,	   1998,	   Yoshida	   et	   al.,	   2011).	   Its	  downregulation	   may	   be	   a	   contributing	   factor	   in	   the	   loss	   of	   PIT1	   and	  endocrine	   cell	   differentiation	   in	   the	   AP.	   These	   studies,	   combined	  with	   the	  results	  presented	  in	  this	  thesis	  suggest	  SOX2	  driven	  proliferation	  is	  required	  to	   produce	   a	   large	   pool	   of	   progenitors	   that	   can	   then	   progress	   toward	  endocrine	  cell	  commitment	  and	  differentiation.	  	  
6.3.2	  Intermediate	  lobe	  
	  The	  phenotype	  observed	  in	  the	  IL	  initially	  appears	  similar	  to	  that	  observed	  in	   the	   AP.	   Sox2	   deletion	   results	   in	   severe	   hypoplasia	   and	   a	   loss	   of	   cell	  identity	   as	   the	  majority	   of	   remaining	   cells	   persist	   as	   POMC-­‐ve	   non-­‐cycling	  progenitors.	   More	   detailed	   analysis	   reveals	   a	   complete	   downregulation	   of	  lineage	   specifier	   PAX7,	   resulting	   in	   a	   change	   of	   cell	   fate	   from	   GR-­‐ve	  melanotrophs	   to	  GR+ve	   corticotrophs	   in	   the	  remaining	  POMC+ve	  population.	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This	   suggests	   that	   SOX2	   plays	   an	   additional	   role	   in	   the	   IL	   and	   that	   it	   is	  necessary	  for	  melanotroph	  lineage	  specification	  (Figure	  6.2).	  This	  correlates	  with	   a	   different	   expression	   pattern	   of	   SOX2	   in	   the	   IL	   compared	   to	   the	  AP	  (Figure	   6.3).	   Weak	   nuclear	   SOX2	   is	   observed	   throughout	   the	   IL	   up	   until	  adulthood	  in	  the	  region	  of	  PAX7	  and	  POMC	  expression,	  while	  cells	  lining	  the	  cleft	   show	  strong	  SOX2	  expression	   (Figure	  6.2,	  6.3).	  Nuclear	  SOX2	   is	  never	  seen	   in	   the	   AP,	   although	   very	   infrequent	   hormone+ve	   cells	   can	   have	   SOX2	  protein	   localised	   in	   the	   cytoplasm,	   (Fauquier	   et	   al.,	   2008;	  Gremeaux	   et	   al.,	  2012).	   This	   indicates	   that	   SOX2	   marks	   two	   populations	   of	   cells	   in	   the	  pituitary;	   terminally	   differentiated	   melanotrophs	   (SOX2LO)	   and	  SC/progenitors	  (SOX2HI).	  Similarly	  adult	  NSC	  can	  be	  classified	  into	  SOX2	  Hi	  and	   Lo	   cells,	   representing	   spatial	   and	   functional	   differences	   (Hutton	   &	  Pevny.,	   2011).	   Loss	   of	   PAX7	   in	   Sox2	  mutant	   IL	   cells	   and	   their	   subsequent	  identity	   switch	   leads	   us	   to	   hypothesise	   that	   SOX2	   may	   directly	   regulate	  PAX7	  expression.	  Analysis	  of	   the	  Pax7	   locus	  did	  not	  reveal	  any	  SOX2	  TFBS	  and	   the	   factors	   involved	   in	   Pax7	   transcriptional	   regulation	   in	   IL	   are	   still	  unknown	  (J.	  Drouin	  personal	  communication),	  but	  this	  needs	  to	  be	  explored	  further.	  	  SOX2	   and	  PAX6	   are	   known	   to	  physically	   interact	   to	   activate	   expression	  of	  δ1-­‐crystallin	   in	   the	   lens	   placode	   (Kamachi	   et	   al.,	   2001).	   PAX7	   shares	  extremely	  high	  homology	  with	  PAX6	  and	   indeed	  both	   contain	  a	  PD,	  which	  interacts	   with	   the	   HMG	   domain	   of	   SOX2	   to	   form	   a	   complex	   on	   the	   δ1-­‐
crystallin	  promoter	  (Kamachi	  et	  al.,	  2001).	  The	  SOX2-­‐PAX6	  complex	  can	  also	  actively	   promote	   the	   expression	   of	   Pax6	   itself.	   In	   addition,	   SOX2	   can	  upregulate	  Pax6	  expression	  in	  head	  ectoderm	  (Aota	  et	  al.,	  2003).	  Based	  on	  these	   data,	   it	   would	   be	   of	   interest	   to	   investigate	   potential	   interactions	  between	  SOX2	  and	  PAX7	  and	  whether	  a	  SOX2-­‐PAX7	  complex	  participates	  in	  
Pax7	   regulation.	   Such	   an	   interaction	   may	   explain	   the	   loss	   of	   PAX7	  expression	  in	  mutants.	  Deletion	  of	  Sox2	  in	  POMC+ve	  cells	  will	  also	  allow	  us	  to	  further	  investigate	  its	  role	  in	  melanotroph	  specification	  and	  its	  involvement	  in	  PAX7	  expression.	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6.4	   SOX2	   regulation	   of	   early	   progenitor	   proliferation	   and	   later	  
IL/melanotroph	  specification	  is	  independent	  
	  As	  suggested	  earlier,	  reduction	  in	  AP	  endocrine	  cell	  numbers	  may	  solely	  be	  a	  consequence	  of	  a	  reduced	  progenitor	  pool	  (see	  above;	  Jayakody	  et	  al.,	  2012).	  This	   suggests	   that	   restoration	   of	   proliferation	   in	   mutants	   should	   also	  promote	   differentiation	   of	   more	   endocrine	   cells.	   However,	   at	   least	   in	   the	  dorsal	   RP,	   restoration	   of	   proliferation	   in	   Sox2;p27kip1	   mutants	   did	   not	  rescue	  the	  differentiation	  defect.	  	  	  Independent	   regulation	   of	   RP	   progenitor	   proliferation	   and	   differentiation	  has	   been	   suggested	   previously	   (Bilodeau	   et	   al.,	   2009).	   In	   this	   study,	  differentiation	   was	   un-­‐perturbed	   following	   the	   homozygous	   deletion	   of	  27kip1,	  p57kp2	  or	  both	   together,	  despite	   the	   increase	   in	  proliferation.	  We	  observe	  a	  converse	  situation	  in	  our	  model:	  restoration	  of	  proliferation	  does	  not	  rescue	  defective	  differentiation	  in	  the	  absence	  of	  SOX2.	  This	  observation	  also	   suggests	   that	   proliferation	   and	   differentiation	   are	   regulated	  independently,	  and	  moreover	  that	  SOX2	  may	  be	  involved	  in	  both	  processes	  in	  the	  IL,	  where	  its	  expression	  is	  normally	  maintained.	  	  	  In	  the	  AL,	  the	  situation	  is	  different	  as	  the	  SOX2	  is	  down-­‐regulated	  when	  cells	  differentiate.	   However,	   SOX2	   may	   also	   play	   an	   additional	   role	   and	   allow	  progenitors	   to	   become	   “competent”	   for	   commitment	   and	   differentiation,	  possibly	   through	   the	   upregulation	   of	   PROP1	   (see	   above).	   Restoration	   of	  proliferation	  using	  CDKI	  null	  mutants	  (Bilodeau	  et	  al.,	  2009)	  on	  a	  FoxG1Cre;	  
Sox2	  fl/fl	  may	  answer	  this	  question.	  	  Classically,	  SOX2	  exerts	  its	  function	  only	  in	  partnership	  with	  another	  TF	  (for	  review	   see	  Kondoh	  &	  Kamachi.,	   2010).	   Interaction	  with	   a	   partner	   such	   as	  PAX6	   in	   the	   lens	   placode	   is	   associated	   with	   acquisition	   of	   lens	   identity,	  through	   the	   activation	   of	   new	   molecular	   cascades	   and	   in	   this	   instance	  promotion	   of	   lens	   differentiation	   (Kamachi	   et	   al.,	   2001).	   Transition	   in	   cell	  fate	   can	   be	   caused	   by	   changing	   one	   of	   the	   two	   TF	   in	   the	   complex,	   for	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example	  neural	  stem	  cells	  are	  characterised	  by	  the	  presence	  of	  SOX2/BRN2	  complexes,	  while	  transition	  to	  neural	  progenitors	  can	  be	  associated	  with	  the	  formation	   of	   a	   SOX11/BRN2	   complex	   (Tanaka	   et	   al.,	   2004).	   These	   studies	  are	   consistent	   with	   a	   change	   in	   fate	   (and	   the	   regulation	   of	   relevant	  processes)	  being	   induced	   through	  pairing	   a	   common	  TF	  with	  different	   co-­‐factors.	  Here	  SOX2	  may	  have	  different	  partners	  to	  regulate	  proliferation	  and	  differentiation.	   PAX7	   is	   a	   likely	   candidate	   for	   forming	   a	   complex	   in	   the	  dorsal	   region	   of	   RP	   to	   promote	   IL	   fate.	   SOX2	   is	   also	   capable	   of	   forming	  complexes	   with	   members	   of	   the	   SIX	   family	   of	   TF,	   notably	   this	   has	   been	  reported	   for	  SIX1	  (Ahmed	  et	  al.,	  2012).	  Moreover	  SOX2	  and	  SIX3	  can	  both	  bind	  the	  Shh	  SBE2	  forebrain	  enhancer,	  indicating	  they	  could	  possibly	  form	  a	  complex	   and	   co-­‐operate	   to	   promote	   Shh	   expression	   (Jeong	   et	   al.,	   2008;	   Li	  Zhao	  et	  al.,	  2012).	  Thus	  SOX2	  may	  also	  promote	  proliferation	  co-­‐operatively	  with	  SIX6	  in	  addition	  to	  activating	  its	  expression.	  The	  switch	  between	  SIX6	  and	   PAX7	   in	   dorsal	   RP	   may	   be	   crucial	   for	   a	   change	   in	   cell	   fate	   from	   a	  proliferative	  progenitor	  to	  a	  future	  melanotroph.	  	  
6.5	  Model	  of	  the	  role	  of	  SOX2	  during	  pituitary	  development	  
	  Based	  on	  the	  data	  presented	  in	  this	  thesis	  and	  previously	  published	  studies,	  we	   can	   now	   propose	   a	   combined	  model	   of	   the	   roles	   of	   SOX2	   in	   pituitary	  development,	  (Figure	  6.3).	  	  	  SOX2	   and	   SIX6	   are	   expressed	   throughout	   RP	   during	   its	   early	   proliferative	  phase,	  prior	  to	  cell	  cycle	  exit	  at	  11.5dpc	  (Davis	  et	  al.,	  2011).	  SOX2	  promotes	  proliferation	  (this	  thesis	  and	  Jayakody	  et	  al.,	  2012),	  at	  least	  in	  part	  through	  the	   upregulation	   of	   SIX6	   and	   repression	   of	   p27kip1.	   This	   early	   SOX2;SIX6	  dependent	   proliferation	   allows	   the	   production	   of	   sufficient	   progenitors	   to	  permit	   both	   early	   and	   late	   cell	   cycle	   exiting	   cells	   to	   be	   generated,	   and	  undergo	  terminal	  differentiation.	  This	  initial	  proliferative	  role	  of	  SOX2	  in	  RP	  is	   essential	   to	   prevent	   hypoplasia	   and	   cellular	   arrest	   in	   a	   non-­‐cycling	  progenitor-­‐like	  state.	  
	   	   	  
	   182	  





















	   	   	  
	   183	  
















	   	   	  
	   184	  
6.6	  Summary	  
	  In	  summary,	  our	  results	  show	  that	  SOX2	  is	  necessary	  for	  the	  proliferation	  of	  early	  RP	  progenitors.	   It	   is	   likely	   that	   SOX2	   regulates	  proliferation	   through	  the	   upregulation	   of	   SIX6,	   whose	   expression	   is	   down-­‐regulated	   upon	   Sox2	  deletion.	  Moreover,	  we	  demonstrate	  a	  genetic	  interaction	  between	  SOX2	  and	  p27kip1,	   in	   the	   dorsal	   region	   of	   RP	   suggesting	   that	   SOX2	   may	   repress	  p27kip1	   expression	   and	   this	   may,	   in	   part,	   be	   necessary	   for	   proliferation.	  Furthermore,	  our	  results	  show	  that	  SOX2	  is	  necessary	  for	  PAX7	  expression	  in	  the	  dorsal	  RP	  and	  IL	  where	  SOX2	  is	  ubiquitously	  expressed.	  Loss	  of	  PAX7	  expression	  due	  to	  Sox2	  deletion,	  results	  in	  a	  switch	  in	  cell	  fate	  in	  the	  IL,	  from	  melanotrophs	   to	   corticotrophs,	   demonstrating	   a	   role	   for	   SOX2	   in	   IL	  melanotroph	   lineage	   specification.	   In	   addition	   we	   provide	   evidence	   that	  these	   two	   processes	   regulated	   by	   SOX2	   in	   the	   developing	   pituitary	   are	  independent,	  as	  rescuing	  the	  proliferation	  defect	  in	  Sox2	  deleted	  mice	  does	  not	   rescue	   differentiation.	   Therefore	   SOX2	   has	   a	   dual	   role	   in	   pituitary	  development	  and	  this	  is	  likely	  to	  depend	  on	  alternative	  binding	  partners	  and	  therefore	  target	  genes,	  that	  will	  be	  identified	  in	  future	  studies.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	   	  
	   185	  
References	  Achermann,	  J.	  C.,	  Meeks,	  J.	  J.,	  &	  Jameson,	  J.	  L.	  (2001).	  Phenotypic	  spectrum	  of	  mutations	  in	  DAX-­‐1	  and	  SF-­‐1.	  Molecular	  and	  Cellular	  Endocrinology,	  
185,	  17–25.	  Ahmed,	  M.,	  Wong,	  E.,	  Sun,	  J.,	  Xu,	  J.,	  Wang,	  F.,	  &	  Xu,	  P.	  (2012).	  Eya1-­‐Six1	  interaction	  is	  sufficient	  to	  induce	  hair	  cell	  fate	  in	  the	  cochlea	  by	  activating	  Atoh1	  expression	  in	  cooperation	  with	  Sox2.	  Developmental	  
Cell,	  22(2),	  377–390.	  doi:10.1016/j.devcel.2011.12.006.Eya1-­‐Six1	  Allaerts,	  W.,	  &	  Vankelecom,	  H.	  (2005).	  History	  and	  perspectives	  of	  pituitary	  folliculo-­‐stellate	  cell	  research.	  European	  Journal	  of	  Endocrinology,	  153,	  1–12.	  doi:10.1530/eje.1.01949	  Ambrosetti,	  D.	  C.,	  Basilico,	  C.,	  Dailey,	  L.,	  Ambrosetti,	  D.,	  Basilico,	  C.,	  &	  Dailey,	  L.	  (1997).	  Synergistic	  activation	  of	  the	  fibroblast	  growth	  factor	  4	  enhancer	  by	  Sox2	  and	  Oct-­‐3	  depends	  on	  protein-­‐protein	  interactions	  facilitated	  by	  a	  specific	  spatial	  arrangement	  of	  factor	  binding	  sites	  .	  Synergistic	  Activation	  of	  the	  Fibroblast	  Growth	  Factor	  4	  En.	  Molecular	  
and	  Cellular	  Biology,	  17,	  6321–6329.	  Amerongen,	  R.	  Van,	  &	  Nusse,	  R.	  (2009).	  Towards	  an	  integrated	  view	  of	  Wnt	  signaling	  in	  development.	  Development,	  136,	  3205–3214.	  doi:10.1242/dev.033910	  Andersen,	  B.,	  Ii,	  R.	  V.	  P.,	  Jenne,	  K.,	  Sornson,	  M.,	  Lin,	  S.,	  Bartke,	  A.,	  &	  Rosenfeld,	  M.	  G.	  (1995).	  The	  Ames	  Dwarf	  Gene	  Is	  Required	  for	  Pit-­‐1	  Gene	  Activation.	  Developmental	  Biology,	  172,	  495–503.	  Anderson,	  A.	  M.,	  Weasner,	  B.	  M.,	  Weasner,	  B.	  P.,	  &	  Kumar,	  J.	  P.	  (2012).	  Dual	  transcriptional	  activities	  of	  SIX	  proteins	  define	  their	  roles	  in	  normal	  and	  ectopic	  eye	  development.	  Development,	  139,	  991–1000.	  doi:10.1242/dev.077255	  Andoniadou,	  C.	  L.,	  Matsushima,	  D.,	  Neda,	  S.,	  Gharavy,	  M.,	  Signore,	  M.,	  Mackintosh,	  A.	  I.,	  …	  Martinez-­‐barbera,	  J.	  P.	  (2013).	  Article	  Sox2	  +	  Stem	  /	  Progenitor	  Cells	  in	  the	  Adult	  Mouse	  Pituitary	  Support	  Organ	  Homeostasis	  and	  Have	  Tumor-­‐Inducing	  Potential.	  Stem	  Cell,	  13(4),	  433–445.	  doi:10.1016/j.stem.2013.07.004	  Andoniadou,	  C.	  L.,	  Signore,	  M.,	  Sajedi,	  E.,	  Gaston-­‐massuet,	  C.,	  Burns,	  A.	  J.,	  Itasaki,	  N.,	  …	  Martinez-­‐,	  J.	  P.	  (2007).	  Lack	  of	  the	  murine	  homeobox	  gene	  Hesx1	  leads	  to	  a	  posterior	  transformation	  of	  the	  anterior	  forebrain.	  
Development,	  134(8),	  1499–1508.	  Aota,	  S.,	  Nakajima,	  N.,	  Sakamoto,	  R.,	  &	  Watanabe,	  S.	  (2003).	  Pax6	  autoregulation	  mediated	  by	  direct	  interaction	  of	  Pax6	  protein	  with	  the	  head	  surface	  ectoderm-­‐specific	  enhancer	  of	  the	  mouse	  Pax6	  gene.	  
	   	   	  
	   186	  
Developmental	  Biology,	  257,	  1–13.	  doi:10.1016/S0012-­‐1606(03)00058-­‐7	  Arriola,	  D.	  J.,	  Mayo,	  S.	  L.,	  Danalea,	  V.,	  Benson,	  C.	  A.,	  Varykina,	  G.,	  Arriola,	  D.	  J.,	  …	  Thackray,	  V.	  G.	  (2012).	  FOXO1	  Transcription	  Factor	  Inhibits	  Luteinizing	  Hormone	  ␤	  Gene	  Expression	  in	  Pituitary	  Gonadotrope	  Cells	  *.	  The	  Journal	  of	  Biological	  Chemistry,	  287,	  33424–33435.	  doi:10.1074/jbc.M112.362103	  Avilion,	  A.	  a,	  Nicolis,	  S.	  K.,	  Pevny,	  L.	  H.,	  Perez,	  L.,	  Vivian,	  N.,	  &	  Lovell-­‐Badge,	  R.	  (2003).	  Multipotent	  cell	  lineages	  in	  early	  mouse	  development	  depend	  on	  SOX2	  function.	  Genes	  &	  Development,	  17(1),	  126–40.	  doi:10.1101/gad.224503	  Avilion,	  A.	  A.,	  Nicolis,	  S.	  K.,	  Pevny,	  L.	  H.,	  Avilion,	  A.	  A.,	  Nicolis,	  S.	  K.,	  Pevny,	  L.	  H.,	  …	  Lovell-­‐badge,	  R.	  (2003).	  Multipotent	  cell	  lineages	  in	  early	  mouse	  development	  depend	  on	  SOX2	  function.	  Genes	  &	  Development,	  126–140.	  doi:10.1101/gad.224503	  Bach,	  I.,	  Scullyt,	  K.	  M.,	  Sawchenkot,	  P.	  E.,	  &	  Rosenfeld,	  M.	  G.	  (1995).	  P-­‐Lim	  ,	  a	  LIM	  homeodomain	  factor	  ,	  is	  expressed	  during	  pituitary	  organ	  and	  cell	  commitment	  and	  synergizes	  with	  Pit-­‐i.	  Proceedings	  of	  the	  National	  
Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America,	  92(March),	  2720–2724.	  Bagci,	  H.,	  &	  Fisher,	  A.	  G.	  (2013).	  Minireview	  DNA	  Demethylation	  in	  Pluripotency	  and	  Reprogramming :	  The	  Role	  of	  Tet	  Proteins	  and	  Cell	  Division.	  Cell	  Stem	  Cell,	  13(3),	  265–269.	  doi:10.1016/j.stem.2013.08.005	  Baird,	  D.,	  Swanston,	  I.,	  &	  Scaramuzzi,	  R.	  (1976).	  Pulsatile	  release	  of	  LH	  and	  secretion	  of	  ovarian	  steroids	  in	  sheep	  during	  the	  luteal	  phase	  of	  the	  estrous	  cycle.	  Endocrinology,	  98,	  1490–1496.	  Baker,	  C.	  V.	  H.,	  &	  Bronner-­‐fraser,	  M.	  (2001).	  Vertebrate	  Cranial	  Placodes	  I	  .	  Embryonic	  Induction.	  Developmental	  Biology,	  61,	  1–61.	  doi:10.1006/dbio.2001.0156	  Balaskas,	  N.,	  Ribeiro,	  A.,	  Panovska,	  J.,	  Dessaud,	  E.,	  Sasai,	  N.,	  Page,	  K.	  M.,	  …	  Ribes,	  V.	  (2012).	  Gene	  Regulatory	  Logic	  for	  Reading	  the	  Sonic	  Hedgehog	  Signaling	  Gradient	  in	  the	  Vertebrate	  Neural	  Tube.	  Cell,	  148(1-­‐2),	  273–284.	  doi:10.1016/j.cell.2011.10.047	  Balthasar,	  N.,	  Coppari,	  R.,	  Mcminn,	  J.,	  Liu,	  S.	  M.,	  Lee,	  C.	  E.,	  Tang,	  V.,	  …	  Lowell,	  B.	  B.	  (2004).	  Leptin	  Receptor	  Signaling	  in	  POMC	  Neurons	  Is	  Required	  for	  Normal	  Body	  Weight	  Homeostasis.	  Neuron,	  42,	  983–991.	  Beccari,	  L.,	  Conte,	  I.,	  Cisneros,	  E.,	  &	  Bovolenta,	  P.	  (2011).	  Sox2-­‐mediated	  differential	  activation	  of	  Six3.2	  contributes	  to	  forebrain	  patterning.	  
	   	   	  
	   187	  
Development	  (Cambridge,	  England),	  164,	  151–164.	  doi:10.1242/dev.067660	  Bhati,	  M.,	  Lee,	  C.,	  Nancarrow,	  A.	  L.,	  Lee,	  M.,	  Craig,	  V.	  J.,	  Bach,	  I.,	  …	  Matthews,	  J.	  M.	  (2008).	  Implementing	  the	  LIM	  code :	  the	  structural	  basis	  for	  cell	  type-­‐specific	  assembly	  of	  LIM-­‐homeodomain	  complexes.	  The	  EMBO	  
Journal,	  27(14),	  2018–2029.	  doi:10.1038/emboj.2008.123	  Bieberich,	  C.	  J.,	  Fujita,	  K.,	  He,	  W.,	  Jay,	  G.,	  Bieberich,	  C.	  J.,	  Fujita,	  K.,	  …	  Jay,	  G.	  (1996).	  Prostate-­‐specific	  and	  Androgen-­‐dependent	  Expression	  of	  a	  Novel	  Homeobox	  Gene.	  The	  Journal	  of	  Biological	  Chemistry.	  doi:10.1074/jbc.271.50.31779	  Bilodeau,	  S.,	  Roussel-­‐Gervais,	  A.,	  &	  Drouin,	  J.	  (2009).	  Distinct	  developmental	  roles	  of	  cell	  cycle	  inhibitors	  p57Kip2	  and	  p27Kip1	  distinguish	  pituitary	  progenitor	  cell	  cycle	  exit	  from	  cell	  cycle	  reentry	  of	  differentiated	  cells.	  
Molecular	  and	  Cellular	  Biology,	  29(7),	  1895–908.	  doi:10.1128/MCB.01885-­‐08	  Bodner,	  M.,	  Castriilo,	  J.,	  Theill,	  L.	  E.,	  Deerinck,	  T.,	  Ellisman,	  M.,	  &	  Karin,	  M.	  (1988).	  The	  pituitary-­‐specific	  transcription	  factor	  GHF-­‐1	  is	  a	  homeobox-­‐containing	  protein.	  Cell,	  55,	  505–518.	  Bowles,	  J.,	  Schepers,	  G.,	  &	  Koopman,	  P.	  (2000).	  Phylogeny	  of	  the	  SOX	  family	  of	  developmental	  transcription	  factors	  based	  on	  sequence	  and	  structural	  indicators.	  Developmental	  Biology,	  227(2),	  239–55.	  doi:10.1006/dbio.2000.9883	  Boyer,	  L.	  A.,	  Lee,	  T.	  I.,	  Cole,	  M.	  F.,	  Johnstone,	  S.	  E.,	  Stuart,	  S.,	  Zucker,	  J.	  P.,	  …	  Young,	  R.	  A.	  (2010).	  Core	  Transcriptional	  Regulatory	  Circuitry	  in	  Human	  Embryonic	  Stem	  Cells.	  Cell,	  122(6),	  947–956.	  doi:10.1016/j.cell.2005.08.020.Core	  Bridgewater,	  L.	  C.,	  Walker,	  M.	  D.,	  Miller,	  G.	  C.,	  Ellison,	  T.	  A.,	  Holsinger,	  L.	  D.,	  Potter,	  J.	  L.,	  …	  Crombrugghe,	  B.	  De.	  (2003).	  Adjacent	  DNA	  sequences	  modulate	  Sox9	  transcriptional	  activation	  at	  paired	  Sox	  sites	  in	  three	  chondrocyte-­‐speci	  ®	  c	  enhancer	  elements.	  Nucleic	  Acids	  Research,	  
31(5).	  doi:10.1093/nar/gkg230	  Brinkmeier,	  M.	  L.,	  Potok,	  M.	  A.,	  Cha,	  K.	  B.,	  Gridley,	  T.,	  Stifani,	  S.,	  Meeldijk,	  J.	  A.	  N.,	  …	  Medical,	  M.	  (2003).	  TCF	  and	  Groucho-­‐Related	  Genes	  Influence	  Pituitary	  Growth	  and	  Development.	  Molecular	  Endocrinology,	  17(June),	  2152–2161.	  doi:10.1210/me.2003-­‐0225	  Brinkmeier,	  M.	  L.,	  Potok,	  M.	  A.,	  Davis,	  S.	  W.,	  &	  Camper,	  S.	  a.	  (2007).	  TCF4	  deficiency	  expands	  ventral	  diencephalon	  signaling	  and	  increases	  induction	  of	  pituitary	  progenitors.	  Developmental	  Biology,	  311(2),	  396–407.	  doi:10.1016/j.ydbio.2007.08.046	  
	   	   	  
	   188	  
Brody,	  J.	  R.,	  &	  Kern,	  S.	  E.	  (2004).	  Sodium	  boric	  acid :	  a	  Tris-­‐free	  ,	  cooler	  conductive	  medium	  for	  DNA	  electrophoresis,	  36(2),	  1–2.	  Budry,	  L.,	  Gauthier,	  Y.,	  Khetchoumian,	  K.,	  Honore,	  A.	  L.,	  Vallette,	  S.,	  Brue,	  T.,	  …	  Drouin,	  J.	  (2012).	  The	  selector	  gene	  Pax7	  dictates	  alternate	  pituitary	  cell	  fates	  through	  its	  pioneer	  action	  on	  chromatin	  remodeling,	  2299–2310.	  doi:10.1101/gad.200436.112.1998	  Campolo,	  F.,	  Gori,	  M.,	  Favaro,	  R.,	  Pellegrini,	  M.,	  Botti,	  F.,	  Rossi,	  P.,	  …	  Dolci,	  S.	  (2013).	  Essential	  Role	  of	  Sox2	  for	  the	  Establishment	  and	  Maintenance	  of	  the.	  Stem	  Cells,	  1408–1421.	  doi:10.1002/stem.1392	  Castrique,	  E.,	  Fernandez-­‐fuente,	  M.,	  Tissier,	  P.	  Le,	  Herman,	  A.,	  &	  Levy,	  A.	  (2010).	  Use	  of	  a	  prolactin-­‐Cre	  /	  ROSA-­‐YFP	  transgenic	  mouse	  provides	  no	  evidence	  for	  lactotroph	  transdifferentiation	  after	  weaning	  ,	  or	  increase	  in	  lactotroph	  /	  somatotroph	  proportion	  in	  lactation.	  Journal	  of	  
Endocrinology,	  49–60.	  doi:10.1677/JOE-­‐09-­‐0414	  Catena,	  R.,	  Tiveron,	  C.,	  Porta,	  S.,	  Ferri,	  A.,	  Cavallaro,	  M.,	  Ottolenghi,	  S.,	  …	  Nicolis,	  S.	  K.	  (2004).	  Molecular	  Basis	  of	  Cell	  and	  Developmental	  Biology :	  Conserved	  POU	  Binding	  DNA	  Sites	  in	  the	  Sox2	  Upstream	  Enhancer	  Regulate	  Gene	  Expression	  in	  Embryonic	  and	  Neural	  Stem	  Cells	  Conserved	  POU	  Binding	  DNA	  Sites	  in	  the	  Sox2	  Upstream	  Enhancer	  Regulate	  Gene	  Expre.	  Journal	  of	  Biological	  Chemistry.	  doi:10.1074/jbc.M405514200	  Cha,	  K.	  B.,	  Douglas,	  K.	  R.,	  Anne,	  M.,	  Liang,	  H.,	  Jones,	  S.	  N.,	  &	  Camper,	  S.	  A.	  (2004).	  WNT5A	  signaling	  affects	  pituitary	  gland	  shape.	  Mechanisms	  of	  
Development,	  121,	  183–194.	  doi:10.1016/j.mod.2003.12.002	  Chambers,	  I.,	  Colby,	  D.,	  Robertson,	  M.,	  Nichols,	  J.,	  Lee,	  S.,	  Tweedie,	  S.,	  &	  Smith,	  A.	  (2003).	  Functional	  Expression	  Cloning	  of	  Nanog	  ,	  a	  Pluripotency	  Sustaining	  Factor	  in	  Embryonic	  Stem	  Cells.	  Cell,	  113,	  643–655.	  Charles,	  M.	  a,	  Suh,	  H.,	  Hjalt,	  T.	  a,	  Drouin,	  J.,	  Camper,	  S.	  a,	  &	  Gage,	  P.	  J.	  (2005).	  PITX	  genes	  are	  required	  for	  cell	  survival	  and	  Lhx3	  activation.	  Molecular	  
Endocrinology	  (Baltimore,	  Md.),	  19(7),	  1893–903.	  doi:10.1210/me.2005-­‐0052	  Chen,	  D.	  I.,	  Zhao,	  M.,	  &	  Mundy,	  G.	  R.	  (2004).	  Bone	  Morphogenetic	  Proteins,	  
22(December),	  233–241.	  doi:10.1080/08977190412331279890	  Chen,	  J.,	  Gremeaux,	  L.,	  Fu,	  Q.,	  Liekens,	  D.,	  Van	  Laere,	  S.,	  &	  Vankelecom,	  H.	  (2009).	  Pituitary	  progenitor	  cells	  tracked	  down	  by	  side	  population	  dissection.	  Stem	  Cells	  (Dayton,	  Ohio),	  27,	  1182–1195.	  doi:10.1002/stem.51	  Chen,	  J.,	  Hersmus,	  N.,	  Van	  Duppen,	  V.,	  Caesens,	  P.,	  Denef,	  C.,	  &	  Vankelecom,	  H.	  (2005).	  The	  adult	  pituitary	  contains	  a	  cell	  population	  displaying	  
	   	   	  
	   189	  
stem/progenitor	  cell	  and	  early	  embryonic	  characteristics.	  
Endocrinology,	  146(9),	  3985–98.	  doi:10.1210/en.2005-­‐0185	  Chou,	  S.,	  Hermesz,	  E.,	  Hatta,	  T.,	  &	  Feltner,	  D.	  (2006).	  Conserved	  regulatory	  elements	  establish	  the	  dynamic	  expression	  of	  Rpx	  /	  HesxI	  in	  early	  vertebrate	  development.	  Developmental	  Biology,	  292,	  533–545.	  doi:10.1016/j.ydbio.2005.12.053	  Conte,	  I.,	  Marco-­‐ferreres,	  R.,	  Beccari,	  L.,	  Cisneros,	  E.,	  Ruiz,	  J.	  M.,	  Tabanera,	  N.,	  &	  Bovolenta,	  P.	  (2010).	  Proper	  differentiation	  of	  photoreceptors	  and	  amacrine	  cells	  depends	  on	  a	  regulatory	  loop	  between	  NeuroD	  and	  Six6.	  
Development,	  137,	  2307–2317.	  doi:10.1242/dev.045294	  Couly,	  G.,	  &	  Le	  Douarin,	  N.	  (1985).	  Mapping	  of	  the	  early	  neural	  primordium	  in	  quail-­‐chick	  chimeras.	  I.	  Developmental	  relationships	  between	  placodes,	  facial	  ectoderm,	  and	  prosencephalon.	  Developmental	  Biology,	  
110,	  422–439.	  Couly,	  G.,	  &	  Le	  Douarin,	  N.	  (1987).	  Mapping	  of	  the	  early	  neural	  primordium	  in	  quail-­‐chick	  chimeras.	  II.	  The	  prosencephalic	  neural	  plate	  and	  neural	  folds:	  implications	  for	  the	  genesis	  of	  cephalic	  human	  congenital	  abnormalities.	  Developmental	  B	  Iology,	  120,	  198–214.	  Dabdoub,	  A.,	  Puligilla,	  C.,	  Jones,	  J.	  M.,	  Fritzsch,	  B.,	  Cheah,	  K.	  S.	  E.,	  Pevny,	  L.	  H.,	  &	  Kelley,	  M.	  W.	  (2008).	  Sox2	  signaling	  in	  prosensory	  domain	  specification	  and	  subsequent	  hair	  cell	  differentiation	  in	  the	  developing	  cochlea.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  
States	  of	  America,	  105,	  18396–18401.	  Dasen,	  J.	  S.,	  Barbera,	  J.	  M.,	  Herman,	  T.	  S.,	  Connell,	  S.	  O.,	  Olson,	  L.,	  Ju,	  B.,	  …	  Rosenfeld,	  M.	  G.	  (2001).	  Temporal	  regulation	  of	  a	  paired-­‐like	  homeodomain	  repressor	  /	  TLE	  corepressor	  complex	  and	  a	  related	  activator	  is	  required	  for	  pituitary	  organogenesis.	  Genes	  &	  Development,	  
1,	  3193–3207.	  doi:10.1101/gad.932601.BMP4	  Dattani,	  M.	  T.,	  Thomas,	  P.	  Q.,	  Brickman,	  J.	  M.,	  Gupta,	  R.,	  Mårtensson,	  I.,	  Toresson,	  H.,	  …	  Robinson,	  I.	  C.	  A.	  F.	  (1998).	  Mutations	  in	  the	  homeobox	  gene	  HESX1	  /	  Hesx1	  associated	  with	  septo-­‐optic	  dysplasia	  in	  human	  and	  mouse.	  Nature	  Genetics,	  19(June),	  125–133.	  Davis,	  S.,	  Ellsworth,	  B.,	  Peréz	  Millan,	  M.,	  Gergics,	  P.,	  Foyouzi,	  N.,	  Schade,	  V.,	  …	  Camper,	  S.	  (2013).	  Pituitary	  gland	  development	  and	  disease:	  from	  stem	  cell	  to	  hormone	  production,	  1–47.	  doi:10.1016/B978-­‐0-­‐12-­‐416021-­‐7.00001-­‐8.Pituitary	  Davis,	  S.	  W.,	  &	  Camper,	  S.	  a.	  (2007).	  Noggin	  regulates	  Bmp4	  activity	  during	  pituitary	  induction.	  Developmental	  Biology,	  305(1),	  145–60.	  doi:10.1016/j.ydbio.2007.02.001	  
	   	   	  
	   190	  
Davis,	  S.	  W.,	  Mortensen,	  A.	  H.,	  &	  Camper,	  S.	  a.	  (2011).	  Birthdating	  studies	  reshape	  models	  for	  pituitary	  gland	  cell	  specification.	  Developmental	  
Biology,	  352(2),	  215–27.	  doi:10.1016/j.ydbio.2011.01.010	  Day,	  R.,	  Koike,	  S.,	  Sakai,	  M.,	  Muramatsu,	  M.,	  &	  Maurer,	  R.	  (1990).	  Both	  Pit-­‐1	  and	  the	  estrogen	  receptor	  are	  required	  for	  estrogen	  responsiveness	  of	  the	  rat	  prolactin	  gene.	  Molecular	  Endocrinology,	  4,	  1964–1971.	  Dong,	  S.,	  Leung,	  K.	  K.	  H.,	  Pelling,	  A.	  L.,	  Lee,	  P.	  Y.	  T.,	  Tang,	  A.	  S.	  P.,	  Heng,	  H.	  H.	  Q.,	  …	  Cheah,	  K.	  S.	  E.	  (2002).	  Circling	  ,	  Deafness	  ,	  and	  Yellow	  Coat	  Displayed	  by	  Yellow	  Submarine	  (	  Ysb	  )	  and	  Light	  Coat	  and	  Circling	  (	  Lcc	  )	  Mice	  with	  Mutations	  on	  Chromosome	  3.	  Genomics,	  79(6),	  777–784.	  doi:10.1006/geno.2002.6783	  Edlund,	  T.,	  Norlin,	  S.,	  &	  Nordstro,	  U.	  (2000).	  Fibroblast	  growth	  factor	  signaling	  is	  required	  for	  the	  proliferation	  and	  patterning	  of	  progenitor	  cells	  in	  the	  developing	  anterior	  pituitary.	  Mechanisms	  of	  Development,	  
96,	  175–182.	  Ellis,	  P.,	  Matthew,	  B.,	  &	  Magness,	  S.	  T.	  (2004).	  SOX2	  ,	  a	  Persistent	  Marker	  for	  Multipotential	  Neural	  Stem	  Cells	  Derived	  from	  Embryonic	  Stem	  Cells	  ,	  the	  Embryo	  or	  the	  Adult.	  Developmental	  Neuroscience,	  27599,	  148–165.	  doi:10.1159/000082134	  Ellsworth,	  B.	  S.,	  Butts,	  D.	  L.,	  &	  Camper,	  S.	  a.	  (2008).	  Mechanisms	  underlying	  pituitary	  hypoplasia	  and	  failed	  cell	  specification	  in	  Lhx3-­‐deficient	  mice.	  
Developmental	  Biology,	  313(1),	  118–29.	  doi:10.1016/j.ydbio.2007.10.006	  Ellsworth,	  B.	  S.,	  Egashira,	  N.,	  Haller,	  J.	  L.,	  Butts,	  D.	  L.,	  Cocquet,	  J.,	  Clay,	  C.	  M.,	  …	  Camper,	  S.	  A.	  (2006).	  FOXL2	  in	  the	  Pituitary :	  Molecular	  ,	  Genetic	  ,	  and	  Developmental	  Analysis.	  Molecular	  Endocrinology,	  20(June),	  2796–2805.	  doi:10.1210/me.2005-­‐0303	  Engelen,	  E.,	  Akinci,	  U.,	  Bryne,	  J.	  C.,	  Hou,	  J.,	  Gontan,	  C.,	  Moen,	  M.,	  …	  Poot,	  R.	  A.	  (2011).	  Sox2	  cooperates	  with	  Chd7	  to	  regulate	  genes	  that	  are	  mutated	  in	  human	  syndromes.	  Nature	  Genetics,	  43(6),	  607–611.	  doi:10.1038/ng.825	  Ericson,	  J.,	  Norlin,	  S.,	  Jessell,	  T.	  M.,	  &	  Edlund,	  T.	  (1998).	  Integrated	  FGF	  and	  BMP	  signaling	  controls	  the	  progression	  of	  progenitor	  cell	  differentiation	  and	  the	  emergence	  of	  pattern	  in	  the	  embryonic	  anterior	  pituitary.	  Development	  (Cambridge,	  England),	  125(6),	  1005–15.	  Retrieved	  from	  http://www.ncbi.nlm.nih.gov/pubmed/9463347	  Escalada,	  J.,	  Cacicedo,	  L.,	  Ortego,	  J.,	  Melian,	  E.,	  &	  Sánchez-­‐Franco,	  F.	  (1996).	  Prolactin	  gene	  expression	  and	  secretion	  during	  pregnancy	  and	  lactation	  in	  the	  rat:	  role	  of	  dopamine	  and	  vasoactive	  intestinal	  peptide.	  
Endocrinology,	  137,	  631–637.	  
	   	   	  
	   191	  
Evans,	  M.,	  &	  Kaufman,	  M.	  (1981).	  Establishment	  in	  culture	  of	  pluripotential	  cells	  from	  mouse	  embryos.	  Fantes,	  J.,	  Ragge,	  N.	  K.,	  Lynch,	  S.-­‐A.,	  McGill,	  N.	  I.,	  Collin,	  J.	  R.	  O.,	  Howard-­‐Peebles,	  P.	  N.,	  …	  FitzPatrick,	  D.	  R.	  (2003).	  Mutations	  in	  SOX2	  cause	  anophthalmia.	  Nature	  Genetics,	  33(4),	  461–3.	  doi:10.1038/ng1120	  Fauquier,	  T.,	  Rizzoti,	  K.,	  Dattani,	  M.,	  Lovell-­‐Badge,	  R.,	  &	  Robinson,	  I.	  C.	  a	  F.	  (2008).	  SOX2-­‐expressing	  progenitor	  cells	  generate	  all	  of	  the	  major	  cell	  types	  in	  the	  adult	  mouse	  pituitary	  gland.	  Proceedings	  of	  the	  National	  
Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America,	  105(8),	  2907–12.	  doi:10.1073/pnas.0707886105	  Favaro,	  R.,	  Valotta,	  M.,	  Ferri,	  A.	  L.	  M.,	  Latorre,	  E.,	  Mariani,	  J.,	  Giachino,	  C.,	  …	  Nicolis,	  S.	  K.	  (2009).	  Hippocampal	  development	  and	  neural	  stem	  cell	  maintenance	  require	  Sox2	  -­‐dependent	  regulation	  of	  Shh.	  Nature	  
Neuroscience,	  12(10),	  1248–1256.	  doi:10.1038/nn.2397	  Fero,	  M.	  L.,	  Rivkin,	  M.,	  Tasch,	  M.,	  Porter,	  P.,	  Carow,	  C.	  E.,	  Firpo,	  E.,	  …	  Roberts,	  J.	  M.	  (1996).	  A	  Syndrome	  of	  Multiorgan	  Hyperplasia	  with	  Features	  of	  Gigantism	  ,	  Tumorigenesis	  ,	  and	  Female	  Sterility	  in	  p27	  Kip1	  -­‐Deficient	  Mice,	  85,	  733–744.	  Ferri,	  A.,	  Favaro,	  R.,	  Beccari,	  L.,	  Bertolini,	  J.,	  Mercurio,	  S.,	  Nieto-­‐lopez,	  F.,	  …	  Nicolis,	  S.	  K.	  (2013).	  Sox2	  is	  required	  for	  embryonic	  development	  of	  the	  ventral	  telencephalon	  through	  the	  activation	  of	  the	  ventral	  determinants	  Nkx2	  .	  1	  and	  Shh.	  Development,	  1261,	  1250–1261.	  doi:10.1242/dev.073411	  Ferri,	  A.	  L.	  M.,	  Cavallaro,	  M.,	  Braida,	  D.,	  Cristofano,	  A.	  Di,	  Canta,	  A.,	  Vezzani,	  A.,	  …	  Nicolis,	  S.	  K.	  (2004).	  Sox2	  deficiency	  causes	  neurodegeneration	  and	  impaired	  neurogenesis	  in	  the	  adult	  mouse	  brain.	  Development	  and	  
Disease,	  3805–3819.	  doi:10.1242/dev.01204	  Fu,	  Q.,	  Gremeaux,	  L.,	  Luque,	  R.	  M.,	  Liekens,	  D.,	  Chen,	  J.,	  Buch,	  T.,	  …	  Vankelecom,	  H.	  (2012).	  The	  adult	  pituitary	  shows	  stem/progenitor	  cell	  activation	  in	  response	  to	  injury	  and	  is	  capable	  of	  regeneration.	  
Endocrinology,	  153(July),	  3224–3235.	  doi:10.1210/en.2012-­‐1152	  Fu,	  Q.,	  &	  Venkelecom,	  H.	  (2012).	  The	  adult	  pituitary	  shows	  stem/progenitor	  cell	  activation	  in	  response	  to	  injury	  and	  is	  capable	  of	  regeneration.	  Stem	  
Cell	  Development,	  18,	  2345–2357.	  Gage,	  P.	  J.,	  &	  Camper,	  S.	  A.	  (1997).	  Pituitary	  homeobox	  2	  ,	  a	  novel	  member	  of	  the	  bicoid-­‐related	  family	  of	  homeobox	  genes	  ,	  is	  a	  potential	  regulator	  of	  anterior	  structure	  formation.	  Human	  Molecular	  Genetics,	  6(3),	  457–464.	  Gage,	  P.	  J.,	  Suh,	  H.,	  &	  Camper,	  S.	  A.	  (1999).	  The	  bicoid	  -­‐related	  Pitx	  gene	  family	  in	  development.	  Mammalian	  Genome,	  10,	  197–200.	  
	   	   	  
	   192	  
Gallardo,	  M.	  E.,	  Lopez-­‐rios,	  J.,	  Fernaud-­‐espinosa,	  I.,	  Sanz,	  R.,	  Ramos,	  C.,	  Ayuso,	  C.,	  …	  Rodrı,	  S.	  (1999).	  Genomic	  Cloning	  and	  Characterization	  of	  the	  Human	  Homeobox	  Gene	  SIX6	  Reveals	  a	  Cluster	  of	  SIX	  Genes	  in	  Chromosome	  14	  and	  Associates	  SIX6	  Hemizygosity	  with	  Bilateral	  Anophthalmia	  and	  Pituitary	  Anomalies.	  Genomics,	  61,	  82–91.	  Garcia-­‐Lavandeira,	  M.,	  Quereda,	  V.,	  Flores,	  I.,	  Saez,	  C.,	  Diaz-­‐Rodriguez,	  E.,	  Japon,	  M.	  a,	  …	  Alvarez,	  C.	  V.	  (2009).	  A	  GRFa2/Prop1/stem	  (GPS)	  cell	  niche	  in	  the	  pituitary.	  PloS	  One,	  4(3),	  e4815.	  doi:10.1371/journal.pone.0004815	  Gaston-­‐Massuet,	  C.,	  Andoniadou,	  C.	  L.,	  Signore,	  M.,	  Sajedi,	  E.,	  Bird,	  S.,	  Turner,	  J.	  M.	  a,	  &	  Martinez-­‐Barbera,	  J.	  P.	  (2008).	  Genetic	  interaction	  between	  the	  homeobox	  transcription	  factors	  HESX1	  and	  SIX3	  is	  required	  for	  normal	  pituitary	  development.	  Developmental	  Biology,	  324(2),	  322–33.	  doi:10.1016/j.ydbio.2008.08.008	  Gaston-­‐massuet,	  C.,	  Lilian,	  C.,	  Signore,	  M.,	  Jayakody,	  S.	  A.,	  &	  Charolidi,	  N.	  (2011).	  Increased	  Wingless	  (	  Wnt	  )	  signaling	  in	  pituitary	  progenitor	  /	  stem	  cells	  gives	  rise	  to	  pituitary	  tumors	  in	  mice	  and	  humans.	  
Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  
America,	  108(28),	  11482–11487.	  doi:10.1073/pnas.1101553108	  Gestri,	  G.,	  Carl,	  M.,	  Appolloni,	  I.,	  Wilson,	  S.	  W.,	  Barsacchi,	  G.,	  &	  Andreazzoli,	  M.	  (2005).	  Six3	  functions	  in	  anterior	  neural	  plate	  specification	  by	  promoting	  cell	  proliferation	  and	  inhibiting	  Bmp4	  expression.	  
Development,	  132,	  2401–2413.	  doi:10.1242/dev.01814	  Gleiberman,	  a	  S.,	  Fedtsova,	  N.	  G.,	  &	  Rosenfeld,	  M.	  G.	  (1999).	  Tissue	  interactions	  in	  the	  induction	  of	  anterior	  pituitary:	  role	  of	  the	  ventral	  diencephalon,	  mesenchyme,	  and	  notochord.	  Developmental	  Biology,	  
213(2),	  340–53.	  doi:10.1006/dbio.1999.9386	  Gleiberman,	  A.	  S.,	  Michurina,	  T.,	  Encinas,	  J.	  M.,	  Roig,	  J.	  L.,	  Krasnov,	  P.,	  Balordi,	  F.,	  …	  Enikolopov,	  G.	  (2008).	  Genetic	  approaches	  identify	  adult	  pituitary	  stem	  cells.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  
States	  of	  America,	  105(17),	  6332–7.	  doi:10.1073/pnas.0801644105	  Goldberg,	  L.	  B.,	  Aujla,	  P.	  K.,	  &	  Raetzman,	  L.	  T.	  (2011).	  Persistent	  expression	  of	  activated	  Notch	  inhibits	  corticotrope	  and	  melanotrope	  differentiation	  and	  results	  in	  dysfunction	  of	  the	  HPA	  axis.	  
Developmental	  Biology,	  358(1),	  23–32.	  doi:10.1016/j.ydbio.2011.07.004	  Gomezmez-­‐Lopez,	  S.	  G.,	  Wiskow,	  O.	  L.	  E.,	  Favaro,	  R.,	  Nicolis,	  S.	  K.,	  Price,	  D.	  J.,	  Pollard,	  S.	  M.,	  &	  Smith,	  A.	  (2011).	  Sox2	  and	  Pax6	  Maintain	  the	  Proliferative	  and	  Developmental	  Potential	  of	  Gliogenic	  Neural	  Stem	  Cells	  In	  Vitro,	  1599,	  1588–1599.	  doi:10.1002/glia.21201	  
	   	   	  
	   193	  
Gorbenko,	  D.,	  Graaff,	  L.	  C.	  G.	  De,	  Visser,	  T.	  J.,	  &	  Hokken-­‐koelega,	  A.	  C.	  S.	  (2013).	  Single-­‐nucleotide	  variants	  in	  two	  Hedgehog	  genes	  ,	  SHH	  and	  HHIP	  ,	  as	  genetic	  cause	  of	  combined	  pituitary	  hormone	  deficiency.	  
Clinical	  Endocrinology,	  78,	  415–423.	  doi:10.1111/cen.12000	  Gordon,	  F.,	  Woodmansee,	  W.	  W.,	  Black,	  J.	  N.,	  Dowding,	  J.	  M.,	  Bendrick-­‐peart,	  J.,	  Wood,	  W.	  M.,	  &	  Ridgway,	  E.	  C.	  (2002).	  Domains	  of	  Pit-­‐1	  required	  for	  transcriptional	  synergy	  with	  GATA-­‐2	  on	  the	  TSH	  b	  gene.	  Molecular	  and	  
Cellular	  Endocrinology,	  196,	  53–66.	  Gremeaux,	  L.,	  Fu,	  Q.,	  Chen,	  J.,	  &	  Vankelecom,	  H.	  (2012).	  Activated	  Phenotype	  of	  the	  Pituitary	  Stem	  /	  Progenitor	  Cell	  Compartment	  During	  the	  Early-­‐Postnatal	  Maturation	  Phase	  of	  the	  Gland.	  Stem	  Cells	  and	  Development,	  
21(5),	  801–813.	  doi:10.1089/scd.2011.0496	  Gubbay,	  J.,	  Collignan,	  J.,	  Koopman,	  P.,	  Capel,	  B.,	  Economou,	  A.,	  Vivian,	  N.,	  …	  Lovell-­‐Badge,	  R.	  (1990).	  A	  gene	  mapping	  to	  the	  sex-­‐determining	  region	  of	  the	  mouse	  Y	  chromosome	  is	  a	  member	  of	  a	  novel	  family	  of	  embryonically	  expressed	  genes.	  Nature,	  246,	  245–250.	  Hagstrom,	  S.	  A.,	  Pauer,	  G.	  J.	  T.,	  Reid,	  J.,	  Simpson,	  E.,	  Crowe,	  S.,	  Maumenee,	  I.	  H.,	  &	  Traboulsi,	  E.	  I.	  (2005).	  SOX2	  Mutation	  Causes	  Anophthalmia	  ,	  Hearing	  Loss	  ,	  and	  Brain	  Anomalies.	  American	  Journal	  of	  Medical	  
Genetics	  A,	  98(August	  2004),	  95–98.	  doi:10.1002/ajmg.a.30803	  Harley,	  V.	  R.,	  Lovell-­‐badge,	  R.,	  &	  Goodfellow,	  P.	  N.	  (1994).	  Definition	  of	  a	  consensus	  DNA	  binding	  site	  for	  SRY.	  Nucleic	  Acids	  Research,	  22(8),	  1500–1501.	  Hébert,	  J.	  M.,	  &	  McConnell,	  S.	  K.	  (2000a).	  Targeting	  of	  cre	  to	  the	  Foxg1	  (BF-­‐1)	  locus	  mediates	  loxP	  recombination	  in	  the	  telencephalon	  and	  other	  developing	  head	  structures.	  Developmental	  Biology,	  222(2),	  296–306.	  doi:10.1006/dbio.2000.9732	  Hébert,	  J.	  M.,	  &	  McConnell,	  S.	  K.	  (2000b).	  Targeting	  of	  cre	  to	  the	  Foxg1	  (BF-­‐1)	  locus	  mediates	  loxP	  recombination	  in	  the	  telencephalon	  and	  other	  developing	  head	  structures.	  Developmental	  Biology,	  222(2),	  296–306.	  doi:10.1006/dbio.2000.9732	  Hermesz,	  E.,	  Mackem,	  S.,	  &	  Mahon,	  K.	  A.	  (1996).	  Rpx :	  a	  novel	  anterior-­‐restricted	  homeobox	  gene	  progressively	  activated	  in	  the	  prechordal	  plate	  ,	  anterior	  neural	  plate	  and	  Rathke	  ’	  s	  pouch	  of	  the	  mouse	  embryo.	  
Development,	  52,	  41–52.	  Himes,	  A.	  D.,	  &	  Raetzman,	  L.	  T.	  (2009).	  Premature	  differentiation	  and	  aberrant	  movement	  of	  pituitary	  cells	  lacking	  both	  Hes1	  and	  Prop1.	  
Developmental	  Biology,	  325(1),	  151–161.	  doi:10.1016/j.ydbio.2008.10.010.Premature	  
	   	   	  
	   194	  
Hosoyama,	  T.,	  Nishijo,	  K.,	  Garcia,	  M.	  M.,	  Schaffer,	  B.	  S.,	  Ohshima-­‐hosoyama,	  S.,	  Prajapati,	  S.	  I.,	  …	  Keller,	  C.	  (2010).	  A	  Postnatal	  Pax7	  Progenitor	  Gives	  Rise	  to	  Pituitary	  Adenomas.	  Genes	  &	  Cancer,	  1,	  388–402.	  doi:10.1177/1947601910370979	  Hui,	  C.,	  Slusarski,	  D.,	  Platt,	  K.,	  Holmgren,	  R.,	  &	  Joyner,	  A.	  (1994).	  Expression	  of	  three	  mouse	  homologs	  of	  the	  Drosophila	  segment	  polarity	  gene	  cubitus	  interruptus,	  Gli,	  Gli-­‐2,	  and	  Gli-­‐3,	  in	  ectoderm-­‐	  and	  mesoderm-­‐derived	  tissues	  suggests	  multiple	  roles	  during	  postimplantation	  development.	  Developmental	  Biology,	  162,	  402–413.	  Hume,	  C.	  R.,	  Bratt,	  D.	  L.,	  &	  Oesterle,	  E.	  C.	  (2007).	  Expression	  of	  LHX3	  and	  SOX2	  during	  mouse	  inner	  ear	  development.	  Gene	  Expression	  Patterns,	  
7(7),	  798–807.	  Hutton,	  S.	  R.,	  &	  Pevny,	  L.	  H.	  (2011).	  SOX2	  expression	  levels	  distinguish	  between	  neural	  progenitor	  populations	  of	  the	  developing	  dorsal	  telencephalon.	  Developmental	  Biology.	  doi:10.1016/j.ydbio.2011.01.015	  Ibrahim,	  S.,	  Moussa,	  S.,	  &	  Childs,	  G.	  (1986).	  Morphometric	  studies	  of	  rat	  anterior	  pituitary	  cells	  after	  gonadectomy:	  correlation	  of	  changes	  in	  gonadotropes	  with	  the	  serum	  levels	  of	  gonadotropins.	  Endocrinology,	  
119,	  629–637.	  Ingraham,	  H.	  A.,	  Lala,	  D.	  S.,	  Ikeda,	  Y.,	  Luo,	  X.,	  &	  Shen,	  W.	  (1994).	  The	  nuclear	  receptor	  steroidogenic	  factor	  1	  acts	  at	  multiple	  levels	  of	  the	  reproductive	  axis.	  Genes	  &	  Development,	  8,	  2302–2312.	  doi:10.1101/gad.8.19.2302	  Inoue,	  K.,	  Couch,	  E.,	  Takano,	  K.,	  &	  Ogawa,	  S.	  (1999).	  The	  structure	  and	  function	  of	  folliculo-­‐stellate	  cells	  in	  the	  anterior	  pituitary	  gland.	  
Archives	  of	  Histology	  and	  Cytology,	  62,	  205–218.	  Jacques,	  E.,	  Puligilla,	  C.,	  Weichert,	  R.	  M.,	  Ferrer-­‐vaquer,	  A.,	  Hadjantonakis,	  A.,	  Kelley,	  M.	  W.,	  …	  Dabdoub,	  A.	  (2013).	  cochlea	  A	  dual	  function	  for	  canonical	  Wnt	  /betacatenin	  signaling	  in	  the	  developing	  mammalian	  cochlea.	  Development,	  139,	  4395–4404.	  doi:10.1242/dev.091801	  James,	  D.,	  Levine,	  A.	  J.,	  Besser,	  D.,	  &	  Hemmati-­‐brivanlou,	  A.	  (2005).	  TGF	  β	  /	  activin	  /	  nodal	  signaling	  is	  necessary	  for	  the	  maintenance	  of	  pluripotency	  in	  human	  embryonic	  stem	  cells.	  Development,	  7,	  1273–1282.	  doi:10.1242/dev.01706	  Japon,	  M.	  a.,	  Rubinstein,	  M.,	  &	  Low,	  M.	  J.	  (1994).	  In	  situ	  hybridization	  analysis	  of	  anterior	  pituitary	  hormone	  gene	  expression	  during	  fetal	  mouse	  development.	  Journal	  of	  Histochemistry	  &	  Cytochemistry,	  42(8),	  1117–1125.	  doi:10.1177/42.8.8027530	  
	   	   	  
	   195	  
Jayakody,	  S.	  A.,	  Andoniadou,	  C.	  L.,	  Gaston-­‐massuet,	  C.,	  Signore,	  M.,	  Cariboni,	  A.,	  Bouloux,	  P.	  M.,	  …	  Martinez-­‐barbera,	  J.	  P.	  (2012).	  SOX2	  regulates	  the	  hypothalamic-­‐pituitary	  axis	  at	  multiple	  levels.	  Journal	  of	  Clinical	  
Investigation,	  122(10),	  6335–6346.	  doi:10.1172/JCI64311DS1	  Jean,	  D.,	  Bernier,	  G.,	  &	  Gruss,	  P.	  (1999).	  Six6	  (Optx2)	  is	  a	  novel	  murine	  Six3-­‐related	  homeobox	  gene	  that	  demarcates	  the	  presumptive	  pituitary/hypothalamic	  axis	  and	  the	  ventral	  optic	  stalk.	  Mechanisms	  of	  
Development,	  84(1-­‐2),	  31–40.	  Retrieved	  from	  http://www.ncbi.nlm.nih.gov/pubmed/10473118	  Jeong,	  Y.,	  Leskow,	  F.	  C.,	  El-­‐jaick,	  K.,	  Roessler,	  E.,	  Muenke,	  M.,	  Yocum,	  A.,	  …	  Epstein,	  D.	  J.	  (2008).	  Regulation	  of	  a	  remote	  Shh	  forebrain	  enhancer	  by	  the	  Six3	  homeoprotein.	  Nature	  Genetics,	  40(11),	  1348–1353.	  doi:10.1038/ng.230.Regulation	  Jonason,	  J.,	  Gavrilova,	  N.,	  Wu,	  M.,	  Zhang,	  H.,	  &	  Sun,	  H.	  (2007).	  Regulation	  of	  SCF(SKP2)	  ubiquitin	  E3	  ligase	  assembly	  and	  p27(KIP1)	  proteolysis	  by	  the	  PTEN	  pathway	  and	  cyclin	  D1.	  Cell	  Cycle,	  6,	  951–961.	  Juuri,	  E.,	  Jussila,	  M.,	  Seidel,	  K.,	  Holmes,	  S.,	  Wu,	  P.,	  Richman,	  J.,	  …	  Thesleff,	  I.	  (2013).	  Sox2	  marks	  epithelial	  competence	  to	  generate	  teeth	  in	  mammals	  and	  reptiles,	  1432,	  1424–1432.	  doi:10.1242/dev.089599	  Kamachi,	  Y.,	  &	  Kondoh,	  H.	  (2013).	  Sox	  proteins :	  regulators	  of	  cell	  fate	  specification	  and	  differentiation.	  Development,	  4144,	  4129–4144.	  doi:10.1242/dev.091793	  Kamachi,	  Y.,	  Uchikawa,	  M.,	  Collignon,	  J.,	  Lovell-­‐badge,	  R.,	  &	  Kondoh,	  H.	  (1998).	  Involvement	  of	  Sox1	  ,	  2	  and	  3	  in	  the	  early	  and	  subsequent	  molecular	  events	  of	  lens	  induction.	  Development,	  2532,	  2521–2532.	  Kamachi,	  Y.,	  Uchikawa,	  M.,	  Kondoh,	  H.,	  &	  Biology,	  C.	  (2000).	  Pairing	  SOX	  off.	  
Trends	  in	  Genetics,	  9525(99),	  2–7.	  Kamachi,	  Y.,	  Uchikawa,	  M.,	  Tanouchi,	  A.,	  Sekido,	  R.,	  &	  Kondoh,	  H.	  (2001).	  Pax6	  and	  SOX2	  form	  a	  co-­‐DNA-­‐binding	  partner	  complex	  that	  regulates	  initiation	  of	  lens	  development.	  Genes	  &	  Development,	  15,	  1272–1286.	  doi:10.1101/gad.887101.good	  Kawamura,	  K.,	  &	  Kikuyama,	  S.	  (1995).	  Induction	  from	  posterior	  hypothalamus	  is	  essential	  for	  the	  development	  of	  the	  pituitary	  proopiomelacortin	  (POMC)	  cells	  of	  the	  toad	  (Bufo	  japonicus).	  Cell	  and	  
Tissue	  Research,	  279,	  233–239.	  Kawamura,	  K.,	  &	  Kikuyama,	  S.	  (1998).	  Morphogenesis	  of	  the	  hypothalamus	  and	  hypophysis:	  their	  association,	  dissociation	  and	  reassociation	  before	  and	  after	  “Rathke.”	  Archives	  of	  Histology	  and	  Cytology,	  61(3),	  189–198.	  
	   	   	  
	   196	  
Kelberman,	  D.,	  de	  Castro,	  S.	  C.	  P.,	  Huang,	  S.,	  Crolla,	  J.	  a,	  Palmer,	  R.,	  Gregory,	  J.	  W.,	  …	  Dattani,	  M.	  T.	  (2008).	  SOX2	  plays	  a	  critical	  role	  in	  the	  pituitary,	  forebrain,	  and	  eye	  during	  human	  embryonic	  development.	  The	  Journal	  
of	  Clinical	  Endocrinology	  and	  Metabolism,	  93(5),	  1865–73.	  doi:10.1210/jc.2007-­‐2337	  Kelberman,	  D.,	  &	  Dettani,	  M.	  (2007).	  Genetics	  of	  septo-­‐optic	  dysplasia.	  
Pituitary,	  10,	  393–407.	  Kelberman,	  D.,	  Rizzoti,	  K.,	  Avilion,	  A.,	  Bitner-­‐glindzicz,	  M.,	  Cianfarani,	  S.,	  Collins,	  J.,	  …	  Dattani,	  M.	  T.	  (2006a).	  Mutations	  within	  SOX2/SOX2	  are	  associated	  with	  abnormalities	  in	  the	  hypothalamo-­‐pituitary-­‐gonadal	  axis	  in	  mice	  and	  humans,	  116(9).	  doi:10.1172/JCI28658.The	  Kelberman,	  D.,	  Rizzoti,	  K.,	  Avilion,	  A.,	  Bitner-­‐glindzicz,	  M.,	  Cianfarani,	  S.,	  Collins,	  J.,	  …	  Dattani,	  M.	  T.	  (2006b).	  Mutations	  within	  SOX2/SOX2	  are	  associated	  with	  abnormalities	  in	  the	  hypothalamo-­‐pituitary-­‐gonadal	  axis	  in	  mice	  and	  humans,	  116(9).	  doi:10.1172/JCI28658.The	  Keramari,	  M.,	  Razavi,	  J.,	  Ingman,	  K.	  A.,	  Patsch,	  C.,	  Edenhofer,	  F.,	  Christopher,	  M.,	  &	  Kimber,	  S.	  J.	  (2010).	  Sox2	  Is	  Essential	  for	  Formation	  of	  Trophectoderm	  in	  the	  Preimplantation	  Embryo.	  PloS	  One,	  5(11).	  doi:10.1371/journal.pone.0013952	  Keri,	  R.	  A.,	  Nilson,	  J.	  H.,	  Keri,	  R.	  A.,	  &	  Nilson,	  J.	  H.	  (1996).	  Molecular	  Genetics :	  A	  Steroidogenic	  Factor-­‐1	  Binding	  Site	  Is	  Required	  for	  Activity	  of	  the	  Luteinizing	  Hormone	  Subunit	  Promoter	  in	  Gonadotropes	  of	  Transgenic	  Mice	  A	  Steroidogenic	  Factor-­‐1	  Binding	  Site	  Is	  Required	  for	  Activity	  of	  the	  Luteinizing	  Hormone	  ␤.	  The	  Journal	  of	  Biological	  Chemistry,	  271,	  10782–10785.	  doi:10.1074/jbc.271.18.10782	  Khonsari,	  R.	  H.,	  Seppala,	  M.,	  Pradel,	  A.,	  Dutel,	  H.,	  Clément,	  G.,	  &	  Lebedev,	  O.	  (2013).	  The	  buccohypophyseal	  canal	  is	  an	  ancestral	  vertebrate	  trait	  maintained	  by	  modulation	  in	  sonic	  hedgehog	  signaling	  The	  buccohypophyseal	  canal	  is	  an	  ancestral	  vertebrate	  trait	  maintained	  by	  modulation	  in	  sonic	  hedgehog	  signaling.	  BMC	  Biology,	  11.	  Kiernan,	  A.	  E.,	  Pelling,	  A.	  L.,	  Leung,	  K.	  K.	  H.,	  &	  Tang,	  A.	  S.	  P.	  (2005).	  Sox2	  is	  required	  for	  sensory	  organ	  development	  in	  the	  mammalian	  inner	  ear.	  
Nature,	  426(1995),	  423–426.	  Kimura,	  S.,	  Hara,	  Y.,	  Pineau,	  T.,	  Fernandez-­‐salguero,	  P.,	  Fox,	  C.	  H.,	  Ward,	  J.	  M.,	  &	  Gonzalez,	  F.	  J.	  (1996).	  The	  T	  /	  ebp	  null	  mouse :	  thyroid-­‐specific	  enhancer-­‐binding	  protein	  is	  essential	  for	  the	  organogenesis	  of	  the	  thyroid	  ,	  lung	  ,	  ventral	  forebrain	  ,	  and	  pituitary.	  Genes	  &	  Development,	  
10,	  60–69.	  King,	  N.,	  Westbrook,	  M.	  J.,	  Young,	  S.	  L.,	  Kuo,	  A.,	  Abedin,	  M.,	  Chapman,	  J.,	  …	  Rokhsar,	  D.	  (2008).	  The	  genome	  of	  the	  choanoflagellate	  Monosiga	  
	   	   	  
	   197	  
brevicollis	  and	  the	  origin	  of	  metazoans.	  Nature,	  451(February),	  783–788.	  doi:10.1038/nature06617	  Kioussi,	  C.,	  Briata,	  P.,	  Baek,	  S.	  H.,	  Rose,	  D.	  W.,	  Hamblet,	  N.	  S.,	  Herman,	  T.,	  …	  Rosenfeld,	  M.	  G.	  (2002).	  Identification	  of	  a	  Wnt/Dvl/beta-­‐Catenin	  -­‐-­‐>	  Pitx2	  pathway	  mediating	  cell-­‐type-­‐specific	  proliferation	  during	  development.	  Cell,	  111,	  673–685.	  Kioussi,	  C.,	  Connell,	  S.	  O.,	  St-­‐onge,	  L.,	  Treier,	  M.,	  Gleiberman,	  A.	  S.,	  Gruss,	  P.,	  &	  Rosenfeld,	  M.	  G.	  (1999).	  Pax6	  is	  essential	  for	  establishing	  ventral-­‐dorsal	  cell	  boundaries	  in	  pituitary	  gland	  development.	  Kishi,	  M.,	  Mizuseki,	  K.,	  Sasai,	  N.,	  Yamazaki,	  H.,	  Shiota,	  K.,	  &	  Nakanishi,	  S.	  (2000).	  Requirement	  of	  Sox2-­‐mediated	  signaling	  for	  differentiation	  of	  early	  Xenopus	  neuroectoderm.	  Development,	  800,	  791–800.	  Kiyokawa,	  H.,	  Kineman,	  R.,	  Manova-­‐Todorova,	  K.,	  Soares,	  V.,	  Frohman,	  L.,	  &	  Koff,	  A.	  (1996).	  Enhanced	  growth	  of	  mice	  lacking	  the	  cyclin-­‐dependent	  kinase	  inhibitor	  function	  of	  p27(Kip1).	  Cell,	  85,	  721–732.	  Kondoh,	  H.,	  &	  Kamachi,	  Y.	  (2010).	  SOX	  –	  partner	  code	  for	  cell	  specification :	  Regulatory	  target	  selection	  and	  underlying	  molecular	  mechanisms.	  The	  
International	  Journal	  of	  Biochemistry	  &	  Cell	  Biology,	  42,	  391–399.	  doi:10.1016/j.biocel.2009.09.003	  Kondoh,	  H.,	  Katoh,	  K.,	  Takahashi,	  Y.,	  Fujisawa,	  H.,	  &	  Yokoyama,	  M.	  (1987).	  Specific	  Expression	  of	  the	  Chicken	  &	  Crystallin	  Gene	  in	  the	  Lens	  and	  the	  Pyramidal	  Neurons	  of	  the	  Piriform	  Cortex	  in	  Transgenic	  Mice.	  
Developmental	  B	  Iology,	  185.	  Kondoh,	  H.,	  Uchikawa,	  M.,	  &	  Kamachi,	  Y.	  (2004).	  Interplay	  of	  Pax6	  and	  SOX2	  in	  lens	  development	  as	  a	  paradigm	  of	  genetic	  switch	  mechanisms	  for	  cell	  differentiation.	  International	  Journal	  of	  Developmental	  Biology,	  48,	  819–827.	  doi:10.1387/ijdb.041868hk	  Koopman,	  P.,	  Gubbay,	  J.,	  Vivian,	  N.,	  Goodfellow,	  P.,	  &	  Lovell-­‐Badge,	  R.	  (1991).	  Male	  development	  of	  chromosomally	  female	  mice	  transgenic	  for	  Sry.	  
Nature,	  351,	  117–121.	  Kopan,	  R.,	  &	  Ilagan,	  M.	  X.	  G.	  (2009).	  The	  canonical	  Notch	  signaling	  pathway:	  unfolding	  the	  activation	  mechanism.	  Cell,	  137(2),	  216–233.	  doi:10.1016/j.cell.2009.03.045.The	  Kouki,	  T.,	  Imai,	  H.,	  Aoto,	  K.,	  Eto,	  K.,	  Shioda,	  S.,	  &	  Kawamura,	  K.	  (2001).	  Developmental	  origin	  of	  the	  rat	  adenohypophysis	  prior	  to	  the	  formation	  of	  Rathke	  ’	  s	  pouch.	  Development,	  128,	  959–963.	  Kretzschmar,	  K.,	  &	  Watt,	  F.	  M.	  (2012).	  Primer	  Lineage	  Tracing.	  Cell,	  148(1-­‐2),	  33–45.	  doi:10.1016/j.cell.2012.01.002	  
	   	   	  
	   198	  
Kumar,	  J.	  P.	  (2009).	  Review	  The	  sine	  oculis	  homeobox	  (	  SIX	  )	  family	  of	  transcription	  factors	  as	  regulators	  of	  development	  and	  disease.	  Cellular	  
and	  Molecular	  Life	  Sciences :	  CMLS,	  66,	  565–583.	  doi:10.1007/s00018-­‐008-­‐8335-­‐4	  Lamolet,	  B.,	  Poulin,	  G.,	  Chu,	  K.,	  Drouin,	  J.,	  &	  Ge,	  L.	  De.	  (2004).	  Tpit-­‐Independent	  Function	  of	  NeuroD1(BETA2)	  in	  Pituitary	  Corticotroph	  Differentiation.	  Molecular	  Endocrinology,	  18(June),	  995–1003.	  doi:10.1210/me.2003-­‐0127	  Lamolet,	  B.,	  Pulichino,	  a	  M.,	  Lamonerie,	  T.,	  Gauthier,	  Y.,	  Brue,	  T.,	  Enjalbert,	  a,	  &	  Drouin,	  J.	  (2001).	  A	  pituitary	  cell-­‐restricted	  T	  box	  factor,	  Tpit,	  activates	  POMC	  transcription	  in	  cooperation	  with	  Pitx	  homeoproteins.	  
Cell,	  104(6),	  849–59.	  Retrieved	  from	  http://www.ncbi.nlm.nih.gov/pubmed/11290323	  Lanctôt,	  C.,	  Lamolet,	  B.,	  &	  Drouin,	  J.	  (1997).	  The	  bicoid-­‐related	  homeoprotein	  Ptx1	  defines	  the	  most	  anterior	  domain	  of	  the	  embryo	  and	  differentiates	  posterior	  from	  anterior	  lateral	  mesoderm.	  Development,	  124,	  2807–2817.	  Langlais,	  D.,	  Couture,	  C.,	  Kmita,	  M.,	  &	  Drouin,	  J.	  (2013).	  Adult	  pituitary	  cell	  maintenance:	  lineage-­‐specific	  contribution	  of	  self-­‐duplication,	  27(C),	  1103–1112.	  doi:10.1210/me.2012-­‐1407	  Laronda,	  M.	  M.,	  &	  Jameson,	  J.	  L.	  (2011).	  Sox3	  Functions	  in	  a	  Cell-­‐Autonomous	  Manner	  to	  Regulate	  Spermatogonial	  Differentiation	  in	  Mice.	  
Endocrinology,	  152(June),	  1606–1615.	  doi:10.1210/en.2010-­‐1249	  Lee,	  B.,	  Rizzoti,	  K.,	  Kwon,	  D.	  S.,	  Kim,	  S.,	  Oh,	  S.,	  Epstein,	  D.	  J.,	  …	  Jeong,	  Y.	  (2012).	  Direct	  transcriptional	  regulation	  of	  Six6	  is	  controlled	  by	  SoxB1	  binding	  to	  a	  remote	  forebrain	  enhancer.	  Developmental	  Biology,	  366(2),	  393–403.	  doi:10.1016/j.ydbio.2012.04.023.Direct	  Lee,	  B.,	  Song,	  H.,	  Rizzoti,	  K.,	  Son,	  Y.,	  Yoon,	  J.,	  Baek,	  K.,	  &	  Jeong,	  Y.	  (2013).	  Genomic	  code	  for	  Sox2	  binding	  uncovers	  its	  regulatory	  role	  in	  Six3	  activation	  in	  the	  forebrain.	  Developmental	  Biology,	  381(2),	  491–501.	  doi:10.1016/j.ydbio.2013.06.016	  Lepore,	  D.	  a,	  Jokubaitis,	  V.	  J.,	  Simmons,	  P.	  J.,	  Roeszler,	  K.	  N.,	  Rossi,	  R.,	  Bauer,	  K.,	  &	  Thomas,	  P.	  Q.	  (2006).	  A	  role	  for	  angiotensin-­‐converting	  enzyme	  in	  the	  characterization,	  enrichment,	  and	  proliferation	  potential	  of	  adult	  murine	  pituitary	  colony-­‐forming	  cells.	  Stem	  Cells	  (Dayton,	  Ohio),	  24(11),	  2382–90.	  doi:10.1634/stemcells.2006-­‐0085	  Lepore,	  D.	  a,	  Roeszler,	  K.,	  Wagner,	  J.,	  Ross,	  S.	  a,	  Bauer,	  K.,	  &	  Thomas,	  P.	  Q.	  (2005).	  Identification	  and	  enrichment	  of	  colony-­‐forming	  cells	  from	  the	  adult	  murine	  pituitary.	  Experimental	  Cell	  Research,	  308(1),	  166–76.	  doi:10.1016/j.yexcr.2005.04.023	  
	   	   	  
	   199	  
Lepore,	  D.	  a,	  Thomas,	  G.	  P.	  L.,	  Knight,	  K.	  R.,	  Hussey,	  A.	  J.,	  Callahan,	  T.,	  Wagner,	  J.,	  …	  Thomas,	  P.	  Q.	  (2007).	  Survival	  and	  differentiation	  of	  pituitary	  colony-­‐forming	  cells	  in	  vivo.	  Stem	  Cells	  (Dayton,	  Ohio),	  25(7),	  1730–6.	  doi:10.1634/stemcells.2007-­‐0012	  Lepper,	  C.,	  Conway,	  S.	  J.,	  &	  Fan,	  C.	  (2010).	  distinct	  genetic	  requirements.	  
Nature,	  460(7255),	  627–631.	  doi:10.1038/nature08209.Adult	  Li,	  H.,	  Collado,	  M.,	  Villasante,	  A.,	  Matheu,	  A.,	  Lynch,	  C.	  J.,	  Canamero,	  M.,	  …	  Martı,	  G.	  (2012).	  p27Kip1	  Directly	  Represses	  Sox2	  during	  Embryonic	  Stem	  Cell	  Differentiation.	  Cell	  Stem	  Cell,	  845–852.	  doi:10.1016/j.stem.2012.09.014	  Li,	  S.,	  Crenshaw,	  E.,	  Rawson,	  E.,	  Simmons,	  D.,	  Swanson,	  L.,	  &	  Rosenfeld,	  M.	  (1990).	  Dwarf	  locus	  mutants	  lacking	  three	  pituitary	  cell	  types	  result	  from	  mutations	  in	  the	  POU-­‐domain	  gene	  pit-­‐1.	  Nature,	  347,	  528–533.	  Li,	  X.,	  Oghi,	  K.	  A.,	  Zhang,	  J.,	  Krones,	  A.,	  Bush,	  K.	  T.,	  Glass,	  C.	  K.,	  …	  Aggarwal,	  A.	  K.	  (2003).	  Eya	  protein	  phosphatase	  activity	  regulates	  Six1	  –	  Dach	  –	  Eya	  transcriptional	  effects	  in	  mammalian	  organogenesis.	  Nature,	  426,	  247–254.	  Lin,	  S.,	  Li,	  S.,	  Drolet,	  D.	  W.,	  &	  Rosenfeld,	  M.	  G.	  (1994).	  Pituitary	  ontogeny	  of	  the	  Snell	  dwarf	  mouse	  reveals	  Pit-­‐1-­‐independent	  and	  Pit-­‐1-­‐dependent	  origins	  of	  the	  thyrotrope.	  Development,	  120,	  515–522.	  Lin,	  Y.,	  Liu,	  G.,	  Zhang,	  Y.,	  Hu,	  Y.-­‐P.,	  Yu,	  K.,	  Lin,	  C.,	  …	  Wang,	  F.	  (2007).	  Fibroblast	  growth	  factor	  receptor	  2	  tyrosine	  kinase	  is	  required	  for	  prostatic	  morphogenesis	  and	  the	  acquisition	  of	  strict	  androgen	  dependency	  for	  adult	  tissue	  homeostasis.	  Development	  (Cambridge,	  
England),	  134(4),	  723–34.	  doi:10.1242/dev.02765	  Lipkin,	  S.	  M.,	  Anders,	  M.	  N.,	  Kalla,	  K.	  A.,	  &	  Sack,	  R.	  A.	  (1993).	  Identification	  of	  a	  novel	  zinc	  finger	  protein	  binding	  a	  conserved	  element	  critical	  for	  Pit-­‐l-­‐dependent	  growth	  hormone	  gene	  expression.	  Genes	  &	  Development,	  7,	  1647–1687.	  doi:10.1101/gad.7.9.1674	  Liu,	  J.,	  Willet,	  S.	  G.,	  Bankaitis,	  E.	  D.,	  Xu,	  Y.,	  Wright,	  C.	  V.	  E.,	  &	  Gu,	  G.	  (2013).	  Non-­‐Parallel	  Recombination	  Limits	  Cre-­‐LoxP-­‐Based	  Reporters	  as	  Precise	  Indicators	  of	  Conditional	  Genetic	  Manipulation.	  Genesis,	  
442(February),	  436–442.	  doi:10.1002/dvg.22384	  López-­‐Juárez,	  A.,	  Remaud,	  S.,	  Hassani,	  Z.,	  Jolivet,	  P.,	  Pierre	  Simons,	  J.,	  Sontag,	  T.,	  …	  Demeneix,	  B.	  (2012).	  Thyroid	  hormone	  signaling	  acts	  as	  a	  neurogenic	  switch	  by	  repressing	  Sox2	  in	  the	  adult	  neural	  stem	  cell	  niche.	  Cell	  Stem	  Cell,	  10,	  531–543.	  López-­‐Ríos,	  J.,	  Gallardo,	  M.,	  Rodriguez	  de	  Córdoba,	  S.,	  &	  Bovolenta,	  P.	  (1999).	  Six9	  (	  Optx2	  ),	  a	  new	  member	  of	  the	  Six	  gene	  family	  of	  transcription	  
	   	   	  
	   200	  
factors	  ,	  is	  expressed	  at	  early	  stages	  of	  vertebrate	  ocular	  and	  pituitary	  development.	  Mechanisms	  of	  Development,	  83,	  155–159.	  Lourenço,	  D.,	  Sc,	  B.,	  Brauner,	  R.,	  Ph,	  D.,	  Lin,	  L.,	  Ph,	  D.,	  &	  Perdigo,	  A.	  De.	  (2009).	  Mutations	  in	  NR5A1	  Associated	  with	  Ovarian	  Insufficiency.	  New	  
England	  Journal	  of	  Medicine,	  360(12),	  1200–1210.	  doi:10.1056/NEJMoa0806228.Mutations	  Ludwig,	  A.,	  Rehberg,	  S.,	  &	  Ã,	  M.	  W.	  (2004).	  Melanocyte-­‐specific	  expression	  of	  dopachrome	  tautomerase	  is	  dependent	  on	  synergistic	  gene	  activation	  by	  the	  Sox10	  and	  Mitf	  transcription	  factors.	  FEBS	  Letters,	  556,	  236–244.	  doi:10.1016/S0014-­‐5793(03)01446-­‐7	  Machinis,	  K.,	  Pantel,	  J.,	  Le,	  J.,	  Camand,	  O.	  J.	  A.,	  Sobrier,	  M.,	  Moal,	  F.	  D.,	  …	  Amselem,	  S.	  (2001).	  Syndromic	  Short	  Stature	  in	  Patients	  with	  a	  Germline	  Mutation	  in	  the	  LIM	  Homeobox	  LHX4.	  American	  Journal	  of	  
Medical	  Genetics	  A,	  69(Mim	  602146),	  961–968.	  Manning,	  L.,	  Ohyama,	  K.,	  Saeger,	  B.,	  Hatano,	  O.,	  Wilson,	  S.	  A.,	  Logan,	  M.,	  …	  Hill,	  M.	  (2006).	  Regional	  Morphogenesis	  in	  the	  Hypothalamus :	  A	  BMP-­‐Tbx2	  Pathway	  Coordinates	  Fate	  and	  Proliferation	  through	  Shh	  Downregulation.	  Developmental	  Cell,	  873–885.	  doi:10.1016/j.devcel.2006.09.021	  Marieb,	  E.	  (2010).	  Essentials	  of	  Human	  Anatomy	  &	  Physiology.	  Martin,	  G.	  R.	  (1981).	  Isolation	  of	  a	  pluripotent	  cell	  line	  from	  early	  mouse	  embryos	  cultured	  in	  medium	  conditioned	  by	  teratocarcinoma	  stem	  cells	  Developmental	  Biology :	  Proceedings	  of	  the	  National	  Academy	  of	  
Sciences	  of	  the	  United	  States	  of	  America,	  78(12),	  7634–7638.	  Martinelli,	  D.	  C.,	  &	  Fan,	  C.	  (2007).	  Gas1	  extends	  the	  range	  of	  Hedgehog	  action	  by	  facilitating	  its	  signaling.	  Genes	  &	  Development,	  21,	  1231–1243.	  doi:10.1101/gad.1546307.1996	  Martinez-­‐barbera,	  J.	  P.,	  Rodriguez,	  T.	  A.,	  &	  Beddington,	  R.	  S.	  P.	  (2000).	  The	  Homeobox	  Gene	  Hesx1	  Is	  Required	  in	  the	  Anterior	  Neural	  Ectoderm	  for	  Normal	  Forebrain	  Formation.	  Developmental	  Biology,	  223,	  422–430.	  doi:10.1006/dbio.2000.9757	  Masui,	  S.,	  Nakatake,	  Y.,	  Toyooka,	  Y.,	  Shimosato,	  D.,	  Yagi,	  R.,	  Takahashi,	  K.,	  …	  Niwa,	  H.	  (2007).	  Pluripotency	  governed	  by	  Sox2	  via	  regulation	  of	  Oct3	  /	  4	  expression	  in	  mouse	  embryonic	  stem	  cells.	  Nature	  Cell	  Biology,	  9(6).	  doi:10.1038/ncb1589	  Matsushima,	  D.,	  Heavner,	  W.,	  &	  Pevny,	  L.	  H.	  (2011).	  Combinatorial	  regulation	  of	  optic	  cup	  progenitor	  cell	  fate	  by	  SOX2	  and	  PAX6.	  
Development	  (Cambridge,	  England),	  138(3),	  443–54.	  doi:10.1242/dev.055178	  
	   	   	  
	   201	  
Matsuura,	  K.,	  Nagai,	  T.,	  Oyama,	  T.,	  Nishi,	  J.,	  Wada,	  H.,	  Sano,	  M.,	  …	  Chem,	  J.	  B.	  (2004).	  Molecular	  Basis	  of	  Cell	  and	  Developmental	  Biology :	  Adult	  Cardiac	  Sca-­‐1-­‐positive	  Cells	  Differentiate	  into	  Beating	  Cardiomyocytes	  Supplemental	  material :	  Adult	  Cardiac	  Sca-­‐1-­‐positive	  Cells	  Differentiate	  into.	  The	  Journal	  of	  Biological	  Chemistry,	  279,	  11384–11391.	  doi:10.1074/jbc.M310822200	  Mirakhori,	  F.,	  Zeynali,	  B.,	  Salekdeh,	  G.	  H.,	  &	  Baharvand,	  H.	  (2013).	  Induced	  Neural	  Lineage	  Cells	  as	  Repair	  Kits :	  So	  Close	  ,	  Yet	  So	  Far	  Away.	  Journal	  
of	  Cellular	  Phyisiology,	  (November),	  728–742.	  doi:10.1002/jcp.24509	  Moerlooze,	  L.	  De,	  Spencer-­‐dene,	  B.,	  Revest,	  J.,	  Hajihosseini,	  M.,	  Rosewell,	  I.,	  &	  Dickson,	  C.	  (2000).	  An	  important	  role	  for	  the	  IIIb	  isoform	  of	  fibroblast	  growth	  factor	  receptor	  2	  (	  FGFR2	  )	  in	  mesenchymal-­‐epithelial	  signalling	  during	  mouse	  organogenesis.	  Development,	  127,	  483–492.	  Mollard,	  P.,	  Hodson,	  D.	  J.,	  Lafont,	  C.,	  Rizzoti,	  K.,	  &	  Drouin,	  J.	  (2012).	  A	  tridimensional	  view	  of	  pituitary	  development	  and	  function.	  Trends	  in	  
Endocrinology	  &	  Metabolism,	  23(6),	  261–269.	  doi:10.1016/j.tem.2012.02.004	  Monahan,	  P.,	  Rybak,	  S.,	  &	  Raetzman,	  L.	  T.	  (2009).	  The	  Notch	  Target	  Gene	  Hes1	  Regulates	  Cell	  Cycle	  Inhibitor	  Expression	  in	  the	  Developing	  Pituitary.	  Endocrinology,	  150(September),	  4386–4394.	  doi:10.1210/en.2009-­‐0206	  Mullen,	  R.,	  Colvin,	  S.,	  Hunter,	  C.,	  Savage,	  J.,	  Walvoord,	  C.,	  Bhangoo,	  A.	  P.	  S.,	  …	  Rhodes,	  S.	  (2007).	  Roles	  of	  the	  LHX3	  and	  LHX4	  LIM-­‐homeodomain	  factors	  in	  pituitary	  development.	  Molecular	  and	  Cellular	  Endocrinology,	  
265-­‐266,	  190–195.	  Mullen,	  R.	  D.,	  Park,	  S.,	  &	  Rhodes,	  S.	  J.	  (2012).	  A	  Distal	  Modular	  Enhancer	  Complex	  Acts	  to	  Control	  the	  LHX3	  Regulatory	  Gene.	  Molecular	  
Endocrinology,	  26(February	  2012),	  308–319.	  doi:10.1210/me.2011-­‐1252	  Nakayama,	  K.,	  Ishida,	  N.,	  Shirane,	  M.,	  Inomata,	  A.,	  &	  Nakayama,	  K.	  (1996).	  Mice	  lacking	  p27(Kip1)	  display	  increased	  body	  size,	  multiple	  organ	  hyperplasia,	  retinal	  dysplasia,	  and	  pituitary	  tumors.	  Cell,	  85,	  707–720.	  Nasonkin,	  I.	  O.,	  Potok,	  M.	  A.,	  &	  Camper,	  S.	  A.	  (2010).	  Cre-­‐mediated	  recombination	  in	  pituitary	  somatotropes.	  Genesis,	  47(1),	  55–60.	  doi:10.1002/dvg.20462.Cre-­‐mediated	  Netchine,	  I.,	  Sobrier,	  M.,	  Krude,	  H.,	  Schnabel,	  D.,	  Maghnie,	  M.,	  Duriez,	  B.,	  …	  Amselem,	  S.	  (2000).	  Mutations	  in	  LHX3	  result	  in	  a	  new	  syndrome	  revealed	  by	  combined	  pituitary	  hormone	  deficiency.	  Nature	  Genetics,	  
25(june),	  182–186.	  
	   	   	  
	   202	  
Niwa,	  H.,	  Miyazaki,	  J.,	  &	  Smith,	  A.	  G.	  (2000).	  Quantitative	  expression	  of	  Oct-­‐3	  /	  4	  defines	  differentiation	  ,	  dedifferentiation	  or	  self-­‐renewal	  of	  ES	  cells.	  
Nature	  Genetics,	  24(april),	  2–6.	  Nolan,	  L.	  A.,	  &	  Levy,	  A.	  (2006).	  A	  Population	  of	  Non-­‐Luteinising	  Hormone	  ⁄	  Non-­‐Adrenocorticotrophic	  Hormone-­‐Positive	  Cells	  in	  the	  Male	  Rat	  Anterior	  Pituitary	  Responds	  Mitotically	  to	  Both	  Gonadectomy	  and	  Adrenalectomy	  Neuroendocrinology.	  Journal	  of	  Neuroendocrinology,	  655–661.	  doi:10.1111/j.1365-­‐2826.2006.01459.x	  Nolan,	  L.,	  Kavanagh,	  E.,	  Lightman,	  S.,	  &	  Levy,	  A.	  (1998).	  Anterior	  pituitary	  cell	  population	  control:	  basal	  cell	  turnover	  and	  the	  effects	  of	  adrenalectomy	  and	  dexamethasone	  treatment.	  Journal	  of	  
Neuroendocrinology,	  3,	  207–215.	  Oesterle,	  E.	  C.,	  Chien,	  W.,	  Campbell,	  S.,	  Nellimarla,	  P.,	  &	  Fero,	  M.	  L.	  (2011).	  p27	  Kip1	  is	  required	  to	  maintain	  proliferative	  quiescence	  in	  the	  adult	  cochlea	  and	  pituitary.	  Cell	  Cycle,	  10,	  1237–1248.	  doi:10.4161/cc.10.8.15301	  Ohuchi,	  H.,	  Hori,	  Y.,	  Yamasaki,	  M.,	  Harada,	  H.,	  Sekine,	  K.,	  Kato,	  S.,	  &	  Itoh,	  N.	  (2000).	  FGF10	  Acts	  as	  a	  Major	  Ligand	  for	  FGF	  Receptor	  2	  IIIb	  in	  Mouse	  Multi-­‐Organ	  Development.	  Biochemical	  and	  Biophysical	  Research	  
Communications,	  277,	  643–649.	  doi:10.1006/bbrc.2000.3721	  Okumura-­‐nakanishi,	  S.,	  Saito,	  M.,	  Niwa,	  H.,	  &	  Ishikawa,	  F.	  (2005).	  Molecular	  Basis	  of	  Cell	  and	  Developmental	  Biology :	  Oct-­‐3	  /	  4	  and	  Sox2	  Regulate	  Oct-­‐3	  /	  4	  Gene	  in	  Embryonic	  Stem	  Cells	  *.	  Journal	  of	  Biological	  
Chemistry.	  doi:10.1074/jbc.M410015200	  Oliver,	  G.,	  Mailhos,	  A.,	  Wehr,	  R.,	  Copeland,	  N.	  G.,	  Jenkins,	  N.	  A.,	  &	  Gruss,	  P.	  (1995).	  Six3	  ,	  a	  murine	  homologue	  of	  the	  sine	  oculis	  gene	  ,	  demarcates	  the	  most	  anterior	  border	  of	  the	  developing	  neural	  plate	  and	  is	  expressed	  during	  eye	  development.	  Development,	  121,	  4045–4055.	  Olson,	  L.	  E.,	  Tollkuhn,	  J.,	  Scafoglio,	  C.,	  Krones,	  A.,	  Zhang,	  J.,	  Ohgi,	  K.	  A.,	  …	  Li,	  X.	  (2006).	  Homeodomain-­‐Mediated	  b	  -­‐Catenin-­‐Dependent	  Switching	  Events	  Dictate	  Cell-­‐Lineage	  Determination.	  Cell,	  125,	  593–605.	  doi:10.1016/j.cell.2006.02.046	  Ornitz,	  D.	  M.,	  &	  Itoh,	  N.	  (2001).	  Protein	  family	  review	  Fibroblast	  growth	  factors	  Gene	  organization	  and	  evolutionary	  history.	  Genome	  Biology,	  2,	  1–12.	  Osumi-­‐yamashita,	  N.,	  Ninomiya,	  Y.,	  Doi,	  H.,	  &	  Eto,	  K.	  (1994).	  The	  Contribution	  of	  both	  Forebrain	  and	  Midbrain	  Crest	  Cells	  to	  the	  Mesenchyme	  in	  the	  Frontonasal	  Mass	  of	  Mouse	  Embryos.	  
Developmental	  B	  Iology,	  164,	  409–419.	  
	   	   	  
	   203	  
Otto,	  C.,	  tom	  Dieck,	  S.,	  &	  Bauer,	  K.	  (1996).	  Dipeptide	  uptake	  by	  adenohypophysial	  folliculostellate	  cells.	  The	  Americal	  Journal	  of	  
Physiology,	  271.	  Oustanina,	  S.,	  Hause,	  G.,	  &	  Braun,	  T.	  (2004).	  Pax7	  directs	  postnatal	  renewal	  and	  propagation	  of	  myogenic	  satellite	  cells	  but	  not	  their	  specification.	  
EMBO,	  23(16),	  3430–3439.	  doi:10.1038/sj.emboj.7600346	  Parker,	  K.,	  &	  Schimmer,	  B.	  (1997).	  Steroidogenic	  factor	  1:	  a	  key	  determinant	  of	  endocrine	  development	  and	  function.	  Endocrine	  Reviews,	  18,	  361–377.	  Pastrana,	  E.,	  Silva-­‐Vargas,	  V.,	  &	  Doetsch,	  F.	  (2011).	  Eyes	  wide	  open:	  a	  critical	  review	  of	  sphere-­‐formation	  as	  an	  assay	  for	  stem	  cells.	  Cell	  Stem	  Cell,	  
8(5),	  486–498.	  doi:10.1016/j.stem.2011.04.007.Eyes	  Pearson,	  C.,	  &	  Placzek,	  M.	  (2013).	  Development	  of	  the	  medial	  hypothalamus:	  forming	  a	  functional	  hypothalamic-­‐neurohypophyseal	  interface.	  
Current	  Topics	  in	  Developmental	  Biology,	  106,	  49–88.	  Peirano,	  R.	  I.,	  Goerich,	  D.	  E.,	  Riethmacher,	  D.,	  Peirano,	  R.	  I.,	  Goerich,	  D.	  E.,	  Riethmacher,	  D.,	  &	  Wegner,	  M.	  (2000).	  Protein	  Zero	  Gene	  Expression	  Is	  Regulated	  by	  the	  Glial	  Transcription	  Factor	  Sox10	  Protein	  Zero	  Gene	  Expression	  Is	  Regulated	  by	  the	  Glial	  Transcription	  Factor	  Sox10.	  
Molecular	  and	  Cellular	  Biology,	  20(9),	  3198–3209.	  doi:10.1128/MCB.20.9.3198-­‐3209.2000.Updated	  Pfäffle,	  R.,	  DiMattia,	  G.,	  Parks,	  J.,	  Brown,	  M.,	  Rosenfeld,	  M.,	  &	  Ingraham,	  H.	  (1992).	  Mutation	  of	  the	  POU-­‐specific	  domain	  of	  Pit-­‐1	  and	  hypopituitarism	  without	  pituitary	  hypoplasia.	  Science,	  275,	  1118–1121.	  Pignoni,	  F.,	  Hu,	  B.,	  Zavitz,	  K.	  H.,	  Xiao,	  J.,	  Garrity,	  P.	  A.,	  &	  Zipursky,	  S.	  L.	  (1997).	  The	  Eye-­‐Specification	  Proteins	  So	  and	  Eya	  Form	  a	  Complex	  and	  Regulate	  Multiple	  Steps	  in	  Drosophila	  Eye	  Development.	  Cell,	  91,	  881–891.	  Pontiggia,	  A.,	  Rimini,	  R.,	  Harley,	  V.	  R.,	  Goodfellow,	  P.	  N.,	  Lovell-­‐badge,	  R.,	  &	  Bianchil,	  M.	  E.	  (1994).	  Sex-­‐reversing	  mutations	  affect	  the	  architecture	  of	  SRY-­‐DNA	  complexes.	  EMBO,	  13(24),	  6115–6124.	  Potok,	  M.	  A.,	  Cha,	  K.	  B.,	  Hunt,	  A.,	  Brinkmeier,	  M.	  L.,	  Leitges,	  M.,	  Kispert,	  A.,	  &	  Camper,	  S.	  A.	  (2008).	  WNT	  Signaling	  Affects	  Gene	  Expression	  in	  the	  Ventral	  Diencephalon	  and	  Pituitary	  Gland	  Growth.	  Developmental	  
Dynmics,	  237(March),	  1006–1020.	  doi:10.1002/dvdy.21511	  Poulin,	  G.,	  Lebel,	  M.,	  Chamberland,	  M.,	  Paradis,	  W.,	  Drouin,	  J.,	  Lebel,	  L.,	  …	  Drouin,	  J.	  (2000).	  Specific	  Protein-­‐Protein	  Interaction	  between	  Basic	  Helix-­‐Loop-­‐Helix	  Transcription	  Factors	  and	  Homeoproteins	  of	  the	  Pitx	  Family	  Specific	  Protein-­‐Protein	  Interaction	  between	  Basic	  Helix-­‐Loop-­‐
	   	   	  
	   204	  
Helix	  Transcription	  Factors	  and	  Homeoproteins	  of	  the	  Pitx	  Family.	  
Molecular	  and	  Cellular	  Biology,	  20,	  4826–4837.	  doi:10.1128/MCB.20.13.4826-­‐4837.2000.Updated	  Poulin,	  G.,	  Turgeon,	  B.,	  &	  Drouin,	  J.	  (1997).	  NeuroD1	  /beta2	  Contributes	  to	  Cell-­‐Specific	  Transcription	  of	  the	  Proopiomelanocortin	  Gene.	  Molecular	  
and	  Cellular	  Biology,	  17(11),	  6673–6682.	  Pulichino,	  A.,	  Vallette-­‐kasic,	  S.,	  Couture,	  C.,	  Gauthier,	  Y.,	  Brue,	  T.,	  David,	  M.,	  …	  Drouin,	  J.	  (2003).	  Human	  and	  mouse	  TPIT	  gene	  mutations	  cause	  early	  onset	  pituitary	  ACTH	  deficiency.	  Genes	  &	  Development,	  17,	  711–716.	  doi:10.1101/gad.1065603	  Pulichino,	  A.,	  Vallette-­‐kasic,	  S.,	  Tsai,	  J.	  P.,	  Pulichino,	  A.,	  Vallette-­‐kasic,	  S.,	  Tsai,	  J.	  P.,	  …	  Drouin,	  J.	  (2003).	  Tpit	  determines	  alternate	  fates	  during	  pituitary	  cell	  differentiation	  Tpit	  determines	  alternate	  fates	  during	  pituitary	  cell	  differentiation.	  Genes	  &	  Development,	  17,	  738–747.	  doi:10.1101/gad.1065703	  Que,	  J.,	  Luo,	  X.,	  Schwartz,	  R.	  J.,	  &	  Hogan,	  B.	  L.	  M.	  (2009).	  Multiple	  roles	  for	  Sox2	  in	  the	  developing	  and	  adult	  mouse	  trachea.	  Development,	  1907,	  1899–1907.	  doi:10.1242/dev.034629	  Quereda,	  V.,	  &	  Malumbres,	  M.	  (2009).	  Cell	  cycle	  control	  of	  pituitary	  development	  and	  disease.	  Journal	  of	  Molecular	  Endocrinology,	  42,	  75–86.	  doi:10.1677/JME-­‐08-­‐0146	  Quinlan,	  R.,	  Tobin,	  J.,	  &	  Beales,	  P.	  (2008).	  Modeling	  ciliopathies:	  Primary	  cilia	  in	  development	  and	  disease.	  Current	  Topics	  in	  Developmental	  Biology,	  
84.	  Quirk,	  C.	  C.,	  Lozada,	  K.	  L.,	  Keri,	  R.	  A.,	  &	  Nilson,	  J.	  H.	  (2001).	  A	  Single	  Pitx1	  Binding	  Site	  Is	  Essential	  for	  Activity	  of	  the	  LH	  ␤	  Promoter	  in	  Transgenic	  Mice.	  Molecular	  Endocrinology,	  15,	  734–746.	  Radovick,	  S.,	  Nations,	  M.,	  Du,	  Y.,	  Berg,	  L.,	  Weintraub,	  B.,	  &	  Wondisford,	  F.	  (1992).	  A	  mutation	  in	  the	  POU-­‐homeodomain	  of	  Pit-­‐1	  responsible	  for	  combined	  pituitary	  hormone	  deficiency.	  Science,	  257,	  115–118.	  Raetzman,	  L.	  T.,	  Cai,	  J.	  X.,	  &	  Camper,	  S.	  A.	  (2008).	  Hes1	  is	  Required	  for	  Pituitary	  Growth	  and	  Melanotrope	  Specification.	  Developmental	  Biology,	  
304(2),	  455–466.	  Raetzman,	  L.	  T.,	  Ward,	  R.,	  &	  Camper,	  S.	  a.	  (2002).	  Lhx4	  and	  Prop1	  are	  required	  for	  cell	  survival	  and	  expansion	  of	  the	  pituitary	  primordia.	  
Development	  (Cambridge,	  England),	  129(18),	  4229–39.	  Retrieved	  from	  http://www.ncbi.nlm.nih.gov/pubmed/12183375	  
	   	   	  
	   205	  
Rajab,	  A.,	  Kelberman,	  D.,	  Castro,	  S.	  C.	  P.	  De,	  Biebermann,	  H.,	  Shaikh,	  H.,	  Pearce,	  K.,	  …	  Dattani,	  M.	  T.	  (2008).	  Novel	  mutations	  in	  LHX3	  are	  associated	  with	  hypopituitarism	  and	  sensorineural	  hearing	  loss.	  Human	  
Molecular	  Genetics,	  17(14),	  2150–2159.	  doi:10.1093/hmg/ddn114	  Reményi,	  A.,	  Lins,	  K.,	  Nissen,	  L.	  J.,	  Reményi,	  A.,	  Lins,	  K.,	  Nissen,	  L.	  J.,	  …	  Wilmanns,	  M.	  (2003).	  Crystal	  structure	  of	  a	  POU	  /	  HMG	  /	  DNA	  ternary	  complex	  suggests	  differential	  assembly	  of	  Oct4	  and	  Sox2	  on	  two	  enhancers.	  Genes	  &	  Development,	  2048–2059.	  doi:10.1101/gad.269303	  Ribes,	  V.,	  &	  Briscoe,	  J.	  (2009).	  Establishing	  and	  Interpreting	  Graded	  Sonic	  Hedgehog	  Signaling	  during	  Vertebrate	  Neural	  Tube	  Patterning :	  The	  Role	  of	  Negative	  Feedback.	  Cold	  Spring	  Harbour	  Perspectives	  in	  Biology,	  
2,	  1–16.	  Rizzoti,	  K.	  (2010).	  Adult	  pituitary	  progenitors	  /	  stem	  cells :	  from	  in	  vitro	  characterization	  to	  in	  vivo	  function.	  European	  Journal	  of	  Neuroscience,	  
32(July),	  2053–2062.	  doi:10.1111/j.1460-­‐9568.2010.07524.x	  Rizzoti,	  K.,	  Akiyama,	  H.,	  &	  Lovell-­‐badge,	  R.	  (2013).	  Mobilized	  Adult	  Pituitary	  Stem	  Cells	  Contribute	  to	  Endocrine	  Regeneration	  in	  Response	  to	  Physiological	  Demand.	  Stem	  Cell,	  13(4),	  419–432.	  doi:10.1016/j.stem.2013.07.006	  Rizzoti,	  K.,	  Brunelli,	  S.,	  Carmignac,	  D.,	  Thomas,	  P.	  Q.,	  Robinson,	  I.	  C.,	  &	  Lovell-­‐Badge,	  R.	  (2004).	  SOX3	  is	  required	  during	  the	  formation	  of	  the	  hypothalamo-­‐pituitary	  axis.	  Nature	  Genetics,	  36(3),	  247–55.	  doi:10.1038/ng1309	  Rodda,	  D.	  J.,	  Chew,	  J.,	  Loh,	  Y.,	  Wang,	  B.,	  Ng,	  H.,	  &	  Robson,	  P.	  (2005).	  Molecular	  Basis	  of	  Cell	  and	  Developmental	  Biology :	  Transcriptional	  Regulation	  of	  Nanog	  by	  Transcriptional	  Regulation	  of	  Nanog	  by	  OCT4	  and	  SOX2	  *.	  doi:10.1074/jbc.M502573200	  Roessler,	  E.,	  Belloni,	  E.,	  Gaudenz,	  K.,	  Jay,	  P.,	  &	  Muenke,	  M.	  (1996).	  Mutations	  in	  the	  human	  Sonic	  Hedgehog	  gene	  cause	  holoprosencephaly.	  Nature	  
Genetics,	  14,	  357–360.	  Roussel-­‐Gervais,	  A.,	  Bilodeau,	  S.,	  Vallette,	  S.,	  Berthelet,	  F.,	  Lacroix,	  A.,	  Figarella-­‐Branger,	  D.,	  …	  Drouin,	  J.	  (2010).	  Cooperation	  between	  cyclin	  E	  and	  p27(Kip1)	  in	  pituitary	  tumorigenesis.	  Molecular	  Endocrinology,	  24.	  Sala,	  A.,	  &	  Calabretta,	  B.	  (1992).	  Regulation	  of	  BALB	  /	  c	  3T3	  fibroblast	  proliferation	  by	  B-­‐myb	  is	  accompanied	  by	  selective	  activation	  of	  cdc2	  and	  cyclin	  D1	  expression.	  Proceedings	  of	  the	  National	  Academy	  of	  
Sciences	  of	  the	  United	  States	  of	  America,	  89(November),	  10415–10419.	  
	   	   	  
	   206	  
Sarkar,	  A.,	  &	  Hochedlinger,	  K.	  (2013).	  The	  Sox	  Family	  of	  Transcription	  Factors :	  Versatile	  Regulators	  of	  Stem	  and	  Progenitor	  Cell	  Fate.	  Stem	  
Cell,	  12(1),	  15–30.	  doi:10.1016/j.stem.2012.12.007	  Sato,	  N.,	  Meijer,	  L.,	  Skaltsounis,	  L.,	  Greengard,	  P.,	  &	  Brivanlou,	  A.	  H.	  (2004).	  Maintenance	  of	  pluripotency	  in	  human	  and	  mouse	  embryonic	  stem	  cells	  through	  activation	  of	  Wnt	  signaling	  by	  a	  pharmacological	  GSK-­‐3-­‐specific	  inhibitor.	  Nature	  Medicine,	  10(1),	  55–63.	  doi:10.1038/nm979	  Schang,	  A.,	  Granger,	  A.,	  Quérat,	  B.,	  Bleux,	  C.,	  Cohen-­‐tannoudji,	  J.,	  &	  Laverrière,	  J.	  (2013).	  Protein-­‐Induced	  Activation	  Are	  Mediated	  by	  a	  Bi-­‐Functional	  Response	  Element	  in	  the	  Rat	  GnRH	  Receptor	  Gene.	  Molecular	  
Endocrinology,	  27(January	  2013),	  74–91.	  doi:10.1210/me.2012-­‐1182	  Schindelin,	  J.,	  Arganda-­‐carreras,	  I.,	  Frise,	  E.,	  Kaynig,	  V.,	  Longair,	  M.,	  Pietzsch,	  T.,	  …	  Cardona,	  A.	  (2012).	  Fiji :	  an	  open-­‐source	  platform	  for	  biological-­‐image	  analysis,	  9(7).	  doi:10.1038/nmeth.2019	  Schneider,	  A.,	  Brand,	  T.,	  Zweigerdt,	  R.,	  &	  Arnold,	  H.	  (2000).	  Targeted	  disruption	  of	  the	  Nkx3	  .	  1	  gene	  in	  mice	  results	  in	  morphogenetic	  defects	  of	  minor	  salivary	  glands :	  parallels	  to	  glandular	  duct	  morphogenesis	  in	  prostate.	  Mechanisms	  of	  Development,	  95,	  163–174.	  Sciavolino,	  P.	  J.,	  Abrams,	  E.	  W.,	  Yang,	  L.	  U.,	  &	  Austenberg,	  L.	  P.	  (1997).	  Tissue-­‐Specific	  Expression	  of	  Murine	  Nkx3	  .	  1	  in	  the	  Male	  Urogenital	  System.	  
Developmental	  Dynmics,	  138(February),	  127–138.	  Scott,	  C.	  E.,	  Wynn,	  S.	  L.,	  Sesay,	  A.,	  Cruz,	  C.,	  Cheung,	  M.,	  Gomez	  Gaviro,	  M.-­‐V.,	  …	  Briscoe,	  J.	  (2010).	  SOX9	  induces	  and	  maintains	  neural	  stem	  cells.	  Nature	  
Neuroscience,	  13(10),	  1181–9.	  doi:10.1038/nn.2646	  Sekido,	  R.,	  &	  Lovell-­‐badge,	  R.	  (2009).	  Sex	  determination	  and	  SRY :	  down	  to	  a	  wink	  and	  a	  nudge ?	  Trends	  in	  Genetics,	  (November),	  19–29.	  doi:10.1016/j.tig.2008.10.008	  Sheng,	  H.	  Z.,	  Moriyama,	  K.,	  Yamashita,	  T.,	  Li,	  H.,	  Potter,	  S.	  S.,	  Mahon,	  K.	  A.,	  …	  Westphal,	  H.	  (1997).	  Multistep	  Control	  of	  Pituitary	  Organogenesis.	  
Science	  (New	  York,	  N.Y.),	  278(5344),	  1809–1812.	  Sheng,	  H.	  Z.,	  Zhadanov,	  A.	  B.,	  Jr,	  B.	  M.,	  Fujii,	  T.,	  Grinberg,	  A.,	  Lee,	  E.	  J.,	  …	  Westphal,	  H.	  (1996).	  Specification	  of	  Pituitary	  Cell	  Lineages	  by	  the	  Homeobox	  Gene	  Lhx3.	  Science	  (New	  York,	  N.Y.),	  272(5264),	  1004–1007.	  Shimamura,	  K.,	  Hartigan,	  D.	  J.,	  Martinez,	  S.,	  Puelles,	  L.,	  &	  Rubenstein,	  J.	  L.	  R.	  (1995).	  Longitudinal	  organization	  of	  the	  anterior	  neural	  plate	  and	  neural	  tube.	  Development,	  3933,	  3923–3933.	  Shinoda,	  K.,	  Lei,	  H.,	  Yoshii,	  H.,	  Nomura,	  M.,	  &	  Niwa,	  O.	  (1995).	  Developmental	  Defects	  of	  the	  Ventromedial	  Hypothalamic	  Nucleus	  and	  Pituitary	  
	   	   	  
	   207	  
Gonadotroph	  in	  the	  Ftz-­‐Fl	  Disrupted	  Mice.	  Developmental	  Dynmics,	  204,	  22–29.	  Shinohara,	  T.	  (1976).	  Quantitation	  of	  b-­‐crystallin	  messenger	  RNA	  during	  lens	  induction	  in	  chick	  embryos	  )	  I.	  Proceedings	  of	  the	  National	  Academy	  
of	  Sciences	  of	  the	  United	  States	  of	  America,	  73(8),	  2808–2812.	  Shirasawa,	  N.,	  Kihara,	  H.,	  &	  Yamaguchi,	  S.	  (1983).	  Cell	  and	  Tissue	  Pituitary	  folliculo-­‐stellate	  cells	  immunostained	  with	  S-­‐IO0	  protein	  antiserum	  in	  postnatal	  ,	  castrated	  and	  thyroidectomized	  rats.	  Cell	  Tissue	  Research,	  
231,	  235–249.	  Sinclair,	  A.,	  Berta,	  P.,	  Palmer,	  M.,	  Hawkins,	  J.,	  Griffiths,	  B.,	  Smith,	  M.,	  …	  Goodfellow,	  P.	  (1990).	  A	  gene	  from	  the	  human	  sex-­‐determining	  region	  encodes	  a	  protein	  with	  homology	  to	  a	  conserved	  DNA-­‐binding	  motif.	  
Nature,	  346,	  240–244.	  Sisodiya,	  S.	  M.,	  Ragge,	  N.	  K.,	  Cavalleri,	  G.	  L.,	  Hever,	  A.,	  Lorenz,	  B.,	  Schneider,	  A.,	  …	  Fitzpatrick,	  D.	  R.	  (2006).	  Role	  of	  SOX2	  Mutations	  in	  Human	  Hippocampal	  Malformations	  and	  Epilepsy.	  Epilepsia,	  47(3),	  534–542.	  Sloop,	  K.	  W.,	  Meier,	  B.	  C.,	  Bridwell,	  J.	  L.,	  Parker,	  G.	  E.,	  Schiller,	  A.	  M.,	  &	  Rhodes,	  S.	  J.	  (1999).	  Differential	  Activation	  of	  Pituitary	  Hormone	  Genes	  by	  Human	  Lhx3	  Isoforms	  with	  Distinct	  DNA	  Binding	  Properties.	  Molecular	  
Endocrinology,	  12(June),	  2212–2225.	  Smith,	  A.	  N.,	  Miller,	  L.,	  Radice,	  G.,	  Ashery-­‐padan,	  R.,	  Lang,	  R.	  A.,	  Smith,	  A.	  N.,	  …	  Lang,	  R.	  A.	  (2009).	  Stage-­‐dependent	  modes	  of	  Pax6-­‐Sox2	  epistasis	  regulate	  lens	  development	  and	  eye	  morphogenesis,	  3377,	  2977–2985.	  doi:10.1242/dev.043802	  Sornson,	  M.,	  Wu,	  W.,	  Dasen,	  J.,	  Flynn,	  S.,	  Norman,	  D.,	  Beamer,	  W.,	  &	  Rosenfeld,	  M.	  (1996).	  Pituitary	  lineage	  determination	  by	  the	  Prophet	  of	  Pit-­‐1	  homeodomain	  factor	  defective	  in	  Ames	  dwarfism.	  Nature,	  384,	  327–333.	  Srinivas,	  S.,	  Watanabe,	  T.,	  Lin,	  C.,	  M,	  C.,	  Tanabe,	  Y.,	  Jessell,	  T.	  M.,	  &	  Costantini,	  F.	  (2001).	  Cre	  reporter	  strains	  produced	  by	  targeted	  insertion	  of	  EYFP	  and	  ECFP	  into	  the	  ROSA26	  locus.	  BMC	  Developmental	  Biology.	  Suh,	  H.,	  Gage,	  P.	  J.,	  Drouin,	  J.,	  &	  Camper,	  S.	  A.	  (2002).	  Pitx2	  is	  required	  at	  multiple	  stages	  of	  pituitary	  organogenesis :	  pituitary	  primordium	  formation	  and	  cell	  specification.	  Development,	  129,	  329–337.	  Surzenko,	  N.,	  Crowl,	  T.,	  Bachleda,	  A.,	  Langer,	  L.,	  &	  Pevny,	  L.	  (2013).	  SOX2	  maintains	  the	  quiescent	  progenitor	  cell	  state	  of	  postnatal	  retinal	  Müller	  glia.	  Development,	  140,	  1445–1456.	  doi:10.1242/dev.071878	  
	   	   	  
	   208	  
Szeto,	  D.	  P.,	  Ryant,	  A.	  K.,	  Connellt,	  S.	  M.	  O.,	  &	  Rosenfeldt,	  M.	  G.	  (1996).	  P-­‐OTX:	  a	  PIT-­‐1-­‐interacting	  homeodomain	  factor	  expressed	  during	  anterior	  pituitary	  gland	  development.	  Proceedings	  of	  the	  National	  Academy	  of	  
Sciences	  of	  the	  United	  States	  of	  America,	  93(July),	  7706–7710.	  Takahashi,	  K.,	  Tanabe,	  K.,	  Ohnuki,	  M.,	  Narita,	  M.,	  Ichisaka,	  T.,	  &	  Tomoda,	  K.	  (2007).	  Induction	  of	  Pluripotent	  Stem	  Cells	  from	  Adult	  Human	  Fibroblasts	  by	  Defined	  Factors.	  Cell,	  861–872.	  doi:10.1016/j.cell.2007.11.019	  Takahashi,	  K.,	  &	  Yamanaka,	  S.	  (2006).	  Induction	  of	  Pluripotent	  Stem	  Cells	  from	  Mouse	  Embryonic	  and	  Adult	  Fibroblast	  Cultures	  by	  Defined	  Factors.	  Cell,	  2,	  663–676.	  doi:10.1016/j.cell.2006.07.024	  Takanaga,	  H.,	  Tsuchida-­‐Straeten,	  N.,	  Nishide,	  K.,	  Watanabe,	  A.,	  Aburatani,	  H.,	  &	  Kondo,	  T.	  (2009).	  TISSUE-­‐SPECIFIC	  STEM	  CELLS	  Gli2	  Is	  a	  Novel	  Regulator	  of	  Sox2	  Expression	  in	  Telencephalic.	  Stem	  Cells,	  165–174.	  doi:10.1634/stemcells.2008-­‐0580	  Takuma,	  N.,	  Sheng,	  H.	  Z.,	  Furuta,	  Y.,	  Ward,	  J.	  M.,	  Sharma,	  K.,	  Hogan,	  B.	  L.	  M.,	  …	  Mahon,	  K.	  A.	  (1998).	  Formation	  of	  Rathke	  ’	  s	  pouch	  requires	  dual	  induction	  from	  the	  diencephalon.	  Development,	  125,	  4835–4840.	  Tanaka,	  M.,	  Lyons,	  G.	  E.,	  &	  Izumo,	  S.	  (1999).	  Expression	  of	  the	  Nkx3	  .	  1	  homobox	  gene	  during	  pre	  and	  postnatal	  development.	  Mechanisms	  of	  
Development,	  85,	  179–182.	  Tanaka,	  S.,	  Kamachi,	  Y.,	  Tanouchi,	  A.,	  Hamada,	  H.,	  &	  Jing,	  N.	  (2004).	  Interplay	  of	  SOX	  and	  POU	  Factors	  in	  Regulation	  of	  the	  Nestin	  Gene	  in	  Neural	  Primordial	  Cells.	  Molecular	  and	  Cellular	  Biology,	  24(20),	  8834–8846.	  doi:10.1128/MCB.24.20.8834	  Tao,	  W.,	  &	  Lai,	  E.	  (1992).	  Telencephalon-­‐Restricted	  Expression	  of	  BF-­‐1	  ,	  a	  New	  Member	  of	  the	  HNF-­‐3lfork	  head	  Gene	  Family	  ,	  in	  the	  Developing	  Rat	  Brain.	  Neuron,	  8,	  957–966.	  Taranova,	  O.	  V,	  Magness,	  S.	  T.,	  Fagan,	  B.	  M.,	  Wu,	  Y.,	  Surzenko,	  N.,	  Hutton,	  S.	  R.,	  &	  Pevny,	  L.	  H.	  (2006).	  SOX2	  is	  a	  dose-­‐dependent	  regulator	  of	  retinal	  neural	  progenitor	  competence.	  Genes	  &	  Development,	  1187–1202.	  doi:10.1101/gad.1407906.ment	  Tétreault,	  N.,	  Champagne,	  M.,	  &	  Bernier,	  G.	  (2009).	  The	  LIM	  homeobox	  transcription	  factor	  Lhx2	  is	  required	  to	  specify	  the	  retina	  fi	  eld	  and	  synergistically	  cooperates	  with	  Pax6	  for	  Six6	  trans-­‐activation.	  
Developmental	  Biology,	  327(2),	  541–550.	  doi:10.1016/j.ydbio.2008.12.022	  
	   	   	  
	   209	  
Thomas,	  P.,	  &	  Beddington,	  R.	  (1996).	  Anterior	  primitive	  endoderm	  may	  be	  responsible	  for	  patterning	  the	  anterior	  neural	  plate	  in	  the	  mouse	  embryo.	  Current	  Biology,	  6,	  1487–1496.	  Thomas,	  P.,	  Johnson,	  B.,	  Rathjen,	  J.,	  &	  Rathjen,	  P.	  (1995).	  Sequence,	  genomic	  organization,	  and	  expression	  of	  the	  novel	  homeobox	  gene	  Hesx1.	  
Journal	  of	  Biological	  Chemistry,	  270,	  3869–3975.	  Tompkins,	  D.	  H.,	  Lange,	  A.	  W.,	  Keiser,	  A.	  R.,	  Wert,	  S.	  E.,	  Bruno,	  M.	  D.,	  &	  Whitsett,	  J.	  A.	  (2011).	  Sox2	  Activates	  Cell	  Proliferation	  and	  Differentiation	  in	  the	  Respiratory	  Epithelium.	  American	  Journal	  of	  
Respiritory	  Cell	  and	  Molecular	  Biology	  Biology,	  45,	  101–110.	  doi:10.1165/rcmb.2010-­‐0149OC	  Toy,	  J.,	  &	  Sundin,	  O.	  H.	  (1999).	  Expression	  of	  the	  Optx2	  homeobox	  gene	  during	  mouse	  development.	  Mechanisms	  of	  Development,	  83,	  183–186.	  Treier,	  M.,	  Gleiberman,	  A.	  S.,	  Connell,	  S.	  M.	  O.,	  Szeto,	  D.	  P.,	  Mcmahon,	  J.	  A.,	  Mcmahon,	  A.	  P.,	  &	  Rosenfeld,	  M.	  G.	  (1998).	  Multistep	  signaling	  requirements	  for	  pituitary	  organogenesis	  in	  vivo.	  Genes	  &	  Development,	  1691–1704.	  doi:10.1101/gad.12.11.1691	  Treier,	  M.,	  O’Connell,	  S.,	  Gleiberman,	  a,	  Price,	  J.,	  Szeto,	  D.	  P.,	  Burgess,	  R.,	  …	  Rosenfeld,	  M.	  G.	  (2001).	  Hedgehog	  signaling	  is	  required	  for	  pituitary	  gland	  development.	  Development	  (Cambridge,	  England),	  128(3),	  377–86.	  Retrieved	  from	  http://www.ncbi.nlm.nih.gov/pubmed/11152636	  Tremblay,	  J.	  J.,	  Lancto,	  C.,	  &	  Drouin,	  J.	  (1998).	  The	  pan-­‐Pituitary	  Activator	  of	  Transcription	  ,	  Ptx1	  (	  Pituitary	  Homeobox	  1	  ),	  Acts	  in	  Synergy	  with	  SF-­‐1	  and	  Pit1	  and	  Is	  an	  Upstream	  Regulator	  of	  the	  Lim-­‐Homeodomain	  Gene	  Lim3	  /	  Lhx3.	  Molecular	  Endocrinology,	  12(June),	  428–441.	  Trowe,	  M.,	  Zhao,	  L.,	  Weiss,	  A.,	  Christoffels,	  V.,	  Epstein,	  D.	  J.,	  &	  Kispert,	  A.	  (2013).	  Inhibition	  of	  Sox2-­‐dependent	  activation	  of	  Shh	  in	  the	  ventral	  diencephalon	  by	  Tbx3	  is	  required	  for	  formation	  of	  the	  neurohypophysis.	  Development,	  2309,	  2299–2309.	  doi:10.1242/dev.094524	  Wang,	  Y.,	  Martin,	  J.	  F.,	  &	  Bai,	  C.	  B.	  (2010).	  Direct	  and	  indirect	  requirements	  of	  Shh/Gli	  signaling	  in	  early	  pituitary	  development.	  Developmental	  
Biology,	  348(2),	  199–209.	  doi:10.1016/j.ydbio.2010.09.024	  Ward,	  R.	  D.,	  Stone,	  B.	  M.,	  Raetzman,	  L.	  T.,	  &	  Camper,	  S.	  a.	  (2006).	  Cell	  proliferation	  and	  vascularization	  in	  mouse	  models	  of	  pituitary	  hormone	  deficiency.	  Molecular	  Endocrinology	  (Baltimore,	  Md.),	  20(6),	  1378–90.	  doi:10.1210/me.2005-­‐0409	  Welm,	  B.	  E.,	  Tepera,	  S.	  B.,	  Venezia,	  T.,	  Graubert,	  T.	  A.,	  Rosen,	  J.	  M.,	  &	  Goodell,	  M.	  A.	  (2002).	  Sca-­‐1	  pos	  Cells	  in	  the	  Mouse	  Mammary	  Gland	  Represent	  
	   	   	  
	   210	  
an	  Enriched	  Progenitor	  Cell	  Population.	  Developmental	  Biology,	  245,	  42–56.	  doi:10.1006/dbio.2002.0625	  West,	  B.	  E.,	  Parker,	  G.	  E.,	  Savage,	  J.	  J.,	  Kiratipranon,	  P.,	  Toomey,	  K.	  S.,	  Beach,	  L.	  R.,	  …	  Rhodes,	  S.	  J.	  (2004).	  Regulation	  of	  the	  Follicle-­‐Stimulating	  Hormone	  Gene	  by	  the	  LHX3	  LIM-­‐Homeodomain	  Transcription	  Factor.	  
Endocrinology,	  145(June),	  4866–4879.	  doi:10.1210/en.2004-­‐0598	  Wetering,	  M.	  Van	  De,	  &	  Clevers,	  H.	  (1992).	  Sequence-­‐specific	  interaction	  of	  the	  HMG	  box	  proteins	  Watson	  -­‐Crick	  double	  helix.	  EMBO,	  1(8),	  3039–3044.	  Wilson,	  S.	  W.,	  &	  Houart,	  C.	  (2004).	  Early	  Steps	  in	  the	  Development	  of	  the	  Forebrain.	  Developmental	  Cell,	  6(2),	  167–181.	  Wood,	  H.	  B.,	  &	  Episkopou,	  V.	  (1999).	  Comparative	  expression	  of	  the	  mouse	  Sox1	  ,	  Sox2	  and	  Sox3	  genes	  from	  pre-­‐gastrulation	  to	  early	  somite	  stages.	  Mechanisms	  of	  Development,	  86,	  197–201.	  Wright,	  E.	  M.,	  Snopek,	  B.,	  &	  Koopman,	  P.	  (1993).	  Seven	  new	  members	  of	  the	  Sox	  gene	  during	  mouse	  development	  family	  expressed.	  Nucleic	  Acids	  
Research,	  21(3),	  1993.	  Wu,	  W.,	  Cogan,	  J.,	  Pfäffle,	  R.,	  Dasen,	  J.,	  Phillips,	  J.,	  &	  Rosenfeld,	  M.	  (1998).	  Mutations	  in	  PROP1	  cause	  familial	  combined	  pituitary	  hormone	  deficiency.	  Nature	  Genetics,	  18,	  147–149.	  Yako,	  H.,	  Kato,	  T.,	  Yoshida,	  S.,	  Inoue,	  K.,	  &	  Kato,	  Y.	  (2011).	  Three-­‐dimensional	  studies	  of	  Prop1-­‐expressing	  cells	  in	  the	  rat	  pituitary	  primordium	  of	  Rathke’s	  pouch.	  Cell	  and	  Tissue	  Research,	  346,	  339–346.	  doi:10.1007/s00441-­‐011-­‐1273-­‐8	  Yoshida,	  S.,	  Kato,	  T.,	  Susa,	  T.,	  Cai,	  L.,	  Nakayama,	  M.,	  &	  Kato,	  Y.	  (2009).	  Biochemical	  and	  Biophysical	  Research	  Communications	  PROP1	  coexists	  with	  SOX2	  and	  induces	  PIT1-­‐commitment	  cells.	  Biochemical	  and	  
Biophysical	  Research	  Communications,	  385(1),	  11–15.	  doi:10.1016/j.bbrc.2009.05.027	  Yoshimura,	  F.,	  Harumiya,	  K.,	  Ishikawa,	  H.,	  &	  Otsuka,	  Y.	  (1969).	  Differentiation	  of	  isolated	  chromophobes	  into	  acidophils	  or	  basophils	  when	  transplanted	  into	  the	  hypophysiotrophic	  area	  of	  hypothalamus.	  
Endocrinologia	  Japanica,	  16,	  531–540.	  Yuan,	  H.,	  Corbi,	  N.,	  Basilico,	  C.,	  &	  Dailey,	  L.	  (1995).	  Developmental-­‐Specific	  activity	  of	  the	  FGF-­‐4	  enhancer	  requires	  the	  synergistic	  action	  of	  Sox2	  and	  Oct-­‐3.	  Genes	  &	  Development,	  2635–2645.	  doi:10.1101/gad.9.21.2635	  
	   	   	  
	   211	  
Zhang,	  X.,	  Ibrahimi,	  O.	  A.,	  Shaun,	  K.,	  Umemori,	  H.,	  Mohammadi,	  M.,	  &	  Ornitz,	  D.	  M.	  (2006).	  Growth	  Factor	  Family :	  THE	  COMPLETE	  Receptor	  Specificity	  of	  the	  Fibroblast	  Growth	  Factor	  Family	  THE	  COMPLETE	  MAMMALIAN	  FGF	  FAMILY.	  Journal	  of	  Biological	  Chemistry,	  281,	  15694–15700.	  doi:10.1074/jbc.M601252200	  Zhao,	  L.,	  Bakke,	  M.,	  Krimkevich,	  Y.,	  Cushman,	  L.	  J.,	  Parlow,	  a	  F.,	  Camper,	  S.	  a,	  &	  Parker,	  K.	  L.	  (2001).	  Steroidogenic	  factor	  1	  (SF1)	  is	  essential	  for	  pituitary	  gonadotrope	  function.	  Development	  (Cambridge,	  England),	  
128(2),	  147–54.	  Retrieved	  from	  http://www.ncbi.nlm.nih.gov/pubmed/11124111	  Zhao,	  L.,	  Zevallos,	  S.	  E.,	  Rizzoti,	  K.,	  Jeong,	  Y.,	  Lovell-­‐badge,	  R.,	  &	  Epstein,	  D.	  J.	  (2012).	  Article	  Disruption	  of	  SoxB1-­‐Dependent	  Sonic	  hedgehog	  Expression	  in	  the	  Hypothalamus	  Causes	  Septo-­‐optic	  Dysplasia.	  
Developmental	  Cell,	  22(3),	  585–596.	  doi:10.1016/j.devcel.2011.12.023	  Zhu,	  C.	  C.,	  Dyer,	  M.	  A.,	  Uchikawa,	  M.,	  Kondoh,	  H.,	  Lagutin,	  O.	  V,	  &	  Oliver,	  G.	  (2002).	  Six3-­‐mediated	  auto	  repression	  and	  eye	  development	  requires	  its	  interaction	  with	  members	  of	  the	  Groucho-­‐related	  family	  of	  co-­‐repressors.	  Development,	  129,	  2835–2849.	  Zhu,	  X.,	  Zhang,	  J.,	  Tollkuhn,	  J.,	  Ohsawa,	  R.,	  Bresnick,	  E.	  H.,	  Guillemot,	  F.,	  …	  Rosenfeld,	  M.	  G.	  (2006).	  Sustained	  Notch	  signaling	  in	  progenitors	  is	  required	  for	  sequential	  emergence	  of	  distinct	  cell	  lineages	  during	  organogenesis.	  Genes	  &	  Development,	  20,	  2739–2753.	  doi:10.1101/gad.1444706.successive	  Zuber,	  M.,	  Perron,	  M.,	  Philpott,	  A.,	  Bang,	  A.,	  &	  Harris,	  W.	  (1999).	  Giant	  eyes	  in	  Xenopus	  laevis	  by	  overexpression	  of	  XOptx2.	  Cell,	  98,	  341–352.	  
 
